An exploration of biochemistry including biotechnology, structural characterization, drug design, and chromatographic analyses by Burns, Kristi Lee
AN EXPLORATION OF BIOCHEMISTRY INCLUDING 
BIOTECHNOLOGY, STRUCTURAL CHARACTERIZATION, DRUG 
DESIGN, AND CHROMATOGRAPHIC ANALYSES 
 
 
 
 
A Dissertation 
Presented to 
The Academic Faculty 
 
 
 
By 
 
 
 
Kristi Lee Burns 
 
 
 
 
In Partial Fulfillment 
Of the Requirements for the Degree 
Doctor of Philosophy in Chemistry and Biochemistry 
 
 
 
 
 
  
Georgia Institute of Technology 
 
May 2007
AN EXPLORATION OF BIOCHEMISTRY INCLUDING 
BIOTECHNOLOGY, STRUCTURAL CHARACTERIZATION, DRUG 
DESIGN, AND CHROMATOGRAPHIC ANALYSES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Approved by:   
   
Dr. Sheldon W. May, Advisor 
School of Chemistry and 
Biochemistry 
Georgia Institute of Technology
 Dr. James C. Powers 
School of Chemistry and 
Biochemistry 
Georgia Institute of 
Technology 
   
Dr. Donald F. Doyle 
School of Chemistry and 
Biochemistry 
Georgia Institute of Technology
 Dr. Stanley H. Pollock 
Department of Pharmaceutical 
Sciences 
Mercer University 
   
Dr. Leslie T. Gelbaum  
School of Chemistry and 
Biochemistry 
Georgia Institute of Technology
  
   
Date Approved:  [September 28, 2006] 
 for my husband, Mark Thomas Carlson, who agreed that staying in 
school and becoming fake doctors together would be a cool idea.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
ACKNOWLEDGEMENT 
 
 
 
I would like to express my thanks to my advisor, Dr. May, 
for his constant support and encouragement.  I owe a special debt 
of gratitude for the many hours he spent with me developing my 
writing; I hope a few of those many lessons shine through in this 
work.  I particularly appreciate his seemingly infinite patience 
and willingness to allow me to develop into a solid laboratory 
researcher, especially during the early years when he must have 
been convinced that I would break each and every piece of 
equipment in his laboratory.  I would like to thank Dr. Charlie 
Oldham, who taught me far more than just how to fix every piece 
of broken equipment.  He taught me day in and day out, with 
patience and sometimes frustrated with a bright red face.  
Charlie, you are a rare gem, thank you. 
I would also like to thank my undergraduate advisor, Dr. 
Elena Rybaka-Akimova, who taught me about the sheer joy and love 
of science, and that there is no stronger driving force in the 
universe than positive reinforcement.  I would like to thank Dr. 
Williams for seeing ‘something’ in me and always backing me up 
behind closed doors.     
I am very grateful for the constant intellectual and 
emotional support provided by my many lab mates.  I would like to 
thank my many lab mates, Jennifer Lane, Maggie Gunnerson, Tiffany 
Huang, Veronica De Silva, Jeremy Thompson, Michael ‘Misha’ 
Lubarsky, Nadia Bogouslouvsky, Kelly ‘KJ’ Dennison, Josh Sasine, 
 v 
and Di Wu for the many lessons you all have taught me.  Michael 
Foster, who honed my thinking skills, always pushing me to think 
quicker, faster, more in depth, and always with a sense of humor.     
Finally, I would like to thank family without whom I could 
never have achieved my goals.   
We thank the National Textile Center for partial support of 
the PHB and iso-CoA work and the National Science Foundation 
Grant # BIR-9306392 for partial funding of the solution NMR 
spectrometers.
 vi 
TABLE OF CONTENTS 
 
 
ACKNOWLEDGEMENTS……………………………………………………………………………………………………………………………vi 
 
LIST OF TABLES………………………………………………………………………………………………………………………………vii 
 
LIST OF FIGURES………………………………………………………………………………………………………………………………ix 
 
LIST OF SYMBOLS AND ABBREVIATIONS…………………………………………………………………………xiii 
 
SUMMARY…………………………………………………………………………………………………………………………………………………xvi 
 
VOLUME I 
 
CHAPTER 1:  PHB INTRODUCTION……………………………………………………………………………………………20 
 
CHAPTER 2:  PHB EXPERIMENTAL…………………………………………………………………………………………118 
 
CHAPTER 3:  PHB RESULTS………………………………………………………………………………………………………131 
 
CHAPTER 4:  PHB DISCUSSION………………………………………………………………………………………………161 
 
CHAPTER 5:  DEVELOPMENT OF A PHB LABORATORY…………………………………………………178 
 
VOLUME II 
 
CHAPTER 6:  ISO-COA INTRODUCTION………………………………………………………………………………186 
 
CHAPTER 7:  ISO-COA EXPERIMENTAL………………………………………………………………………………209 
 
CHAPTER 8:  ISO-COA RESULTS……………………………………………………………………………………………218 
 
CHAPTER 9:  ISO-COA DISCUSSION……………………………………………………………………………………240 
 
CHAPTER 10:  ISO-COA CONCLUSION…………………………………………………………………………………316 
 
CHAPTER 11:  SELENIUM REDOX CYCLING INTRODUCTION……………………………………318 
 
CHAPTER 12:  SELENIUM REDOX CYCLING EXPERIMENTAL……………………………………324 
 
CHAPTER 13:  SELENIUM REDOX CYCLING RESULTS AND DISCUSSION…………329 
 
CHAPTER 14:  CYCLOOXYGENASE INHIBITORS………………………………………………………………339 
 
APPENDIX 1:  PHB MODEL…………………………………………………………………………………………………………366 
 
APPENDIX 2:  PHB LABORATORY……………………………………………………………………………………………376 
 
REFERENCES:………………………………………………………………………………………………………………………………………387 
 vii 
LIST OF TABLES 
 
 
 
Table 1 12 Principles of Green Chemistry Developed by the U.S. 
Environmental Protection Agency………………………………………………………30 
 
Table 2 ASTM Terminology and Definitions……………………………………………………34 
 
Table 3 Structure of Commercial Bio-Based or Green Polymers 
and the Monomer Constituents………………………………………………………………52 
 
Table 4 Physical Properties of Various PHA in Comparison with 
Conventional Plastics…………………………………………………………………………………73 
 
Table 5 PHB Clones used in Enzyme Isolations………………………………………119 
 
Table 6 Stoichiometric Relationships for In Vitro Enzymatic 
Reactions………………………………………………………………………………………………………………136 
 
Table 7 HPLC Limits of Detection for CoA, Acetyl-CoA and β-
hydroxybutyryl-CoA………………………………………………………………………………………147 
 
Table 8 Goodness of Fit for the PHB Synthetic Model……………………157 
 
Table 9 Goodness of Fit upon Varying the β-ketothiolase 
Parameters……………………………………………………………………………………………………………158 
 
Table 10 Goodness of Fit upon Varying the Acetoacetyl-CoA 
Reductase Parameters…………………………………………………………………………………159 
 
Table 11 Goodness of Fit for the Parameters for the PHB 
Synthase Reaction…………………………………………………………………………………………160 
 
Table 12 Development of C. necator Growth Media…………………………………179 
 
Table 13 Chemical Synthesis of CoA and Iso-CoA……………………………………194 
 
Table 14 Selectivity of Enzymes Examined for 2’- vs. 3’- 
Phosphate Activity………………………………………………………………………………………202 
 
Table 15 Iso-CoA 1H- and 31P-NMR Chemical Shift Assignments and 
Coupling Constants………………………………………………………………………………………230 
 
Table 16 1H NMR Chemical Shift Parameters for  
Iso-coenzyme A…………………………………………………………………………………………………231 
 
Table 17 Eight Literature Accounts that Examine 2'- vs. 3'-
phosphate Specificity………………………………………………………………………………241 
 
 viii 
Table 18 Enzymatic Interactions with Dephospho-CoA-containing 
Compounds………………………………………………………………………………………………………………244 
 
Table 19 Protein Residue Interactions with the 3'-phosphate of 
CoA………………………………………………………………………………………………………………………………276 
 
 
Table 20 Overview of the Activities and Active Sites of COX-I 
and COX-II……………………………………………………………………………………………………………345 
 
Table 21 The Fitzgerald Hypothesis……………………………………………………………………352 
 
Table 22 Kinetic and Thermodynamic Parameters for the β-
ketothiolase, Acetoacetyl-CoA Reductase and PHB 
Synthase Reactions………………………………………………………………………………………368 
 
Table 23 Components of C. necator Growth Medium…………………………………377 
 
Table 24 Components of Nitrogen-Limited Media………………………………………379 
 
 ix 
LIST OF FIGURES 
 
 
 
Figure 1 Material Recycling Quota (in %) Reached in European 
Countries…………………………………………………………………………………………………………………43 
 
Figure 2 Estimate of World Wide Peak Oil Production…………………………45 
 
Figure 3 Industrial Synthesis of Natureworks PLA…………………………………54 
 
Figure 4 Fossil Energy Requirement for some Petroleum Based 
Polymers and PLAs……………………………………………………………………………………………57 
 
Figure 5 Metabolic Engineering and Pathways for the Microbial 
Production of 1,3-Propanediol in E. coli………………………………64 
 
Figure 6 Chemical Synthesis of Nodax Polymer……………………………………………74 
 
Figure 7 Enzymatic Biosynthesis of PHB in C. necator………………………77 
 
Figure 8 Model of Regulation of PHA Granule Formation by the 
Transcriptional Regular Protein, PhaR………………………………………82 
 
Figure 9 Systems for the In Vitro Synthesis of PHA……………………………87 
 
Figure 10 Chemoenzymatic Synthesis of PHB……………………………………………………111 
 
Figure 11 Proposed Chemical Recycling of Biopolyesters using 
Biocatalysts………………………………………………………………………………………………………112 
 
Figure 12 Overlaid HPLC Chromatograms for the Step-wise In Vitro 
Synthesis of PHB……………………………………………………………………………………………132 
 
Figure 13 Quantitative Time Courses of Metabolite Concentrations 
for the In Vitro Synthesis of PHB………………………………………………134 
 
Figure 14 Overlaid HPLC Chromatograms of Commercial CoA and 
Acyl-CoA Samples……………………………………………………………………………………………139 
 
Figure 15 Representative Chromatograms of CoA, Acetyl-CoA, 
Acetoacetyl-CoA, and β-hydroxybutyryl-CoA…………………………142 
 
Figure 16 Stacked Chromatograms of an Unidentified Substance…144 
 
Figure 17 HPLC Standard Curves for Acetyl-CoA, CoA, and β-
hydroxybutyryl-CoA………………………………………………………………………………………148 
 
Figure 18 Metabolic Modeling of PHB Synthesis and Spiking 
Experiments…………………………………………………………………………………………………………150 
 x 
Figure 19 Stacked Chromatograms of the Acetoacetyl-CoA Spiking 
Experiment……………………………………………………………………………………………………………154 
 
Figure 20 Stacked Chromatograms of the NADPH and Acetoacetyl-CoA 
Reductase Spiking Experiment……………………………………………………………155 
 
Figure 21 Last Step in the Total Synthesis of Iso-CoA……………………188 
 
Figure 22 Chemical Structure of Acetyl-Coenzyme A………………………………191 
 
Figure 23 HPLC-MS and HPLC-MS/MS of Commercial CoA Sample…………220 
 
Figure 24 Exact Mass and MS/MS of CoA and Isomer Purified by 
HPLC from Commercial CoA………………………………………………………………………221 
 
Figure 25 HPLC-MS and HPLC-MS/MS Analyses of Commercial Acetyl-
CoA Samples…………………………………………………………………………………………………………222 
 
Figure 26 HPLC-MS and HPLC-MS/MS Analyses of Commercial 
Acetoacetyl-CoA Samples…………………………………………………………………………223 
 
Figure 27 HPLC-MS and HPLC-MS/MS Analyses of Commercial β-
hydroxybutyryl-CoA Samples…………………………………………………………………224 
 
Figure 28 1H-NMR of HPLC-purified Samples of CoA and Iso-CoA…226 
 
Figure 29 1H-1H COSY of Iso-CoA…………………………………………………………………………………227 
 
Figure 30 The Chemical Structures and Interconversion of NAD(P)H 
and NAD(P)+…………………………………………………………………………………………………………228 
 
Figure 31 1H-31P HMQC of Iso-CoA………………………………………………………………………………229 
 
Figure 32 The HPLC Elution Profile of Commercial CoA, Acetyl-
CoA, Acetoacetyl-CoA, and β-hydroxybutyryl-CoA……………232 
 
Figure 33 The First Example of Enzymatic Acyl-transfer Reactions 
occurring with the 2’-isomers of CoA-containing 
Compounds………………………………………………………………………………………………………………234 
 
Figure 34 Regioselective Synthesis of Iso-CoA from CoA…………………237 
 
Figure 35 Acid-catalyzed Synthesis of Iso-CoA…………………………………………239 
 
Figure 36 Proposed Structure of the [β-cyclodextrin-CL—adenosine 
cyclic phosphate] Ternary Complex………………………………………………295 
 
Figure 37 The Theoretical Mechanism for the Acid-catalyzed 
Hydrolysis of CoA to Iso-CoA……………………………………………………………297 
 
 xi 
Figure 38 Nucleotide Phosphate Derivatives Known or Suggested to 
have Activity as Second Messengers in Cellular Signal 
Transduction………………………………………………………………………………………………………303 
 
Figure 39 The tRNA Splicing Pathway of Yeast……………………………………………304 
 
Figure 40 NAD+-dependent Signaling Pathways generating Pyridine 
Nucleoside Diphosphate Derivatives……………………………………………308 
 
Figure 41 Biosynthesis of Coenzyme A…………………………………………………………………313 
 
Figure 42 Biosynthesis of NAD(P)H…………………………………………………………………………314 
 
Figure 43 The Formation of Peroxynitrite………………………………………………………319 
 
Figure 44 The Reaction of Peroxynitrite with Reduced 
Glutathione…………………………………………………………………………………………………………320 
 
Figure 45 The Peroxynitrite-dependent Oxidation of 
Organoselenium Compounds………………………………………………………………………321 
 
Figure 46 Selenium and Sulfur-Containing Compounds Protect pUC19 
Plasmid DNA from Peroxynitrite-mediated Single Strand 
Nicking……………………………………………………………………………………………………………………330 
 
Figure 47 HPLC Chromatograms Illustrating the Protective Effects 
of HOMePAESe against Peroxynitrite-mediated DNA 
Damage………………………………………………………………………………………………………………………331 
 
Figure 48 Catalytic Redox Cycle Established with reduced 
Glutathione, and Phenylaminoethyl Selenides can 
Protect DNA from Peroxynitrite-induced Damage………………333 
 
Figure 49 HPLC Chromatograms of the Reactions between HOMePAES, 
Peroxynitrite, and GSH……………………………………………………………………………335 
 
Figure 50 Proposed reaction between HOMePAES and ONOO- Producing 
Nitro-HOMePAES and a HOMePAES dimer…………………………………………337 
 
Figure 51 Nitration and Dimerization of Tyrosine in the Presence 
of Peroxynitrite……………………………………………………………………………………………338 
 
Figure 52 The Cyclic and Linear Pathways of Arachidonic Acid 
Metabolism……………………………………………………………………………………………………………340 
 
Figure 53 The Cyclic Pathway of Arachidonic Acid Metabolism……341 
 
Figure 54 The Reactions Catalyzed by PGH Synthase (PGHS) …………343 
 
Figure 55 Selective COX-II Inhibitors………………………………………………………………350 
 
 xii 
Figure 56 Meta-terphenyl Compounds Developed as COX 
Inhibitors…………………………………………………………………………………………………………………………………………356  
 
Figure 57 Synthesis of MDB as a Scaffold for other Meta-
terphenyl Derivative Compounds………………………………………………………358 
 
Figure 58 Percent Inhibition of COX-I and COX-II In Vitro…………361 
 
Figure 59 Meta-terphenyl Derivatives Assayed for the Ability to 
Inhibit COX-I and Cox-II in an In Vitro Colorimetric 
Assay…………………………………………………………………………………………………………………………362 
 
Figure 60 Percent Inhibition of COX-II in Whole Blood……………………364 
 
Figure 61 Initial Rate Plots for Inhibition of the Condensation 
Reaction by CoA………………………………………………………………………………………………371 
 
Figure 62 The Chemical Structure of Poly-β-hydroxybutyrate………376 
 
 
 xiii 
LIST OF SYMBOLS AND ABBREVIATIONS 
 
 
 
AcCoA    acetyl coenzyme A 
AcAcCoA   acetoacetyl-CoA 
ATP    adenosine triphosphate 
CDB 1-(carboxymethyl)-3,5-diphenyl-2-
methylbenzene 
 
CNP    2’,3’-cyclic-nucleotide 3’- 
phosphodiesterase 
CoA    free coenzyme A 
COSY     correlation spectroscopy  
COX    cyclooxygenase 
DCW    dry cellular (cell) weight 
DMSO    dimethyl sulfoxide 
DTNB Ellmann’s reagent, 5,5'-dithiobis(2-
nitrobenzoic acid) 
 
EBSELEN 2-phenyl-1,2-benzisoselenazole-3(2H)-one 
EDC  1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide  
 
EDTA    ethylenediaminetetraacetic acid 
EGF    epidermal growth factor 
ELISA    enzyme-linked immunosorbent assay 
EPPS  4-(2-Hydroxyethyl)piperazine-1-
propanesulfonic acid  
 
GI gastrointestinal 
GSH glutathione, reduced form 
GSSG glutathione, oxidized disulfide dimer form 
HBCoA    β-hydroxybutyryl-CoA 
 xiv 
hCNP-CF   human brain 2’,3’-cyclic-nucleotide 3’- 
phosphodiesterase 
 
HMQC  heteronuclear multiple quantum correlation  
HOMePAES [(±)1-(4’-hydroxyphenylthio)-2-
aminopropane] hydrochloride 
 
HOMePAESe 1-(4’-hydroxyphenylseleno)-2-aminoethane 
HPLC    high performance liquid chromatography 
IC50    inhibition constant at 50 percent 
LB media   Luria-Bertani media 
MDB    1-methanesulfonamide-3,5-diphenyl benzene 
MS     mass spectrometry  
MST    methylsulfone terphenyl 
MRM     multiple reaction monitoring 
NADPH reduced β-nicotinamide-adenine dinucleotide 
phosphate 
 
NADP+ oxidized β-nicotinamide-adenine 
dinucleotide phosphate 
 
NMR     nuclear magnetic resonance  
NSAID    non-steroidal anti-inflammatory drugs 
OD600 optical density (absorbance) at a 
wavelength of 600 nanometers. 
 
PAES [2-(phenylthio)ethylamine] hydrochloride 
PAESe 1-(phenylseleno)-2-aminopropane.   
PGHS prostaglandin H synthase 
PHB    poly-(β)-hydroxybutyric acid 
PMSF    phenylmethanesulfonyl fluoride 
RP-HPLC reversed phase high performance liquid 
chromatography 
 
SDS    sodium dodecyl sulfate 
 xv 
TBAHS    tetrabutylammonium hydrogen sulfate  
TCEP    triscarboxyethyl phosphine 
 
 xvi 
SUMMARY 
 
 
This thesis has several topics, which we list here and then 
summarize in more detail.  The topics are: 
I. POLY-(BETA)-HYDROXYBUTYRIC ACID 
A. ANALYSIS OF THE IN VITRO BIOSYNTHESIS OF POLY-(BETA)-
HYDROXYBUTYRIC ACID 
B. DESIGN AND OPTIMIZATION OF A POLY-(BETA)-HYDROXYBUTYRIC 
ACID EDUCATIONAL LABORATORY 
II. ISO-COENZYME A:  THE FIRST STRUCTURAL CHARACTERIZATION, 
ENZYMATIC ANALYSIS, AND REGIOSELECTIVE SYNTHESIS 
III. RATIONAL DESIGN AND ANALYSIS OF NOVEL SELECTIVE 
PROSTAGLANDIN SYNTHASE-2 NON-STEROIDAL ANTIINFLAMMATORY DRUGS FOR 
THE TREATMENT OF INFLAMATION 
IV. SELENIUM REDOX CYCLING IN THE PROTECTIVE EFFECTS OF 
ORGANOSELENIDE-ANTIOXIDANTS AGAINST PEROXYNITRITE-INDUCED DNA 
DAMAGE 
 
Poly-(β)-hydroxybutyric acid (PHB) is a biodegradable, 
thermoplastic biopolyester produced as a carbon-energy storage 
source by bacteria that are challenged by nutrient limitation.  
While production of PHB for industrial applications is generally 
accomplished via fermentation, in vitro enzymatic synthesis can 
be an attractive alternative.  We now report a detailed analysis 
of the in vitro biosynthesis of PHB using the three-enzyme system 
from Cupriavidus necator.  We have developed quantitative HPLC 
 xvii 
methodology which resolves CoA, acetyl-CoA, acetoacetyl-CoA, and 
β-hydroxybutyryl-CoA with baseline resolution and then utilized 
this methodology to elucidate the fluctuations in metabolite 
concentrations and the effect of each individual enzyme on the 
overall system.  The experimental results were then used to 
design the first kinetic model for in vitro PHB biosynthesis.  
All previous modeling studies of PHB production have been 
designed to analyze in vivo biosyntheses, typically in bacteria 
but also in yeast and plants.  Our results can therefore serve as 
a basis for further development of the potential of in vitro 
enzymatic syntheses of polyesters as a compliment to the more 
widely used approach of in vivo production of these polymers. 
 
Iso-coenzyme A (iso-CoA) is an isomer of coenzyme A (CoA) 
in which the monophosphate is attached to the 2’-carbon of the 
ribose ring.  While iso-CoA was first reported in 1959 by Khorana 
and coworkers to be a byproduct of the chemical synthesis of CoA, 
relatively little literature attention has been focused on iso-
CoA or on acyl-iso-CoA compounds.  We now report, in chapters 6 
through 10, the first structural characterizations of iso-CoA, 
acetyl-iso-CoA, acetoacetyl-iso-CoA, and β-hydroxybutyryl-iso-CoA 
using MS, MS/MS, and homo- and hetero-nuclear NMR analyses.  All 
previous characterizations of the structure of iso-CoA have been 
based on chromatographic analyses, which ultimately rest on 
comparisons with the degradation products of CoA and NADPH, or 
have been based on assumptions regarding enzyme specificity.  We 
 xviii 
describe HPLC methodology to separate the isomers of several iso-
CoA-containing compounds with baseline resolution.  We also 
report here the first examples of iso-CoA-containing compounds 
acting as substrates in enzymatic acyl-transfer reactions.  
Finally, we describe a simple synthesis of iso-CoA from CoA, 
which utilizes β-cyclodextrin to produce iso-CoA with high 
regioselectivity.  We also demonstrate a plausible mechanism, 
which accounts for the existence of up to 18% of the iso-CoA 
isomers in commercial preparations of CoA-containing compounds.  
Considering that approximately 9% of all classified enzymes 
utilize CoA or acyl-CoA substrates, we anticipate that these 
results will provide the necessary methodology and impetus for 
investigating iso-CoA compounds as potential pseudosubstrates or 
inhibitors of the more than 350 known CoA-utilizing enzymes.   
In Chapters 11 through 13 we report that phenylaminoethyl 
selenide compounds protect DNA from peroxynitrite-mediated 
single-strand breaks (1).  Moreover, these organoselenium 
compounds protect DNA more effectively than their sulfur 
analogues.  Additionally, the ability of glutathione to enhance 
the protective effects of the selenium-containing compounds 
against peroxynitrite-induced DNA damage suggests that a selenium 
redox cycle, in which the peroxynitrite-generated selenoxide is 
recycled back to a selenide via glutathione, has been 
established.  The mechanism of protection against peroxynitrite 
mediated DNA damage was investigated by HPLC for the selenium- 
and corresponding sulfur-containing compounds.  HPLC analysis 
 xix 
shows that phenylaminoethyl selenides are quickly oxidized by 
peroxynitrite forming selenoxides as the sole selenium-containing 
product.  Moreover, in the presence of reduced glutathione, the 
selenide to selenoxide ratio was higher suggesting the 
establishment of a glutathione-mediated catalytic redox cycle.  
Phenylaminoethyl sulfide (PAES) was, likewise, shown to react 
slowly with peroxynitrite to form a small quantity of the 
sulfoxide as the main product but no redox cycle could be 
established with the sulfur analogues (1).  Finally, the unique 
chemistry of the reaction between peroxynitrite and HOMePAES was 
investigated using HPLC and HPLC/MS.   
 Finally, in chapter 14, we report the development of novel 
CDB derivatives, which are selective COX-II inhibitors.  A series 
of compounds were assayed with an in vitro colorimetric inhibitor 
screening and with a whole blood ELISA screening and the results 
indicate that MST is a selective inhibitor of COX-II.
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CHAPTER 1 
PHB Introduction 
 
 
A Brief History of Enzyme Catalysis.  Enzymes are nature’s 
catalysts.  These proteins catalyze a rich variety of metabolic 
transformations, doing so with very high catalytic rates under 
mild conditions, and with high regioselectivity and 
stereospecificity.  Given the vast potential of enzymes, it seems 
obvious that societies would foster development of this 
technology.  Indeed, enzymatic reactions have been exploited for 
millennia by cultures which use bacterial enzymes to ferment milk 
into yogurt and kefir, yeast enzymes to bake and brew, the enzyme 
rennin from stomachs of ruminant animals for cheese production, 
and even proteases from fruits like papaya (papain) and pineapple 
(bromelain) to tenderize meat (2).   
 
Modern enzyme technology.  Modern enzyme technology dates 
to the 1833 partial isolation of an amylase enzyme, diastase, by 
Payen and Persoz (3).  The slow advance of enzyme technology 
through the rest of the 19th and early into the 20th century laid 
the foundation for the leaps in enzyme biotechnology of the last 
50 years.  Early advances of particular note include Berzelius’s 
1835 (4) general theory of catalysis and Kuhne’s 1878 coinage of 
the descriptive term ‘enzyme’ (from the Greek ‘en’ for in and 
‘zyme’ for yeast).  Despite Kuhne’s apparently deliberate 
coinage, he did not prove that enzymes were distinct entities 
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from the yeast from whence they came and this contention remained 
unproven until 1897 when the Buchner brothers generated ethanol 
from glucose using a cell-free yeast extract.  Theoretical 
advances like the 1894 publication of Emil Fisher’s lock-and-key 
hypothesis proved just as important in advancing enzymology as 
the more tangible crystallization of the first enzyme, Jack Bean 
urease, by Sumner in 1926, which led to his determination that 
enzymes were proteins (4). 
 
Enzymes in Industrial Biotechnology.  The use of enzymes in 
industrial biotechnology can be traced back to Christian Hansen’s 
1874 industrial scale saline extraction of chymosin from calf 
stomachs (5), which was used for cheese production.  This was 
shortly followed by Japanese scientist Jokichi Takamine’s 
development of an industrial scale isolation of takadiastase, a 
well-known fungal amylase.  Takamine’s 1894 patent was the first 
for enzymology and this important enzyme was critical to the 
early structural determinations of sugar-containing compounds 
including CoA, NAD(P)H, and DNA (5).   
Despite the 19th and early 20th century advances in enzyme 
biotechnology the commercial potential for enzymes was not fully 
explored or implemented in earnest until after the close of the 
Second World War.  In the leather industry, trypsin-containing 
pancreatic extracts were first developed in 1917, but these 
extracts did not replace the disgusting historical practice of 
using pigeon and dog excrement in the leather bating process 
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until after WWII (5).  The detergent industry finally grasped the 
full potential of enzymes in the late 50’s and early 60’s with 
the development of Alcalase, a pH stable (pH 8-10) microbial 
alkaline protease, which was successfully incorporated into 
commercial laundry detergents.  The starch industry also 
flourished from innovations like the use of fungal amylases for 
syrup production in the 1950’s, amyloglucosidases—which could 
entirely hydrolyze starch to glucose—in the 1960’s, and glucose 
isomerases (glucose to fructose) in the 1970’s.  By combining the 
action of these enzymes, in the 1980’s, the starch industry 
successfully developed a process for producing high fructose corn 
syrup from starch (5); this has remained the starch industry’s 
most dominant sweetener with a global annual sales topping 1 
billion.   
 
Industrial Enzymes the Second Revolution.  The advances in 
molecular biology and genetic engineering of the 1980’s prompted 
a second ‘revolution’ in the industrial enzyme sector which 
facilitated the generation of the first recombinant enzyme, 
Lipolase®, which was released in 1987 as a detergent additive 
(6).  More recent advances center around protein engineering 
which can employ rational design techniques, like site-directed 
mutagenesis, which led to Novozyme’s development of a bleach-
stable detergent enzyme—Everlase® (7).  Another recent 
engineering methodology is the non-rational technique of directed 
evolution (8), which Diversa Corp. (9) employed to optimize a 
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xylanase enzyme so that it is stable at temperatures in excess of 
90oC (10).   
 
Rationale for the use of Industrial Enzymes.  There are 
numerous reasons that enzymes are considered highly attractive 
for industrial syntheses (11-14).  Enzymes are well known for the 
capacity to catalyze reactions under very rapid rates with 
exquisite selectivity; thus, generating fewer unwanted side 
effects, less by-products and lower product clean-up costs than 
with traditional syntheses (14).  Enzymes are often able to 
function under pH, temperature and pressure, and solvent 
conditions that are amenable to life.  Furthermore, enzymes 
derived from extremophiles or via genetic modification can 
efficiently catalyze reactions under conditions extreme to life; 
this type of enzymatic reactions can be exploited for energy 
savings and pollution prevention.  Unlike many chemical 
biocatalysts, which are often made of heavy transition metals or 
toxic compounds, enzymes themselves are non-toxic and 
biodegradable to the environment; thus, eliminating at least one 
potentially expensive waste stream (5,11-13,15).   
 
Enzymes are now an integral part of the industrial 
biotechnology sector.  As of 2003 the global sales of industrial 
enzymes were estimated at $2.3 billion with 35% in detergents, 
28% in food applications, 17% in agriculture/feed, 10% in textile 
processing, and the remaining 10% divided among paper/pulp, 
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leather, synthesis of fine/bulk chemicals, personal care, and 
fuel industries (2,16).  The classic rationale in favor of 
employing enzymes in industrial synthesis is their exquisite 
regio- and enantio-selectivity.  However, a paradigm shift is 
occurring within industry to an emphasis on industrial 
sustainability.   
 
White Biotechnology.  Sustainability, with regard to 
industrial biotechnology, refers to specifically integrating the 
traditionally disparate industrial objectives of increasing 
market shares, engaging in environmentally sustainable practices, 
and promoting socially acceptable practices, into a single 
harmonious triad.  This general trend has led to the development 
of the term white (or industrial) biotechnology, a phrase 
recently coined by the 2003 European Association for 
Bioindustries (EuropaBio) Conference (16).  White biotechnology 
refers to all bio-based sustainable industrial chemistry and is 
distinguished from plant-based (green) or medical-based (red) 
biotechnologies (16).  White biotechnology has been high on 
international agendas over the past few years as evinced by 
several recent publications by the OCED (17,18), EuropaBio (19), 
SusChem, (20)—a dedicated website for the European Technology 
Platform for Sustainable Chemistry containing representatives 
from many of the major European chemical manufactures—and the 
Road Map for Biomass Technologies in the United States (21,22).  
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Development of a sustainable bio-based economy that uses 
eco-efficient bioprocesses and renewable bio-resources is 
considered a “key strategic challenge for the 21st century” by the 
30 nation consortium of the OECD (the Organization for Economic 
Cooperation and Development) (17,18).  White biotechnology, which 
is critical to this initiative, encompasses the entire sphere of 
bio-based products, including utilization of bio-feedstock and 
the development of microbial bioreactors, and enzyme 
biotechnology obviously plays a critical role in this rapidly 
developing field.   
A classic example of the potential of white-enzyme 
biotechnology to alleviate environmental concerns while 
increasing company profit margins was developed and implemented 
by the Mitsubishi-Rayon Co (22).  In this case, the immobilized 
enzyme nitrile hydratase has replaced the two previous 
techniques, which used either a copper catalyst or sulfuric-acid 
hydrolysis to synthesize acrylonitrile from acrylamide (22).  The 
nitrile hydratase process decreases reaction temperatures, 
increases single-pass conversion rates to 100%, eliminates the 
need for product concentration, and decreases energy and CO2 
emissions 5 fold (11).  In this instance, enzyme technology has 
created a more efficient and environmentally friendly process, 
decreased production costs, and increased the resulting bottom 
line. 
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White Biotechnology in the Pharmaceutical Industry.  The 
pharmaceutical industry is increasingly incorporating white and 
enzyme biotechnology into their syntheses because in this 
industry high enzyme costs are easily offset by the high profit 
margins of the pharmaceuticals.  In certain situations, enzyme 
specificity can be used in enantioselective syntheses in order to 
avoid undesirable byproducts, which may pose a public health 
risk.  The lessons learned from the tragic side effects of one of 
the thalidomide isomers prompted the FDA’s current stance of 
pushing pharmaceutical companies to identify and market only the 
active enantiomer of a drug (23).  Marketing only the active 
isomer reduces the risk of unintended and potentially dangerous 
side effects.   
Additionally, enzyme biotechnology will likely be exploited 
in the pharmaceutical industry’s latest tactic of patenting 
single isomeric forms of drugs, which were previously marketed as 
isomeric mixtures, in order to maintain patent and marketing 
exclusivity.  To date, so called chiral switch drugs, which 
include Nexium—the S enantiomer of Prilosec, Lexapro—the S 
enantiomer of Celexa, Focalin—the R,R diasteriomer of Ritalin, 
and Xyzal—the R enantiomer of Zyrtec, have been generated via 
chiral syntheses and purifications, but new selective enzyme 
technologies are on the horizon (24,25).   
The pharmaceutical industry also utilizes enzyme 
biotechnology for the design of syntheses, which increase 
efficiency by decreasing the number of synthetic steps, reduce 
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costs by eradicating or downsizing the use of expensive chiral 
precursors, and eliminating costly and complex downstream isomer 
purifications.  DSM has been enzymatically synthesizing 
cephalexin on an industrial scale for several years (26).  In 
this case, an in house immobilized penicillin G acylase enzyme 
(27,28), called Assemblase 7500 (26), was developed which 
catalyzes the conversion of D-phenylglycine amide and 7-amino 
desacetoxy cephalosporanic acid to the cephalosporin analog, 
cephalexin (26,29).  In this instance, the careful design of the 
immobilized enzyme has increased the efficiency of downstream 
processing (26).  An immobilized enzyme with a density less than 
water was designed which can be removed easily by skimming the 
immobilized enzyme off the top of the reaction solution in which 
the product has precipitated and sunk to the bottom (26).  The 
commercial chemo-enzymatic production of cephalexin is preferred 
over the traditional 10-step chemical method because it uses less 
input chemicals, obviates the need for hazardous solvents like 
phosphorous pentachloride and dichloromethane; this reduces the 
waste stream (19,30).  Overall, DSM’s enzyme process reduces 
materials used and energy consumption by 65% and reduces overall 
costs by 50% (19).   
 
White-Enzyme Biotechnology Increases Product Value.  Enzyme 
biotechnology has the potential to add value to products while 
increasing profit margins and protecting the environment.  In the 
textile industry, tremendous advances have been achieved by 
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employing enzymes in the fabric polishing process (6,12,31,32).  
This process, known as bio-polishing, imparts a softness to 
fabrics that lasts multiple washing cycles; the traditional 
chemical processes last only a few washes and have a higher 
environmental impact (12).  In a related process, enzymes like 
cellulose (31,32) are being used to achieve the ‘stone-washed’ 
appearance of denim without the use of pumice stones, which are a 
non-renewable mined resource.  The economic rationale for using 
enzymatic bio-stoning instead of pumice stones is not immediately 
apparent since enzyme costs are roughly equivalent pumice stones.  
However, a complete economic accounting clearly indicates that 
enzymes are more cost effective when considering that the 
enzymatic bio-stoning decreases damage to fabrics, product 
variation, rejected fabrics, reduces wear and tear on washing 
machines, eliminates stone storage and disposal costs, manual 
labor for de-stoning and removing pumice grit from garments, and 
increases machine space for garments instead of stones (12).  
 
Green Chemistry.  Green chemistry is a major component of 
sustainable industry and white biotechnology (14).  The term 
green chemistry was coined over 10 years ago (33) and is defined 
as the design, development and implementation of chemicals, 
processes and products that reduce or eliminate the use or 
generation of substances hazardous to human health and the 
environment (33-35).  The 12 principles of green chemistry laid 
out by the US Environmental Protection Agency (35,36), listed in 
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Table 1, clearly indicate the intimate connection between enzyme 
biotechnology and green chemistry .   
Indeed, the 2005 Presidential Green Chemistry Challenge 
Award for Alternative Synthesis Pathways was presented to 
Novazyme and the Archer Daniels Midland Company for their joint 
development and commercialization of NovaLipidTM an enzymatic 
process for interesterification of vegetable oils using Lipozyme® 
(37,38).  This enzymatic process positively affects human health 
by replacing partially hydrogenated vegetable oils with 
interesterified oils, which contain higher polyunsaturated fatty 
acid levels and no unhealthy trans-fats.  Additionally, this 
process benefits the environment by eliminating certain 
byproducts, waste streams, and several harsh chemicals, and by 
increasing product yields from edible oil resources (37,38).  
This technology will likely be quite desirable to the food 
industry because of the new FDA mandate requiring that 
manufacturers list trans fatty acids on the Nutrition Facts panel 
of foods and some dietary supplements (39).   
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Table 1.  12 Principles of Green Chemistry Developed by the U.S. Environmental Protection Agency 
(35,36).   
1 Prevent waste Design chemical syntheses to prevent waste, leaving no waste to treat or 
clean up. 
2 Design safer chemicals 
and products 
Design chemical products to be fully effective, yet have little or no 
toxicity. 
3 Design less hazardous 
chemical syntheses 
Design syntheses to use and generate substances with little or no 
toxicity to humans and the environment. 
4 Use renewable feed 
stocks 
Use raw materials and feed stocks that are renewable rather than 
depleting.  Renewable feedstocks are often made from agricultural 
products or are the wastes of other processes; depleting feedstocks are 
made from fossil fuels (petroleum, natural gas, or coal) or are mined. 
5 Use catalysts, not 
stoichiometric 
reagents 
Minimize waste by using catalytic reactions.  Catalysts are used in 
small amounts and can carry out a single reaction many times.  They are 
preferable to stoichiometric reagents, which are used in excess and work 
only once. 
6 Avoid chemical 
derivatives 
Avoid using blocking or protecting groups or any temporary modifications 
if possible.  Derivatives use additional reagents and generate waste. 
7 Maximize atom economy Design syntheses so that the final product contains the maximum 
proportion of the starting materials.  There should be few, if any, 
wasted atoms. 
8 Use safer solvents and 
reaction conditions 
Avoid using solvents, separation agents, or other auxiliary chemicals.  
If these chemicals are necessary, use innocuous chemicals. 
9 Increase energy 
efficiency 
Run chemical reactions at ambient temperature and pressure whenever 
possible. 
10 Design chemicals and 
products to degrade 
after use 
Design chemical products to break down to innocuous substances after use 
so that they do not accumulate in the environment. 
11 Analyze in real time 
to prevent pollution 
Include in-process real-time monitoring and control during syntheses to 
minimize or eliminate the formation of byproducts. 
12 Minimize the potential 
for accidents 
Design chemicals and their forms (solid, liquid, or gas) to minimize the 
potential for chemical accidents including explosions, fires, and 
releases to the environment. 
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Green Plastics.  Green plastics, named after the green 
chemistry movement and interchangeably called bio-based 
plastics/polymers, are defined as any or all polymers produced in 
a manner consistent with green chemistry (40).  Green plastics 
include polymers that are synthesized from agricultural and 
petroleum feed stocks, and may or may not be degradable, 
biodegradable, or compostable (40,41).  Once only a fledgling 
enterprise, green plastics are currently growing into a mature 
international industry.   
Petrochemically Derived Green Plastics.  Perhaps the most 
liberal use of the green plastics classification applies to the 
traditional petrochemically derived polymers, which are 
synthesized using the principles of green chemistry.  An 
excellent example of this type of green chemistry is the Ultimer 
Process that was developed by the Nalco chemical company and was 
awarded the 1999 Presidential Green Chemistry Award in the 
Alternative Solvents/Reaction Chemistry category (42).  The 
Ultimer process utilizes an aqueous dispersion polymerization 
technique to generate water stable colloids of acrylamide 
polymers.  This technique eliminates the use of hydrocarbon 
solvents and surfactants, utilizes a byproduct of nylon synthesis 
that would otherwise be treated as industrial waste, generates a 
product of higher quality then the chemical process, and 
therefore is more cost efficient (42).    
Biopolymers are Green Plastics.  Likely the most narrowly 
defined category of green plastics are known as biopolymers, 
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which are polymeric substances that are specifically formed in a 
biological system (43).  Bioplastics have been organized into 
eight classes as follows:  polynucleotides (DNA, RNA); polyamides 
(peptides and proteins including enzymes, silk, keratin, and 
collagen); polysaccharides (starch, glycogen, cellulose, chitin); 
polyisoprenes (rubbers and some gels); lignin (the phenolic 
polymer that acts as the cementing matrix in wood); 
polyphosphates (believed to be involved in signal transduction); 
poly-β-hydroxyalkanoic acids or PHAs (PHB, PHBV); and the newly 
discovered polythioesters (44).   
Classifications of Other Green Plastics.  Many green 
polymers do not fit into the previously discussed categories of 
biopolymers or green petrochemical plastics.  These green 
plastics may be derived from fossil fuels or agricultural 
feedstocks, produced chemosynthetically or biologically, and may 
be degradable, biodegradable or compostable.  Various 
organizations have established controlled scientifically 
verifiable standards for classifying the characteristics of 
degradable, biodegradable, and compostable plastics; the ASTM 
terminology and standards are listed in Table 2 (45-48).  We note 
that even the historic petrochemically derived plastics , 
including nylon-66, polyethylene, and polypropylene, can 
disintegrate over time via chemical and photochemical mechanisms 
and sheer forces, and under certain conditions these polymers can 
eventually decay into a friable powder; however this process 
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requires decades to years, which disqualifies these polymers as 
readily degradable or green (49,50).   
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Table 2.  ASTM Terminology and Definitions (45,46). 
Polymer A substance consisting of molecules characterized by the repetition (neglecting 
ends, branch junctions, and other minor irregularities) of one or more types of 
monomeric units.   
Plastic A material that contains as an essential ingredient one or more organic polymeric 
substances of large molecular weight, is solid in its finished state, and, at some 
stage in its manufacture or processing into finished articles, can be shaped by 
flow. 
Degradable 
plastic 
A plastic designed to undergo a significant change in its chemical structure under 
specific environmental conditions, resulting in a loss of some properties that may 
be measured by standard methods appropriate to the plastic and the application in a 
period of time that determines its classification. 
Biodegradable 
plastic 
A degradable plastic in which the degradation results from the action of naturally 
occurring microorganisms such as bacteria, fungi, and algae. 
Compostable 
plastic 
A plastic that undergoes degradation by biological processes during composting to 
yield carbon dioxide, water, inorganic compounds, and biomass, at a rate consistent 
with known compostable materials and leaves no visible, distinguishable or toxic 
residue.   
• A plastic product is considered to have demonstrated satisfactory disintegration 
if after 12 weeks in a controlled composting test, no more than 10% of its 
original dry weight remains after sieving on a 2.0-mm sieve. 
• A plastic product is considered to demonstrate a satisfactory rate of 
biodegradation by achieving [60% or 90% depending on polymer composition] 
conversion to carbon dioxide within [a 180 days or 365 for radiolabeled 
materials] 
• A plastic product can demonstrate satisfactory terrestrial and aquatic safety if 
it [has] concentrations of regulated heavy metals less than 50% of those 
prescribed for sludges or composts in the country where the product is sold, and 
the germination rate and the plant biomass of the sample composts [have] no less 
than 90% of the corresponding blank composts for two different plant species.   
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The physical characteristics of degradable and 
biodegradable polymers are a direct result of the chemical 
structure of the polymer and are not dependent on the polymer 
feedstock or the production method (40,41,51).  Consequently, 
there are degradable compostable plastics that are chemically 
synthesized from fossil fuels and even biopolymers that do not 
biodegrade or that degrade so slowly that they are considered 
non-degradable (37,38,47).  Poly (ε-caprolactone) is a classic 
example of a polymer that is biodegradable, compostable and 
synthesized chemically from fossil fuels (40,51-53).   
Compostability of Green Polymers.  Polymers can be 
officially classified as compostable if they fit the ASTM 
standards, listed in Table 2, which require the polymer to 
degrade or biodegrade to a non-toxic indistinguishable residue 
within a specified time period (45,46).  Oddly, the somewhat 
arbitrary ASTM time limits for compostable polymers cause leaves 
and wood to be classified as non-compostable.  Consequently, the 
cellulose and lignin found in wood and leaves represent brilliant 
examples of polymers that are considered biodegradable but not 
compostable, without further processing (41,54).  ASTM’s 
composting standards can also create limitations for industrial 
polymers regarding polymer thicknesses, composition, and 
additives.   
Poly-(β)-mercaptopropionate: the non-biodegradable 
biopolymer.  Steinbuchel and coworkers (55) recently reported the 
first non-biodegradable biopolymer, poly-(β)-mercaptopropionate.  
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This polythioester did not biodegrade in soil, compost and 
activated sludge microcosms or when placed in 74 different 
environmental samples containing bacteria and fungi.  The 
polythioester class of biopolymers were very recently discovered 
by Steinbuchel and coworkers and are considered unnatural 
biopolymers which can only be produced as homopolymers by 
engineered E. coli (55).  The authors suggest that the lack of 
biodegradation observed with poly-(β)-mercaptopropionate might be 
because microorganisms capable of hydrolyzing the thioester 
linkage have not evolved in nature (55).  This example highlights 
the importance of the chemical structure of the polymer in the 
ability to biodegrade.  
The Effect of Antioxidants on Polymer Biodegradation.  
Polymer additives can also affect the ability of polymers to 
degrade or biodegrade.  Cis-poly(isoprene) is biodegradable 
whether it is produced naturally by the rubber tree or chemically 
from petrochemical feed stocks; however, antioxidants additives 
in the polymer will prevent biodegradation of cis-poly(isoprene) 
which will then require decades to degrade (51).  Additives that 
prevent biodegradation can also occur naturally as in the case of 
tannins in certain trees like the sequoia which retard microbial 
growth to such an extent that the trees require centuries to 
biodegrade (51). 
The Effect of Pro-oxidants on Polymer Degradation:  Oxo-
(bio)degradable Polymers.  Another class of polymers, which 
seemingly hover on the razor edge of green plastics, are the oxo-
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(bio)degradable and photo-(bio)degradable plastics (51,56-59).  
Two well accepted mechanisms for biodegradation of polymers are 
hydro-biodegradation and oxo-biodegradation (56).  Hydro-
biodegradation pertains primarily to polymers containing 
heteroatom linkages, such as polyesters and polyamides, while 
oxo- and photo-biodegradation concerns non-hydrolysable polymers 
like the polyolefins (56).  The natural biopolymers lignin, 
rubber and humus degrade via oxo-biodegradation; typically lignin 
degrading fungi such as white rot fungi promote biodegradation 
possibly by employing lignin peroxidases, manganese-dependendent 
peroxidases, and laccases to promote oxidative biodegradation 
(54).   
Oxo-biodegradable plastics are produced either by adding 
pro-oxidants (56,58) or by omitting anti-oxidants that are 
usually added to traditional petrochemical polymers.  Indeed, the 
polymer industry has spent considerable effort in the development 
of anti-oxidant additives that prevent oxo-biodegradation and 
produce highly stable polymers; unfortunately, this excellent 
stability is now known to create end-of-life disposal problems 
(56).  Oxo-biodegradable plastics exhibit nearly identical 
properties to the traditional petrochemically derived polymers, 
which are already entrenched in the world market.  The potential 
promise of these polymers is to create plastics with industrially 
desirable characteristics and to prevent the end-of-life problems 
for landfills and marine environments.   
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Research is currently underway to create oxo-degradable 
polymers that are programmed to degrade after a given time 
period, or only under certain conditions (56).  Oxo-biodegradable 
plastics could be marketed to farmers for programmed-life 
mulching plastics that prevent erosion and degradation of soil in 
fallow fields but degrade in time for planting (56).  Currently, 
Symphony Plastics markets oxo-biodegradable plastics for 
producing bags and sacs.  A closely related class of green 
polymers is the photo-biodegradable polymers, which have 
additives that accelerate degradation when exposed to light.  It 
is likely that polymers with both pro-oxidative and pro-photo-
biodegradative properties are being developed (56).   
The arguments against pro-degradative polymers focus on the 
potential toxicity of the oxidants and photosensitive additives; 
this is of particular interest for composting environments (41).  
Moreover, the polymer additive must remain stable and soluble 
during process of polymer oxo-biodegradation.  As oxo-
biodegradation occurs polymers often pass through a gel phase 
which can alter the solubility or stability of the polymer 
additive; if a reduction in additive solubility occurs the 
additive may be partitioned out of the polymer which will render 
the polymer inert to further biodegradation (48).  Recent 
biometric studies of CO2 formation have confirmed that 
bioconversion of polyethylene is viable; moreover, the 
observation of greater than 60% mineralization within 180 days 
suggests that these polymers are viable applicants for 
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compostable plastics (48,56).  The long term effects of 
microscopic polymer particles and bioconversion of polymers on 
microorganisms remains to be determined.   
 
The Cost of Traditional Plastics on Waterways.  The boom of 
the plastics industry in most first world countries, including 
the US, Europe and Japan, over the past 40 years has largely 
contributed to today’s ‘disposable’ economy and serious 
environmental dilemmas regarding solid waste management and 
disposal (60).  Waterways are historic sites for dumping solid 
wastes including plastics, which unfortunately are particularly 
recalcitrant to degradation in marine environs.  Recently, the 
detrimental effect of traditional plastics on marine environments 
has received substantial interest (61-66).   
It has come to light that enormous swaths of the oceans 
contain alarmingly high levels of plastics, which apparently 
accumulate in certain areas due to oceanographic convergences and 
eddies known as gyres (62).  The North Pacific central gyre, has 
an abundance and mass of neustonic [floating in the surface film 
of water] plastic approximately 3 and 7 fold higher, 
respectively, than that recorded anywhere else in the pacific 
ocean (61,66).  Generations of poor solid waste management may 
have created more than unattractive beachscapes (61,62) and 
entanglement or suffocation hazards for marine life (61,64).  The 
microscopic friable powders which traditional recalcitrant 
polymers can form have recently been shown to be present in 
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marine samples and incorporated into single celled marine 
organisms (63).  The accumulation of plastics and potentially 
toxic additives in marine environments have as yet unknown 
consequences, which includes the potential for bioaccumulation of 
toxins as larger species feed on ‘plastic-laden’ microorganisms 
(63,66).  
 
Plastics Filling Landfills.  Plastics also contribute a 
substantial and unnecessary quantity of landfill waste.  In New 
York City plans are currently under development to ship the 
50,000 tons of solid waste that are generated each day to 
southern and western states (67).  Low plastic prices have 
resulted in an influx of cheaply made ‘disposable’ plastic 
products that are intended for limited use before disposal.  
These type of products, rising populations, and the extremely 
slow decomposition of plastics have created solid waste disposal 
problems (68).  Serious solid waste disposal problems have lead 
to the creation of packaging waste disposal laws such as the 
Extended Producer Responsibility (EPR) laws, which  place some of 
the waste disposal costs on the product manufacturer (69).  Take-
back laws are a type of EPR law in which consumers may return 
product packaging to the manufacturer (often in the store) in 
order to avoid consumer-end disposal costs (69).   
 
Government-mandated Recycling Systems.  Government-mandated 
recycling systems can increase environmental awareness and 
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consumer desire for biodegradable products.  Japan has invested 
heavily in biodegradable polymers as part of a goal to create a 
closed-loop no waste economy; this is particularly important 
because of Japan’s high population density on a small isolated 
land mass (70,71).  In Germany the Duales System Deutschland AG 
(DSD AG) which was founded in the 1991, is probably the most 
stringent EPR-type system in the world (72).  The DSD provides 
two options for manufactures and retailers:  1.)  to ‘take-back’ 
sales packaging for reuse or recycling, typically in the store, 
or 2.)  pay a fee toward Germany’s privately run collection and 
reprocessing system known as Der Grune Punkt (The Green Dot), in 
which a green dot is placed on the item, which can then be 
disposed of at central locations or via curbside recycling (72).   
The Green Dot.  Germany’s Green Dot system has resulted in 
recycling rates that far exceeded the legislated mandates (73).  
The Green Dot has been adopted by 24 countries world wide; 5 of 
these countries now have recycling rates in excess of 50%, as 
shown in Figure 1 (73).  These recycling rates are substantially 
better than in the US where recycling rates are currently about 
28% (74).  Successful government-regulated recycling systems 
other than the Green Dot have been developed in non-EU countries 
including Great Britain, Canada, Australia, and Japan.  Critics 
of Germany’s Green Dot system cite antitrust issues regarding the 
single private DSD Company, problems including creating a glut of 
recyclables with out the infrastructure to convert these 
materials into useful products or energy, and general program 
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confusion (72).  Moreover, the Green Dot system does not 
necessarily promote environmentally responsible practices since 
all ‘green’ products—such as certain biodegradable plastics—are 
not necessarily included; this is in part because legislation 
does not keep pace with biotechnology (72).  
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Figure 1.  Material Recycling Quota (in %) Reached in European Countries.  Reproduced from 
Braunegg et al (73). 
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Oil Reserves Affect the Future of Polymer Production.  In 
the U.S. approximately 10% of output from crude-oil refineries is 
used in the industrial production of polymers (75).  World wide 
oil supplies are limited resources, and the US Energy Information 
Administration conservatively estimates that conventional oil 
resources will peak in the year 2044 and will be significantly 
depleted in another 25 years, as shown in Figure 2 (76).  While 
estimate dates for peak oil are notoriously inaccurate, often 
shifting forward as predicted dates approach, and peak oil 
production depends heavily on future technologies, estimates of 
this sort clearly underscore the finite nature of world oil 
resources and the importance of investing in alternative bio-
based feed stocks for polymer production (76).  The U.S. 
Departments of Agriculture and Energy estimate that the U.S. is 
capable of generating one billion tons of annually-renewable 
biomass feed stocks each year (77).
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Figure 2.  Estimate of World Wide Peak Oil Production. Reproduced from Caruso (76). 
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Today’s high oil prices and the national dependence on 
foreign oil may provide further incentives for developing 
polymers from bio-based feed stocks (78).  The current climb in 
crude oil prices has substantially increased the market prices of 
petrochemically derived polymers.  This provides an opportunity 
for agriculturally derived biopolymers, which are becoming 
increasingly cost competitive with traditional polymers.   
Oil supplies and prices are also highly dependent on the 
world economy and political situations.  Indeed, the current US 
administration has stated that reducing dependence on foreign oil 
is a matter of economic and national security (78).  On Aug 9th 
2005 the US Energy Policy Act of 2005 was signed (78).  The bill 
suggests doubling funding for renewable feed stocks, including 
cellulosic biomass for bio-fuels and other products by 2008 (78).  
However, the bill does little in the short term to reduce US oil 
consumption or increase use of biomass-based biopolymers since no 
mandates are suggested that would boost energy production from 
renewable feed stocks (79).  Moreover, many critics suggest that 
the bill lacks focus (79), especially when considering that a NAS 
study was commissioned on converting motor vehicle trips to 
bicycle trips (80).  
 
Are Biopolymers Sustainable?  Can biotechnology move us 
toward a sustainable society?  This question, proposed in 1999, 
by Gerngross (81) in a Nature Biotechnology paper, of the same 
name, has created an enduring controversy amongst the scientific 
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community and general media.  In this paper Gerngross shows that 
the production of 1 kg of PHA requires 2.39 kg of fossil fuels 
whereas only 2.36 kg is required for polystyrene synthesis (81).  
While the difference in fossil fuel requirements between the two 
polymers is only 0.13 kg, Gerngross makes the critical argument 
that PHA production combusts the entire 2.36 kg of fossil fuels, 
whereas only 1 kg of fossil fuels are burned in the manufacture 
of polystyrene with the balance sequestered in the polystyrene 
itself.  Consequently, Gerngross suggests that fermentation-
derived PHA polymers provide no advantage over petrochemical 
polymers with respect to sustainability (81). 
In 2001, Gerngross and colleagues at Monsanto Company, 
Ecobalance, Inc., and Cereon Genomics (82) published a study 
which showed no difference in greenhouse gas emissions between 
the production of polyethylene via petrochemical means and PHB 
produced from corn that was genetically engineered to contain 
PHA; this was consistent with Gerngross’ previous publication 
(81).  While the calculations and conclusions drawn by Gerngross’ 
1999 publication (81) are not in doubt, the comprehensiveness of 
the study parameters have been reevaluated in more recent 
literature reports with intriguing results.   
Gerngross’ 2001 publication (81) indicated that the 
greenhouse gas emission profile was greatly improved for PHA over 
polyethylene when corn stover (the mature, cured stalks of grain 
with the ears removed) was used as a fuel source which replaced, 
in part, fossil fuels.  The energy source for biopolymer 
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production is critical to these types of analyses since 
alternative fuel sources like corn stover, wind, water, and solar 
energy can drastically alter the energy profile and increase the 
attractiveness of PHA production from an energy and greenhouse 
gas emissions standpoint.  Considering that each corn plant 
typically produces only two ears of corn, using the huge 
quantities of corn silage for energy production seems obvious.  
Indeed, biomass energy is commonly used as a fuel source in other 
agricultural industries such as the sugar industry which 
regularly uses sugar cane bagasse to fuel sugar extraction 
(82,83).  However, the Corn Belt states currently use a 
disproportionate quantity of coal for electricity generation; 
this is a result of tradition and a lack of infrastructure, which 
if remedied could substantially increase the efficiency of 
biopolymer production from corn (82).  On the other hand, there 
is no particular reason that the energy derived from corn stover 
must be used for producing agriculturally-derived biopolymers; 
instead this energy could be applied to the production of 
petrochemically-derived polymers, which would further depress the 
cost of this type of polymer (82).   
Doi and coworkers (84) published a 2003 study which 
contradicted Gerngross’ previous conclusions and indicated that 
PHA produced via by bacterial fermentation of the renewable 
carbon resource, soybean oil, could have markedly lower energy 
consumption and carbon dioxide greenhouse gas emissions than 
typical petrochemical polymers (84).  In 2005, Kim and Dale (85) 
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published a painstakingly thorough assessment of PHA derived from 
no-tilled corn.  The authors suggest that the disparity between 
the conclusions of the Gerngross (81,82) and the Doi (84) studies 
result from differential approaches to allocating parameters in 
the corn wet milling process, PHA fermentation yields, and the 
operational data in the PHA fermentations and recovery.   
Specifically, Kim and Dale (86) suggest that the Gerngross 
analysis (81,82) failed to account for the environmental burden 
of converting corn grain to dextrose and byproducts, and that the 
study by Doi and Coworkers (84) did not consider soil nitrogen 
and carbon dynamics in the agricultural ecosystem.  Kim and Dale 
(85) conclude that by using today’s technology there is no 
significant advantage to PHA production over polystyrene.  
However, the authors suggest that corn grain based PHA is more 
favorable than polystyrene in terms of global warming and non-
renewable energy concerns (85). Moreover, technologies expected 
to be available in 2-3 years, which improve fermentation 
efficiency and recovery of bacterial bioreactor derived PHA 
(85,87), such as an integrated production system, can 
substantially reduce the environmental impacts of PHA, excepting 
eutrophication.  The integrated production system discussed in 
the publication uses corn stover and the corn grain for dextrose 
production and lignin-rich residues are used to generate the 
steam and electricity needed for the PHA fermentation process; 
however, the technology for PHA from corn stover is not currently 
available on a commercial basis (85,87).   
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One intriguing study suggests that PHA production could be 
produced in an economically advantageous manner when integrated 
with sugar and ethanol production in the Brazilian sugar cane 
industry (83).  Apparently, the 1970’s oil crisis prompted the 
Brazilian government to combine sugar mills with distilleries for 
the integrated production of sugar and ethanol; thus, an 
extensive milling infrastructure was built which generates such 
an energy excess, by incinerating bagasse, that sugarcane 
processing is actually energetically self-sufficient.  
Consequently, integrating PHA production as a percentage of the 
Brazilian sugar cane milling/ethanol generating process could add 
a high profit margin product, PHA, to the relatively low priced 
sugar sales, and with minimal infrastructure alteration (83).   
So how can we answer the question that Gerngross proposed 
in his 2000 Scientific American article entitled “How Green are 
Green Plastics” (75)?  After all currently available data is 
considered, Gerngross’ (75,81,82) dismissal of fermentation-
derived PHA polymers as an environmentally sustainable 
alternative to petrochemical polymers clearly needs to be 
reconsidered; however, PHA is not a clear winner either (84,85).  
Agriculturally derived biopolymers may indeed be green under the 
appropriate carefully controlled and well-studied conditions.  
Industrial plants must be designed with considerations that 
incorporate location, to reduce agricultural transportation 
costs, crop and land maintenance issues like no-tillage systems 
need be evaluated, and renewable energy sources must be employed 
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(85).  Perhaps, the best answer to Gerngross’ question may be 
that the ‘greenness’ of a polymer, like many commercial products, 
greatly depends upon the particular characteristics of a given 
polymer, which are governed by the chemical structure, the 
polymer growth and cultivation conditions, the efficiency of 
industrial plant design, the current market conditions, and the 
governmental and cultural mandates and practices. 
 
Natureworks PLA.  In April of 2002, Cargill-Dow officially 
opened the first global-scale plastic resin manufacturing 
facility, which is capable of producing 300,000 metric tons of 
Natureworks PLA each year (88).  The Natureworks products shown 
in Table 3 are polymer resins and fibers which are biodegradable, 
and synthesized from lactic acid derived from annually renewable 
resources (89).  As shown in Figure 3 (90), Natureworks PLA is 
generated when starch, obtained from corn kernel endosperms, is 
enzymatically converted to dextrose which is used as a feed stock 
for bacterial fermentations that generate lactic acid; this 
lactic acid then undergoes dehydration to lactides which are 
chemically polymerized to PLA (89-91).   
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Table 3.  Structure of Commercial Bio-Based or Green Polymers and 
the Monomer Constituents.   
Polymer 
Name & 
Trademark 
Company Monomer(s) Polymer Structure 
PHB Metabolix 
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CH3
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O O X
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Table 3 Continued 
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Figure 3.  Industrial Synthesis of Natureworks PLA.  Reproduced 
from Herrick (90). 
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Properties of PLA.  PLA has properties similar to 
polystyrene with respect to gloss, clarity, temperature stability 
and processability while its flavor and odor barrier properties 
and resistance to grease and oil are similar to PET (91).  PLA 
has GRAS (Generally Regarded As Safe) Status for food packaging 
since PLA decomposes to lactic acid at levels that are well below 
those deemed safe for consumption (89).  PLA is heat sealable at 
temperatures lower than polypropylene and polyethylene.  
Different formulations affect rigidity and flexibility, and 
copolymerization can greatly affect PLA properties (89).  The 
stereochemistry of PLA significantly affects the products 
crystallinity (89,91).  Since various bacterial strains produce 
different lactic acid isomers or ratios of isomers, the 
crystallinity of the final PLA can be controlled during the 
fermentation stage by careful selection of bacterial strains.  
Indeed, blends of the stereoisomers often have better mechanical 
properties than isotactic PLA polymers.  By modifying the 
stereochemical blend and therefore the resultant crystallinity 
PLA can be processed on most conventional machinery including 
blown film, extrusion, thermoforming, and injection molding.  
Furthermore, polymer branching can be induced by reacting PLA 
with hydrogen peroxide in order to make PLA amenable to extrusion 
coating of paper for drinking cup applications (89,91,93).      
The Green Possibilities for PLA.  How green is PLA?  
Cargill-Dow published a Life Cycle Assessment (LCA) study in 
2003, which reported that their first generation PLA production 
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system consumes 22-55% less energy from fossil fuels than do 
petrochemical polymers (94).  Moreover, by implementing plans for 
energy generation from wind power and biomass, PLA could consume 
up to an outstanding 90% less energy than conventional 
petrochemical polymers (94). However, the authors fail to discuss 
the very same issue that Gerngross raised regarding the greenness 
of PHAs.  As shown in Figure 4 (94), unlike petrochemical 
polymers which sequester a large portion of fossil fuels in the 
polymer itself , 100% of the fossil fuels required to produce 
PLAs are burned and generate greenhouse gasses.  Consequently, 
when comparing the consumption of fossil fuels for energy 
production with concomitant greenhouse gas production, we see 
that PLA production burns more fossil fuels than HIPS, GPPS, 
LDPE, PET-SSP, PP or PET-AM.  Moreover, PLA is only truly 
advantageous with respect to fossil fuel expenditure when its 
energy requirements are derived from wind and biomass; these 
technologies are not currently available.  The study also 
analyzed greenhouse gas emissions for global climate change 
effects and found that PLA was better than most polymers and 
equal to PP and LDPE.  In addition, employing biomass and wind 
energy for the remaining energy balance requirements could 
effectively ‘close the loop’ on carbon related to energy 
generation, and yield a negative greenhouse gas impact for PLA 
pellets.  The potential for PLA to act as a greenhouse gas sink 
is not feasible with any petrochemically derived polymer (94).  
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Figure 4.  Fossil Energy Requirement for some Petroleum Based 
Polymers and PLAs.  The cross-hashed parts of the bars represent 
the fossil energy used as chemical feedstock (the fossil resource 
to build the polymer chain).  The solid part of each bar 
represents the gross fossil energy use for the fuels and 
operations supplies used to drive the production processes.  PC, 
polycarbonate; HIPS, high impact polystyrene; GPPS, general 
purpose polystyrene; LDPE, low density polyethylene; PET SSP, 
polyethylene terephthalate solid state polymerization (bottle 
grade); PP, polypropylene; PET AM, polyethylene terephthalate, 
amorphous (fibers and film grade); PLA1, polylactide (first 
generation); PLA B/WP, (polylactide, biomass/wind power 
scenario).  Reproduced from Vink et al (94). 
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Cargill-Dow’s Joint PLA Venture is Dissolved.  “Customers 
are not willing to pay a premium for environmentally friendly 
polymers.”  This statement, made by Andrew N. Livers, president 
and CEO of Dow Chemical, during a conference call to analysts, 
was in response to questions regarding Dow’s decision to withdraw 
from Cargill-Dow, a 50-50  joint venture between Cargill, Inc and 
Dow Chemical (95) for the development and marketing of 
NatureWorks PLA.  Early in January 2005, Dow contributed 170 
million to Cargill-Dow and transferred its 50% interest in the 
joint venture back to Cargill, Inc. in return for a release from 
its commitments regarding Cargill-Dow’s debt obligations (96).  
This news came as a shock to the burgeoning bioplastics industry 
despite attempts by both companies to downplay the news, and 
Cargill’s public commitment to the future of PLA (97).  As the 
world’s largest privately owned company and corn merchant, 
Cargill, Inc. has the solid financial wherewithal, backing, and 
assets to see the newly renamed Natureworks PLA company to 
success (97).   
Cargill Supports Natureworks PLA.  Natureworks PLA has yet 
to be in the black, and it is this slow movement toward 
profitability in addition to the slower than expected development 
of the bioplastics industry that appears to have been the 
motivating force behind Dow’s retreat (98).   Developing a new 
plastics market takes time, and Dow may have miscalculated just 
how long it would take to build the PLA market to a level that 
would bring a return on investments (97,98).  Poor management and 
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company leadership may also have hindered the market advancement 
of PLA (88).  In 2003, Kathleen Bader was appointed CEO of 
Natureworks PLA to bring the company into focus and into the 
black (88,98).  Initial restructuring included eliminating 
research into frivolous product lines like developing 
biodegradable PLA products to replace golf tees and tea bags, 
(products that are already biodegradable), reducing the number of 
projects from 16 to just 2 (packaging and fibers), and reducing 
polymer production costs by producing fewer but larger batches of 
PLA in order to reduce expensive startup costs (88).   
Natureworks PLA becomes Cost Competitive.  Natureworks PLA 
now sells for less than $1 U.S. per pound and is cost competitive 
with PET (88).  Moreover, with the cost of oil today spiking to 
records of greater than $70 U.S. per barrel, the cost advantage 
of PLA over PET is increasing (88,90).  Wild Oats, an organic 
food store that switched to PLA packaging, has seen deli sales 
rise by more than 15 percent, in large part due to customer 
acceptance of their eco-packaging; moreover, the company has been 
buffered from soaring oil prices and now pays 3-5 percent less 
for their eco-friendly packaging (88,90,99).  Cargill reports 
that for every $5 increase per barrel of oil, PLA gains a ‘penny-
a-pound’ advantage over PET, and they further maintain that PLA 
will remain cost competitive even if oil-prices drop back to the 
mid-$20s per barrel (88,90).   
Problems with Market Acceptance.  Despite the potential 
economic and environmental attributes of PLA, market acceptance 
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of biopolymers has been less than stellar and Bader, CEO of 
NatureWorks PLA, has yet to land a major national contract (88).  
PLA is a hard sell because many companies refuse to believe that 
a plastic, which decomposes at 140 C under composting conditions, 
could withstand normal storage in facilities in the Deep South.  
While it is true that PLA water bottles will get tiny bubble-like 
imperfections after storage for 8 months, Bader insists that no 
one wants to drink 8 month old water (88).  Surprisingly, PLA has 
hit a nerve with eco-friendly retailers, such as Patagonia, which 
refused PLA products on the basis that some of the feed stock 
could be from corn that is genetically engineered (88).     
 
Ecoflex.  In April 2005, BASF announced plans to nearly 
double production of Ecoflex by opening a second plant in 
Schwarzheide, GE capable of producing 6,000 m.t./year, which 
brings BASF’s Ecoflex capacity up to 14,000 m.t./year (100-102).  
Ecoflex is a biodegradable, aliphatic-aromatic copolyester of 
adipic acid, terephthalic acid, and 1,4-butanediol derived from 
petrochemical or bio-based feed stocks (40), as shown in Table 3.  
Since its introduction in 1998, Ecoflex has become the leading 
synthetic biodegradable material on the world market.  This 
popularity is due in large part to its good thermoplastic 
properties, which are comparable to LDPE.  Ecoflex can be used in 
starch blends or alone in flexible films and is used in the 
packaging and flexible films sectors in products like disposable 
packaging, paper coating, shopping bags, and agricultural 
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sheeting (103).  BASF’s decision to increase production comes on 
the heals of the recently passed amendment to the German 
Packaging ordinance, which now exempts all biodegradable 
packaging from the DSD recycling fee until 2012, irrespective of 
the material basis.  Since Ecoflex is now included in the 
exemption to the DSD Fee, BASF expects the demand for Ecoflex to 
rise and the plant, expected to go online in 2006, will enable 
BASF to meet market demand (103).     
 
Mater-Bi.  Another major international manufacturer of 
biodegradable plastics is Novamont of Italy, the producers of 
Mater-Bi, a family of starch-based resins that typically contain 
greater than 60% starch with the remainder being some other 
biodegradable material(s), often poly-ε-caprolactone (53,89,104), 
as shown in Table 3.  The Mater-Bi family of resins is used in a 
wide range of applications including compostable thin films for 
shopping bags, mulching, packaging and hygiene (105).  Mater-Bi 
can be thermotransformed to make non-transparent hard trays for 
fresh food packaging, and extrusion technology can be employed to 
make nets for fruits and vegetables.  Injection molding of Mater-
Bi is used to produce cutlery and antistatic combs and some 
Mater-Bi foams are biodegradable and water soluble for use in 
packaging.  One example is a Mater-Bi resin containing 60% starch 
and 40% poly-ε-caprolactone, which has properties similar to 
LDPE, and can therefore be handled on conventional film blowing 
equipment with only minor adjustments (89,106).  Poly-ε-
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caprolactone serves to provide added strength and water 
resistance to the Mater-Bi line of products (41).  Recently, 
Novamont joined with Goodyear to develop Mater-BiTM Biofiller 
which is produced from maize starch to act as a biofiller for use 
in tire mixtures (107).  In September 2004, Novamont acquired 
EastarBio, the copolyester business and technology platform of 
Eastman Chemical Company (107).   
 
Sorona.  In 2000, DupontTM unveiled Sorona® a family of 
poly(trimethylene terephthalate), PTT, also called 3GT polyesters 
(108).  Unlike the historically dominant 2GT polymers, including 
polyethylene terephthalate (PET) which are synthesized from 
ethylene glycol (2G) and terephthalic acid monomers, 3GT polymers 
are comprised of 1,3-propanediol (3G) and terephthalic acid 
monomers (109).  While the attractive physical properties of 3GT 
polymers have been known for years, this polymer class was not 
previously marketable due to difficulties with polymer processing 
requirements and purity, and the high cost of 1,3-propanediol.  
The Sorona® polymers are being targeted primarily as fibers for 
the textile and apparels market but also have applications in 
fibers, plastics, film, and engineering components (109).  
Currently the Sorona® polymers are not biodegradable because 
Dupont claims that this is undesirable for their target market; 
however, the company states that Sorona® polymers can easily be 
designed with biodegradability in mind if a market becomes 
available (110).   
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The 1,3-propanediol used to synthesize Sorona® polymers is 
currently obtained from non-renewable resources.  However, in 
1995 Dupont teamed up with Genencor Inc. (111) and in 2003 Dupont 
was awarded the Presidential Green Chemistry Challenge Award in 
the Alternative Solvents and Reaction Conditions Category for 
developing the microbial production of 1,3-propanediol (112).  As 
shown in Figure 5, the microbial production of 1,3-propanediol 
has been accomplished by genetically engineering a pathway into 
E. coli, which effectively generates 1,3-propanediol from the 
glycerol produced during glucose metabolism (113). 
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Figure 5.  Metabolic Engineering and Pathways for the Microbial Production of 1,3-Propanediol in 
E. coli.  Abbreviations are as follows:  DAR1, glycerol 3-phosphate dehydrogenase; GPP2, glycerol 
3-phosphate phosphatase; dhaB1-3, glycerol dehydratase; yqhD, dhaT, a known 1,3-propanediol 
oxidoreductase in bacteria that performs this type of reaction; yqhD, a previously uncharacterized 
1,3-propanediol oxidoreductase endogenous to E. coli shown to have a higher activity than dhaT; 
gap, glyceraldehydes 3-phosphate dehydrogenase; tpi, triosephosphate isomerase.  Modified from 
Nakamura et al (113).  
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Poly-β-hydroxyalkanoates.  Poly-β-hydroxyalkanoates (PHAs) 
are a relatively large class of biodegradable polyesters produced 
by certain bacteria as a reserve source of carbon and reducing 
potential, and are typically generated when the bacteria 
undergoes an environmental stress such as nutrient deficiency.  
Over 150 different hydroxyalkanoic acids have been reported in 
the literature as monomers for PHAs (114).  Poly-β-hydroxybutyric 
acid (PHB), shown in Table 3, discovered near the turn of the 20th 
century, was the first identified and characterized PHA 
(115,116).  PHB is the simplest, most widely studied of the PHA 
biopolymers, and is a thermoplastic with characteristics similar 
to polypropylene or polyethylene (89).  PHB can be extruded, spun 
into fibers, molded, or made into films.  As a homopolymer, PHB 
is considered too brittle for most commercial applications (115); 
however, PHB copolymers which typically contain hydroxyalkanoic 
acid monomers such as valerate [PHB-(V), BioPol] (116) or 
hydroxyhexanoate [PHB-HHx, Nodax] (117), have significantly more 
attractive mechanical properties for the commercial market 
(89,116).   
The History of PHB.  Early literature accounts of PHB date 
as far back as the late 1800’s, but it was Maurice Lemoinge in 
1923 who first identified and characterized the biopolymer 
present in Bacillus subtilis and Bacillus megabacterium that 
would later be known as PHB (115).  During the period from 1923 
to 1927, Lemoinge showed that autolysates of B. subtilis in 
distilled water contained an acidic compound, which was 
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eventually identified as the same compound as that found in the 
urine of diabetics, β-hydroxybutyric acid (118).  During this 
period, Lemoinge proposed the existence of so-called 
‘macromolecules’ as high molecular weight molecules to a very 
skeptical audience.  Over the next decades, Lemoinge and 
coworkers continued to publish studies on PHB, which they termed 
‘lipide-β-hydroxbutyrique’.  Indeed, it appears that Lemoinge’s 
nomenclature relegated studies of PHB to relative obscurity; 
because, while PHB was well known among microbiologists and even 
included in early textbooks, PHB was classified as a lipid 
instead of a macromolecule or polyester (118).  Consequently, the 
significance of PHB and Lemoinge’s theories regarding 
macromolecular structure did not reach the wider scientific 
community; thus, the 1953 Nobel Prize in Chemistry was awarded to 
Hermann Staudinger for his discoveries in the field of 
macromolecular chemistry (119).  PHB would remain veiled until 
its nearly simultaneous rediscovery by two independent 
laboratories, in the US and Great Brittan, in 1958 and 1959 
(116). 
W.R. Grace Company Attempts Commercialization of PHB.  The 
first attempt to commercialize PHB was undertaken by W.R. Grace 
Company of Maryland in 1960 (89,116).  Researchers at the company 
proposed that PHB’s stereoregular, isotactic nature and its 180 C 
melting point, which is near that of polypropylene, might confer 
PHB with mechanical properties that could compete effectively 
with polyolefins, with biodegradability as an added benefit.  
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Initially, large test batches of PHB were produced for molded 
plastics and absorbable sutures with the bacteria, Rhizobium, 
which was reported to generate up to 58% of its dry cell weight 
as PHB.  Two years later, W. R. Grace Company abandoned this 
project citing poor thermal stability of the PHB as the rationale 
for abandoning the project.  In 1964, Webber and Baptist 
published a summary of their research at W.R. Grace Company 
entitled ‘Bacteria Produce Polyester Thermoplastic’; this was one 
of the first publications on this subject to reach the wider 
polymer chemistry community (89,116).   
ICI Commercializes PHB.  The homopolymer PHB has a high 
melting point of 180 C and undergoes slow crystallization to form 
large spherulitic structures, which impart brittleness and 
undesirable mechanical properties for molded plastics and films.  
PHB’s high melting point also makes it venerable to thermal 
degradation via ester pyrolysis during melt processing.  
Application of nucleating agents and careful handling can 
significantly improve the final mechanical properties of PHB; 
consequently, Imperial Chemical Industries of Great Britain (ICI) 
was able produce small items, like golf teas, from PHB using 
extrusion molding.   
ICI Commercializes the PHB Copolymer BioPol.  ICI began 
developing BioPol a PHA biopolymer for market in 1975 (120).  
BioPol, shown in Table 3, is a copolymer designated PHB(V), which 
contains β-hydroxybutyric acid and β-hydroxyvalaric acid 
monomers.  Research at ICI showed that the random copolymer, 
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PHB(V), had a lower melting point than the homopolymer; this 
results in advantageous mechanical properties that are 
intermediate between polypropylene and polyvinylchloride.  The 
PHB(V) copolymer, trademarked BioPol, could be processed into 
blown film, cast film, calendered (pressed between rollers or 
plates in order to smooth and glaze into thin into sheets) and be 
made into bottles by injection and extrusion blow molding (89).   
In 1982, ICI introduced BioPol to market; this was in the 
wake of the 1970’s oil crisis in which, like today, high oil 
prices had made non-petroleum based biopolymers economically 
attractive (120).  BioPol was produced by commercial scale 
fermentation of W. eutrophus H16 (now Cupriavidus necator), a 
bacterial strain acquired from Schlegel who had reported high 
levels of PHB accumulation in this strain in the 1950’s.  Indeed, 
it was later shown that the H16 strain could generate up to 80% 
of its dry cell weight as PHB(V) when cultured on glucose 
(89,116).  The rate of biodegradation of BioPol ranged from a few 
days for very thin cast films to nine months for shampoo bottles 
under anaerobic sewage conditions (89).  By 1991, ICI’s BioPol 
market was successful; Wella of Germany was using PHB to 
manufacture biodegradable shampoo bottles, and ICI expanded 
production from 25 tons/year to 300 tons/year with expectations 
to open a commercial-sized plant with a 10,000 ton capacity by 
1996 (89,116).   
Other Companies Attempt PHB Commercialization.  It comes as 
no surprise that by 1991 several other companies were also 
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marketing small quantities of PHB (89).  Seibu Gas Company, also 
produced PHB using an autotrophic strain of the bacteria C. 
necator which generated PHB using CO2 as a feedstock (89). 
Another enterprise, a state owned subsidiary of Petrochemie 
Danube of Austria, called btF mbH, produced 20 tons of PHB per 
year for use in controlled release drug delivery systems.  PHB 
has been shown to be biocompatible, although it decomposes 
extremely slowly in the human body.  btF mbH produced PHB using 
the bacteria A. Latus which generates PHB during the active 
growth phase; this is in contrast to most PHB producing bacteria 
which must undergo two-phase culture wherein the bacteria is 
first cultured under optimal growth conditions in order to reach 
the desired biomass and PHB production is then induced by 
nutrient depravation.   
ICI’s Success with PHB.  Although the price for BioPol was 
30 times greater than polypropylene, ICI’s BioPol enterprise was 
profitable; by 1992, production had reached 600,000 lb/year in 
the UK, and hair care products in blow-molded bottles with 
injection-molded caps were successfully marked in North America.  
Expanded production for larger markets consistently deflated 
production costs for BioPol until market prices reached $8-10 
U.S. per pound in the early 1990’s, and ICI anticipated that 
their planned expansion would drive prices down to about $4 U.S. 
per pound.   
The Commercial Fall of BioPol.  In 1993, ICI transferred 
BioPol to Zeneca Bio Products, one of ICI’s spin off units, and 
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ICI exited the biopolymer field (89).  Zeneca Bio Products was 
expected to continue ICI’s plans of opening a 10,000 ton capacity 
plant in 1995 (121).  However, in 1996 Monsanto acquired the 
BioPol trademark and all patent rights from Zeneca Bio Products.  
Monsanto continued to market BioPol, even producing credit cards 
for Greenpeace in 1997.  Disposable cups, planters, cutlery, 
compost bags, packaging for personal care products, fish nets, 
and disposable razors numbered among the products made from 
BioPol (89).  Monsanto was also heavily involved in studies to 
genetically engineer plants for PHB production, and initial 
results were promising, with one Arabidopsis plant reported to 
contain 14% PHB (122,123).  However, the possibility of creating 
stable, viable plants capable of producing PHB in quantities high 
enough for economical polymer recovery was simply too distant for 
Monsanto.  Consequently, in 1998 Monsanto announced the end of 
BioPol production, research and development.  This marked the end 
of commercial PHA production (89).   
Metabolix Obtains Monsanto’s Interests in PHB.  In May of 
2001, Metabolix, a small startup company founded by Oliver 
Peoples of MIT, acquired all of Monsanto’s interests and rights 
to BioPol (124).  In 2005, Metabolix won the Presidential Green 
Chemistry Challenge Small Business Award for their progress 
toward producing PHAs in both bacterial bioreactors and in plant 
tissues (38,42).  Reports indicate that genetically engineered E. 
coli bacteria can generate up to 95% of their dry cellular weight 
as PHB (125).  A high yield of PHB in the intracellular bacterial 
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granules is economically important because the generated PHB must 
be separated and purified from non-PHB bacterial cell matter in a 
process that is often time consuming, solvent intensive, and 
expensive.  Currently, Metabolix claims that their PHB production 
methodology will be cost competitive with traditional 
petrochemically-derived polymers (105).   
The Future of Commercial PHB.  In November 2004, Archer 
Daniels Midland Company (ADM) and Metabolix announced the 
establishment of a 50:50 joint venture and plans to open a 50,000 
ton per year production facility for manufacturing PHB products 
including film, coated paper, and molded goods from engineered 
bacteria (126,127).  Additionally in March 2005, Metabolix 
announced a two-year collaboration with Innovene, the new olefin 
and derivative subsidiary of BP, to develop switchgrass 
biopolymer technology (127,128).  Metabolix is attempting to 
genetically engineer switchgrass for PHA production.  Switchgrass 
(Panicum virgatum) also known as Panic grass, is one of the hardy 
perennial grasses that populate the Tallgrass Prairie ecosystem 
of North America.  Reaching heights of 6 feet, Switchgrass, which 
is often harvested for hay, may potentially yield large 
quantities of biopolymer and biomass (129).  Abundant quantities 
of biomass could be used as a cheep, energy efficient, annually 
renewable source of energy for fueling the recovery of PHB from 
the grass.  This is similar to the technique of using bagasse to 
fuel sugar plants (83), and may prove critical to reducing PHB 
production costs.  
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Nodax.  Nodax is a family of PHA copolymers that are being 
developed by Proctor & Gamble and Kaneka, which are composed of 
β-hydroxybutyric acid and medium chain length β-hydroxyalkanoic 
acid monomers (117) as shown in Table 3.  The mechanical 
properties of PHAs are highly dependent on the monomer structure.  
Medium chain length β-hydroxyalkanoic acids are generally defined 
as having between 6 and 16 carbon units and are differentiated 
from short chain length β-hydroxyalkanoic acids, which have less 
than 5 carbon units (130).  Copolymers containing the β-
hydroxybutyric acid and β-hydroxyhexanoic acid monomers, which 
generate PHB(Hx), are the simplest group of PHAs in the Nodax 
family.  Other monomers used in the Nodax family include β-
hydroxyoctanoic acid, to generate PHB(O), and β-hydroxydecanoic 
acid, PHB(D) (117).  While relatively small percentages of the 
medium chain length β-hydroxyalkanoic acid monomers are 
incorporated into the final Nodax copolymer, the material 
properties can be substantially different from the PHB monomer 
(117), as illustrated by the data shown in Table 4 (131).  
Several grades of Nodax are being prepared for market; these are 
classified according to molecular weight, the constituent 
monomers, and the percentage of the medium chain length monomer 
incorporated into the final polymer.  This strategy offers a wide 
array of mechanical properties and provides the Nodax family of 
biopolymers with exceptional commercial market flexibility (117).  
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Table 4.  Physical Properties of Various PHA in Comparison with 
Conventional Plastics.  Reproduced from Chen et al (131).   
Samples  Tm  
(1C)  
Tg  
(1C)  
Tensile 
strength 
(Mpa)  
Elongation  
at break  
(%)  
PHB  177    4      43         5  
P(HB-co-10% HV)  150   ---      25        20  
P(HB-co-20% HV)  135   ---      20       100  
P(HB-co-10% HHx) 127  -1     21      400 
P(HB-co-17% HHx) 120  -2     20      850 
Polypropylene 170  ---      34       400 
Polystyrene  110   ---      50         —  
HB: 3-hydroxybutyrate; HV: 3-hydroxyvalerate; HHx: 3-
hydroxyhexanoate 
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Chemical Synthesis of Nodax.  Recently, Proctor & Gamble 
and Kaneka reported the development of a chemical ring-opening 
polymerization of the Nodax polymers (117).  All other commercial 
PHA polymers have been produced via fermentation biosynthesis 
because biofermentations ensure formation of an isotactic 
polymer.  The isotactic character of biologically-produced PHAs 
is critical to the physical, mechanical, and thermochemical 
properties.  However, Proctor & Gamble and Kaneka have developed 
chemical PHA syntheses that produce satisfactorily isotactic 
polymers by using the catalyst/initiator, ethylzine isopropoxide, 
and highly enantiomerically enriched lactone monomers for the 
ring opening polymerization of β-lactones as shown in Figure 6 
(117) .  
 
 
 
Figure 6.  Chemical Synthesis of Nodax Polymer.  Reproduced from 
(117) 
 
 
A biofermentation process has also been developed for the 
synthesis of the Nodax family of biopolymers.  Although there are 
slight differences between the synthetically and biologically 
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derived polymers, due to their differing degrees of isotacticity, 
the synthetic reaction does produce good yields (117).  Proctor & 
Gamble and Kaneka are currently evaluating bio-production sites 
for developing and commercializing the Nodax family of 
biopolymers in the U.S., Europe, and Asia (132).   
 
In Vitro Enzymatic Syntheses.  While production of PHB for 
industrial applications is generally accomplished via industrial 
scale bioreactors, in vitro enzymatic synthesis is an attractive 
alternative for several reasons.  In vitro polymer production 
obviates the necessity for polymer extraction from bacterial 
cells.  Another consideration is that polymer synthesis within 
cells is subject to limitations related to the cellular uptake 
and possible toxicity of substrates, which limits the range of 
polymers that can be produced in vivo (133,134).  In contrast, 
the enzymes used by C. necator in the biosynthesis of PHB accept 
a wide variety of alternative substrates, thus making possible in 
vitro production of novel homopolymers or copolymers.  It has 
also been suggested that the physical size of the polymer 
produced during in vitro syntheses is not restricted by the 
physical size of the bacterial cell, as is the case with 
biofermentations (44).  Indeed, reports indicate that in some 
cases PHB polymer produced in vitro has a higher molecular weight 
than polymer generated in vivo (44,135).  In addition to 
potentially increasing polymer chain length, in vitro PHA 
syntheses may also allow for better control of polymer 
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polydispersity.  As mentioned previously, bacterial biosyntheses 
of PHB by C. necator require a two-phase fermentation process.  
In the first phase, large quantities of bacteria are accumulated 
under optimal conditions, and then a secondary nutrient-limiting 
fermentation is required for polymer accumulation.  In vitro 
syntheses eliminate the need for the initial growth phase prior 
to polymer accumulation.  Finally, with in vitro syntheses the 
quantities and selection of enzymes and substrates can be 
carefully controlled, intricately manipulated, analyzed, and even 
modeled to better understand PHB production in both in vitro and 
in vivo systems (136).   
 
Enzymatic Production of PHB in C. necator.  PHB is produced 
in many bacteria, including C. necator, via a pathway consisting 
of three enzymes as shown in Figure 7.  The first enzyme, β-
ketothiolase, catalyzes the Claisen ester condensation of two 
acetyl-CoA molecules, producing one CoA and one acetoacetyl-CoA 
molecule.  Acetoacetyl-CoA is then utilized by the NADPH-
dependent enzyme, acetoacetyl-CoA reductase, to produce β-
hydroxybutyryl-CoA.  Finally, PHB synthase catalyzes the 
polymerization of β-hydroxybutyryl-CoA, forming PHB and releasing 
CoA.  In vivo this PHB synthesis pathway is highly regulated by 
CoA product inhibition, NADPH/NADP+ ratios, and acetyl-CoA 
availability (137).
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Figure 7.  Enzymatic Biosynthesis of PHB in C. necator. 
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PHA Depolymerases.  Several additional proteins are 
involved in the biosynthesis and biodegradation of PHB in vivo 
(138).  Several bacteria employ PHA depolymerases to degrade 
PHAs.  C. necator has been shown to exhibit five different PHA 
depolymerases designated as PhaZ1 (139), PhaZ2 (140), PhaZ3 
(140), PhaZ4 (141), and PhaZ5 (142).  The best studied PHA 
depolymerase, PhaZ1, has been shown by western blot to be 
expressed in nitrogen-limited, carbon-rich environments, but not 
in complete nutrient rich environments (138).  We note that a 
granule associated D-(-)-β-hydroxybutyrate oligomer hydrolase has 
also been detected in C. necator and to avoid confusion with the 
depolymerases, this enzyme is designated as PhaY (138).   
Studies of the PHA depolymerase enzymes are integral to 
understand the rate and mechanism of PHA biodegradation in the 
different microenvironments, such as in landfills or compost 
facilities.  Several groups have investigated relationships 
between PHA chemical structure, crystallinity, and even various 
environmental situations on PHA depolymerase function and 
degradation rate (143-146).  The presence of PHA depolymerase 
enzymes are obviously not desirable if the objective is to 
produce large quantities of PHA.  Consequently, researchers have 
genetically modified bacteria that do not have depolymerase 
enzymes to contain the genes for PHA production (125).  Metabolix 
now report a genetically engineered E. coli Strain K-12, which 
lacks PHA depolymerase enzymes, and can generate up to 90% of its 
dry cell weight as PHB (147).   
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The Phasins.  First discovered in 1995 by Steinbuchel and 
Coworkers (148,149), the phasins, PhaP, are a fascinating class 
of proteins, which appear to be integral to production of PHA in 
vivo. The phasins are a non-catalytic class of proteins that 
represent up to 5% of the total cell protein of PHA laden cells; 
these proteins tightly associate with both native and synthetic 
PHB granules by binding the hydrophobic domain of the polymer 
while exposing their hydrophilic/amphiphilic domain to the cell 
cytoplasm (138). Four PhaP gene homologues, which generate the 
Phasin proteins, have been identified and are reported to be 
expressed in C. necator (138,142).  The individual role of each 
phasin, designated PhaP1-4, is not yet known but PhaP1 and PhaP2 
have been shown to bind PHB granules in vitro (142).   
The high binding affinity and the large quantity of phasins 
is believed to prevent aggregation of the PHB and therefore 
stabilize the formation of PHA granules (138).  Phasins also 
dramatically affect the rate of the PHA synthase enzyme, 
presumably by shifting the reaction equilibrium toward the 
direction of PHA synthesis by effectively removing the polymer 
product from solution by stabilizing the granule formation (138).  
Insertion of the PhaP gene from C. necator into the P. aeruginosa 
genome increases the activity the PHA synthase enzyme by 
approximately 50% (138,150).  Additionally, C. necator mutants 
that lacked the ability to produce Phasins could generate PHB but 
did so at a much slower rate and nearly all the PHB was in a 
single granule instead of many small granules as is typical 
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(138,148).  Also, experiments in which the PhaP genes were 
deleted from bacteria, showed production of 50% less PHA with 
respect to non-modified controls grown under identical conditions 
(138,151).  Finally, experiments which overexpressed Phasins 
showed multiple small PHA granules (138,152).   
Phasin Regulation.  Phasins are regulated via an 
exquisitely sensitive and elegant mechanism, which was proposed 
by Potter and Steinbuchel (138), and is illustrated in Figure 8.  
The transcriptional repressor, PhaR, from C. necator binds at the 
PhaR promoter, the PhaP promoter region, and the PHA granule 
surface.  As shown in Figure 8, Situation A, under conditions of 
normal growth, in which no PHA exists, PhaR is bound to the 
promoter regions of PhaP1 (a phasin gene) and PhaR; this serves 
to repress transcription of PhaP and prevent overexpression of 
the PhaR repressor protein.  In the initial stages of PHA 
production, shown in Situation B, PhaR begins to associate with 
the areas of the PHA granule that are not in direct contact with 
the constitutively expressed PHA synthase enzyme.  The 
association between PhaR and the PHA granule effectively lowers 
the cytoplasmic concentrations of PhaR until the levels of PhaR 
are no longer high enough to repress PhaP transcription, as shown 
in Situation C.  At this point, illustrated by Situation D, PhaP 
transcription continues to generate the Phasin protein until the 
PHB granule is nearly covered with Phasins.  The PHB granule has 
a higher affinity for phasins than PhaR so, as Situation E 
indicates, the PhaR transcriptional repressor is eventually 
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displaced from the granule surface.  This results in higher 
cytoplasmic concentrations of cytoplasmic PhaR which favor the 
binding of PhaR to the PhaP promoter leading to eventual shut 
down of phasin production and consequently of further PHB 
synthesis (138).  
  82
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  Model of Regulation of PHA Granule Formation by the 
Transcriptional Regular Protein, PhaR.  Reproduced from Potter et 
al (138).     
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Several lines of evidence support the proposed mechanism for 
Phasin regulation of PHA production (138).  Deletion mutants of 
PhaR constitutively express high levels of PhaP1.  PhaC (PHB 
synthase) deletion mutants, which obviously generate no PHB, 
produce no PhaP gene products (153).  PhaR and PhaC double 
deletion mutants express high levels of PhaP (154).  This 
evidence suggests that PhaR binds to the promoter region and 
represses transcription of PhaP (138).  Western blots using 
antibodies for PhaR and other proteins that copurify with the PHA 
granule indicate that PhaR does indeed bind the PHA granule 
(155).  Additionally, the gel shift between PhaR and a known DNA 
binding sequence is reversed by the presence of PHA suggesting 
that PhaR does indeed bind to PHA and with a higher affinity than 
to the DNA sequence (138,155).   
 
A History of In Vitro Syntheses of PHB.  In vitro or cell 
free enzymatic syntheses have been reported in the literature 
since the early 20th century (156).  Indeed, cell free syntheses 
were integral to elucidating most of the biochemical pathways 
that are so familiar today (156,157).  Thus, it comes as no 
surprise that in vitro techniques were employed for the 
elucidation of the biochemical pathways for PHB.   
As early as 1961, Merrick and Doudoroff (158) reported in 
the Journal Nature, an in vitro synthesis of radioactive PHB, 
which used particulate fractions of cell free extracts from B. 
megabacterium and R. rubrium, two bacteria that were know at the 
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time to generate PHB.  Merrick and Doudoroff chemically 
synthesized the radioactive β-hydroxybutyryl-CoA substrate for 
the in vitro radioactive PHB synthesis (158) from radioactive β-
hydroxybutyric acid, which was produced via alkaline hydrolysis 
of radioactive PHB, that had been synthesized in vivo by feeding 
the bacteria R. rubrium radioactive acetate (158).  The enzyme 
for Merrick and Doudoroff’s synthesis was isolated from bacterial 
cells by osmotic lysis using lysozyme followed by sonic 
oscillation and centrifugation to separate the polymer granules 
from the cell membrane.  The enzyme isolation technique and in 
vitro reaction results suggest that Merrick and Doudoroff did 
indeed successfully isolate the enzyme PHB synthase; however, the 
extract was quite crude and the authors mention that enzyme 
kinetics were complicated by the presence of a depolymerase 
(158).   
First Multi-Step In Vitro Enzymatic PHB Syntheses.  In 
1977, Saito et al. (159) reported the first multi-step in vitro 
enzymatic synthesis of PHB.  The authors used the radioactive 
acetyl-CoA substrate, the NADPH cofactor, and three enzymes, β-
ketothiolase, acetoacetyl-CoA reductase and PHB synthase, which 
were crudely purified from Z. ramigeria for the in vitro PHB 
synthesis (159).  The authors also identified two distinct 
acetoacetyl-CoA reductase enzymes, which were specific for either 
NAD(H) or NADP(H) and determined that only the NADPH-dependent 
enzyme was involved in PHB synthesis.  The NADPH-dependent 
acetoacetyl-CoA reductase enzyme stereoselectively produces the 
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D-(-)-isomer of β-hydroxybutyric acid, which is the only isomer 
that the PHB synthase enzyme is capable of polymerizing into PHB.  
As discussed previously, the isotactic property of PHB is 
essential to its mechanical properties and it is the 
enantioselectivity of the NADPH-dependent acetoacetyl-CoA 
reductase and PHB synthase enzymes which ensure that PHB is 
indeed isotactic (159).   
In 1988, Haywood et al. (160) reported the multi-step in 
vitro synthesis of radiolabeled PHB using enzymes from C. 
necator.  Consistent with Saito’s (159) previous study, Haywood 
et al. (160) identified and kinetically analyzed the NADH- and 
NADPH-dependent acetoacetyl-CoA reductase enzymes and found that, 
like the enzyme from Z ramigeria, the NADPH-dependent enzyme 
exclusively generated the D-(-)-isomer of β-hydroxybutyryl-CoA. 
By reconstituting the complete three enzyme system, the authors 
established that the NADPH-dependent acetoacetyl-CoA reductase 
enzyme is involved in the synthesis of PHB in C. necator since 
the NADH-dependent acetoacetyl-CoA reductase did not produce 
appreciable quantities of PHB activity (160). 
 
Other In Vitro Syntheses of PHB.  Several other in vitro 
enzymatic syntheses, diagrammed in Figure 9 (44), have been 
reported in the literature with varying degrees of complexity and 
success.  The simplest ‘in vitro’ synthesis system involves a 
single enzyme, typically PHB synthase, which polymerizes PHB from 
β-hydroxybutyryl-CoA.  Considering, that this one-enzyme in vitro 
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synthesis is nothing more than the native reaction for the PHB 
synthase enzyme it is not surprising that there have been 
multiple literature reports describing this system since Merrick 
and Doudoroff’s (158) initial 1961 report.  Additionally, 
Haywood, Anderson and Dawes reported this one-enzyme in vitro 
synthesis in a 1989 report on the C. necator PHB synthase 
reaction stoichiometries, enzyme kinetics, and C4-C5 chain length 
specificity (161).  
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Figure 9.  Systems for the In Vitro Synthesis of PHA.  Modified 
from Steinbuchel (44).     
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One Enzyme In Vitro Syntheses.   
First Complete Isolation of PHB Synthase for the One Enzyme 
In Vitro Synthesis.  The 1994 report by Gerngross et al. (162) is 
probably considered the seminal modern report on the PHB synthase 
reaction, in large part because this paper details the procedure 
for overexpressing and obtaining highly pure PHB synthase from E. 
coli.  The key developments of the Gerngross et al. (162) paper 
include reengineering the 5’-end of the wild type gene to 
increase expression of the soluble form of the PHB synthase 
enzyme and transforming the gene into an E. coli strain that was 
deficient in the protease, ompT, which helps to avoid substantial 
proteolysis during isolation.  Additionally, the nonionic 
detergent Hecameg was added to all buffers to increase enzyme 
stability (162).   
With quantities of overexpressed and highly purified enzyme 
in hand, Gerngross and Martin (135) reported an in vitro PHB 
polymerization system in 1995 that was capable of generating PHB 
granules with molecular weights in excess of 10 x 106 Da.  The 
molecular weight of PHB produced in vitro in this study exceeds 
that of the PHB generated in vivo by an order of magnitude 
possibly suggesting that the polymer size restrictions that are 
present in vivo do not affect in vitro syntheses.  Indeed, the 
authors suggest that the enzyme in the in vitro system may be 
incapable of transferring to a new chain (135).  Gerngross and 
Martin (135) obtained enantiomerically pure (R)-β-hydroxybutyryl-
CoA substrate by using the NADPH-dependent acetoacetyl-CoA 
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reductase enzyme to catalyze the enantioselective reduction of 
acetoacetyl-CoA followed by HPLC purification of the β-
hydroxybutyryl-CoA enantiomer.  The PHB synthesized by the PHB 
synthase one-enzyme system formed granules within minutes, which 
reached 3µM.  Moreover, granule mass and polymer molecular weight 
depended on PHB synthase concentrations, with higher synthase 
concentrations favoring lower polymer molecular weights and 
greater numbers of small granules (135).   
One Enzyme In Vitro Synthesis in C. vinosum.  Steinbuchel 
and coworkers published an extensive study of the PHB synthase 
reaction from Chromatium vinosum.  This study of a class III 
(163) synthase was complete with UV reaction time courses, phase-
contrast microscopy, and attractive secondary electron 
micrographs of gold-coated PHB granules.  Reactions were carried 
out using purified (R)-β-hydroxybutyrl-CoA that was obtained by 
transesterification of CoA and (R)-β-hydroxybutyric acid 
catalyzed by propionyl-CoA transferase.  In contrast to the 
enzymes from C. necator, NAD+ and NADP+, but not the respective 
reduced forms, inhibited the synthase from C. vinosum.  Stubbe 
also published an examination of the kinetics of His6-tagged PHB 
synthase from C. vinosum (163,164).   
 One Enzyme In Vitro Synthesis in C. necator.  The C. 
necator PHB synthase enzyme, overexpressed in and purified from 
E. coli, was employed by Lenz et al. in a 1999 (118) study of the 
enzyme’s kinetics with β-hydroxybutyryl-CoA and β-hydroxyvaleryl-
CoA as substrates for the one-enzyme in vitro polymerization 
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reaction.  This study closely examines the enzyme lag phase, 
which had previously been reported by Gerngross and Martin (135).  
The report demonstrates that the lag phase phenomena is dependent 
on detergent (Hecameg) and BSA concentrations, and could be 
eliminated by adding either 50% glycerol to the crude enzyme 
extract or by priming the reaction with the β-hydroxybutyryl-CoA 
substrate (118).  In the absence of the lag phase, PHB synthase 
showed straight-forward Michaelis-Menten kinetics, with KM values 
determined for β-hydroxybutyryl-CoA and β-hydroxyvaleryl-CoA, and 
a KI of 370 •M found for CoA (118).   
In a 2000 study, Lenz (165) and coworkers expanded upon 
their previous work (118) by demonstrating that the addition of 
multihydroxyl compounds could eliminate the lag phase of PHB 
synthase.  Additionally, the KM values for β-hydroxybutyryl-CoA 
and β-hydroxyvaleryl-CoA were revised, the KM for γ-
hydroxybutyryl-CoA was determined, Kcat values for all substrates 
were obtained, and CoA was found to be a competitive inhibitor 
with a revised KI of 108 µM with respect to β-hydroxybutyryl-CoA.  
Furthermore, the authors showed that the active form of the PHB 
synthase enzyme was the dimer, not the monomer form, by using 
equilibrium experiments and size exclusion chromatography in the 
presence and absence of 20% fructose (165). 
In the same year, Su et al. (166) used the one-enzyme PHB 
synthase in vitro system to produce homopolymers, random and 
block copolymers containing the β-hydroxybutyric acid and β-
hydroxyvaleric acid monomers.  The results of this study were 
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consistent with previous kinetic analyses, which indicate that 
PHB synthase prefers β-hydroxybutyryl-CoA to β-hydroxyvaleryl-
CoA.  In contrast to synthesis of the PHB homopolymer, which goes 
to completion, synthesis of the PHV homopolymer (V = valerate) 
was terminated at approximately 90% conversion.  Likewise, PHB(V) 
copolymer synthesis required four times longer to reach 100% 
completion than did synthesis of the PHB homopolymer.  In 
contrast to the in vivo syntheses in C. necator, PHB(V) 
copolymers synthesized in vitro were not essentially random, 
instead they exhibited characteristics consistent for a more 
blocky copolymer, which would be expected for this sort of in 
vitro batch copolymerization.   
The experiments by Su et al. (166) established that the 
synthesis of PHB in vitro meets the criteria for a living 
polymerization reaction, in which each PHB synthase enzyme 
initiates the polymerization reaction for a single polymer chain 
and continues chain propagation with no branching, chain 
transfer, or termination until the substrate is exhausted or the 
reaction quenched.  This in vitro PHB synthesis exhibits a 
classic diagnostic characteristic for living polymers, 
specifically that higher monomer to enzyme (initiator) ratios 
result in a higher molecular weight polymer.  Living polymers 
typically have molecular weight distributions approaching unity, 
which describes the uniformity of polymer molecular weights.  
However, this in vitro system exhibits somewhat broad molecular 
weight distributions but Su et al. (166) report that the 
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polydispersity is within a reasonable range for living polymers, 
and suggest that this variance could occur if the rate of polymer 
initiation is slower than chain propagation   
In subsequent reports, Lenz and Coworkers (167,168) 
successfully developed a one-step purification procedure for the 
PHB synthase from E. coli that harbored the plasmid containing 
the PhbC gene from C. necator.  The isolated PHB synthase enzyme 
was then used in the in vitro one-enzyme synthesis of PHA 
copolymers that contained the β-hydroxybutyric acid and β-
hydroxypropionic acid monomers.  Kinetic analyses indicated that 
CoA was a competitive inhibitor of β-hydroxypropionyl-CoA with a 
KI of 85 µM; this level of inhibition could explain the low 
degree of β-hydroxypropionyl-CoA polymerization, which was 
reported at less than 40%.  Lenz and coworkers also established 
that, in solution, the PHB synthase enzyme exists in both 
monomeric and dimeric forms.  Mutagenesis analyses indicated that 
a cystine thiol, C319, is present on each monomer subunit and 
forms a single catalytic active site at the dimmer interface for 
polymer initiation and propagation. 
One Enzyme In Vitro Synthesis with the PHB Synthase from E. 
shaposhnikovii.  Lenz, Goodwin, and Coworkers (169) studied the 
enzyme kinetics and substrate specificities of the PHB synthase 
from Ectothiorhodospira shaposhnikovii.  In a follow up study 
(170), the authors use PHB synthase to synthesize the novel 
homopolymers poly-β-hydroxy-3-cyclopropylpropionic acid and poly-
β-hydroxy-4-chlorobutyric acid using the PHB synthase from E. 
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shaposhnikovii.  It is highly unlikely that these unusual 
homopolymers could be synthesized in vivo.  Thus, this work 
highlights the promise of in vitro syntheses for creating novel 
polymers that would likely not be generated in vivo due to 
constraints in cellular uptake, potential cell toxicity, or the 
absence of in vivo pathways for monomer generation (171).   
In solution the C. necator PHA synthase enzyme exists 
either as the non-active monomer or the active dimer; this is 
typical of Class I PHA synthase enzymes (168).  Class III 
synthases, of which the enzyme E. Shapshnikovii is classified, 
differ significantly in structure; specifically, the enzyme from 
E. shaposhnikovii is comprised of two protein subunits designated  
PhaE and PhaC which interact to form either a dodecamer 
containing 12 PhaE and 12 PhaC subunits, or a hexamer of 6 PhaE 
and 6 PhaC subunits (171).  The dodecameric form of the PHB 
synthase enzyme exhibits a higher specific activity for PHB 
polymerization than the hexameric form.  Akin to the C. necator 
enzyme, results suggest that the E. shaposhnikovii PHB synthase 
enzyme may catalyze a living polymerization with each catalytic 
site consisting of two PhaE and two PhaC subunits (171).   
In Vitro One Enzyme Synthesis with A. vinosum.  In vitro 
one-enzyme polymerization systems have been developed with PHB 
synthase enzymes from several other organisms.  The His6-tagged 
PHA synthase derived from Allochromatium vinosum was used for the 
in vitro one-enzyme synthesis of several PHA compounds by Stubbe, 
Sinskey and Coworkers (172).  A thorough analysis of this 
  94
enzyme’s kinetics and substrate preferences demonstrated that, 
like the Class III enzyme from E. Shaposhnikovii, the A. vinosum 
enzyme has broad substrate specificity and a relatively non-
specific binding pocket.  In contrast to the Class I C. necator 
enzyme, the enzyme from A vinosum accepts moieties that lack 
large portions of the substrate’s CoA moiety such as (R)-β-
hydroxybutyryl N-acetylcysteamine thioester and (R)-β-
hydroxybutyryl-D-pantetheine thioester (172).  A loose binding 
pocket and relatively broad substrate specificity is somewhat 
characteristic of the Class III PHA synthases (172).   
In Vitro One Enzyme Synthesis with T. thermophilus.  
Pantazaki et al. (173) used the PHB synthase enzyme from the 
thermophilic bacterium Thermus thermophilus in the one-enzyme in 
vitro synthesis of PHB.  The authors also analyzed the in vitro 
activities of the β-ketothiolase and acetoacetyl-CoA reductase 
enzyme from T. thermophilus and established that this bacterium 
utilizes a similar pathway for PHB biosynthesis as C. necator and 
several other PHA generating bacteria.  The  reported KM for 
(D,L)-β-hydroxybutyryl-CoA is 250 µM and the molecular weight of 
the enzyme does not permit classification of this PHB synthase as 
either type I , II or III; thus, this may represent a fourth 
class of PHB synthases.  The authors (173) also suggest that this 
enzyme may be modified by phosphorylation since dephosphorylation 
in alkaline phosphatase assays inactivate the enzyme.  In 
contrast to all other PHB synthase enzymes that have been 
reported in the literature the T. thermophilus enzyme did not 
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exhibit a lag phase (173); however, this may be due to problems 
with sample purity.   
 
Granule Morphology for the In Vitro Synthesis of PHB.  
Recently, Doi and Coworkers (174) reported an AFM study of 
granule morphology for the one-enzyme in vitro synthesis of PHA.  
While AFM has been used to study in vivo granule formation (175-
177), this is the first report to examine in vitro granule 
formation with AFM (174).  Previously, Nobes et al (178) examined 
the morphology of PHA granules produced via one-enzyme in vitro 
syntheses with transmission electron microscopy (TEM) and cryo-
TEM.  Doi and coworkers (174) note that AFM directly images the 
surface of bio-based materials without the sample preparations 
needed for TEM, which can result in artifacts.  The authors used 
AFM to show the time dependent reaction time course of in vitro 
PHA synthesis.  Initially, AFM detected spherical 2.7 ± 0.6 nm 
particles, which were the PHA synthase enzymes that had been 
isolated from C. necator and deposited on highly oriented 
pyrolytic graphite (HOPG).  Within five minutes of initiating the 
reaction with the substrate β-hydroxybutyryl-CoA, AFM showed 
fibrillar strands of 0.3 nm thickness extending approximately 25 
nm from the PHA synthase enzymes.  This suggests that in the 
initial reaction stages a PHB-enzyme conjugate is formed (174).   
Doi and Coworkers (174) reported a second set of AFM 
experiments in which the β-hydroxybutyryl-CoA substrate was 
consumed within four minutes.  In these experiments, AFM showed 
  96
rapid formation of PHB-enzyme conjugates and granule formation 
from individual micelles within one minute.  In the initial 
stage, granules formed varying in size from 50 to 200 nm, with 
the larger granules appearing to be aggregates containing between 
two and five of the smaller 50 nm granules.  After 3 minutes, 
nearly all the β-hydroxybutyryl-CoA had been consumed and the AFM 
image showed fewer but substantially larger PHB structures, which 
appeared to be comprised of several smaller, 150-400 nm, 
spherical granules.  At ten minutes, fully six minutes after the 
reaction reached completion, the AFM images showed massive PHB 
clusters with lengths in excess of 10 µm.  Additionally, multiple 
smaller 100-250 nm particles now extended from the surface of the 
massive 10 •M PHB clusters.   
The authors speculate that the morphological change from a 
smooth surface at three minutes to a ‘pincushioned’ appearance at 
ten minutes might result from the ejection of water from the 
granule (174).  This conjecture is supported by the AFM images in 
which the surface spheres physically appeared similar to water 
(they were clear), and by the previous results of the TEM study 
by Nobes et al (174).  Moreover, an examination of these 100-250 
nm protrusions revealed a periodical phase shift over the 
surface, which measured 20-30 nm; this corresponds to the size of 
the PhaC enzyme from C. necator.  Treatment of the massive 
granules with Proteinase K, a general protease, resulted in 
morphological changes.   
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Model of Granule Morphology.  Doi and Coworkers (174) used 
the results from the AFM studies to develop a model of PHB 
granule formation.  The authors suggest that granule coalescence 
continues after completion of PHB synthesis, which leads to the 
formation of granule clusters exceeding 10 µM in size.  The 
ejection of water from granule clusters eventually changes the 
surface morphology so that 100-250 nm PHB granules, which are 
densely covered with PHA synthase enzymes, cover the surface of 
the large 10µM granules.  The ‘pincushioned’ appearance of PHB 
granules does not occur in vivo, and the authors suggest this 
morphology may occur in vitro because granules are able to 
interact more freely with one another (174).  We note that the 
authors fail to suggest that the morphological discrepancy 
between granules formed in vitro and in vivo could very likely be 
due to the presence of phasin proteins in vivo, which cover and 
stabilize granules in vivo.   
 
Limitations of One-Enzyme In Vitro Systems for PHA 
Synthesis.  One-enzyme in vitro PHB syntheses are ideal for 
dissecting enzyme mechanism, kinetics and substrate specificity.  
However, these systems suffer from two major drawbacks:  1.)  the 
costs of the acyl-CoA substrate make PHB production prohibitively 
expensive, in excess of $500.00 U.S. per pound of PHB produced 
(44), 2.) CoA generates significant product inhibition that 
substantially retards the PHB synthase enzyme and lowers final 
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PHB yields (44).  These limitations have prompted the development 
of several multi-enzyme systems for PHA synthesis (44). 
 
In Vitro Multi-Enzyme Systems for PHB Synthesis.  Jossek 
and Steinbuchel (179) used three enzymes, acetyl-CoA synthetase, 
propionyl-CoA transferase and PHB synthase in an in vitro 
synthesis of PHB from acetate, as shown in Figure 9, Panel C.  In 
this system, acetyl-CoA was generated from acetate by the 
commercially available ATP-dependent enzyme, acetyl-CoA 
synthetase, which was from Sachromyces cerevisiae.  Acetyl-CoA 
and D-(-)-β-hydroxybutyric acid are then used to synthesize D-(-
)-β-hydroxybutyryl-CoA by the action of purified propionyl-CoA 
transferase from Clostridium propionicum.  PHB synthase then 
polymerizes the D-(-)-β-hydroxybutyryl-CoA to PHB (179), and the 
byproduct of this reaction, CoA, is recycled to generate further 
acetyl-CoA by the above mentioned acetyl-CoA synthetase.  The 
authors (179) also reported an abbreviated two-enzyme system, 
illustrated in Figure 9, Panel B, which used only propionyl-CoA 
transferase and PHB synthase.  Unfortunately, this abbreviated 
two-enzyme system suffered from significant CoA product 
inhibition, and the cost of acetyl-CoA was prohibitively high.   
This study highlights the importance of the addition of the 
acetyl-CoA synthetase enzyme, which recycles CoA and generates 
acetyl-CoA, de novo.  Recycling the CoA will alleviate CoA-
product inhibition of the PHB synthase reaction thus allowing 
polymer synthesis to proceed.  Moreover, the three-enzyme system 
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utilizes the inexpensive substrate, acetate, as a feedstock and 
hydrolysis of ATP to AMP and Pi drives the reaction forward.  
Since AMP and acetate are the only inputs into this system, the 
cost for PHB production is limited by the price of the more 
expensive substrate, ATP; this reduces polymer costs to 
approximately $15 per pound (179).  Although this cost reduction 
makes polymer production feasible on a semi-preparative scale , 
this price is obviously still too high for commercial viability.  
Another disadvantage of this system is that propionyl-CoA 
transferase generates both isomers of β-hydroxybutyryl-CoA; thus, 
either enantiomerically pure starting materials must be used or 
half of the β-hydroxybutyryl-CoA that is generated by the 
propionyl-CoA transferase reaction will remain unreacted during 
polymer synthesis (179).   
In 2002, Liu and Steinbuchel (180) introduced another 
system, diagrammed in Figure 9, Panel D, for the in vitro 
biosynthesis of PHB from β-hydroxybutyric acid.  This system used 
the enzymes butyrate kinase and phosphotransbutyrylase that were 
derived from Clostridium acetobutylicum, and a class III PHB 
synthase that was derived from E. coli, which harbored a plasmid 
containing the gene from Chromatium vinosum.  In this system, the 
enzyme butyrate kinase catalyses the ATP-dependent activation of 
β-hydroxybutyric acid; this forms β-hydroxybutyryl phosphate, 
with the liberation of ADP.  The high energy phosphodiester bond 
of β-hydroxybutyryl phosphate is then converted to a high energy 
thioester linkage by the enzyme phosphotransbutyrylase with 
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inorganic phosphate released.  Finally, the β-hydroxybutyryl-CoA 
undergoes polymerization by the PHA synthase enzyme (180), 
liberating CoA in the process.   
Liu and Steinbuchel (180) developed this system to overcome 
a design flaw of the previous Jossek and Steinbuchel system 
(179).  In the Jossek and Steinbuchel system (179), the 
acetoacetyl-CoA synthetase enzyme converts ATP to AMP with 
release of pyrophosphate, as shown in Figure 9, Panel C.  As 
discussed above, the cost of ATP sets the price for producing PHB 
in these types of in vitro systems (44).  Since converting ATP to 
AMP consumes two ATP equivalents, recycling AMP back to ATP 
requires two enzymatic reactions; this is metabolically 
expensive.  Liu and Steinbuchel’s (180) three-enzyme system, 
which uses butyrate kinase, consumes only one ATP equivalent; 
thus, future implementation of ATP recycling would require only 
one enzyme and less cost.  We do note that recycling of ATP was 
not actually implemented in this system (180).   
The three-enzyme system developed by Liu and Steinbuchel 
(180), shown in Figure 9, Panel D, elegantly recycles CoA by 
using the enzyme phosphotransbutyrylase to catalyze the 
thioesterification of CoA and β-hydroxybutyryl-phosphate to β-
hydroxybutyryl-CoA.  The phosphotransbutyrylase enzyme acts to 
effectively decrease CoA-product inhibition of the PHB synthase 
enzyme, which facilitates polymer synthesis.  Moreover, the 
authors (180) suggest that the phosphotransbutyrylase reaction 
rapidly converts CoA to β-hydroxybutyryl-CoA, thus effectively 
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sequestering CoA in the form of β-hydroxybutyryl-CoA, which 
further diminishes any inhibition of PHB synthase by CoA.   
One of the disadvantages of this three-enzyme system, which 
Liu and Steinbuchel (180) specifically address, is  the lack of 
substrate flexibility of the phosphotransbutyrylase enzyme.  
Indeed, homopolymers containing the poly-γ-hydroxybutyric acid 
and poly-γ-hydroxyvaleric acid monomers could not be synthesized 
in vitro.  However, this system could synthesize copolymers 
containing β-hydroxybutyric acid and γ-hydroxybutyric acid 
monomers that contained from 1 to 46 mole percent of the γ-
hydroxybutyric acid monomer (180).  This system’s poor substrate 
flexibility stems from the specificity of the 
phosphotransbutyrylase enzyme and is particularly regrettable 
because the class III PHA synthase from Chromatium vinosum is 
known to have broad substrate flexibility (180).  Another 
drawback of this system is the inability to produce the D-(-)-β-
hydroxybutyryl-CoA isomer exclusively (181).  This situation is 
likened to the previous system developed by Jossek and 
Steinbuchel (179) in which synthesis of PHB will waste half of 
the enzymatically synthesized β-hydroxybutyryl-CoA, or 
enantiomerically pure D-(-)-β-hydroxybutyric acid must be used as 
a feedstock for this reaction (181).  
Qi, Steinbuchel and Rehm (150) developed an interesting in 
vitro PHA synthesis, which used the class II PHB synthase from 
Pseudomonas aeruginosa, as shown in Figure 9, Panel E.  This was 
also the first literature account to successfully purify a class 
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II PHA synthase; the authors used convenient His6-tagged 
technology to facilitate isolation of this notoriously difficult 
to purify enzyme (150).  Class II PHA synthases are similar to 
the Class I in that they consist of a single subunit, which 
exists in solution as monomers or dimers (150,173).  Typically, 
the molecular weight of Class I and Class II synthases vary 
somewhat.  Class II PHA synthases, mainly found in the 
Pseudomonias genome, prefer medium chain length β-hydroxy fatty 
acids (C6-C14), which are typically derived in vivo from de novo 
fatty acid biosynthesis and fatty acid β-oxidation.  PHAs formed 
from medium chain length monomers tend to be latex-like polymers 
(150,173).   
As depicted in Figure 9, Panel E, Qi, Steinbuchel and 
Rehm’s (150) two-enzyme in vitro synthesis used commercially 
available acetyl-CoA synthetase, which was derived from a 
Pseudomonias species [E.C. 6.2.1.3], to catalyze the ATP-
dependent thioesterification of (R,S)-β-hydroxydecanoate and CoA 
to form (R,S)-β-hydroxydecanoyl-CoA with liberation of AMP and 
pyrophosphate.  The class II PHA synthase from P. aeruginosa then 
polymerized the (R,S)-β-hydroxydecanoyl-CoA to poly-β-
hydroxydecanoic acid (150).  This two-enzyme system (150) took 
advantage of the broad substrate flexibility of the Pseudomonias-
derived acetyl-CoA synthetase, which could synthesize β-
hydroxydecanoyl-CoA.  Furthermore, the acetyl-CoA synthase 
reaction effectively recycled CoA, which prevented any CoA 
product inhibition and favored PHA synthesis.   
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The authors (150) note that the weight average molar mass 
for PHB synthesis with the Class II PHB synthase from P. 
aeruginosa was 9.8 x 104 g/mol.  This value is substantially 
lower than the average molar masses observed for the in vitro PHB 
syntheses that used the class I, C. necator, and class III, C. 
vinosum, PHB synthases, which were approximately >12 x 106 g/mol 
(135) and 1.6 x 106 g/mol (179), respectively.  The study reports 
that each PHA synthase enzyme synthesizes only about 0.6 polymer 
chains, which indicates that this should be classified as a 
living polymerization.  The same drawbacks occur with this system 
as discussed for the previous systems; specifically, that the 
enantioselectivity of the PHB synthase enzyme results in a 
desirable isotactic polymer by either wasting half of the β-
hydroxydecanoyl-CoA synthesized enzymatically in this system or 
requires costly, enantiomerically pure β-hydroxydecanoic acid be 
provided as a substrate (150).   
Recently, Satoh et al. (182) published a system that was 
nearly identical to the system developed by Qi et al (150).  
Satoh et al. (182) reported the in vitro synthesis of the 
copolymer poly-(β)-hydroxybutyrate-co-(γ)-hydroxybutyrate [P(βHB-
co-γHB)] which used His6-tagged PHA synthase isolated from E. 
coli, which harbored the plasmid containing the C. necator PhaC 
gene, and an acyl-CoA synthase from Pseudomonias oleovorans.  In 
this system, the acyl-CoA synthetase enzyme catalyzed the ATP-
dependent thioesterification of CoA and the hydroxyalkanoic acid 
to the respective hydroxyalkanoyl-CoA, which was then polymerized 
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via the PHA synthase.  The enzyme pyrophosphatase, which 
hydrolyzes pyrophosphate to inorganic phosphate, was also added 
to the reaction mixture presumably to drive the reaction forward 
by removing the pyrophosphate product, although the authors do 
not discuss this decision.  Despite striking similarities between 
this system and the one developed by Qi et al. (150) to 
synthesize poly-β-hydroxydecanoic acid with enzymes from P. 
aeruginosa, Satoh et al. (182) does not mention the previous work 
and the authors (182) are apparently ignorant of the previously 
published system.   
The system developed by Qi et al. (150) (Figure 9, Panel E) 
efficiently recycled CoA; likewise, the Satoh et al. system was 
reported to recycle CoA 4.2 times during the synthesis of 1.5 mg 
of the poly-γ-hydroxybutyric acid homopolymer (182).  Perhaps the 
largest contribution of the Satoh (182) publication is the 
reported ability to produce copolymers with strict control over 
monomer composition (182).  The authors also reported the in 
vitro production of the poly-(γ)-hydroxybutyric acid homopolymers 
with a polydispersity and number average molecular weight of 1.5 
and 9.3 x 105, respectively (182). 
In 2003, Satoh et al. (181) reported the enzymatic 
synthesis of PHB from acetate with cofactor recycling.  As shown 
in Figure 9, Panel F, this system uses three His6-tagged enzymes 
that were isolated from E. coli, which harbored plasmids 
containing the genes for PHB synthesis from C. necator.  In 
addition, His6-tagged acetyl-CoA synthetase enzyme and the 
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commercially available glucose dehydrogenase were used in this 
system for cofactor recycling.  His6-tagged acetyl-CoA synthetase 
catalyzed the ATP-dependent thioesterification of acetate and CoA 
to produce acetyl-CoA, AMP, and Pi.  Condensation of acetyl-CoA 
to acetoacetyl-CoA with CoA liberation was catalyzed by the 
enzyme β-ketothiolase.  Acetoacetyl-CoA was dehydrated to β-
hydroxybutyryl-CoA by the action of the NADPH-dependent 
acetoacetyl-CoA reductase, which consumed one NADPH producing 
NADP+.  NADP+ was recycled to NADPH by glucose dehydrogenase, with 
consumption of the relatively inexpensive substrate glucose.  PHB 
synthase polymerized the β-hydroxybutyryl-CoA to PHB with CoA 
liberation.  The acetyl-CoA synthetase reaction serves to recycle 
the CoA liberated by the β-ketothiolase and PHB synthase 
reactions; this effectively closes the loop (181).   
Acetate, D-glucose, and ATP are the feed stocks for this 
five-enzyme system developed by Satoh et al. (181), and because 
ATP is the most expensive of the substrate it essentially sets 
the cost for this in vitro synthesis of PHB.  Recycling of CoA by 
the acetyl-CoA synthetase reaction effectively reduces CoA 
concentrations, which decrease inhibition of the PHB synthase and 
the β-ketothiolase reaction; this facilitates the forward 
polymerization reaction.  An attempt by Satoh et al. (181) to 
employ a truncated two-enzyme system, which used only β-
ketothiolase and acetoacetyl-CoA reductase, resulted in 
prohibitively low substrate conversions, which were less than 6%; 
this emphasizes the critical importance of cofactor recycling.  
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The authors suggest that recycling the CoA produced by the 
condensation of acetyl-CoA prevented CoA-mediated product 
inhibition of the β-ketothiolase enzyme and therefore facilitated 
the overall reaction progress (181).  This certainly seems a 
reasonable contention considering that CoA is reported to be a 
competitive inhibitor of the β-ketothiolase and PHB synthase 
enzymes (181). 
Using this system, Satoh et al. (181) produced 5.6 mg of 
PHB in a 5 mL reaction mixture, which had a low polydispersity of 
1.36 and a weight average molecular weight of 6.64 x 106.  The 
reaction was monitored for CoA, acetyl-CoA, acetoacetyl-CoA and 
β-hydroxybutyryl-CoA using a novel HPLC system; this was the 
first report to actually monitor all CoA-containing metabolites.  
However, this methodology required over 55 minutes to analyze 
each reaction time point.  During the course of the complete 
five-enzyme reaction, CoA and NADPH were reported to be recycled 
at least 26 times in a 24-hour period.  Like all systems that use 
acetyl-CoA synthetase, the AMP produced is difficult to recycle; 
consequently, this system is limited by the cost of consuming two 
ATP equivalents for each reaction.  This system is the first 
system to recycle both CoA and NADP+.  Furthermore, all of the β-
hydroxybutyryl-CoA generated is of the correct enantiomeric form 
so 100 % of it can be polymerized by the PHB synthase enzyme.   
Satoh et al. (181) does mention a potential system for 
recycling AMP to ATP, which uses the enzymes polyphosphate-AMP 
phosphotransferase from Myxococcus xanthus and polyphosphate 
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kinase from E. coli.  While this ATP regeneration system, 
developed by Satoh and coworkers (183), appears to be a feasible 
solution for recycling ATP in the in vitro PHB system, to date 
the authors have not reported this or any other AMP recycling 
system (181).   
 
Immobilized In Vitro PHB Syntheses.  Immobilized in vitro 
PHB syntheses have been successfully developed by Kim et al. 
(184) using a His10-tagged C. necator PHA synthase enzyme, which 
was immobilized via a tether to a Ni-NTA derivatized surface.  
PHA synthase catalyzed the polymerization of β-(R)-
hydroxybutyryl-CoA to PHB while immobilized on Ni-NTA derivatized 
agarose beads and/or silicon wafers.  Lithographic techniques 
were used to control the location of the Ni-NTA derivatized 
surface; this defined the location of the bound PHA synthase and 
subsequent polymer formation.  This novel fusion of surface 
initiated polymerization and in vitro PHA synthesis may have 
applications in thin films, controlled adhesion, protective 
coatings, and improved material biocompatibility (184).   
In a nearly identical study, Paik et al. (185) reported an 
approach to end-functionalization of PHB.  First, His(10)-tagged 
PHB synthase catalyze the in vitro synthesis of PHB; this creates 
PHB-enzyme conjugates.  Then, the PHB-enzyme conjugates, were 
collected by centrifugation, rinsed, and dissolved in chloroform.  
Finally, the PHB-enzyme conjugates were placed in a chloroform 
solution containing a Ni-NTA substrate, which was composed of 
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agarose beads or silicon; this coupled the (His)10-tagged enzyme-
PHB complex to the surface of the substrate.  Nile red dye 
confirmed the presence of PHB on the substrate surface.  AFM 
studies showed that the Ni-NTA silicon surface was coated with 
enzyme-PHB complex with an average thickness of 15 nm and evenly 
distributed grain structures with diameters between 30 and 50 nm 
(185).  These results substantially differed from samples created 
with the Kim et al. (184) surface initiated polymerization 
method, which had a polymer film thickness of 200 nm and a grain 
diameter of 600 nm.  Paik et al. (185) suggest that the 
considerable morphological discrepancies between the two 
methodologies results from increased steric constraints in the 
system developed by Paik et al (185).  The Paik et al. (185) 
system requires that the large enzyme-PHB conjugates compete with 
one another for access to the activated substrate surface.  In 
contrast, less steric hindrance exists with the surface initiated 
polymerization system developed by Kim et al. (184) in which the 
small molecule substrate, β-hydroxybutyryl-CoA, diffuses to the 
enzyme-laden substrate surface where polymer accumulation 
commences.   
An interesting variation of the technique of using 
immobilized PHA enzymes was developed recently by Lee et al 
(186).  In this system, the genomic DNA containing the substrate 
binding domain (SBD) from the PHB depolymerase enzyme of 
Alcaligenes faecalis T1 was used to generate novel fusion 
proteins.  These SBD-containing fusion proteins were capable of 
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selectively binding to PHB via the SBD, which effectively acts as 
a capture ligand; this allowed the fusion-proteins to be 
immobilized on a PHB microbead.  Confocal microscopy and flow 
cytometry studies indicated that this technique (186) 
successfully immobilized SBD-fusion proteins of the SARS 
coronavirus envelope protein, enhanced green fluorescent protein, 
and red fluorescent protein.  Immunoassays were also performed 
using these SDB-fusion proteins, suggesting that these protein 
chimeras were stable and could be applied for use in 
immunoassays.   
This system exhibits several significant advancements over 
today’s bead-based systems.  For example, non-specific absorption 
of the non-fusion-enhanced green fluorescent protein was 
virtually nonexistent, a significant advancement.  Additionally, 
with this system there is no need to chemically modify or alter 
the micro-beads in any way, because the fusion protein binds 
directly to the PHA polymer itself.  Moreover, generation of the 
fusion protein is accomplished easily with recombinant bacteria 
harboring the fusion gene-containing plastid, so this system 
should be simple to implement and applicable to a wide variety of 
proteins.  Finally, different PHA microbeads could be developed 
to broaden the potential applications of this system with regard 
to microbead solubility, size, and solvent system (186).   
 
Chemoenzymatic Synthesis of PHB.  Chemoenzymatic syntheses 
have gained substantial popularity in recent years, as these 
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systems tend to exploit the advantages of traditional chemical 
syntheses, while incorporating the advances offered by newer in 
vitro enzymatic syntheses.  Tajima et al. (187) developed a 
chemoenzymatic synthesis of PHB with CoA recycling that used a 
water-solvent two-phase system as shown in Figure 10.  In this 
system, thiophenol-(R)-β-hydroxybutyrate is first dissolved in 
the organic phase, and the PHA synthase and CoA are in the 
buffered aqueous phase.  Under slightly alkaline conditions at pH 
7.5, ester exchange will occur between the CoA and thiophenol 
moieties generating β-hydroxybutyryl-CoA.  PHB synthase then 
polymerizes the β-hydroxybutyryl-CoA to PHB, and the CoA 
liberated by this process is recycled to convert further β-
hydroxybutyryl-thiophenol to β-hydroxybutyryl-CoA.  A two-phase 
hexane-buffered water system was necessary to maintain low levels 
of thiophenol.  The thiophenol was such a significant inhibitor 
of PHB synthase that it prevented any measurable reaction in a 
single aqueous phase system.  A PHB synthase/PEG complex was also 
developed by the authors, which stabilized the enzyme and 
enhanced enzymatic activity by 1.4 fold in the presence of minute 
quantities of organic solvents (187). 
  
111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.  Chemoenzymatic Synthesis of PHB (187).  
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Recently, Doi and coworkers (188) published a truly novel 
and innovative in vitro enzymatic system for recovering and 
recycling PHA which is shown in Figure 11.  In this system, 
granulated Candida Antarctica lipase B immobilized on silica was 
used to depolymerize a dilute solution of PHB into cyclic PHA 
oligomers.  These cyclic polymers had molecular weights in the 
hundreds, and were then concentrated and repolymerized by the 
same lipase enzyme.  Repolymerized oligomers had much lower 
molecular weights than the parent PHB, approximately 7000 Da; 
however, repolymerization of cyclic copolymers with ε-
caprolactone and β-propiolactone could generate terpolymers with 
molecular weights of 21,000 and an 84% yield (188).  PHA 
depolymerases from various bacteria were also used to 
depolymerize PHA into linear monomers, dimers, and trimers.  The 
immobilized lipase did repolymerize these small monomers and 
oligomers; but molecular weights only ranged in the low thousands 
(188). 
 
 
 
Figure 11.  Proposed Chemical Recycling of Biopolyesters using 
Biocatalysts.  (1) Degradation by PHB depolymerase in buffer into 
hydroxy acid type R-3HB oligomer.  (2)  Degradation by lipase in 
organic solvent into cyclic oligomer.  Reproduced from Kaihara et 
al (188). 
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Metabolic Models of PHB Synthesis.  Currently, all 
published metabolic models of PHB synthesis focus on analyzing 
and predicting the behavior of in vivo systems (178,189-211).  
Such models often focus on parameters including cell growth rate, 
glucose concentration and percent polymer accumulation.  On the 
other hand, in an in vitro enzymatic system substrate 
concentrations, turnover rates, and enzyme levels are critical to 
understanding the metabolic flux through the in vitro system.  
Consequently, structured kinetic mathematical models, in which 
the effects of initial enzyme and metabolite concentrations on 
the rates of flux PHB synthesis are simulated, are ideal for 
critically analyzing in vitro PHB synthesis.  Of the multitude of 
metabolic models developed to simulate in vivo PHB synthesis 
three publications clearly stand out for their obvious relevance 
to the field, thorough explanations, and notably in depth 
analyses (189-191).  These publications were used to develop our 
in vitro PHB synthetic model.   
In 1998, Leaf and Srienc (190) published what is perhaps 
the seminal work on structured kinetic models of PHB synthesis.  
The authors (190) focused on developing a model of in vivo PHB 
synthesis in C. necator.  By using the reversible complex kinetic 
equations for each of the three enzymes used in PHB synthesis by 
C. necator, Leaf and Srienc (190) could examine issues including 
the potential rate limiting steps, regulatory feedback controls, 
and the outcome of various rate expressions.  Individual 
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metabolite and enzyme concentrations could also be examined with 
this system.   
Leaf and Srienc’s (190) simulations indicated that, in 
actuality no single enzyme could be considered rate limiting 
because each enzyme substantially contributed to the overall flux 
of PHB synthesis.  Additionally, the reaction byproducts, NADP+ 
and CoA were both observed to significantly hinder flux through 
the system; this critically important information would have been 
overlooked by many less complex models (190).  Simplified models 
often make assumptions regarding the reversibility of rate 
limiting enzymatic reactions and adjust the rate equations 
according to these assumptions.  Specifically, the inhibition of 
the β-ketothiolase reaction by CoA, and the inhibition of the 
acetoacetyl-CoA reductase reaction by NADP+ is a direct 
consequence of the reversibility of these reactions.  The 
reaction products, CoA and NADP+, compete with substrates for 
enzyme binding sites, and a model that assumes the reactions are 
irreversible would be inaccurate.   
The following year, Daae and Dunnill (191) from University 
College, London collaborated with a team at Monsanto company to 
design a metabolic model of the production of the BioPol 
copolymer, [PHB(V)], in plants.  When this model was being 
developed, Monsanto was developing genetically modified plants 
that could produce PHB.  Consequently, the Leaf and Srienc (190) 
model was modified to account for copolymer production in plants.   
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The Daae and Dunnill (191) model modified the mathematical 
models to include parameters that describe the cycles of light 
and dark that affect enzyme activity, expression, and the varying 
pH levels in plants.  Additionally, simulating the desirable 
product, BioPol--the PHB(V) copolymer, required that different 
pathways be calculated for the two different β-hydroxyalkanoic 
acid monomers, and that the enzyme inhibition that resulted from 
monomers competition for enzyme active sites be taken into 
account.  In plants, the major enzyme that catalyzes the 
condensation of acetyl-CoA and propionyl-CoA to ketovaleryl-CoA 
is the BktB β-ketothiolase, instead of the PhbA β-ketothiolase 
that generates acetoacetyl-CoA from acetyl-CoA.  Consequently, 
the kinetic equation and parameters for the BktB β-ketothiolase 
reaction were used in the Daae and Dunnill simulation (191).   
The simulations performed by Daae and Dunnill (191) 
indicated that the light/dark cycles have a profound effect on 
the flux of the PHB system.  The authors (191) also incorporated 
metabolic control analysis and the results suggested that, in 
contrast to the results by Leaf and Srienc (190), the β-
ketothiolase step substantially affects the rate of copolymer 
production; however, all enzymes affect the copolymer-monomer 
ratio.  Finally, simulation results showed that variations in 
substrate and cofactor levels can considerably impact copolymer 
ratio and production (191). 
van Wegen, Lee, and Middelberg (189) published a third 
metabolic model featuring metabolic control analysis and 
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metabolic flux analysis.  This model investigated in vivo PHB 
production in recombinant E. coli, which harbored the genes 
encoding β-ketothiolase, NADPH-dependent acetoacetyl-CoA 
reductase, and PHB synthase from C. necator.  The simulation 
results (189) indicated that pathway flux was highly dependent on 
the acetyl-CoA/CoA ratio, and the acetyl-CoA and CoA 
concentrations.  Additionally, it was observed that the 
NADPH/NADP+ ratio exerts to a lesser extent and that the 
contribution of the NADPH concentration is negligible to pathway 
flux.  Consistent with the results of the simulation developed by 
Leaf and Srienc (190), no single enzyme was apparently 
responsible for system flux.   
The van Wegen, Lee, and Middelberg (189) study did consider 
the quantitative effects of the metabolites acetyl-CoA and β-
hydroxybutyryl-CoA using laboratory derived HPLC measurements.  
The concentration of acetoacetyl-CoA was estimated at 0.11 µg.  
g/RCM which is around 300 fold less than the β-hydroxybutyryl-CoA 
concentrations; this explains why no acetoacetyl-CoA was detected 
in this study by HPLC (136,190).  The enzyme activities obtained 
in the simulation were comparable to previous literature values.  
Interestingly, simulations of this system indicated that oxygen 
limitation triggered PHA production.  Finally, the simulation and 
laboratory results indicate that during the first two hours of 
PHB synthesis, control of polymer production is similar to that 
observed in C. necator; specifically, that TCA cycle flux is 
quelled causing a rise in acetyl-CoA levels and concomitant drop 
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in CoA concentrations.  However, after two hours the acetyl-CoA 
levels return to normal in the recombinant E. coli system and 
continued PHB production likely results from increased enzyme 
expression; this contrasts the situation in C. necator where 
polymerization is apparently driven by metabolite concentrations 
(190).   
 
Our In Vitro Synthesis of PHB.  In this study, we report a 
detailed analysis of the in vitro synthesis of PHB via the three-
enzyme pathway that is utilized by C. necator.  We have developed 
an HPLC method that permits baseline separation of CoA, acetyl-
CoA, acetoacetyl-CoA, and β-hydroxybutyryl-CoA within 30 min.  By 
sequentially adding each enzyme in the PHB synthetic pathway, and 
utilizing our HPLC system to, simultaneously, determine the 
concentrations of each CoA-containing compound, we are able to 
examine the effects of each of the enzymes as they are 
successively coupled for PHB synthesis.  Detailed stoichiometric 
analyses of each step in the PHB pathway demonstrate good 
agreement with the putative synthetic mechanism.  The 
concentrations of acetoacetyl-CoA in our enzymatic PHB synthesis 
system were well below the limit of detection by HPLC.  This 
phenomena was investigated via two separate metabolite spiking 
experiments.  Finally, a metabolic model, based on the work of 
Leaf and Srienc (190), was utilized to examine the kinetic and 
thermodynamic parameters of each reaction defining the PHB 
synthesis pathway.   
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CHAPTER 2 
PHB:  EXPERIMENTAL 
 
Materials.  The sterile filtered antibiotics kanamycin, 
ampicillin, and spectinomycin, the DEAE Sepharose and Blue Matrex 
chromatographic supports, the lithium salts of CoA, acetyl-CoA, 
and β-hydroxybutyryl-CoA, and the sodium salt of acetoacetyl-CoA 
were purchased from Sigma.  Solutions of all CoA-containing 
compounds were prepared in 25 mM potassium phosphate buffer at pH 
4.0, and stored at -70 C.  The E. coli clones harboring plasmids 
for the Cupriavidus necator [Cupriavidus necator has previously 
been called Wautersia eutropha, Ralstonia eutropha, Alcaligenes 
eutropha, and Hydromonias eutropha] renamed  β-ketothiolase, 
acetoacetyl-CoA reductase, and PHB synthase used in this work 
were a generous gift from the Monsanto Co. and have been 
described elsewhere (212,213).  The Methyl-HIC chromatography 
support was purchased from Bio-Rad (Hercules, CA).  Anameg was 
purchased from Anatrace (Maumee, OH) and triscarboxyethyl 
phosphine (TCEP) was from Molecular Probes (Eugene, OR).  All 
solvents were of HPLC or Optima Grade.  Coomassie Plus Protein 
Assay Reagent was purchased from Pierce Biotechnology.  All other 
compounds were obtained from Fisher Scientific.   
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PHB Clones.  Three separate E. coli clones hosting plasmids 
(Table 5) which harbored the genes for phbA, phbB, and phbC, 
respectively, were graciously donated by the Monsanto Co.   
 
 
Table 5.  PHB Clones used in Enzyme Isolations. 
Bacteria Strain Plasmid Cloned 
Gene 
Enzyme 
Expressed  
Common Enzyme 
Name 
E. coli DH5α pMON25636 phbA PhbA β-ketothiolase 
E. coli JM101 pMON25628 phbB PhbB acetoacetyl-CoA 
reductase 
E. coli UT10 pMON25629 phbC PhbC PHB synthase 
 
 
Bacterial Cell Culture.  Bacteria were cultivated as 
described in Slater et al. (213) except that bacteria producing 
acetoacetyl-CoA reductase and PHB synthase were grown in the 
presence of 50 ppm spectinomycin or kanamycin, and were induced 
with 1 mM isopropyl-β-D-thiogalactopyranoside or nalidic acid, 
respectively.  The bacteria used to generate the β-ketothiolase 
enzyme were cultivated in the presence of 75 ppm of ampicillin 
and induced with 1 mM of isopropyl-β-D-thiogalactopyranoside.  
Briefly, a frozen suspension of bacterial cells was rapidly 
thawed in a water bath at 37 C.  The bacterial suspension, 1 mL, 
was then used to inoculate a 250 mL shake flask containing 150 mL 
of antibiotic-laden LB media, which was cultivated aerobically at 
37 C and 250 rpm.  When the culture reached an OD600 of 0.6 
absorbance units, it was transferred to a 1.8 L shake flasks 
  120
containing 1.3 L of fresh media and antibiotic.  Upon reaching an 
O.D.600 of 0.6 absorbance units, 1 mM of the appropriate inducing 
agent was added to the large shake flask in order to initiate 
enzyme expression.  Three hours post induction the cells were 
harvested by centrifugation at 13,800 x g for 10 min.  The 
harvested cell paste was stored at -70 C.  Nalidic Acid was used 
to induce PhbB enzyme expression whereas PhbA and PhbC were 
induced with isopropyl-β-D-thiogalactopyranoside.   
 
Amplification and Storage of Bacterial Strains.  The 
original E. coli clones obtained from Monsanto Co. were amplified 
and stored for future use in the following manner.  A shake flask 
containing 150 mL of sterile antibiotic-laden Luria-Bertani (LB) 
media was inoculated with 10 µL of the desired clone and the 
flask shaken at 250 rpm. and 37 C.  When an OD600 of 0.6 
absorbance units was obtained, signaling the mid-log growth phase 
,the cells were aseptically harvested by centrifugation for 10 
min at 13,800 x g.  The bacterial cell pellet was resuspended 
into 10 mL of fresh media, which contained 50% LB media and 50% 
ethylene glycol.  The solution was transferred to 15 mL 
polypropylene centrifuge tubes and stored at -70 C.   
 
Acyl-CoA Compound Storage.  CoA, acetyl-CoA, acetoacetyl-
CoA, and β-hydroxybutyryl-CoA solutions were prepared at a 
concentration of 2.5 mM in 25 mM potassium phosphate buffer at pH 
4.0.  Solutions were stored in 100 µL aliquots at -70 C.  
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Aliquots were thawed, used once, and discarded.  No sample 
degradation was observed by HPLC over a one-month period.    
 
Enzyme Isolations.  Unless stated otherwise, all enzyme 
isolation steps were performed at 4oC utilizing a Pharmacea ACTA 
Explorer FPLC system.  Spectroscopic measurements were obtained 
with a Hewlett Packard 8453 UV-Vis Spectrophotometer with UV-
Visible Chemstation Software.  One unit of enzyme (U) corresponds 
to 1 µmol of product produced per min. 
Protein Concentration Determination.  Protein 
concentrations were determined using the Bradford (214)  
Coomassie Plus Protein Assay Reagent, purchased from Pierce 
Biotechnology, and was used as per the manufactures instructions.   
β-ketothiolase.  β-ketothiolase was isolated using a 
procedure adapted from Davis et al (215).  Bacterial cell paste, 
approximately 3.1 g, was resuspended in 10 mL of buffer A (20 mM 
Tris pH 7.8, 1 mM EDTA, 5% glycerol, 1% β-mercaptoethanol, and 
0.2 mM PMSF) and lysed with a Branson Sonifier 250 on an ice salt 
bath, using three consecutive rounds of 45 seconds of sonication, 
0.4 s exposure per 1 second and 60% amplitude, followed by 
cooling.  Cellular debris was cleared by centrifugation at 35,300 
x g for 30 min and the protein was precipitated with 20% (w/v) 
polyethylene glycol 8000.  The precipitated protein was pelleted 
by centrifugation at 33,300 x g for 45 minutes, re-dissolved in 
buffer A, and applied to a DEAE-Sepharose CL6B column that was 
pre-equilibrated in buffer A.  A step-gradient was employed with 
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increasing concentrations of buffer B (buffer A + 1M NaCl) and 3-
min fractions were collected as follows:  0-60 min, 0% B; 60-120 
min, 0-60% B; 120-180 min, 60% B; 180-200 min, 60-100% B.  The 
pool of active fractions was concentrated and the buffer 
exchanged to buffer A by ultrafiltration with an Amicon Stirred 
Cell (Millipore Co.) containing an YM10 membrane.  The sample was 
then loaded onto a 60 mL Blue Matrex column that was pre-
equilibrated with buffer A.  A 300 min linear gradient was 
employed with 0-100% buffer C (buffer A + 3M NaCl) and 6 mL 
fractions.  After the active fractions were pooled, concentrated, 
and the buffer exchanged to buffer A, the enzyme was diluted 50% 
with ethylene glycol and stored at -20oC.   
The specific activity was determined using a continuous 
spectrophotometric assay, which followed consumption of the 
magnesium chelated enolate of acetoacetyl-CoA monitored at λ = 
303 nm (213).  In these assays, 750 µL of the assay solution 
containing 150 mM EPPS pH 8.0, 66 µM acetoacetyl-CoA, 66 µM CoA, 
and 50 mM MgCl2 was initiated by enzyme addition.  The decrease 
in absorbance at λ = 303 nm was followed for 120 s and the 
initial rates determined from the linear portion of the plot for 
conversion to specific activity.  β-ketothiolase was typically 
purified 3.8 fold with a specific activity of 58 U/mg.  One unit 
of enzyme (U) corresponds to one µmol of product produced per 
minute.  
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Enzyme activities for individual fractions obtained during 
the isolation were determined by end-point analysis.  Briefly, 
the assay solution, 750 µL, was initiated with 50 •L of the 
isolation fractions, incubated 10 min, and the absorbance at λ = 
303 nm determined.  Active fractions exhibited lower relative 
absorbance values.  
Acetoacetyl-CoA reductase.  Acetoacetyl-CoA reductase was 
isolated in a procedure modified from Haywood et al (160).  
Bacterial cell paste, typically 5 g, was dissolved in 10 mL of 
buffer A (12 mM Tris pH 8.3, 9.8 mM β-mercaptoethanol, 1 mM EDTA, 
0.2 mM PMSF, and 1% glycerol) and cooled on an ice salt bath.  
The bacterial cells were lysed with a Branson Sonifier using four 
consecutive rounds of 30 seconds of sonication, 0.4 s exposure 
per 1 second and 60% amplitude, followed by cooling.  After 
centrifugation at 31,000 x g for 20 min to remove the cellular 
debris, the supernatant was loaded onto a 50 mL Sepharose-CL6B 
column that was pre-equilibrated with buffer A.  A step gradient 
elution profile with a 1.0 mL/min flow rate and collection of 7 
mL fractions was performed as follows:  0-120 min, 100% buffer A; 
120-150 min, 0-10% buffer B (buffer A +1M NaCl); 150-210 min, 10-
100% buffer B; 210-370 min, 100% buffer B.  After concentration 
with an Amicon Stirred Cell containing an YM10 membrane and 
exchange to buffer A, the pool of active fractions was applied to 
a 40 mL Blue Matrex column that was pre-equilibrated with buffer 
A.  A 300 min linear gradient from 0-100% buffer C (buffer A + 2M 
NaCl) was performed with 6 min sample collection.  The final pool 
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of enzyme was concentrated and desalted via ultrafiltration 
followed by further concentration to a volume of 1 mL with a 
Millipore Centricon.  The final enzyme concentrate was diluted 
50% with ethylene glycol and was stored at -20oC.   
Specific activities were determined in the forward 
enzymatic direction using a spectrophotometric method which 
followed the decrease in absorbance at λ = 340 nm, which results 
from NADPH consumption (160).  The reaction was initiated by 
addition of 2 µL of enzyme to 750 µL of the assay solution 
containing 100 mM Tris pH 8.0, 66µM NADPH, 66µM acetoacetyl-CoA.  
The reaction was followed for 120 s at λ = 340 nm and the linear 
portion of the plot used to determine the initial rates for 
calculating the specific activity.  Acetoacetyl-CoA isolations 
typically provided enzyme that was purified 7.2 fold with a 
specific activity of 41.9 U/mg.     
Enzyme activities for individual fractions obtained during 
the isolation were determined by end-point analysis.  The 
reaction was initiated by addition of 50 µL of the isolation 
fraction to 750 µL of the assay solution.  After incubating for 
10 min, the absorbance at λ = 340 nm was determined and active 
fractions identified by finding the largest relative decrease in 
UV absorbance.   
PHB Synthase.  PHB synthase was isolated based on a 
procedure outlined in Song et al. (167) except that the protease 
inhibitor benzamidine was added to the lysis buffer.   
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Bacterial cells, approximately 3 g, which harbored a plasmid 
containing the PHB synthase gene enzyme, were dissolved in 20 mL 
of lysis buffer, (50 mM potassium phosphate pH 7.0, 5% glycerol, 
and 5 mM benzamidine) and cooled on an ice-salt bath.  The 
bacterial cells were lysed with a Branson Sonifier using four 
consecutive rounds of 30 seconds of sonication, 0.4 s exposure 
per 1 second and 60% amplitude, followed by cooling.  After 
cellular debris was removed by centrifugation at 31,000 x g for 
20 min, 15% ammonium sulfate was added slowly to the supernatant 
on ice.  After equilibrating for 20 minutes to ensure adequate 
protein precipitation, the solution was centrifuged at 31,000 x g 
for 40 minutes.  The supernatant was collected and ammonium 
sulfate was added to reach a final concentration of 50%.  After 
adequate time for protein precipitation on ice, the protein 
pellet was collected by centrifugation at 31,000 x g for up to 2 
hours.  The 50% ammonium sulfate pellet was resuspended in buffer 
A (50 mM potassium phosphate pH 7.0, 5% glycerol, 0.05% Anameg™, 
1.0 M ammonium sulfate) and applied to a 5 mL methyl-HIC column 
that was equilibrated with the same buffer.  After an initial 
six-column volume wash, the enzyme was eluted with a 12 column-
volume linear gradient from 0-100% buffer B (buffer A with no 
ammonium sulfate) at 2 mL/min with 1 mL fraction collection.  
Active fractions were pooled and concentrated with an Amicon 
Stirred Cell using an YM10 membrane followed by further 
concentration with a Millipore Centricon™ to reach a final volume 
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of approximately 0.5 mL.  The isolated PHB synthase was separated 
into 55 µL aliquots, snap frozen in liquid nitrogen, and stored 
at -70 C.  PHB synthase was purified 22 fold with a specific 
activity of 1.42 x 10-02 U/mg.    
The specific activity was determined using a continuous 
spectrophotometric assay modified from Fukui et al. (216), which 
detected production of the CoA free thiol via Ellmann’s reagent.  
Initially a continuous assay based on the work by Fukui et al. 
(216) was employed.  Unfortunately, the characteristic yellow 
color, which indicates that Ellmann’s reagent is reacting with 
free thiols, was observed in solutions containing the PHB 
synthase enzyme even in the absence of CoA.  Consequently, this 
method was modified by adding 50µL of the enzyme to 750µL of the 
assay solution (76 µM DTNB in 20 mM potassium phosphate at pH 
7.0), obtaining an initial background absorbance at λ = 412 nm, 
and then initiating the reaction with 10 µL of the β-
hydroxybutyryl-CoA (133µM, final volume 810 µL) substrate.  
Simple subtraction of the background rate from the total provided 
the initial enzyme reaction rate, which could be converted to 
specific activity.   
The relative enzyme activities for individual column 
fractions eluted during the isolation were often determined using 
a related end point analysis.  In this situation the U.V. 
absorbance at λ = 412 nm was monitored for the entire set of 
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column fractions at discrete time intervals so that the 
difference in the absorbance between time steps indicated the 
relative enzyme activity in each fraction.  Time intervals were 
necessarily long enough to minimize the time required to hand 
initiate roughly 40 reaction test tubes while brief enough that 
the enzyme reaction in the most active test tubes had not reached 
completion.   
Alternatively, an end point analysis using HPLC detection 
was employed.  This assay simultaneously measured the consumption 
of β-hydroxybutyryl-CoA and the liberation of CoA by the PHB 
synthase enzyme, and the consumption of acetyl-CoA from an 
unknown origin.  The reaction was initiated by addition of 50 µL 
of each isolation fraction to 750 µL of a solution containing 150 
mM EPPS pH 8.0, 65 µM of β-hydroxybutyryl-CoA, 80 µM of acetyl-
CoA, and 5 mM TCEP.  After a brief incubation period, the 
reaction was quenched with perchloric acid at a final 
concentration of 0.57 M and the samples centrifuged in 
preparation for HPLC analysis.   
 
High Performance Liquid Chromatography (HPLC).  HPLC 
analyses were performed on a Waters LC Module I Plus HPLC system 
with auto-injection of samples using the Millennium 
Chromatography Manager Software (Waters, Milford, MA, USA).  A 
Waters NovaPak C18 Reverse Phase column, 4 µm particle size, 150 
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mm x 4.6 mm I.D. was used with a Phenomenex SecurityGuardTM 
containing a C18, 4 mm length x 3.0 mm I.D., guard cartridge.  
Isocratic analysis was performed at a wavelength of 261 nm with a 
mobile phase containing 96% 150 mM citrate buffer pH 5.0: 4% 
acetonitrile and a flow rate of 1.0 mL/min.  All buffers were 
double filtered through a 0.45 µm and a 0.22 um HVLP filter from 
Millipore.  The mobile phase was premixed prior to sparging with 
H2 gas and the column pre-equilibrated with mobile phase for at 
least 1 hour prior to sample analysis.  Concentrations of CoA-
containing compounds were calculated from the individual HPLC 
standard curves.   
Standard curves, shown in Figure 17, were obtained under 
conditions equivalent to the in vitro enzymatic experiments and 
showed excellent linearity with R2 coefficients of 0.9999.  Under 
these conditions, the retention times were as follows: CoA, 5.8 
min; acetyl-CoA, 18.5 min; acetoacetyl-CoA, 21.1 min; β-
hydroxybutyryl-CoA, 26.2 min.  The smaller peaks that elute after 
each CoA-containing compound are the 2’-phospho isomers and 
exhibit the following retention times:  iso-CoA, 7.1; acetyl-iso-
CoA, 25.5; acetoacetyl-iso-CoA, 26.9; β-hydroxybutyryl-iso-CoA, 
33.6 min.  The co-elution of acetoacetyl-iso-CoA and β-
hydroxybutyryl-CoA did not pose a problem in our experiments, 
because acetoacetyl-iso-CoA concentrations were always below the 
limit of detection by HPLC.   
  129
In Vitro Enzymatic Syntheses.  All experiments were 
performed in a shaking water bath at 37oC and enzymes were kept 
on ice.  In a typical experiment, 5 mM TCEP, 1.0 mM NADPH, and 16 
µM acetyl-CoA in a solution of 150 mM EPPS at a final of pH 7.8 
was pre-equilibrated at 37oC for approximately 10 min.  The 
enzymatic reaction was initiated by the addition of β-
ketothiolase at time zero.  Subsequently, 80 µL of acetoacetyl-
CoA reductase was added at 3 min 30 s followed by the addition of 
175 µL of PHB synthase at 10 min 30 s.  At set time points, 90 •L 
aliquots were quenched by addition to 10 µL of ice-cold 
perchloric acid ([HClO4] final = 0.27 M).  Quenched samples were 
centrifuged to remove the precipitated protein, and the 
supernatant was transferred to the appropriate vials for 
autoinjection of 50 µL onto the HPLC column.  Quantitation of 
metabolite concentrations for stoichiometric analysis was 
determined by integrating the areas of the HPLC peaks and 
converting to concentration by using the appropriate standard 
curves.   
In experiments that entailed spiking, 40 µL acetoacetyl-CoA 
reductase and 100 µL of NADPH, which increased the NADPH 
concentration by 0.5 mM, were added sequentially at 40 min 30 s 
and 40 min 38 s; and then acetoacetyl-CoA was added at a final 
concentration of 7.8 µM at 50 min 30 s.  Quenched samples were 
centrifuged for 10 minutes to pellet the protein, and the 
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supernatant was transferred to the appropriate vials for 
autoinjection of 50 µL onto the HPLC column. 
 
Enzymatic Rate Simulations.  Simulations were performed by 
coupling the integrated rate equations for each of the three-
enzymes in the PHB pathway.  The GEPASI (217-219) software 
package was used for kinetic simulations, fitting, and 
optimization.  Changes in enzyme activities were simulated by 
proportionally altering the enzyme maximal rates.  Excel was used 
for calculating kinetic constants, Haldane relationships, and for 
displaying the GEPASI output data.  This simulation was developed 
using literature derived kinetic constants, and the equilibrium 
constants and maximal rates were determined by fitting the model 
to the in vitro HPLC data. 
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CHAPTER 3 
PHB:  RESULTS 
 
 
In Vitro Biosynthesis of PHB.  The enzyme system used in 
this work for in vitro PHB synthesis consists of (Figure 7) β-
ketothiolase, acetoacetyl-CoA reductase, and PHB synthase.  As 
depicted in the HPLC chromatograms in Figure 12, PHB synthesis 
was accomplished by individually adding each enzyme to an acetyl-
CoA solution and allowing the reaction to reach equilibrium 
briefly before adding the next enzyme.  With this approach, the 
reaction progress could be monitored in a sequential manner to 
elucidate the fluctuations in metabolite concentrations and the 
effect of each individual enzyme on the overall three-enzyme 
system for synthesizing PHB.
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Figure 12.  Overlaid HPLC Chromatograms for the Step-wise In 
Vitro Synthesis of PHB.  Overlaid HPLC chromatograms depict the 
changes in metabolite concentrations upon sequential additions of 
enzyme during the in vitro synthesis of PHB.  The reaction was 
initiated by addition of β-ketothiolase at time 0, followed by 
acetoacetyl-CoA reductase at 3.5 min, and PHB synthase at 10.5 
min.  The chromatograms are overlaid to depict the changes in 
metabolite concentrations over the time course of the reaction 
from initiation at time zero to the reaction conclusion, as shown 
from front to back, respectively.  
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β-ketothiolase.  The in vitro synthesis of PHB was initiated 
by the addition of β-ketothiolase to a solution of acetyl-CoA, as 
shown in the HPLC time course in Figure 13, Panel A.  This single 
enzyme reaction resulted in only negligible changes in the 
concentrations of acetyl-CoA, and CoA and no acetoacetyl-CoA 
formation was detected.  These results are consistent with the 
known equilibrium constant for the β-ketothiolase reaction which 
strongly favors thiolysis of acetoacetyl-CoA (220).
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Figure 13.  Quantitative Time Courses of Metabolite 
Concentrations for the In Vitro Synthesis of PHB.  Time courses 
for CoA, acetyl-CoA, and β-hydroxybutyryl-CoA.  Panel A: The 
reaction is initiated upon addition of β-ketothiolase at 0 min to 
a solution containing 16 µM acetyl-CoA, 1.0 mM NADPH, and 5 mM 
TCEP in 150 mM EPPS buffered at a final pH of 7.8.  Negligible 
changes in the concentrations of CoA, acetyl-CoA, and β-
hydroxybutyryl-CoA are evident (see text).  Panel B:  
Acetoacetyl-CoA reductase is added at 3.5 min and the reaction 
allowed to reach equilibrium.  Stoichiometric changes in 
metabolite concentrations occur, corresponding to consumption of 
5.35 µM of acetyl-CoA, formation of 2.74 µM of β-hydroxybutyryl-
CoA, and liberation of 2.71 µM of CoA.  Panel C:  PHB synthase is 
added and the reaction allowed to proceed.  5.32 µM of CoA is 
liberated during the consumption of 2.88 µM of acetyl-CoA and 
2.55 µM of β-hydroxybutyryl-CoA.  
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β-ketothiolase & Acetoacetyl-CoA Reductase.  As shown in 
Figure 13, Panel B, the addition of acetoacetyl-CoA reductase 
immediately results in a substantial decrease in acetyl-CoA and 
simultaneous increases in β-hydroxybutyryl-CoA and CoA 
concentrations.  As expected these changes occur with a 
stoichiometry of 2 acetyl-CoA consumed: 1 CoA formed : 1 β-
hydroxybutyryl-CoA formed.  This is confirmed by the quantitative 
HPLC results shown in Table 6, which show that 2.74 •M of β-
hydroxybutyryl-CoA and 2.71 •M of CoA are generated in the 
enzymatic consumption of 5.35 •M of acetyl-CoA.  Since the 
concentration of β-hydroxybutyryl-CoA (2.74 •M) and CoA (2.71 •M) 
reach a total of 5.45, it is logical that all of the acetyl-CoA 
(5.35 •M) consumed in the enzymatic reactions was used to 
generate these species, within a 1.8% margin of error.  In this 
situation, the large forward equilibrium constant for the 
acetoacetyl-CoA reductase reaction drives the system forward by 
overcoming the strong reverse equilibrium for the β-ketothiolase 
reaction (221).  After approximately 55% of the initial acetyl-
CoA is consumed, the reaction reaches equilibrium (see below).  
Consistent with literature reports on PHB synthesis both in vivo  
(189) and in vitro (181), we detect no buildup of acetoacetyl-CoA 
(Figure 12).  
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Table 6.  Stoichiometric Relationships for In Vitro Enzymatic Reactions. 
a acetyl-CoA 
b β-hydroxybutyryl-CoA 
c acetoacetyl-CoA 
* % Error shown in parenthesis was determined with % error = |((actual-calculated)/actual)| x 100. 
e While the stoichiometric relationship for the quantity of CoA consumed to the acetyl-CoA 
generated should be 1 CoA : 2 AcCoA.  The experimentally measured quantity of CoA consumed, 1.81 
µM does not equal ½ of the acetyl-CoA 2.81; this is believed to result from additional CoA, which 
was present as a contaminant in the acetoacetyl-CoA spike.  Alternatively, some CoA could have 
been produced in the polymerization if HBCoA to PHB but this latter case is not believed to be a 
major factor in such a short (8 s) time span.  
 ∆ AcCoAa 
•M 
(% Errord) 
∆ CoA 
•M 
(% Errord)
∆ HBCoAb 
•M 
(% Errord)
∆ HBCoA 
+ 
∆ AcCoA 
β-ketothiolase & Acetoacetyl-CoA Reductase 
Figure 13, Panel B 
-5.35 
(+1.8%) 
+2.71 
 
+2.74 
 
--- 
∆ 2 AcCoA =  ∆ CoA + ∆ HBCoA 
5.35 ≈ 2.74 + 2.71 = 5.45 
 
    
β-ketothiolase, Acetoacetyl-CoA Reductase & PHB Synthase
Figure 13, Panel C 
-2.88 +5.32 
(+2.1%) 
-2.55 --- 
∆ CoA =  ∆ AcCoA + ∆ HBCoA 
5.32 ≈ 2.88 + 2.55 = 5.43 
 
    
β-ketothiolase, Acetoacetyl-CoA Reductase & PHB Synthase
Concatenated from 0-40 min;  Figure 13, Panel A-C 
-8.27 
(-0.1%) 
8.04 0.22 
Remaining
--- 
AcCoA = CoA + Residual HBCoA 
8.27 ≈ 8.04 + 0.22 = 8.26 
 
    
β-ketothiolase, Acetoacetyl-CoA Reductase & PHB Synthase
Spiked with 7.84 µM of acetoacetyl-CoA 
5.63  
[1/2 = 2.81]
1.81e 5.03 7.84 
(0%) 
7.84 µM AcAcCoAc spike = HBCoA + ½ AcCoA 
7.84 ≈ 2.81 + 5.03 = 7.84  
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β-ketothiolase, Acetoacetyl-CoA Reductase & PHB Synthase.  
The in vitro time courses, shown in Figure 13, Panel C, 
illustrate how the addition of the PHB synthase enzyme shifts the 
equilibrium of the three-enzyme system toward PHB polymer 
production.  The PHB synthase reaction is irreversible and thus 
polymerization of β-hydroxybutyryl-CoA, by PHB synthase, 
stimulates the condensation of additional acetyl-CoA molecules, 
and CoA is liberated by both the β-ketothiolase and PHB synthase 
reactions.  Under these circumstances, the reaction proceeds with 
stoichiometries that reflect that the total consumption of 
acetyl-CoA, 2.88 µM,  and β-hydroxybutyryl-CoA, 2.55 µM, which 
equals a sum of 5.43 µM, is equivalent to the total quantity of 
CoA released, 5.32 µM with a 2% margin of error.   
Stoichiometries of the Concatenated Biosynthetic Pathway.  
Overall, we observe a stoichiometric conservation of CoA-moieties 
for the time courses of the concatenated enzymatic system of β-
ketothiolase, acetoacetyl-CoA reductase & PHB synthase over the 
entire time course from 0 to 40 min.  Thus, under the conditions 
of Figure 13, 8.27 µM of CoA-moieties are consumed, as acetyl-
CoA, and 8.26 µM CoA-moieties are present in the form of CoA 
(8.04 µM) and β-hydroxybutyryl-CoA (0.22 µM).  
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High Performance Liquid Chromatography.   
HPLC Peak Determination.  It is evident from Figure 14 that 
two peaks are visible in each commercial sample of CoA, acetyl-
CoA, acetoacetyl-CoA, and β-hydroxybutyryl-CoA, respectively.  
Detailed mass spectrometric and NMR structural analyses carried 
out in this laboratory established that the earlier-eluting peaks 
represent the authentic CoA or acyl-CoA compounds, whereas the 
later-eluting peaks correspond to the 2’-phophate isomers (or 
iso-CoA-forms) of each compound; these experiments are described 
elsewhere (222).  In addition, it is evident from Figure 12 that 
over the time course of the enzymatic reactions that both the CoA 
and the iso-CoA-forms of these compounds are enzymatically 
metabolized.   
HPLC Optimization.  We developed an optimized HPLC 
methodology, based on several previous separations of similar 
CoA-containing compounds (223-225), which separates CoA, acetyl-
CoA, acetoacetyl-CoA and β-hydroxybutyryl-CoA with baseline 
resolution (Figure 14).  Our methodology allows for convenient 
isocratic elution, which provides baseline separation in about 30 
min.  The mobile phase developed for this separation provides the 
strong buffering capacity necessary for excellent resolution, 
good peak shape, and reproducible retention times but does not 
employ harsh ion-pairing agents (226) or high phosphate 
concentrations which damage silica columns (227).   
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Figure 14.  Overlaid HPLC Chromatograms of Commercial CoA and 
Acyl-CoA samples.  Representative HPLC C18 chromatograms of CoA, 
acetyl-CoA, acetoacetyl-CoA, and β-hydroxybutyryl-CoA are shown.  
Elution conditions are described in the text.  For each CoA 
containing compound the iso-CoA-form appears as a small later-
eluting peak with the following retention times:  iso-CoA, 7.1; 
acetyl-iso-CoA, 25.5; acetoacetyl-iso-CoA, 26.9; β-
hydroxybutyryl-iso-CoA, 33.6 min.
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Ion Pairing Agents in the Mobile Phase.  Several groups 
have reported methodology for separating acyl-CoA compounds via 
HPLC (223,226,228-238).  Two strategies have been reported in the 
literature to suppress the charges on the phosphate moiety; this 
facilitates interaction between the compound and the stationary 
phase, which is crucial for separation by reverse phase 
chromatography.  The ion-pairing technique, developed by Baker 
and Schooley in 1979 (229), utilizes a mobile phase containing an 
ion-pairing reagent, such as tetrabutyl ammonium hydrogen 
sulfate.  This method was attempted in our laboratory and 
successfully separated CoA, β-hydroxybutyryl-CoA, and NADPH, 
however; acetyl-CoA and acetoacetyl-CoA coeluted.   
Strong Buffer in the Mobile Phase.  The alternate strategy 
of using a strong buffering agent, typically 100-200 mM 
phosphate, in the mobile phase was developed by Ingebretsen and 
Farstad (239), modified by DeBuysere and Olson (226), and adapted 
for used in this investigation.  While, this strategy does avoid 
the use of corrosive ion pairing agents, the historic use of 
phosphate buffer at high concentrations has been reported to be 
highly damaging to silica-based columns (227); the use of 
phosphate buffers significantly shortened column lifetimes in our 
laboratory.  Consequently, sodium citrate was used in the mobile 
phase in this laboratory because of its strong ionic strength, 
which suppresses sample ionization and provides buffering 
capacity for acidic samples without extensive column degradation.   
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Ammonium Acetate Mobile Phase for MS Experiments.  A second 
mobile phase, described in Chapter 7 (Iso-CoA:  Experimental) was 
used for the HPLC-MS analysis of the iso-CoA compounds (222), 
which required the use of a volatile buffer.  This mobile phase, 
which was based on the report of Norwood et al. (235), used the 
volatile buffer ammonium acetate in the mobile phase to achieve 
resolution of all CoA-containing compounds as shown in Figure 15.  
The ammonium acetate mobile phase was not used for any of the 
time course or quantitative stoichiometric analyses because, as 
Figure 15 illustrates, high sample acidity resulted in 
significant tailing.  Additionally, column retention times with 
the ammonium acetate mobile phase tended to be highly variable.  
These relatively large shifts in retention times are believed to 
result from minor variations in mobile phase preparations, sample 
pH, air temperatures around the column, and the extent of column 
equilibration.  
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Figure 15.  Representative Chromatograms of CoA, Acetyl-CoA, 
Acetoacetyl-CoA, and β-hydroxybutyryl-CoA.  Sample was treated 
with perchloric acid at a final concentration of 0.57 M with a 
mobile phase of 96% of 200 mM ammonium acetate: 4% acetonitrile.   
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Reducing Agents for CoA and Enzyme Activity.  Reducing 
agents are essential for accurate quantitation of free CoA 
because they prevent oxidation of CoA to the CoASSCoA disulfide 
dimer.  Under the conditions used in these investigations, at pH 
7.8, approximately 50% of CoA was oxidized after two hours in the 
absence of reducing agents (data not shown).  The traditional 
thiol-containing reducing agent, β-mercaptoethanol, generated an 
unidentified peak, labeled in red in Figure 16 Panel A, which 
likely results from formation of a mixed disulfide between β-
mercaptoethanol and CoA (223).  The location of the unknown peak 
is extremely close to the expected location for acetoacetyl-CoA; 
however, as Figure 16 Panel B illustrates acetoacetyl-CoA elutes 
separately from the peak for the unknown compound.  We note that 
this phenomena was only observed in experiments with very low 
substrate concentrations.
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Figure 16.  Stacked Chromatograms of an Unidentified Substance.  
A.)  Chromatogram showing the unidentified peak, which is 
purportedly the mixed disulfide of CoA and β-mercaptoethanol via 
HPLC at 19 min.  B.)  Solution in Panel A is spiked with 
acetoacetyl-CoA to illustrate that the unknown peak is not 
acetoacetyl-CoA but rather some unique compound.
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Since the unknown substance nearly coelutes with acetoacetyl-CoA, 
we chose the alternative reducing agent triscarboxyethyl 
phosphine (TCEP) to avoid difficulties with quantitation of 
acetoacetyl- and β-hydroxybutyryl-CoA.  TCEP is a somewhat newly 
available reducing agent, which is a water soluble, odorless, 
trialkylphosphine that reacts with disulfides to form two free 
thiols and the phosphine oxide (240). TCEP does not interact with 
any of the acyl-CoA compounds tested in this study (Data not 
shown).  TCEP was also substituted for β-mercaptoethanol, to 
maintain the activity of the β-ketothiolase and acetoacetyl-CoA 
reductase enzymes during storage.  Comparisons of the activities 
for enzymes stored in β-mercaptoethanol and those rinsed and then 
stored with TCEP were nearly identical, and were also higher than 
enzymes stored without reducing agents.   
 
Selection of Organic Eluent and Isocratic Elution.  
Acetonitrile and methanol have been reported in the literature 
for separations of acyl-CoA compounds, but only acetonitrile 
provided adequate resolution for the acyl-CoA compounds used in 
this study.  Methanol did not resolve acetoacetyl-CoA and β-
hydroxybutyryl-CoA without increasing run times in excess of 60 
minutes, which resulted in band broadening.  We note that this 
system is extremely sensitive to minor changes in acetonitrile 
concentration such that retention times would shift by ten minute 
from a 0.5% increase in acetonitrile.  Consequently, isocratic 
elution was more convenient because it avoided the extensive re-
  146
equilibrations that would be necessary after each gradient.  We 
confirm the report by Hermans-Lokkerbol et al. (237), that the 
elution order of acetoacetyl-CoA and acetyl-CoA are reversed when 
acetonitrile rather than methanol is used in the mobile phase.   
Column Selection.  The columns attempted for this 
separation were the Alltech Platinum EPS C8, the Waters 
Spheresorb C8 and C18, the Phenomenex Luna HexylPhenyl, the 
Phenomenex Hydro-RP Synergy C18 column, and the NovaPak C18 
Reverse Phase column.  Most full size, 250 mm. length, columns 
were capable of resolving all CoA compounds; however, the run 
times were often in excess of 70 min to achieve baseline 
separation.  Consequently, the NovaPak C18 reverse phase column 
was used because the increase in resolution provided by its 
small, 4 Å particles, permitted the use of a shorter column 
length, 150 mm, which ultimately reduced run times and allowed 
baseline separation within 33 min.  
Standard Curves and Limits of Detection.  As shown in 
Figure 17, standard curves prepared from the areas under the 
peaks, which were adjusted for the presence of the iso-CoA 
isomers, showed excellent linearity with R2 coefficients of 
0.9999.  Baseline separation was achieved for all CoA-containing 
compounds including acetoacetyl-CoA, as indicated in Figure 14.  
However, no acetoacetyl-CoA was detected during any of the in 
vitro experiments; therefore, no standard curve was determined 
for this compound.  The HPLC limits of detection for CoA, acetyl-
CoA and β-hydroxybutyryl-CoA listed in Table 7 were determined 
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with both the acetate and the citrate mobile phases.  Sodium 
citrate has a greater UV absorbance than sodium acetate at 260 nm 
so the baseline for the sodium citrate mobile phase has slightly 
higher noise levels; this resulted in marginally higher limits of 
detection.   
 
 
Table 7.  HPLC Limits of Detection for CoA, Acetyl-CoA and β-
hydroxybutyryl-CoA.  A C18 Reverse Phase HPLC column run with 
mobile phases containing sodium acetate or sodium citrate as 
described in the text.   
 Acetate buffer Citrate buffer 
CoA 1.7 pmol 3.1 pmol 
acetyl-CoA 3.3 pmol 6.5 pmol 
β-hydroxybutyryl-CoA 3.1 pmol 12.6 pmol 
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Figure 17.  HPLC Standard Curves for Acetyl-CoA, CoA, and β-
hydroxybutyryl-CoA. 
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PHB Metabolic Model.  We have developed a structured 
kinetic model to simulate the in vitro synthesis of PHB using the 
HPLC data gathered in this study.  This model is based on the 
work of Leaf and Srienc (190), van Wegen et al. (189), and Daae 
et al. (191), who modeled the in vivo synthesis of PHB in C. 
necator, recombinant E. coli, and the Arabidopsis thaliana plant, 
respectively.  This is the first report of a metabolic model that 
simulates the in vitro biosynthesis of PHB.  The model was 
developed with the BioPathway Explorer and GEPASI (217-219) 
modeling software packages.  Kinetic parameters were gathered 
either from the literature, from laboratory analysis, or were 
determined by fitting the simulation to the time course data.  
Excel was used for calculating kinetic constants, Haldane 
relationships, and for displaying the GEPASI output data.  Figure 
18 shows the simulation depicted with solid lines, in comparison 
to the laboratory data gathered by HPLC indicated by data points.  
The simulation was performed by coupling the integrated rate 
equations for each of the three-enzymes in the PHB pathway.   
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Figure 18.  Metabolic Modeling of PHB Synthesis and Spiking 
Experiments.  The HPLC data for the in vitro synthesis of PHB is 
displayed with the data points.  Lines show the results of the 
metabolic model.  The labeled arrows indicate enzyme or substrate 
additions as follows:  A. 0 min, β-ketothiolase; B.  3.5 min, 
acetoacetyl-CoA reductase; C.  10.5 min, PHB synthase; D.  40.5 
min, NADPH and acetoacetyl-CoA reductase; E.  50.5 min, 
acetoacetyl-CoA.  
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Stepwise Simulation of In Vitro PHB Synthesis.  Initially, 
when only the β-ketothiolase enzyme is added (Point A), both the 
simulation and the experimental data show no consumption of 
acetyl-CoA and no production of products.  Addition of 
acetoacetyl-CoA reductase (Point B) results in catabolism of 
acetyl-CoA with production of CoA and β-hydroxybutyryl-CoA, with 
excellent agreement between the experimental data and the model.  
PHB synthase addition (Point C) drives the entire biosynthesis 
forward resulting in further consumption of acetyl-CoA and 
liberation of CoA as seen in both the experimental data and in 
the simulation.  The simulation predicts acetoacetyl-CoA 
concentrations in the very low nanomolar range, reaching 1.3 nM 
within 1 s, 0.05 nM in 25 min, and 0.01 nM after 40 min (Figure 
18).  Since concentrations this low would be well below the limit 
of detection by HPLC, the metabolic model is consistent with the 
observed lack of acetoacetyl-CoA accumulation in the in vitro 
biosynthesis system (Figure 12).
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HPLC Spiking Experiments.  HPLC spiking experiments were 
undertaken to further clarify the lack of acetoacetyl-CoA 
accumulation throughout the time course of the reaction.  The 
overlaid HPLC chromatograms in Figure 14 clearly show that under 
our elution conditions acetoacetyl-CoA is well resolved from the 
other CoA compounds, and its buildup would be easily detectable.  
In Figure 18, Point E, the reaction mixture was spiked with 
acetoacetyl-CoA, and the HPLC chromatograms of the reaction 
mixture immediately before and immediately after spiking are 
shown in Figure 19.  It is evident that even as early as eight 
seconds after spiking no acetoacetyl-CoA is detectable, whereas 
large changes in CoA, acetyl-CoA, and β-hydroxybutyryl-CoA are 
clearly evident.  This suggests that the added acetoacetyl-CoA 
was rapidly consumed both by the β-ketothiolase enzyme, producing 
two equivalents of acetyl-CoA, and also by the acetoacetyl-CoA 
reductase enzyme, generating one equivalent of β-hydroxybutyryl-
CoA.  The stoichiometric correlations, listed in Table 6, support 
this contention since adding all of the 5.03 µM of β-
hydroxybutyryl-CoA to one-half of the 5.63 µM of acetyl-CoA (1/2 
equals 2.81 µM) exactly equals the quantity of acetoacetyl-CoA 
that was added to spike the reaction, 7.84 •M. 
A second spiking experiment (Figure 18, Point D) was also 
carried out in which additional acetoacetyl-CoA reductase and 
NADPH were added, and it is clear from Figure 18, Point D, and 
Figure 20 that this does not substantially affect the 
concentration of any of the CoA-containing compounds.  It is also 
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evident from Figure 18 that the experimental data and simulation 
are in good agreement for the entire time course of the 
experiment and for both spiking experiments, including the return 
to low nanomolar concentrations of the acetoacetyl-CoA levels as 
early as one second after spiking.
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Figure 19.  Stacked Chromatograms of the Acetoacetyl-CoA Spiking 
Experiment.  In this experiment 7.8 µM of acetoacetyl-CoA was 
added to a reaction mixture containing the substrates and the 
enzymes β-ketothiolase, acetoacetyl-CoA reductase, PHB synthase.
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Figure 20.  Stacked Chromatograms of the NADPH and Acetoacetyl-
CoA Reductase Spiking Experiment.  In this experiment, 0.5 mM 
NADPH and 40 •M of acetoacetyl-CoA reductase were added to the 
reaction mixture, which contained the substrates and the enzymes 
β-ketothiolase, acetoacetyl-CoA reductase and PHB synthase.  
Panel A is before spiking, and Panel B and Panel C are 38 s and 
10 min post spiking, respectively.  
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The goodness of fit for the metabolic model was explored by 
varying the reaction parameters.  The step in which the PHB 
reaction was spiked with acetoacetyl-CoA was chosen for this 
analysis because all three enzymes were present and the goodness 
of fit was high in this section.  To perform this analysis each 
reaction parameter was varied by plus or minus 10 fold and the 
simulation was run to determine the sum of squares, standard 
deviation, and RMS error for each parameter variation.  As shown 
in Table 8, the reaction with no parameters changed exhibited a 
sum of squares of 1.019 and the goodness of fit upon varying each 
of the reaction parameters are listed in Tables 9-11.   
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Table 8.  Goodness of Fit for the PHB Synthetic Model. 
Sum of squares  Standard deviation  RMS error  
1.019 0.319 0.304 
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Table 9.  Goodness of Fit for the β-ketothiolase Parameters. 
 Normal 
Values 
Sum of squares 
 
Standard deviation 
 
RMS error 
 
  x 10  
fold 
÷ 10  
fold 
x 10  
fold 
÷ 10  
fold 
x 10  
fold 
÷ 10  
fold 
Keq 4.00 x 10-5 58.164 41.508 2.412 2.037 2.299 1.943 
Vr (µM/s) 2924.00  1.019  1.019 0.319 0.319 0.304 0.304 
Vf (µM/s)    9.75  0.801  4.474 0.283 0.669 0.270 0.638 
Ksum •M 1238.00 13.865  0.476 1.178 0.218 1.123 0.208 
Ka •M     0.158 ---      
Kb •M 1237.84 ---      
Kp •M   16.00  3.605  0.746 0.600 0.273 0.572 0.260 
Kq •M   44.00 48.013  1.497 2.191 0.387 2.089 0.369 
Kia •M   46.74 ---      
Kib •M 1237.84  1.019  1.019 0.319 0.319 0.304 0.304 
Kip •M   15.78  0.802  4.473 0.283 0.669 0.270 0.638 
Kiq •M     0.147  1.019  1.019 0.319 0.319 0.304 0.304 
 
  
159 
Table 10.  Goodness of Fit for the Acetoacetyl-CoA Reductase Parameters.   
 Normal 
Values 
Sum of squares 
 
Standard deviation 
 
RMS error 
 
  x 10  
fold 
÷ 10  
fold 
x 10  
fold 
÷ 10  
fold 
x 10  
fold 
÷ 10  
fold 
Keq •M 2.16 x 109 44.063  64.498 2.099 2.540 2.001 2.421 
Vr (µM/s)  135.09 27.692 248.368 1.664 4.984 1.587 4.752 
Vf (µM/s) 1486.00  7.513  20.284 0.867 1.424 0.826 1.358 
Ka •M   19.00  0.900   1.032 0.300 0.321 0.286 0.306 
Kb •M    5.00 10.356   2.440 1.018 0.494 0.970 0.471 
Kp •M   16.50  0.960   1.025 0.310 0.320 0.295 0.305 
Kq •M   31.00  0.513   1.135 0.227 0.337 0.216 0.321 
Kia •M   50.00  0.799   0.518 0.283 0.228 0.269 0.217 
Kib •M   28.83 ---      
Kip •M    5.00  1.429   0.918 0.378 0.303 0.360 0.289 
Kiq •M   47.15  1.019   1.006 0.319 0.317 0.304 0.302 
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Table 11.  Goodness of Fit for the Parameters for the PHB Synthase Reaction. 
 Normal 
Values 
Sum of squares 
 
Standard deviation 
 
RMS error 
 
  x 10  
fold 
÷ 10  
fold 
x 10  
fold 
÷ 10  
fold 
x 10  
fold 
÷ 10  
fold 
Vf   0.309 55.203 40.068 2.350 2.002 2.240 1.909 
KM •M 103.00 39.442 50.159 1.986 2.240 1.894 2.135 
KI •M 108.00  1.111  2.850 0.333 0.534 0.318 0.509 
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CHAPTER 4 
PHB:  DISCUSSION 
 
 
In 1977 Saito et al. (159) reported the first multi-enzyme 
in vitro enzymatic synthesis of PHB using crudely purified 
enzymes from Z. ramigeria, then later Haywood et al. (160) used 
enzymes isolated from C. necator; both monitored PHB production 
via incorporation of radiolabeled [1-14C]acetyl-CoA.  Recently, 
Satoh et al. (181) reported the enzymatic synthesis of PHB from 
acetate with cofactor recycling using the three C. necator 
enzymes plus the enzymes acetyl-CoA synthetase and glucose 
dehydrogenase.  Satoh et al. (181) implemented cofactor recycling 
because prohibitively low substrate conversion (<6%) was 
encountered with the two-enzyme system, which contained only β-
ketothiolase and acetoacetyl-CoA reductase.  These authors 
suggested that recycling the CoA produced by the condensation of 
acetyl-CoA prevented CoA-mediated product inhibition of the β-
ketothiolase enzyme and therefore facilitated overall reaction 
progress (181).  While cofactor recycling does effectively 
increase overall reaction yields, it also entails inclusion of 
additional enzymes, which alter metabolite flux and create an 
enzyme system that is more complex than the three-enzyme C. 
necator biosynthetic system. 
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The results presented here provide a clear illustration of 
the individual effect of each of the three key enzymes from C. 
necator on the in vitro progress of PHB biosynthesis.  We have 
circumvented the problem of cofactor inhibition by dramatically 
reducing initial substrate concentrations such that cofactors do 
not accumulate to levels capable of significant enzyme 
inhibition.  Each enzymatic reaction was performed in a step-wise 
manner and monitored by HPLC in order to elucidate the 
fluctuations in metabolite concentrations and the effect of each 
individual enzyme on the overall system.  Our strategy of using 
low substrate concentrations to overcome product inhibition 
proved to be successful since the two-enzyme system sans cofactor 
recycling, which consists of β-ketothiolase and acetoacetyl-CoA 
reductase, achieved 55% conversion of the acetyl-CoA substrate in 
our experiments, as compared to the less than 6% conversion 
obtained by Satoh et al. (181)  After addition of the third 
enzyme, PHB synthase, approximately 83% of the initial acetyl-CoA 
was consumed within 40 min.  These results validate our strategy 
of lowering initial enzyme substrate concentrations to achieve a 
well-behaved model system. 
 
We report here the development of optimized HPLC 
methodology which separates CoA, acetyl-CoA, acetoacetyl-CoA, and 
β-hydroxybutyryl-CoA with baseline resolution in approximately 30 
min, which is approximately half of the time required by the only 
procedure (181) reported in the literature to separate this 
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series of CoA compounds.  Convenient isocratic elution and 
selection of an efficient column facilitated shorter run times.  
It is significant that this method gives baseline resolution of 
acetoacetyl-CoA so that we were able to unequivocally demonstrate 
that this compound does not accumulate to detectable levels in 
the enzymatic system.  Baseline separation was also essential to 
accomplish accurate quantitation, which was necessary to obtain 
the excellent stoichiometric mass balances reported in this 
study.  Our mobile phase does not employ harsh ion-pairing agents 
(226) or high phosphate concentrations which damage silica 
columns (227), yet still provides the strong buffering capacity 
necessary for excellent resolution, good peak shape, and 
reproducible retention times.  
 
Three Enzyme System.   
 
β-ketothiolase.  The series of in vitro enzymatic reactions 
performed in this study were designed specifically to delineate 
the mechanisms by which the enzymes and metabolites affect 
overall pathway flux for PHB synthesis.  As Figure 13 indicates 
initiation of the reaction with β-ketothiolase results in only 
minor changes in acetyl-CoA and CoA concentrations, and no 
acetoacetyl-CoA is detected by HPLC.  The equilibrium of β-
ketothiolase is reported in the literature to range from 1 x 10-4 
(190,207) to 6 x 10-6 (221,241,242), which strongly favors 
thiolysis of acetoacetyl-CoA to acetyl-CoA.  Therefore, it seems 
reasonable that the reaction equilibrium would allow only very 
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small concentrations of acetoacetyl-CoA concentrations to 
accumulate and this would be below the limit of detection by 
HPLC.  We note that stoichiometric analysis for the β-
ketothiolase reaction was not possible because the acetoacetyl-
CoA could not be detected or quantified by HPLC. 
β-ketothiolase and acetoacetyl-CoA reductase.  Addition of 
the acetoacetyl-CoA reductase enzyme to the reaction mixture as 
illustrated in Figure 13 Panel B generates an immediate and 
substantial decrease in acetyl-CoA concentrations with a 
corresponding increase in the concentrations of CoA and β-
hydroxybutyryl-CoA.  In this situation β-hydroxybutyryl-CoA is 
generated by the acetoacetyl-CoA reductase catalyzed reduction of 
acetoacetyl-CoA (refer to Figure 7).  The depletion of acetyl-CoA 
and generation of CoA suggests that the acetoacetyl-CoA is being 
consumed by the by acetoacetyl-CoA reductase, which would 
displace the unfavorable equilibrium of the β-ketothiolase 
reaction effectively driving the β-ketothiolase reaction toward 
the forward thiolysis direction.  This phenomenon is supported by 
the equilibrium constants in the literature for the enzymatic 
reactions.  When coupling the two enzymes, the large forward 
equilibrium constant of the acetoacetyl-CoA reductase reaction, 
which ranges in the literature from 5 x 109 (221) to 6.3 x 1011 
(243), overcomes the large reverse β-ketothiolase equilibrium 
constant (between 1 x 10-4 (190,207) and 6 x 10-6 (221,241,242)); 
this effectively drives the entire reaction system forward.  The 
coupled reaction does not reach completion; instead, equilibrium 
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is achieved after about 10 min with approximately 55% of the 
acetyl-CoA starting material consumed (Figure 13).  The 
equilibrium constant, which was calculated from the laboratory 
derived HPLC data at 10 min is 8.6 x 104; this agrees well with 
the 5.1 x 104 value for the equilibrium constant which was 
determined by Gilbert et al. (221) for the same reaction 
catalyzed by pig heart thiolase and β-hydroxybutyryl-CoA 
dehydrogenase.  Furthermore, excellent stoichiometric results 
were obtained (Table 7) which show that 2 acetyl-CoA molecules 
generate 1 β-hydroxybutyryl-CoA and one CoA molecule, with a low 
1.8% margin of error.   
β-ketothiolase, acetoacetyl-CoA reductase, and PHB Synthase.  
Addition of a third enzyme, PHB synthase, results in the 
consumption of acetyl-CoA and β-hydroxybutyryl-CoA with 
liberation of CoA as shown in Figure 13, Panel C.  The PHB 
synthase catalyzed polymerization reaction is regarded as 
irreversible; therefore, addition of this enzyme will drive the 
entire reaction toward polymer formation.  Indeed, the movement 
of the system toward PHB production accounts for each of the 
changes in metabolite concentrations that occur upon addition of 
the PHB synthase enzyme (Figure 13, Panel C).  The concentration 
of β-hydroxybutyryl-CoA decreases as it is consumed by the PHB 
synthase enzyme to generate PHB.  Likewise, acetyl-CoA 
concentrations decrease in response to the decrease in β-
hydroxybutyryl-CoA.  This is a result of the consumption of the 
product of the β-ketothiolase reaction, acetoacetyl-CoA, by the 
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acetoacetyl-CoA reductase enzyme, which stimulates the β-
ketothiolase reaction to consume further acetyl-CoA and liberate 
CoA.  We note that CoA is liberated in two processes, by both the 
β-ketothiolase and the PHB synthase reactions; this results in a 
stoichiometric relationship in which two CoA molecules are 
released for every acetyl-CoA and β-hydroxybutyryl-CoA molecule 
consumed.  Under these circumstances, the reaction proceeds with 
stoichiometries that reflect the liberation of 5.32µM of CoA, in 
the β-ketothiolase and the PHB synthase reactions, corresponding 
to a cumulative consumption of acetyl-CoA and β-hydroxybutyryl-
CoA of 5.42µM, as reported in Table 6.   
Overall Analysis.  HPLC analysis of the concatenated in 
vitro enzymatic reaction over the entire time course of the 
reaction from start to finish (T=0 to 40 min) confirms 
stoichiometric conservation of CoA-moieties.  In this 
investigation (Table 7), the quantity of CoA moieties consumed in 
the reaction as acetyl-CoA equals the concentration of CoA 
moieties liberated, in the form of free CoA and β-hydroxybutyryl-
CoA, with an excellent experimental error of 0.1%.   
 
Acetoacetyl-CoA Spiking Experiments and Stoichiometry.  
Acetoacetyl-CoA was not detected by HPLC in any of the enzyme 
experiments performed in this study.  This phenomena has been 
reported in the literature in both in vivo (189) and in vitro 
(181) experiments, but has never been thoroughly explored or 
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explained.  We investigated this lack of acetoacetyl-CoA by 
performing spiking experiments.  The absence of the accumulation 
of acetoacetyl-CoA during the enzymatic reactions was initially 
investigated using a spiking experiment which explored the 
hypothesis that acetoacetyl-CoA was present but potentially 
invisible to detection by HPLC.  As Figure 18, Point D and Figure 
20 shows, additional NADPH and acetoacetyl-CoA reductase were 
added to the three-enzyme in vitro system in an attempt to drive 
the acetoacetyl-CoA reductase reaction forward.  Theoretically, 
if acetoacetyl-CoA were present, but the detection by HPLC was 
masked, doubling the concentration of acetoacetyl-CoA reductase 
and adding 0.5 mM NADPH should convert the residual acetoacetyl-
CoA to β-hydroxybutyryl-CoA, which would be easily detectable by 
HPLC.  As seen in Figure 18, Point D and Figure 20, no 
significant change in the concentration of β-hydroxybutyryl-CoA 
is observed upon spiking the reaction.  This experiment provides 
initial evidence that the steady state concentrations of 
acetoacetyl-CoA are maintained at extremely low levels, which are 
below the limit of detection by HPLC. 
To further assess the premise that the steady state 
concentrations of acetoacetyl-CoA were below the limit of HPLC 
detection, a spiking experiment was performed in which 7.84 µM of 
acetoacetyl-CoA was added to the in vitro three-enzyme system at 
t = 50 min.  As the HPLC elution profiles in Figure 19 
illustrate, no acetoacetyl-CoA is visible in the sample acquired 
only eight seconds after spiking; however, there are significant 
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increases in acetyl-CoA and β-hydroxybutyryl-CoA.  The sharp 
increase in these two metabolites indicates that upon addition of 
acetoacetyl-CoA, β-ketothiolase rapidly converts the acetoacetyl-
CoA to acetyl-CoA while, simultaneously, acetoacetyl-CoA 
reductase reduces the acetoacetyl-CoA to β-hydroxybutyryl-CoA.  
Basically, the system reacts to rapidly decrease the 
concentration of the spiked acetoacetyl-CoA; it does this through 
both thiolysis and reduction. 
Stoichiometric quantification of the products formed 
immediately after acetoacetyl-CoA spiking support the assertion 
that acetoacetyl-CoA is quantitatively converted to acetyl-CoA 
and β-hydroxybutyryl-CoA in the three-enzyme system.  The time 
point taken immediately (eight seconds) after spiking with 
acetoacetyl-CoA was used to calculate the resulting concentration 
changes.  This time point was chosen because in this small time 
span little formation of PHB has occurred; therefore, all carbon 
units should be accounted for amongst the CoA-containing 
compounds (acetyl-CoA, β-hydroxybutyryl-CoA, and CoA).  In this 
situation, one molecule of acetoacetyl-CoA is converted to either 
one molecule of β-hydroxybutyryl-CoA or two molecules of acetyl-
CoA with consumption of CoA.  Therefore, the sum of the increase 
in β-hydroxybutyryl-CoA plus one-half of the increase in acetyl-
CoA should equal the concentration of acetoacetyl-CoA used to 
spike the experiment.  As listed in Table 6, 7.84 µM of 
acetoacetyl-CoA was added to the reaction mixture; eight seconds 
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after spiking an increase of 5.628 µM of acetyl-CoA (½ acetyl-CoA 
is 2.814) and 5.033 µM of β-hydroxybutyryl-CoA were detected, 
which result in a calculated sum of 7.84 µM.  The stoichiometries 
clearly demonstrate excellent correlation to the quantity of 
acetoacetyl-CoA (7.84 µM) used to spike the reaction.  
The results of the two previous spiking experiments clearly 
support the premise that low steady state concentrations of 
acetoacetyl-CoA are maintained during the in vitro enzymatic 
synthesis of PHB.  The absence of acetoacetyl-CoA is not believed 
to be an artifact or due to a difficulty in detecting 
acetoacetyl-CoA by HPLC.  This phenomenon does agree with the 
equilibrium constants and apparent Michaelis-Menten constant for 
acetoacetyl-CoA for the β-ketothiolase reaction (Keq = 10-5; KM = 
44µM), which lies strongly in the reverse direction, and the 
acetoacetyl-CoA reductase reaction (Keq = 1010; Kacetoacetyl-CoA = 5µM), 
which drives the reaction forward.  This suggests that the 
acetoacetyl-CoA produced by β-ketothiolase will rapidly react 
with the acetoacetyl-CoA reductase enzyme thus maintaining very 
low steady state concentrations of acetoacetyl-CoA.  We note 
that, it is feasible that some acetoacetyl-CoA decomposed during 
the course of the reaction.  Acetoacetyl-CoA is known to be 
labile at neutral and basic pH; however, the acid quenching step 
of the procedure should prevent significant decomposition prior 
to sample analysis. 
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Metabolic Model of the PHB Pathway.  Metabolic modeling is 
a convenient tool to evaluate complex enzymatic pathways.  
Multiple literature reports detail the development of PHB 
metabolic models (189-206,208-211,244); however, all of these 
models were designed to analyze in vivo biosynthesis, typically 
in bacteria but also in yeast and plants.  Furthermore, few if 
any, of these simulations use laboratory data for the PHB pathway 
metabolites:  acetyl-CoA, CoA, acetoacetyl-CoA, and β-
hydroxybutyryl-CoA.  Instead, many use parameters, such as 
glucose concentration, cell growth rate, and product 
accumulation, which may not be amenable to straightforward 
kinetic/thermodynamic analyses.  The detailed HPLC data of PHB 
metabolites that was obtained in this study are ideal for the 
development of a PHB metabolic model.   
We report here the development of the first kinetic model 
of in vitro PHB biosynthesis.  This is the first structured 
kinetic metabolic model developed using in vitro data of 
metabolite concentrations, which simulates the in vitro 
biosynthesis of PHB; it is based on the work of Leaf and Srienc 
(190), van Wegen et al. (189), and Daae et al (191).  This model 
should serve to elucidate the interplay between the kinetics and 
thermodynamics, which govern each step in the enzymatic pathway 
for PHB synthesis.  Future optimization of the system flux using 
metabolic modeling could aid in the optimization and design of 
this and other enzymatic systems.   
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Results of the PHB Pathway Simulation.  The model 
accurately shows that addition of the first enzyme, β-
ketothiolase, generates only negligible changes in metabolite 
concentrations.  This is consistent with the equilibrium constant 
for this reaction (1 x 10-4 (190,207) to 6 x 10-6 (221,241,242)), 
which strongly favors thiolysis of acetoacetyl-CoA.  The model 
does appear to deviate slightly from the experimental HPLC-data 
by showing some hydrolysis of acetyl-CoA by the β-ketothiolase 
enzyme (Figure 18, Point A); acetyl-CoA hydrolysis liberates 
stoichiometric amounts of CoA without generating any acetoacetyl-
CoA.  The hydrolysis observed in our in vitro system occurs with 
a first order rate constant of approximately 3 x 10-3 s-1, which 
is not too dissimilar to the first order rate constant for 
hydrolysis of the Ac-S-enzyme (k = 2.6 x 10-4 s-1 at pH 6.8 and 25 
C) reported in the literature for the porcine heart thiolase 
(221).  On the other hand, Thompson et al. (242) report that the 
Z.ramigeria β-ketothiolase catalyzed rates of condensation (kcat 
810 s-1 (242)) and thiolysis (kcat 71 s-1 (242)) are several 
magnitudes greater (3 x 106 and 3 x 105 fold, respectively) than 
the rate of hydrolysis of the Ac-S-enzyme by porcine heart 
thiolase (221,242,245).  The authors suggest that this implies 
that the β-ketothiolase catalyzed rates of condensation and 
thiolysis will effectively overwhelm any enzymatic hydrolysis of 
the Ac-S-enzyme so hydrolysis should not be observed.  
Nevertheless, some hydrolysis of acetyl-CoA was observed in vitro 
in our system and it is possible that this hydrolysis might occur 
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because the system is at equilibrium and, unlike the Thompson et 
al. report (242), our ketothiolase-only system does not contain 
enzymes capable of displacing the unfavorable equilibrium, which 
permit the reaction to proceed and prevent observable enzymatic 
hydrolysis.   
Addition of the second enzyme (Figure 18, Point B), 
acetoacetyl-CoA reductase, generates a dramatic decrease in the 
acetyl-CoA concentration and increases in CoA and β-
hydroxybutyryl-CoA levels.  In this situation, the model shows 
excellent correlation to the in vitro HPLC-data.  These 
simulation results indicate that the large forward equilibrium 
constant of the acetoacetyl-CoA reductase reaction (5 x 109 (221) 
to 6.3 x 1011 (243)) overcomes the large reverse β-ketothiolase 
equilibrium constant; thus, effectively driving the simulated 
system forward.  The simulation also reaches equilibrium after 
approximately 55% of the starting material is consumed, which is 
consistent with the in vitro HPLC data.   
In the third step, when the PHB synthase enzyme is added, 
the simulation shows consumption of the β-hydroxybutyryl-CoA, 
which had accumulated in the previous step; this effectively 
displaces the previously established equilibrium and shifts the 
system toward PHB polymer production.  The simulation confirms 
that the irreversible polymerization of β-hydroxybutyryl-CoA does 
indeed shift the entire three-enzyme system towards PHB 
production, and simultaneously stimulates the condensation of 
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additional acetyl-CoA, with CoA liberated by both the β-
ketothiolase and PHB synthase reactions.   
While the simulation of the third step (Figure 18, Point C) 
agrees reasonably well with the experimental data, it is apparent 
that some deviation from the experimental data occurs.  This is 
likely because a simplified kinetic equation for the PHB synthase 
reaction is employed in the model.  Studies by Goodwin and 
coworkers (165,167,168) established that the PHB synthase 
reaction exhibits a substantial lag phase prior to achieving 
maximal reaction rates.  The lag phase is a consequence of the 
formation of the enzymatically active homodimers from the 
inactive monomer enzyme form, and also results from an initiation 
phase in which the enzyme must be primed with either substrate or 
a multihydroxyl compound in order to achieve maximal rates 
(165,167,168).  The straightforward irreversible Michaelis-Menten 
kinetic equation with substrate inhibition that was used in this 
model does not include the priming or lag phase; therefore, the 
model deviates somewhat from the experimental data in this step 
(Point C).   
One of the more interesting observations from the 
simulation is that there is no accumulation of acetoacetyl-CoA.  
In this regard the simulation is consistent with our in vitro 
experiments as well as with the literature reports on PHB 
synthesis both in vivo (189) and in vitro (246).  Since low 
acetoacetyl-CoA concentrations are seen in the simulated data it 
seems reasonable to conclude that it is the physical equilibrium 
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and apparent Michaelis-Menten constants that govern the β-
ketothiolase and reductase enzymatic reactions, which generate in 
this phenomena.  Indeed, the equilibrium for the β-ketothiolase 
reaction strongly favors thiolysis of the acetoacetyl-CoA; in 
addition, the kcat/KM for the acetoacetyl-CoA reductase reaction 
from Z. ramigeria is near diffusion controlled at 1.8 x 108 M-1 s-1 
(220) so establishment of the equilibrium state should be 
extremely rapid.  Thus, the data strongly suggests that it is the 
action of the β-ketothiolase and acetoacetyl-CoA reductase 
enzymes, which maintain the vanishingly low levels of acetyl-CoA.   
 The inherently low levels of acetoacetyl-CoA in this system 
are particularly evident in the spiking experiments.  In the 
simulation of the experiment in which 7.84 •M of acetoacetyl-CoA 
is used to spike the reaction mixture, the concentration of 
acetoacetyl-CoA returns to 1.3 nM within 1 s, reaches 0.05 nM in 
25 min and 0.01 nM after 40 min (Figure 18).  This rapid 
reestablishment of extremely low levels of acetoacetyl-CoA with 
concomitant increases in acetyl-CoA and β-hydroxybutyryl-CoA 
suggest that the enzymes, acetoacetyl-CoA reductase and β-
ketothiolase, act to rapidly metabolize the acetoacetyl-CoA.  In 
effect, the simulation shows that the acetoacetyl-CoA 
simultaneously undergoes β-ketothiolase mediated thiolysis in 
addition to reduction by the acetoacetyl-CoA reductase.  
Likewise, the simulation also matches the in vitro data by 
showing a rebound in which acetyl-CoA and β-hydroxybutyryl-CoA 
concentrations begin to drop and CoA concentrations rise.  This 
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rebound is no doubt a result of the forward movement of the PHB 
synthase reaction, which is driving the reaction towards PHB 
polymer production.  Since these behaviors can be simulated, they 
must result from the kinetic and thermodynamic constants that 
govern these equations. 
The simulation of the NADPH and acetoacetyl-CoA reductase 
spiking experiment shows good agreement with the in vitro data 
(Figure 18, Point D), which suggests that acetoacetyl-CoA is 
indeed maintained at low levels (i.e. it is not masked to 
analysis by HPLC).  It is clear that the reaction is currently 
moving at a velocity that can not be influenced by spiking in 
this manner.  Under these reaction conditions, the acetoacetyl-
CoA reductase reaction is not rate limiting, but it seems likely 
that addition of more of the β-ketothiolase or the PHB synthase 
enzymes might possibly speed the reaction.   
The stringent regulation of acetoacetyl-CoA, which is 
observed in this and other PHB synthesis systems, might result 
from the metabolic importance of acetoacetyl-CoA.  Acetoacetyl-
CoA is critical to several metabolic processes including fatty 
acid β-oxidation, ketogenesis, mitochondrial fatty acid 
elongation, and, in certain bacteria, PHB synthesis (247).  This 
metabolic importance could have lead to a tendency for 
acetoacetyl-CoA to be carefully regulated in vivo.  Additionally, 
acetoacetyl-CoA is labile at neutral and basic pH so the tight 
control of acetoacetyl-CoA concentrations could result from the 
need to rapidly metabolize this compound before substantial in 
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vivo hydrolysis.  Labile reaction intermediates are often 
carefully regulated in vivo through kinetic and thermodynamic 
mechanisms, which include substrate channeling, to prevent the 
loss of valuable unstable intermediates (248).   
 
Kinetic and thermodynamic parameters used in this model 
were gathered from the literature, from laboratory analysis, by 
fitting the simulation to the time course data, and by 
calculations based on the kinetic rate and Haldane equations.  It 
is clear that the simulation closely mimics the in vitro data 
(Figure 18).  The rate for the PHB synthase reaction, which was 
determined by simulated fit, is approximately seven fold greater 
than the literature and laboratory derived values; this 
correlates reasonably well.  However, the rate for the β-
ketothiolase and acetoacetyl-CoA reductase reactions which were 
determined by simulated fit were each 64 fold greater than the 
laboratory determined maximal rates.  This larger discrepancy 
likely reflects the use of kinetic and thermodynamic constants 
from the literature, which were gathered under somewhat different 
experimental conditions, i.e. temperature, buffer type, ionic 
strength, magnesium concentration.   
 
It is possible that the large deviations in reaction rates 
for the β-ketothiolase and acetoacetyl-CoA reductase reactions 
are evidence for substrate channeling.  Substrate channeling has 
been relatively well established for the long chain β-
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ketothiolase and acetoacetyl-CoA reductase enzymes which are 
involved in fatty acid β-oxidation in mitochondria (249).  
However, substrate channeling has never been reported for PHB 
production in bacteria.  Furthermore, substrate channeling tends 
to be a very controversial subject and much more evidence would 
be required to state, definitively, whether substrate channeling 
is present.   
 A statistical analysis of how each parameter in the model 
affects the goodness of fit is shown in Tables 8-11.  It is clear 
that altering the equilibrium constant, the Ksum (Ksum = Ka + Kb), 
and the Kq of the β-ketothiolase reaction dramatically decrease 
the goodness of fit.  For the acetoacetyl-CoA reductase reaction 
the goodness of fit is most significantly affected by altering 
the equilibrium constant, the rate constants, or the Kb.  
Adjusting any of the parameters in the PHB synthase reaction make 
the goodness of fit worse with the rate constant and KM 
exhibiting the greatest impact.  We note that for the parameters 
in both the acetoacetyl-CoA reductase reaction and β-ketothiolase 
reaction changing certain parameters can make the goodness of fit 
better; however, this increased fit is not substantial (i.e. 
greater than an order of magnitude).  Moreover, altering certain 
of these parameters may make other sections of the simulation 
worse since the simulation was designed by combining each step in 
the synthesis of PHB (See Figure 18, Points A-E).  
 
  178
CHAPTER 5 
DEVELOPMENT OF A PHB LABORATORY 
 
 
As part of a multidisciplinary Polymer Science and 
Engineering laboratory course, which was cross-listed between 
five departments, we developed a hands-on laboratory for 
culturing, producing, isolating, and purifying the bacterial 
biopolyesters PHB.  Poly-β-hydroxybutyrate (PHB) is an 
intracellular polymer that accumulates in the cytoplasm of 
bacterial cells if a carbon source is provided, and if at least 
one nutrient, such as nitrogen, is limited.  Because it is a 
biodegradable polyester, there is much interest in its 
production.  In addition to being biodegradable, PHB possesses 
piezoelectric properties and has characteristics similar to 
polypropylene, making it suitable for a wide range of 
applications in surgery, medicine, agriculture, the food 
industry, and environmental protection.   
 
The Discovery of PHB.  Since the discovery of PHB in the 
early 1800th century, intense interest has been directed toward 
optimizing bacterial production.  In the 1950s, Schlegel and 
coworkers (116,250,251) first discovered that PHB could be 
produced by knallgas bacteria (Hydrogenomonas).  The authors 
reported methodology for cultivating this Hydrogenomonas 
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bacteria, which was recently renamed Cupriavidus necator, and for 
generating PHB in vivo.  C. necator is one of many bacterial 
species that will produce PHB under nitrogen-limiting conditions.  
It has been reported in the literature that C. necator is able to 
produce up to 60% of its biomass in the form of PHB, when using 
fructose as the carbon source.   
 
Two Phase Cultivation of PHB.  PHB production in C. necator 
requires a two phase cultivation, whereby a given quantity of 
bacteria are initially grown under optimal growth conditions, and 
then the bacteria are transferred to a nitrogen-limited minimal 
media for the bacterial generation of PHB.  In this laboratory, 
all bacterial cultivations were performed via batch fermentation 
in order to minimize expensive equipment and provide students 
with an easily accessible methodology.  For this laboratory, C. 
necator was initially cultivated with twice concentrated L.B 
media.  As shown in Table 12, supplementing the traditional LB 
growth media with yeast extract and ammonium sulfate doubled the 
mass of PHB and the dry cell weight of C. necator, and increased 
the percent yield of PHB.   
 
 
 
Table 12.  Development of C. necator Growth Media.    
aDCW:   Dry Cellular Weight 
bNB:    Nutrient Broth 
cSupp:  Supplemented with ammonium sulfate
 Final OD600 Final DCWa g Mass PHB g % PHB 
NBb 12.5 o.28 0.15  51.0% 
2xNB 24.9 0.46 0.24 51.3 % 
2xNB Suppc 37.9 0.84 0.45 53.4 % 
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Bacterial production of PHB in this laboratory was 
performed by transferring the C. necator bacterial cells into a 
nutrient-limited minimal media, which was modified from 
Schlegel’s original media (250) using the literature reports of 
Repaske and Coworkers (252,253) and Meier-Schneiders et al (251).  
Specifically, Co2+ & Cr3+ were added to increase PHB production as 
discussed in the literature (251-253).  In addition, a chelated 
form of iron, ferric ammonium citrate, was used because this form 
of iron remained in solution over a substantially longer period 
(days instead of hours).  The non-chelated iron form, iron (III) 
chloride, rapidly precipitated out of solution and resulted in 
orange-colored PHB due, presumably, to contamination of the 
polymer with iron.   
 
Laboratory Layout.  This laboratory is designed in such a 
way that the students can perform the entire PHB cultivation 
process in several short sessions over one week.  In the first 
session, the students can make the growth media, autoclave and 
leave it to cool.  A short follow up session will allow students 
to inoculate their media with the C. necator bacteria and begin 
incubating the bacteria.  In a third session the students can 
pellet, wash and transfer the cultured mass of C. necator cells 
to the minimal media for PHB production.  For convenience, this 
PHB laden cell mixture can be stored in a refrigerator for up to 
one week before PHB extraction and purification analysis.  
Finally, the students can perform the PHB extraction and 
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purification in a single four hour session or two-two hour 
sessions.   
Coagulant Methods Aid Removal of PHB-Laden Cells from the 
Culture Media.  Chang and coworkers have developed methodology, 
which more efficiently separates the bacterial cells of C. 
necator from the fermentation broth by employing Al- and Fe-based 
coagulants.  Bacterial cells are typically removed from culture 
broth via centrifugation or filtration; however, the very small 
particle size of C. necator bacterial cultures results in very 
low sedimentation rates (254).  Fe- and Al-based coagulants 
utilized by Chang and coworkers (254) effectively increase 
particle sizes thus increasing sedimentation rates and 
facilitating removal of cellular material from the fermentation 
broths (254).  Indeed, the energy demand decreased by 89-97% when 
coagulation methodology was employed (255).  Further analyses 
revealed that coagulant based methodology coupled with PHB 
extraction via chemical digestion with sodium 
hypochlorite/chloroform generated PHB with 90-94% recoveries and 
98-99% purities (255).  Chang and coworkers (255) note that Al-
based coagulants are more advantageous than the Fe-based 
counterparts since these were observed to colorize the final 
product (255).  While these methodologies are ideal for 
implementation in industrial processes, this strategy seemed 
excessive for a small-scale student laboratory and was not 
utilized herein.   
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Extraction of PHB.   
Solvent Extraction.  Historically, the majority of PHB 
purifications employ a solvent, such as chloroform, to extract 
the PHB granules from inside the bacterial cell (255-259).  These 
methods typically require pretreatment of the cell mass via 
milling or grinding, and spray-, freeze-, or oven-drying of the 
bacterial mixture, which increases the solvent extractability.  
Since these methods typically require a lengthy drying processes 
followed by a long, typically 24 hour, extraction period this 
methodology is not conducive to being performed in a hands-on 
student laboratory.   
Extraction via Enzymatic Digestion.  Zeneca (formerly ICI) 
developed an enzymatic digestion method for purifying PHB (255-
257,260,261).  This technique involved the thermal treatment of 
PHB-laden bacterial cells followed by enzymatic digestion and 
washing of the cells with an anionic surfactant and possibly 
EDTA.  This solublized the non-PHB cellular material and thereby 
purified the PHB.  Specialty reagents used in this technique 
(such as proteases) increase extraction costs and require careful 
treatment of the cells; therefore, this technique was not chosen 
for the student laboratory.   
Hypochlorite Extraction Methods.  Other well known 
techniques involve the use of hypochlorite (261-263) or 
hypochlorite/chloroform dispersions (257) to purify PHB from the 
bacterial cell.  In the hypochlorite/chloroform dispersion 
methodology, the hypochlorite serves to digest the non-polymer 
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cellular material, disrupt the cell, bleach the polymer, and 
reduce the solution viscosity.  Likewise, the chloroform serves 
to extract and purify the PHB and it protects the PHB molecules 
from the hypochlorite (257,259).  Treatment with hypochlorite can 
cause severe degradation of the PHB; therefore, hypochlorite 
concentrations must be carefully controlled to produce PHB of 
good quality.  The hypochlorite techniques were not selected in 
order to avoid possible PHB degradation during the student 
laboratory; this ensured that students would have high molecular 
weight PHB with good polydispersity for future analyses.   
Extraction of PHB from E. coli with NaOH.  In 1999, Choi 
and Lee (256) developed and optimized a method for recovering PHB 
from genetically engineered E. coli cells.  This technique took 
advantage of the fragility of the E. coli bacterial cell.  The 
authors treated the cells with 0.2 N NaOH at 30o C for one hour 
and recovered PHB with a purity of 98.5%.  PHB recovered with 
this method cost only US$ 3.66/Kg of PHB, which was approximately 
25% cheaper than PHB recovered with the surfactant-hypochlorite 
digestion method.  E. coli engineered to express the PHB 
generating enzymes from C. necator is not commercially available 
and the applicability of this method to C. necator bacteria is 
currently unknown so this method was not further investigated for 
the student laboratory (256).   
Detergent Extraction.  Chang and coworkers (264) developed 
a simple and effective method for recovering PHB from C. necator 
cells, which employed direct addition of a detergent, SDS, to the 
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culture broth; this dissolved the non-PHB cellular material which 
allowed recovery of a PHB pellet by centrifugation.  Using this 
method the authors observed purities as high as 97% when 
SDS/Biomass ratios were greater than 0.4.  This technique 
required addition of SDS to the culture broth, followed by 
shaking for one hour, heat treatment via autoclave, and 
washing/centrifugation (264).  PHB granules have strong 
associations with the proteins that physically surround the 
granule so the authors found that the autoclaving treatment was 
necessary to facilitate protein removal from the PHB (264).  This 
methodology was adapted for use in the student laboratory.   
 
Techniques Used in This Student Laboratory.  The purpose of 
this student laboratory (detailed in Appendix 2) is to 
familiarize the student with the production of PHB using C. 
necator, and to provide a biopolymer sample that can be 
characterized and compared with other types of polymers.  The 
methodology developed by Chang and coworkers (264) was modified 
for use in this student laboratory.  SDS concentrations were 
adjusted to optimize PHB extraction.  EDTA was added to the 
cellular mixture to aid in cell lysis and because it helped to 
chelate heavy metals; this generated a product with less 
coloration.  The PHB bacterial cells were pelleted via 
centrifugation prior to detergent addition in order to optimize 
extraction of PHB under our laboratory conditions.  The 
autoclaving step was made optional (although autoclaving the 
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solution generates the highest quality product) and was replaced 
with a boiling step for student laboratories lacking large-scale 
autoclave equipment.  The detergent shaking step and the 
autoclaving/boiling steps were shortened to facilitate completion 
within a single laboratory period.  Finally, a chloroform 
purification and methanol precipitation procedure was developed 
in order to remove remaining non-PHB cellular material and to 
provide the students with high quality chloroform soluble PHB for 
future analyses.  
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CHAPTER 6 
ISO-COENZYME A:  INTRODUCTION 
 
 
Iso-coenzyme A.  Iso-coenzyme A (iso-CoA) is an isomer of 
coenzyme A (CoA) in which the monophosphate is attached to the 
2’-carbon of the ribose ring.  Iso-CoA was first reported in 1959 
by Khorana and coworkers (265,266) to be a byproduct of the 
chemical synthesis of CoA.  The final step of this synthesis 
entailed acid-catalyzed hydrolysis of cyclic-coenzyme A (Figure 
21), to produce a 50:50 mixture of two products which were 
separated using ECTEOLA-cellulose ion exchange chromatography 
(265,266).  Direct structural analysis was not readily available 
in 1959; consequently, the authors deduced the structure of iso-
CoA by establishing that, in contrast to CoA, iso-CoA was not a 
substrate for the enzyme phosphotransacetylase (265,266).  
Khorana and coworkers also used paper chromatography of 
phosphodiesterase hydrolysates to show that enzymatic hydrolysis 
of iso-CoA produces adenosine-2’,5’-diphosphate, exclusively 
(265,266).   
The position of the phosphate on the nucleotide 
diphosphates, which were used as standards by Khorana and 
coworkers, was originally determined by Cohn and coworkers (267).  
These authors used a clever an ion-exchange technique, which 
exploited borate’s ability to complex with cis-α-glycols, 
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exclusively.  Ribose 3’-phosphate, unlike ribose 2’-phosphate, 
contains a cis-α-glycol moiety; this forms a complex with borate, 
which generates a different ion-exchange elution profile than 
does ribose 2’-phosphate.
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Figure 21.  Final Step in the Total Synthesis of Iso-CoA.  
Chemical hydrolysis of cyclic-CoA (I) produces two products, CoA 
(II) and Iso-CoA (III).  Carbons are labeled according to 
d’Ordine et al (268). 
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The History of Coenzyme A.  In 1963, the Nobel foundation 
awarded its coveted prize to Fritz Lipmann (269) for ‘the 
discovery of Coenzyme A and its importance for intermediary 
metabolism’.  While Lipmann certainly played a pivotal role in 
this seminal research, elucidation of the structure of Coenyzme 
A, shown in Figure 22, was determined through years of methodical 
research by teams of scientists who painstakingly identified each 
individual portion of the CoA structure (269-279).  Lipmann’s 
discovery of CoA dates back to a 1945 publication (270,271) which 
was the first mechanistic account demonstrating acetylation of 
sulfanilamide in vitro with pigeon liver extracts; this was in 
contrast to other studies carried out in perfused organs, on 
intact animals, or in vitro with rabbit liver slices.   
 
Determination of the Structure of CoA.  The initial advance 
towards determining the structure of CoA, shown in Figure 22, was 
provided in 1947 by Dr. Beverly Guirard of Dr Roger William’s 
laboratory who detected pantothenic acid upon prolonged enzymatic 
treatment of CoA, and β-alanine after acid hydrolysis of CoA 
extracts (272).  By 1950, Novelli and Kaplan, of Lipmann’s 
laboratory, had reported that CoA preparations contained large 
quantities of adenylic acid (273)—the A in CoA stands for 
adenylic acid—and identified the pyrophosphate bridge (274).  
Additionally, Snell and coworkers (275) determined that the 
sulfur-containing moiety that was detected in CoA was 
thioethanolamine linked in a peptide bond to pantothenic acid.  
   
 190
The following year, Baddiley and Thain (276) identified the 5’-
adenylic acid moiety though chemical cleavage and further honed 
in on the CoA structure by determining that the pyrophosphate 
bridge attached at the 4-position of pantothenic acid.  The year 
1952 brought an initial account, by Wang, Shuster and Kaplan 
(277), placing the CoA monophosphate on the 3’-carbon of the 
adenosine ribose moiety (278,279).  Finally, in 1953 Novelli (now 
at Case Western) completed the structural analysis of CoA by 
presenting the enzymatic synthesis of CoA (270,280).  
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Figure 22.  Chemical Structure of Acetyl-Coenzyme A (281). 
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Chemical Syntheses of CoA.  Since Khorana’s original work, 
four additional chemical syntheses of CoA have been reported 
(282-287), and as summarized in Table 13, in each of these 
syntheses the free 3’-phosphate group is protected by forming a 
2’,3’-cyclic moiety.  In Khorana’s the Total Synthesis of 
Coenzyme A (265,266), 2’,3’-cyclic-CoA was produced by the 
formation of a adenosine-2’,3’ cyclic phosphate-5’-
phosphormorpholidate and D-panetheine-4’ phosphate to produce 
2’,3’-cyclic-CoA.  In 1972, Hashimoto and Mukaiyama (286) 
optimized Khorana’s method by utilizing the coupling agents 
triphenylphosphine and 2,2’-dipyridyl disulfide to produce the 
key intermediates in high yields.  Michelson’s (282,283) 1964 
synthesis used P1-adenosine (2’, 3’-cyclic phosphate)-5’-P2-
diphenylpyrophosphate and pantethine 4’,4’-bis-phosphate in 
pyridine to produce the 2’, 3’-cyclic-CoA product.  Shimizu et 
al. (284,285) synthesized CoA by generating an intermediate 
containing a thiazoline moiety on the pantothenate arm; acid 
catalyzed hydrolysis of the thiazoline moiety then generated CoA.  
2’,3’-cyclic CoA was produced by Taguchi et al. (287), in 1976, 
by reacting adenosine-5’ 2-dimethylamino-4-nitrophenyl phosphate 
with D-pantethine-4’,4”-diphosphate in the presence of acetic 
acid in pyridine.  A key intermediate in each of these syntheses 
is a 2’, 3’-cyclic moiety which is then hydrolyzed either 
chemically, to produce CoA and iso-CoA (265,266,283-285,287), or 
enzymatically using the regioselective enzyme ribonuclease T2, 
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which Michelson (282,283) first used to produce CoA from cyclic 
CoA (282-286).
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Table 13.  Chemical Syntheses of CoA and Iso-CoA. 
Acid-Catalyzed 
Hydrolysisa  
Enzyme-Catalyzed 
Hydrolysisb 
Comments 
Author 
and  
Date 
Key reaction intermediates for forming cyclic-CoA 
or CoA  
Yes No 
Yes No 
Khorana   1959 
          1961 
(265,266)  Ado
O
OO
HH
HH
P
O OH
O
HH
PN
O-
O
OH
P
O
OHO
N N
SH
O O
HHOHH
CH3H3C
H
H H
H
H
H
H
HH
H
O
2'3'
+
 
No Yes Hashimoto 1972 
(286) Optimized Khorana’s synthesis using oxidation 
reduction condensation coupling agents 
No Yes 
Yes Yes 
Michelson 1961 
          1964 
(282,283)  First enzymatic hydrolysis of cyclic-CoA 
Ado
O
OO
HH
HH
P
O OH
O
HH
PO
O-
O
OH
P
O
OHO
N N
S
O O
HHOHH
CH3H3C
H
H H
H
H
H
H
HH
H
2'3' +
P
O
S  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 195
Table 13 Continued 
Yes Yes 
Yes Yes 
adenosine-2’,3’-cyclic phosphate compound is 
enzymatically hydrolyzed by ribonuclease T2 prior 
to reaction with cysteamine to give the thiazoline 
moiety on the pantothenate arm, which is then 
hydrolyzed to afford CoA 
Shimizu  1965 
         1967 
(284,285) 
Ado
O
OHO
HH
HH
O
HH
P
O
P
O
HO
O
O
OH
N N
SO
HHOHH
CH3H3C
H
H
H
H
H
H
H
H
H
PO
OH
OH
2'3'
 
Yes No Taguchi  1976 
(284,285) Ado
O
OO
HH
HH
P
O OH
O
HH
PO
OH
O
OH
P
O
OHO
N N
S
O O
HHOHH
CH3H3C
H
H H
H
H
H
H
HH
H
2'3' +
S
N
O2N
 
aAcid-catalyzed hydrolysis produces an equilibrium mixture of the 
2’- and 3’-phosphate isomers. 
bEnzyme-catalyzed (Ribonuclease T2) hydrolysis regioselectively 
generates the 3’- isomer. 
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Characterizations of Iso-CoA Analogues and Derivatives.  No 
full structural characterization of iso-CoA has ever been 
reported in the literature.  Nevertheless, there exist literature 
reports of synthetic CoA and iso-CoA analogues, some of which 
have been characterized using techniques including 1D-NMR and MS.  
In this regard, Retey and coworkers have synthesized several 
carba(dethia)-CoA (or CH2-CoA) analogs (288-295), in which the 
sulfur of CoA is replaced by a methylene, as mixtures of the 2’- 
and 3’-phosphate isomers.  Retey and coworkers synthesized an 
isomeric mixture of the 2’- and 3’-isomers of propionyl-CH2-CoA 
(288,289,295), partially purified the isomers with DE-32 
cellulose chromatography using a LiCl gradient.  Their analysis 
by 1H-NMR and 31P-NMR of the HPLC-purified isomers indicated that 
approximately 9% of the 2’-isomer remained.   
In a subsequent publication, the authors synthesized an 
isomeric mixture of propionyl-dethia-(dicarba)-CoA (propionyl-
CH2CH2-CoA), purified the isomers to approximately 91% and 
reported 1H-NMR, 31P-NMR, and FAB-MS for the CoA isomer only.  In 
a similar paper, Brendelberger and Retey synthesized an isomeric 
mixture of isobutyryl-CH2-CoA (291,292); the 1H-NMR spectra of the 
ion-exchange-purified 3’-isomer indicated that approximately 15% 
of the 2’-phospho-CH2-CoA isomer remained after chromatographic 
purification.  These isobutanoyl-2’- and 3’-isomers were purified 
to homogeneity in a later publication (293) via repeated DEAE-
cellulose chromatography and then the pure isomers were 
characterized by 1H-NMR and 31P-NMR.  Wagner and Retey (294) 
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synthesized an isomeric mixture of myristoyl-CH2-CoA and 
successfully purified each isomer to homogeneity using an 
extremely lengthy RP-HPLC method; then the HPLC-purified isomers 
were characterized by 1H-NMR, 31P-NMR, and FAB-MS.  Finally, Retey 
and coworkers (290) synthesized propionyl-CoA and briefly 
reported that the compound was not contaminated with the 2’-
phosphate isomer as demonstrated by the presence of only one 
anomeric 1H-NMR peak.  Stewart, Wieland and coworkers (296-299) 
also synthesized equilibrium mixtures of the CH2-CoA analogues, 
acetonyl-CH2-CoA and heptadecan-2-onyl-CH2-CoA; unfortunately, 
they were unable to separate the 2’- and 3’-phosphate isomers and 
the NMR spectra for heptadecan-2-onyl-CH2-CoA could only be 
obtained with isomeric mixtures (297).   
The few remaining synthetic analogs of CoA and iso-CoA 
reported in the literature were characterized using enzymatic 
activity assay and paper chromatography of enzyme digests, 
instead of NMR or MS, because, like iso-CoA, these compounds were 
synthesized before the ready availability of NMR and MS analyses.  
An isomeric mixture of benzoyl-seleno-CoA was first reported by 
Gunther and Mautner (300), who found that these benzoyl isomers 
could be separated with ECTEOLA Cl- ion-exchange chromatography 
and homogenous preparations of seleno-CoA and seleno-iso-CoA were 
obtained following removal of the benzoyl group.  Another 
derivative, oxy–CoA, which contains a hydroxyl group instead of 
the free thiol present in CoA, was synthesized by Stewart and 
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coworkers (301), and the isomers were purified to homogeneity by 
TEAE-cellulose column chromatography.   
Recently, Minkler et al. (302) reported the identification 
of the 2’-phosphate isomer of malonyl-CoA in commercial samples 
(302).  These authors obtained homogeneous samples of two peaks 
observed in the commercial sample of malonyl-CoA by RP-HPLC and 
analyzed each HPLC-purified isomer by UV, HPLC/MS/, HPLC-MS/MS 
and 1D-NMR.  MS and MS/MS analyses indicated that both HPLC-
purified samples exhibited identical [M-H]- quasi-molecular ions 
at m/z 852.2, an observation consistent with the presence of 
isomers of malonyl-CoA.  Finally, the 1H-NMR spectra of 2’,5’-ADP 
was found to be comparable to the spectra of the unknown HPLC-
purified isomer; thus, the authors concluded that the unknown 
HPLC-purified sample was the 2’-phosphate isomer of malonyl-CoA, 
or malonyl-iso-CoA.  This recent NMR, MS, and MS/MS analysis is 
the only literature account of a 2’-phosphate isomer of a 
naturally occurring CoA-containing compound published since 
Khorana’s seminal iso-CoA paper; nevertheless, a complete 
structural characterization of iso-CoA has heretofore never been 
achieved. 
 
The Enzymatic Activity of Iso-CoA-containing Compounds and 
Analogues.  The issue of whether or not enzymes, which act upon 
CoA-containing substrates, discriminate between the 2’- and 3’- 
phosphate isomers is of obvious relevance to the design of new 
classes of inhibitors and pseudosubstrates.  An extensive review 
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of the literature, summarized in Table 14, revealed that, prior 
to this study, only ten of the more than 350 CoA-utilizing 
enzymes have been assayed with the 2’-phosphate isomers of 
coenzyme A; moreover, eight of these enzymes were assayed with 
synthetic, non-natural, derivatives of CoA isomers and in only 
five of cases were purified isomer substrates used.   
Enzymes that Reject Iso-CoA-containing Compounds.  As 
previously discussed, in Khorana’s early work the enzyme 
phosphotransacetylase was reported to be unreactive towards 
purified iso-CoA (265,266).  The historic use of 
phosphotransacetylase for CoA quantitation has resulted in 
multiple publications that have provided solid evidence that this 
enzyme is strictly selective for 3’-phosphate-containing 
compounds.  As Table 14 indicates, phosphotransacetylase is not 
inhibited by oxy-iso-CoA (301) or any adenosine compound 
containing a 2’-phosphate moiety (303).  The significance of the 
phosphate moiety is highlighted by the discovery that 3’-
pyrophospho-CoA exhibits two times the activity of CoA (304).   
Other enzymes that do not accept 2’-phosphate compounds 
have been reported by Retey and coworkers (288,289).  The authors 
report that methylmalonyl-CoA pyruvate carboxylase distinguishes 
between the isomers, reacting exclusively with propionyl-CH2-CoA 
(288,289), and FAD-dependent isobutanoyl-CoA dehydrogenase is 
reactive with isobutanoyl-CH2-CoA but not with the iso-CoA analog 
(293).  We note that, while the publications by Retey and 
coworker used partially purified isomers, they do not show any 
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data supporting their contention that the 2’-phosphate isomers 
are not inhibitors.   
Enzymes that Accept Iso-CoA-Containing Compounds.  Other 
enzymes appear to accept the 2’-phosphate isomers as inhibitors 
or substrates.  Wagner et al. (294) have reported that both HPLC-
purified myristoyl-CH2-CoA and myristoyl-CH2-iso-CoA competitively 
inhibit N-myristoyltransferase, and Rossier (305) reported that 
choline acetyltransferase is inhibited by ion-exchange-purified 
samples of both seleno-CoA and seleno-iso-CoA, although in both 
cases the iso-CoA analogs are somewhat less potent.  Thorpe et 
al. (298) reported that substrate mixtures containing both CH2-
iso-CoA and CH2-CoA derivatives are utilized by the general acyl-
CoA dehydrogenate to reduce enzyme bound FAD.  No significant 
difference in FAD reduction was observed when different isomer 
ratios were assayed (i.e. isomeric ratios of 1:1 vs. 65:45) 
suggesting that acyl-CoA dehydrogenase does not discriminate 
between the isomers.   
In the cases of citrate synthase and carnitine 
palmitoyltransferase, Ciardelli et al. (297) argue that these 
enzymes do not discriminate between isomers.  Unfortunately, the 
authors draw this conclusion by kinetically comparing S-
heptadecyl-CoA, a thioether analog of CoA, to an isomeric mixture 
of heptadecanoyl-CH2-CoA; the structure of these inhibitors is 
simply too disparate to draw a clear conclusion from the data.  
Nikawa et al. (299) examined acetyl-CoA carboxylase and fatty 
acid synthase  with isomeric mixtures of acetonyl-CH2-CoA and 
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acetonyl-CH2-iso-CoA, but these isomers were not purified so no 
conclusion regarding enzyme specificity for phosphate position is 
possible. Clearly, this issue needs to be reexamined for many of 
the CoA-utilizing enzymes using purified and fully characterized 
iso-CoA substrate analogues. 
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Table 14.  Selectivity of Enzymes Examined for 2’- vs. 3’- Phosphate Activity. 
Enzyme/Reaction 
Compound 
R 2’ 3’ Pure 
Y/N 
Substrate 
(KM) 
Inhibitor 
(KI) 
Accepts 2’-phosphate isomers as substrates 
Accepts 2’-phosphate isomers as inhibitors 
Rejects 2’-phosphate isomers as substrates 
Rejects 2’-phosphate isomers as inhibitors 
Specificity unclear 
[E.C. 1.1.1.36] Acetoacetyl-CoA Reductase (222) 
Acetoacetyl-CoA + NADPH ⇌ β-hydroxybutyryl-CoA + NADP+ 
Accepts 2’-isomers as substrates with equal affinity.  Isomers were run together in the same assay 
but were quantitated separately by HPLC.   
Acetoacetyl-CoA AcAcS H P No† Yes --- 
Acetoacetyl-iso-CoA AcAcS P H No† Yes --- 
β-hydroxybutyryl-CoA HBS H P No† Yes --- 
β-hydroxybutyryl-iso-CoA HBS H P No† Yes --- 
[E.C. 1.3.99.3] AcCoA Dehydrogenase (298,306) 
Acetyl-CoA + FAD ⇌ D2-trans-enoyl-CoA + CoA + FADH2  
Accepts 2’-isomer as an inhibitor (in isomeric mixture).  Different isomer ratios exhibited the 
same KM’s this enzyme putatively does not discriminate between isomers. 
Heptadecan-2-only-CH2-CoA HpCH2 Mix 
1:1 
No Yes(58% of 
palmitoyl-CoA)†  
--- 
Heptadecan-2-onyl-CH2-CoA HpCH2 Mix 
65:45
No Yes† --- 
S-heptadecyl-CoA      -S- H P Yes No Kd = 17nM; KI < 40 nM Competitive 
Octanoyl-CoA OcS H P Yes 2.21 µM  --- 
Octanoyl-dephospho-CoA OcS H H Yes 1.09 µM  --- 
[E.C. 1.3.99.12] FAD-dependent  isobutanoyl-CoA Dehydrogenase (293)    
Isobutanoyl-CoA + FAD ⇌  Methacrylyl-CoA + FADH2 
Rejects 2’-phosphate isomer as a substrate 
Table 14 Continued 
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Isobutanoyl-CH2-CoA IsoCH2 H P Yes Yes --- 
Isobutanoyl-CH2-iso-CoA IsoCH2 P H Yes No --- 
[E.C. 2.1.3.1] Methylmalonyl-CoA pyruvate carboxylase (transcarboxylase) (288,289)   
Propionyl-CoA + oxaloacetate ⇌  Methylmalonyl-CoA + pyruvate 
Rejects 2’-phosphate isomers as a substrate.  Good example with fully purified isomers 
Propionyl-CH2-CoA PrCH2 H P Yes Yes --- 
Propionyl-CH2-iso-CoA PrCH2 P H Yes No --- 
[E.C. 2.3.1.5] Arylamine N-acetyltransferase (300)   
4-aminoazobenzene + ATP ⇌ 4-acetamidoazobenzene + ADP 
Accepts 2’-phosphate isomer as a substrate.*** 
***Reference does not name this enzyme; thus, this is not considered a valid case.   
CoA SH H P Yesa Yes†† --- 
Iso-CoA SH P H Yesa Yes (slight) --- 
Se-CoA SeH H P Yesb Yes --- 
Se-Iso-CoA SeH P H Yesb No --- 
Dephospho-CoA SH H H --- Yes --- 
dephospho-Se-CoA SeH H H --- Yes --- 
[E.C. 2.3.1.6] Choline Acetyltransferase (305,307,308) 
Choline + Acetyl-CoA ⇌ CoA + Acetyl-Choline 
Accepts 2’-phosphate isomer as an inhibitor:  Se-CoA has a 3.5 x better KI than Se-iso-CoA 
CoA SH H P ?d 0.25 µM (3.8)  1.8 µM w.r.t. to AcCoA Competitive 
Se-CoA SeH H P Yesb ---    7 µM Competitive 
Se-iso-CoA SeH P H Yesb ---   25 µM Competitive 
dephospho-CoA SH H H ?d 27 µM (39)  500 µM Competitive 
dephospho-Se-CoA SeH H H Yes ---  700 µM Competitive 
Ado-3’-P-5’-P --- H P ?d ---  415 µM Competitive 
Ado-2’-P-5’-P --- P H ?d --- 2200 µM Competitive 
Ado-5’-P --- H H ?d --- 2500 µM Competitive 
Table 14 Continued 
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Acetyl-CoA AcS H P Yes 25.7 µM Yes 
Acetyl-dephospho-CoA AcS H H Yes 54.8 µM Yes 
Acetylcholine --- - - --- 400 µM (0.9)  
 
Rejects 2’-phosphate compounds as substrates 
Rejects 2’-phosphate compounds as inhibitors 
CoA SH H P Yesa Yes No 
Iso-CoA SH P H Yesa No No 
Se-CoA SeH H P Yesb No No 
Oxy-CoA OH H P Yesc No 0.35 µM Competitive 
Isomeric Mix of Oxy-CoA OH Mix No No  0.6 µM 
Oxy-iso-CoA OH P H Yesc No No only 0.5 % of oxy-CoA 
Dephospho-CoA SH H H --- 0.5% CoA --- 
Dephospho-CoA SH H H --- 10% of CoA --- Lactobacillus fermenti only 
3’-pyrophospho-CoA SH PP H --- 2x CoA --- (also from C. kluyveri,  
CoA-SS-CoA SCoA H P --- No --- L. mesenteroides, E. coli) 
      Inhibition Rate Percent (%) 
      E. coli Cl. kluyveri 
Ado-3’-P-5’-PP --- H P --- No 62 33 
Ado-2’-P-5’-PP --- P H --- No 5 5 
Ado-3’-P-5’-PP-CH3 --- H P --- No 33 22 
Ado-2’-P-5’-PP-CH3 --- P H --- No 0 2 
Ado-5’-P --- H H --- No 2 0 
Ado-3’-P --- H P --- No 0 0 
ADP --- H H --- No 48 0 
ATP --- H H --- No 37 0 
Ado-3’-P-5’-P --- H P --- No 36 2 
Ado-3’-P-5’-PP-CH2CH(CH3)2 --- H P --- No 81 43 
[E.C. 2.3.1.16] β-ketothiolase (222) 
2 Acetyl-CoA ⇌ Acetoacetyl-CoA + CoA 
Table 14 Continued 
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Accepts 2’-phosphate isomers as substrates with equal facility.  Isomers were run together in the 
same assay but were quantitated separately by HPLC. 
CoA SH H P No† Yes --- 
Iso-CoA SH P H No† Yes --- 
Acetyl-CoA AcS H P No† Yes --- 
Acetyl-iso-CoA AcS P H No† Yes --- 
Acetoacetyl-CoA AcAcS H P No† Yes --- 
Acetoacetyl-iso-CoA AcAcS P H No† Yes --- 
[E.C. 2.3.1.21] Carnitine Palmitoyltransferase (297) 
Palmitoyl-CoA + carnitine ⇌ palmitoylcarnitine + CoA 
Specificity is unclear.  Isomeric mixture inhibits and authors propose that the enzyme doesn’t 
discriminate but further experiments are warranted.   
Heptadecan-2-onyl-CH2-CoA HepCH2 Mix No --- 1.35 µM (@ <30 µM P-CoA) competitive 
S-heptadecyl-CoA HepS H P Yes --- 3.34 µM (@ <30 µM P-CoA) competitive 
[E.C. 2.3.1.85] Fatty acid Synthase (299,309,310) 
acetyl-CoA + n malonyl-CoA + 2nNADPH + 2nH+ ⇌ long-chain fatty acid + (n+1)CoA + nCO2 + 2n NADP+ 
Specificity is unclear.  Isomeric mixture inhibits and authors propose that the enzyme doesn’t 
discriminate but further experiments are warranted. 
Acetonyl-CH2-CoA + iso AcCH2 Mix No --- No 
Ado-2’-P --- P H Yes --- Prevents inactivation 
Ado-3’-P --- H P Yes --- No protection 
CoA SH H P --- --- Increase inactivation rate (stops 
inhibition)  
Dephospho-CoA SH H H --- --- Increase inactivation rate (stops 
inhibition)  
[E.C. 2.3.1.97] N-myristoyltransferase (294,311)   
Octapeptide + myristoyl-CoA ⇌ myristoyl-peptide + CoA 
Accepts 2’-isomers as inhibitors.  3’-phosphate isomer has a 6.7 x better KI than the 2’-isomer.  
This is a clear example using fully purified isomers. 
Table 14 Continued 
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Myristoyl-CH2-CoA MyrCH2 H P Yese --- 0.3 µM competitive 
Myristoyl-CH2-iso-CoA MyrCH2 P H Yese --- 2 µM competitive 
     Kd (nM) % Act  
Lauryl-CoA LryS P H    62  44%  
Lauryl-dephospho-CoA LryS H H  8380  21%  
Myristoyl-CoA MyrS P H    15 100%  
Myristoyl-dephospho-CoA MyrS H H   124  73%  
Palmitoyl-CoA PalmS P H    26 1.6%  
Palmitoyl-dephopho-CoA PalmS H H   232   4%  
[E.C. 2.3.3.1] Citrate Synthase (296,297,312,313) 
Oxaloacetate + Acetyl-CoA ⇌ CoA + Citrate 
Specificity is unclear.  Isomeric mixture inhibits and the authors propose that the enzyme does 
not discriminate between isomers based on the results with S-heptadecyl-CoA but further 
experiments are warranted. 
Acetonyl-CH2-CoA + Iso AcCH2 Mix No --- 13.2 µM Competitive 
Heptadecan-2-onyl-CH2-CoA HepCH2 Mix 
1:1 
No --- 6-7.5 µM; 3.7 µM is ≈ to Palmitoyl-CoA 
@ 4.1 µM; Noncompetitive 
S-heptadecyl-CoA HepS H P Yes --- 1-1.5 µM; 1.2 µM is ≈ to Palmitoyl-CoA 
@ 4.1 µM; Noncompetitive  
110 µM CoA SH H P Yes --- 109% activity after 10 min  
130 µM dephospho-CoA SH H H Yes --- 110% activity after 10 min 
Acetyl CoA AcS H P Yes 4 x 10-4 --- 
Acetyl-dephospho-CoA AcS H H Yes 1/3 of Acetyl-CoA --- 
[E.C. 6.4.1.2] Acetyl-CoA Carboxylase (299,314) 
ATP + Acetyl-CoA + HCO3- ⇌ ADP + Pi + Malonyl-CoA 
Specificity is unclear.  Isomeric mixture inhibits but experiments with purified isomers were not 
performed.   
Acetonyl-CH2-CoA + iso AcCH2 Mix No 96 µM --- 
 
Table 14 Continued 
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Acetyl-CoA AcS H P Yes Yes  --- 
Acetyl-dephospho-CoA AcS H H Yes Yes ≈Acetyl-CoA --- 
[E.C. Not Currently Classified] PHB Synthase (222) 
β-hydroxybutyryl-CoA ⇌ PHB + CoA 
Accepts 2’-phosphate isomers as substrates with equal facility.  Isomers were run together in the 
same assay but were quantitated separately by HPLC. 
β-hydroxybutyryl- CoA HBS H P No† Yes --- 
β-hydroxybutyryl-iso-CoA HBS P H No† Yes --- 
CoA SH P H No† Yes (Product) --- 
iso-CoA SH P H No† Yes (Product) --- 
† These compounds were not purified prior to enzymatic analysis but the reaction was monitored by 
HPLC and the isomers were well resolved by HPLC; thus, the result of isomer specificity with these 
enzymes is clear.  
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Herein we report the first structural characterizations of 
iso-CoA, acetyl-iso-CoA, acetoacetyl-iso-CoA, and β-
hydroxybutyryl-iso-CoA.  All previous characterizations of the 
structure of iso-CoA have been based on chromatographic analyses 
(265,266), which ultimately rest on comparisons with the 
degradation products of CoA and NADPH (267,277,315), or have been 
based on assumptions regarding enzyme specificity (284,285,287).  
We describe HPLC methodology to separate the isomers of several 
CoA-containing compounds, and the characterization of iso-CoA 
structures using MS, MS/MS, and NMR analyses.  Our experiments 
reveal the existence of up to 18% of the 2’-phosphate isomer in 
commercial preparations of several CoA-containing compounds, 
which are listed as having purities of 90-99%.  We also report 
here the first examples of iso-CoA-containing compounds acting as 
substrates in enzymatic acyl-transfer reactions.  Finally, we 
describe a simple synthesis of iso-CoA from CoA, which utilizes 
β-cyclodextrin to produce iso-CoA with high regioselectivity, and 
we demonstrate a plausible mechanism, which accounts for the 
existence of iso-CoA isomers in commercial preparations of CoA-
containing compounds.  
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CHAPTER 7 
ISO-COENZYME A:  EXPERIMENTAL 
 
 
Materials.  The lithium salts of CoA (93% purity) purified 
from yeast, acetyl-CoA (93% purity), β-hydroxybutyryl-CoA (99% 
purity), the sodium salt of acetoacetyl-CoA (90% purity), 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), β-
cyclodextrin and tetrabutyl ammonium hydrogen sulfate (TBAHS) 
were purchased from Sigma (St. Louis, MO).  Triscarboxyethyl 
phosphine (TCEP) was from Molecular Probes (Eugene, OR).  All 
HPLC or Optima Grade solvents and all other compounds were 
obtained from Fisher Scientific. 
 
HPLC Mass Spectrometry.  Commercial CoA and acetyl-CoA 
standards were analyzed with a Micromass Quattro LC triple 
quadrupole tandem mass spectrometer equipped with an ESI source 
connected to an Hewlett-Packard series 1100 HPLC system.  
Resolution of the isomers was achieved with an Agilent Hypersil 
AA-ODS 2.3 x 200 mm column attached to a Phenomenex 
SecurityGuardTM (C18, 4 mm length x 3.0 mm I.D.), using an 
isocratic mobile phase of 96% 200 mM ammonium acetate pH 6.0: 4% 
acetonitrile at a flow rate of 0.2 mL/min.  ESI mass spectra were 
obtained in the positive ion mode with nitrogen used as the 
nebulizer and desolvation gas at flow rates of approximately 80 
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and 580 L/h, respectively.  The cone voltage was set to 50 V and 
the capillary voltage to 3.5 kV.  Tandem mass spectrometry 
(MS/MS) using multiple reaction monitoring (MRM) was performed on 
the (M+H)+ ions of the isomers of CoA (m/z 768), acetyl-coA (m/z 
810), acetoacetyl-CoA (m/z 852), and β-hydroxybutyryl-CoA (m/z 
854) using argon as the collision gas at a collision energy of 20 
eV for the collision induced dissociation of the precursor ion.  
The commercial standards were monitored at the following 
transitions: CoA at m/z’s 768?159, 768?261 and 768?428; acetyl-
CoA at m/z 810?303 and m/z 810?428; acetoacetyl-CoA at m/z’s 
852?135, 852?243, 852?261, 852?345, and 852?428; β-
hydroxybutyryl-CoA at m/z’s 854?136, 854?245, 854?347 and 
854?428. 
 
Semi-Prep HPLC Purification of CoA and the Isomer.  A 100 
µL aliquot containing, at most, 3 mg of a commercial sample of 
CoA in 5 mM TCEP was injected onto an Allsphere ODS-2 semi-prep 
column, 250 mm x 10 mm I.D. with a Phenomenex SecurityGuardTM 
containing a C18, 4 mm length x 3.0 mm I.D., guard cartridge.  
Peaks were manually collected using isocratic elution with a 
mobile phase of 97.5% 200 mM ammonium acetate pH 6.0: 2.5% 
acetonitrile at a flow rate of 7 mL/min with detection at 261 nm.  
Lyophilization of the collected effluent provided 
chromatographically pure samples of CoA and the isomer.   
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High Resolution ESI MS of HPLC-Purified Samples.  Exact 
Mass and MS/MS analyses were performed using HPLC-purified 
samples of CoA and the isomer on an Applied Biosystems QSTAR XL 
hybrid quadrupole-TOF LC/MS/MS mass spectrometer.  The QSTAR XL 
was operated in the positive ion mode using a needle voltage of 
5500 V.  MS analysis was performed over a mass range of m/z 310-
1500 and MS/MS spectra of the m/z 768 precursor ion were obtained 
over the mass range of m/z 50-800. 
 
NMR Analysis.  NMR spectra of iso-CoA were obtained in D2O 
in a 5 mm sample tube on a Bruker DRX 500 spectrometer at 500.13 
mHz for 1H and 202.46 mHz for 31P using an inverse triple 
resonance probe maintained at 298K.  The COSY experiment was 
performed using the standard Bruker program cosyprqf, with 
presaturation during the 2 s relaxation delay on the HOD signal, 
2048 data points in the F2 dimension and 128 increments in F1.  
The data matrix was processed to give a matrix of 1024 x 1024 
points, and a sine-bell apodization function was applied before 
Fourier transformation. 
The parameters for the two-dimensional heteronuclear 
multiple quantum correlation (1H-31P HMQC) experiment are as 
follows:  hmqcqf standard Bruker program, 1.5 s recycle delay, 
1024 data points in F2 and 128 increments in F1, 8 Hz coupling 
constant, GARP 31P decoupling during  acquisition; shifted sine-
squared apodization before Fourier transform.  The chemical shift 
assignments for the HPLC-purified CoA and iso-CoA are labeled 
   
 212
above their respective peaks in the proton spectra.  The few 
unlabeled peaks were either due to the iso-CoA disulfide formed 
during purification and analysis, in the absence of reducing 
agents, or to an unknown impurity.  Coupling constants were 
obtained through successive decoupling experiments, and the 
unresolved coupling constants were then obtained by simulating 
the spectra using the gNMR (316) and MestRe-C (317) software 
packages.  1H-NMR analysis(500 MHz, 99.99% D2O, reference to 4.67 
ppm water peak) δ8.41 (s, 1, H8), 8.18 (s, 1, H2), 6.18 (d, 1, 
H1’, J1’,2’ = 5.15 Hz), 4.98 (m, 1, H2’, J2’,3’ = 5.09 Hz, J2’,P2’ = 
8.69 Hz), 4.56 (t, 1, H3’, J3’,4’ = 4.56 Hz), 4.32 (m, 1, H4’, J4’,5a’ 
= 3.92 Hz, J4’,5b’ = 2.83 Hz, J4’,P5’ = 2.00 Hz), 4.18 (m, 1, H5b’, 
J5b’,P5’ = 4.58 Hz), 4.13 (m, 1, H5a’, J5a’,P5’ = 5.08 Hz, J5a’,5b’ = 
11.63 Hz), 3.92 (s, 1, H3”), 3.73 (dd, 1, H1”, J1”,1” = 9.90 Hz, 
J1”,P1” = 5.09 Hz), 3.48 (dd, 1, H1”, J1”,P1” = 4.83 Hz), 3.38 (t, 2, 
H5”, J5”,6” = 6.53 Hz), 3.24 (t, 2, H8”, J8”,9” = 6.59 Hz), 2.54 (t, 
2, H9”), 2.37 (t, 2, H6”), 0.89 (s, 3, H10”), 0.67 (s, 3, H11”).  
31P-NMR analysis (202.46 MHz, 99.99% D20) δ -0.90 (s, 1, P2’), -
9.63 (d, 1, P1”), -10.21 (d, 1, P5’).  
 
Analytical HPLC Procedure.  HPLC analyses of CoA, acetyl-
CoA, acetoacetyl-CoA and β-hydroxybutyryl-CoA and the isomers 
were performed on a Waters LC Module I Plus HPLC system with 
auto-injection of samples using the Millennium Chromatography 
Manager Software (Waters, Milford, MA, USA).  A Waters NovaPak C18 
Reverse Phase column, 4 µm particle size, 150 mm x 3.9 mm I.D. 
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was used with a Phenomenex SecurityGuardTM containing a C18, 4 mm 
length x 3.0 mm I.D., guard cartridge.  Isocratic analyses were 
performed at a wavelength of 261 nm with a mobile phase 
containing 96% of 200 mM ammonium acetate pH 6.0: 4% acetonitrile 
at a flow rate of 1.0 mL/min.  The mobile phase was premixed 
prior to sparging with helium gas and the column pre-equilibrated 
with mobile phase for at least one hour prior to sample analysis.  
Under these HPLC conditions, the retention times and purities are 
listed as follows: CoA, 4.25 min, 90%; iso-CoA, 5.5 min, 10%; 
acetyl-CoA, 12.75 min, 85%; acetyl-iso-CoA, 17.1 min, 15%; 
acetoacetyl-CoA, 14.5 min, 82%; acetoacetyl-iso-CoA, 19.5 min, 
18%; β-hydroxybutyryl-CoA, 18.25 min, 97%; β-hydroxybutyryl-iso-
CoA, 24.6 min, 3%.   
Four different mobile phases adequately resolved the 2’- 
and 3’-phosphate isomers:  96% 200 mM sodium phosphate pH 5.5: 4% 
acetonitrile; 96% 150 mM sodium citrate pH 5.5: 4% acetonitrile; 
96% 200 mM sodium acetate pH 5.5: 4% acetonitrile; 82% of 10 mM 
TBAHS in H20 at pH 5.5: 18% Acetonitrile with 10 mM TBAHS.  
However, we note that the ion-pairing mobile phase, which 
contained TBAHS, reversed the isomer elution order such that the 
3’-phosphate isomer eluted before the 2’-phosphate isomer.  
Additionally, isomers were resolved for each CoA-containing 
sample using four different RP-HPLC columns, and three different 
HPLC systems using both UV-Vis and MS detection.  Freshly opened 
CoA-containing samples dissolved in water exhibited two peaks by 
HPLC, and HPLC-purified samples did not interconvert in deionized 
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water, at pH 3 or pH 11 (data not shown).  Therefore, the 2’-
phosphate isomer is a stable compound and this suggests that it 
was not generated accidentally in this laboratory. 
 
Enzymatic analysis of Iso-CoA and Acyl-iso-CoA compounds.  
The enzymes β-ketothiolase (E.C. 2.3.1.16), acetoacetyl-CoA 
reductase (E.C. 1.1.1.36), and PHB synthase (E.C. currently not 
classified) which all utilize CoA-containing substrates were 
examined for the ability to react with the respective iso-CoA-
containing analogs.  Sequential enzymatic reactions were carried 
out in a solution of 16 µM acetyl-CoA isomers, 1.0 mM NADPH and 5 
mM TCEP in 150 mM EPPS at a final of pH 7.8 and 37 C.  The 
reaction was initiated by addition of 26.5 µL of β-ketothiolase, 
followed by 80 µL of acetoacetyl-CoA reductase at 3.5 min and 
finally 175 µL of PHB synthase at 10.5 min.  In this manner β-
ketothiolase condensed two molecules of acetyl-CoA liberating CoA 
and producing acetoacetyl-CoA for consumption by the acetoacetyl-
CoA reductase, which formed the β-hydroxybutyryl-CoA for 
polymerization by the synthase enzyme to PHB, with liberation of 
CoA.  Enzyme reactions were quenched at appropriate times with 
0.27 M ice-cold perchloric acid followed by centrifugation prior 
to analysis with 50 µL injections by HPLC as described above.  
 
Regioselective Synthesis of Iso-CoA (3) 
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CoA disulfide (CoASSCoA).  HPLC-purified CoA (II), 10 mg 
(13 mM), was dissolved in 1 mL of 20 mM ammonium carbonate pH 
8.5, reacted overnight at 37 C, and then lyophilized to produce 
CoA-disulfide with 100% yield by HPLC.  The reaction progress was 
monitored via HPLC using the HPLC procedure described above 
except the mobile phase contained 6% acetonitrile.   
Cyclic-CoA-disulfide.  The CoA-disulfide lyophile was 
dissolved in 1 mL of 20 mM MES pH 6.0, 10 mg (52 mM) of 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide (EDC) was added and the pH 
readjusted.  Reaction progress was monitored by HPLC after 
rapidly reducing an aliquot of the disulfide to the free thiol 
with TCEP at pH 8.0 for 2 min.  When the reaction was complete, 
the entire mixture was lyophilized.  The lyophile was dissolved 
in 200 mM Ammonium Acetate pH 6.0 buffer and the entire solution 
applied to a 500 mg Supelco C8 solid phase extraction cartridge 
that was pre-equilibrated with the same buffer.  Residual EDC and 
the urea byproduct were eluted from the cartridge with the 
equilibration buffer, and the cyclic-CoA-disulfide was eluted in 
ca. 5 mL with 90% 200 mM ammonium acetate pH 6.0: 10% 
acetonitrile.  The cyclic-CoA-containing fractions were pooled 
and lyophilized.   
Regioselective Synthesis of Iso-CoA (III).  The cyclic-CoA-
disulfide lyophile was dissolved in 160 mL of 0.05 mM bicarbonate 
buffer (I=0.01) pH 9.5 containing 3 M KCl and 15 mM β-
cyclodextrin and the pH readjusted.  The solution was stirred at 
300C, with the pH maintained at 9.5, for approximately 5 days or 
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until the reaction was complete by HPLC, at which point the pH 
was adjusted to pH 3.0 to quench the reaction.  This provided a 
final solution of iso-CoA with 92% regioselectivity by HPLC.  
Acetone precipitation and filtration served to remove some of the 
KCl and β-cyclodextrin from the iso-CoA-containing solution and 
permitted rotary evaporation followed by vacuum evaporation to 
dryness.  Residual β-cyclodextrin was removed by repeated 
trituration with DMF and the remaining solid dried by washing 
with ethyl ether.  The final solid was then dissolved in 200 mM 
ammonium acetate pH 6.0, the pH readjusted, and the solution 
desalted by passing through a 500 mg Supelco C8 solid phase 
extraction cartridge that was pre-equilibrated with 200 mM 
ammonium acetate pH 6.0.  The desalted isomeric mixture of 92% 
iso-CoA: 8% CoA was eluted as previously described and the 
desalted mixture lyophilized.  Final purification of iso-CoA was 
performed by dissolving the desalted lyophile in a minimal 
quantity of 5 mM TCEP in EPPS pH 8.0, to reduce the CoA-disulfide 
to the free thiol, subjected to semi-prep HPLC as previously 
described, and lyophilized.   
 
Acid Catalyzed synthesis of Iso-CoA (III).  HPLC-purified 
CoA (II), 1.6 mg, was dissolved in 0.5 mL of 0.5 M HCl, and the 
reaction monitored by HPLC at room temperature until equilibrium 
was reached; this generated a mixture of 60% CoA (II) and 40% 
iso-CoA (III).  The identity of iso-CoA produced in this manner 
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was confirmed by NMR analysis after HPLC purification and 
lyophilization, as described previously. 
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CHAPTER 8 
ISO-COENZYME A:  RESULTS 
 
 
Mass Spectrometric Structural Characterization of CoA and 
acetyl-CoA Samples.  The HPLC-MS and HPLC-MS/MS chromatograms 
obtained for commercial CoA samples are shown in Figure 23.  The 
left portion of panel A shows an HPLC-MS chromatogram of a 
commercial CoA sample, which exhibits 2 peaks with identical 
(M+H)+ ions at m/z 768; this suggests that commercial CoA samples 
contain two compounds with identical masses.  Therefore, HPLC-
MS/MS experiments using multiple reaction monitoring (MRM) were 
carried out to garner further structural information.  It is 
evident from the right portion of Panel A that the CoA samples 
exhibit two peaks for the MRM transitions m/z 768?159, m/z 
768?261, and m/z 768?428.  Thus, these HPLC-MS and HPLC-MS/MS 
results suggest the presence of isomeric compounds with virtually 
identical fragmentation patterns.  To confirm these analyses, 
each peak in the commercial CoA sample was purified by 
preparative HPLC, and high resolution exact masses and MS/MS 
analyses were performed individually on each isomer.  As shown in 
Figure 24, the two HPLC-purified samples exhibited identical 
exact masses (M+H)+ of 768.1264 with an error of 5.09 ppm with 
respect to the calculated molecular mass of CoA.  Additionally, 
the MS/MS (precursor ion m/z 768) spectra for the two HPLC-
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purified samples depict nearly identical fragmentation patterns, 
which exhibit only minor variations in the relative populations 
of ions at m/z 136, m/z 159, and m/z 330.   
These results unequivocally confirm the presence of 
isomeric forms of CoA in the commercial material, and the MS/MS 
results showing that these isomers exhibit virtually identical 
fragmentation patterns indicate that these isomers have extremely 
similar structures.  HPLC-MS and HPLC-MS/MS experiments were also 
carried out with commercial acetyl-CoA, acetoacetyl-CoA, and β-
hydroxybutyryl-CoA; likewise, these experiments revealed the 
presence of two isomeric compounds with identical (M+H)+ ions, 
which exhibited identical fragments by HPLC-MS/MS using MRM at 
the observed transitions (Figures 25-27). 
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Figure 23.  HPLC-MS and HPLC-MS/MS of Commercial CoA Sample.  The 
HPLC-MS extracted ion chromatogram for a commercial CoA sample, 
shown in the left panel, exhibits two peaks with identical (M+H)+ 
ions, m/z 768.  The right panels show the HPLC-MS/MS 
chromatograms for the transitions m/z 768?159, m/z 768?261, and 
m/z 768?428.  Subsequent NMR analysis established that the 
earlier-eluting compound, 11.1 min, is authentic CoA and the 
later-eluting compound, 13.8 min, is iso-CoA.  The putative 
fragmentation patterns are indicated below.   
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Figure 24.  Exact Mass and MS/MS of CoA and Isomer Purified by HPLC from Commercial CoA.  The 
commercial CoA sample was purified by preparative HPLC, and each peak was subjected to high 
resolution ESI-MS (Inserts) and MS/MS analyses.  Authentic CoA is shown on the left and iso-CoA is 
depicted on the right.  The inserts are the exact mass spectra for each HPLC-purified isomer, 
which exhibited an m/z 768.1264 with an error of 5.09 ppm with respect to the calculated molecular 
mass of CoA.
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Figure 25.  HPLC-MS and HPLC-MS/MS Analyses of Commercial Acetyl-
CoA Samples.  HPLC-MS of commercial acetyl-CoA exhibited two 
distinct peaks with identical (M+H)+ ions, m/z 810.  The earlier-
eluting peak is the authentic acetyl-CoA, and the later-eluting 
peak is acetyl-iso-CoA, which is consistent with the extensive MS 
and NMR analyses performed on CoA and iso-CoA.  HPLC-MS/MS 
experiments exhibited identical product ions at the m/z 810?303 
and m/z 810?428 transitions.  The proposed fragmentation 
patterns are shown. 
Acetyl-CoA:         R2 = H     R3 = PO3H2 
Acetyl-CoA Isomer:  R2 = PO3H2  R3 = H 
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Figure 26.  HPLC-MS and HPLC-MS/MS Analyses of Commercial 
Acetoacetyl-CoA Samples.  HPLC-MS of commercial acetoacetyl-CoA 
exhibited two distinct peaks with identical (M+H)+ ions, m/z 852.  
The earlier-eluting peak is the authentic acetoacetyl-CoA, and 
the later-eluting peak is acetoacetyl-iso-CoA.  HPLC-MS/MS 
experiments exhibited identical product ions at the m/z’s 
852?135, 852?243, 852?261, 852?345, 852?428 transitions.  The 
proposed fragmentation patterns are shown.
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Figure 27.  HPLC-MS and HPLC-MS/MS Analyses of Commercial 
β-hydroxybutyryl-CoA Samples.  HPLC-MS of commercial β-
hydroxybutyryl-CoA exhibited two distinct peaks with 
identical (M+H)+ ions, m/z 854.  The earlier-eluting peak is 
the authentic β-hydroxybutyryl-CoA, and the later-eluting 
peak is β-hydroxybutyryl-iso-CoA.  HPLC-MS/MS experiments 
exhibited identical product ions at the m/z’s 854?136, 
854?245, 854?347, and 854?428 transitions.  The proposed 
fragmentation patterns are shown. 
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Structural characterization of Iso-CoA by NMR.  1D 1H-NMR 
spectra for the two HPLC-purified isomers of CoA are shown in 
Panels A and B of Figure 28, respectively.  The spectrum in Panel 
A, for the earlier-eluting isomer, is very similar to several 
previously-published CoA spectra (268,318-322), and the chemical 
shift assignments were made according to d’Ordine et al (268).  
In contrast, the spectrum shown in Panel B, for the later-eluting 
isomer, is very different in the 4-5 ppm region.  Therefore, 2D 
1H-1H COSY experiments (Figure 29) were obtained for this isomer 
in order to assign the chemical shifts.  The chemical shift 
assignments and coupling constants are listed in Table 15.  As 
indicated in Table 16, the chemical shift values for NADP+ and 
NADPH, which are shown in Figure 30 to possess the same 2’-
phosphate adenosine diphosphate moiety as iso-CoA, correlate well 
with the relevant protons of iso-CoA.   
It is evident that for the later-eluting isomer the 2’-
proton is shifted downfield by approximately 0.20 ppm while the 
3’- and 4’-protons are respectively shifted up-field by 0.15 and 
0.20 ppm, and the two 5’-protons have significantly different 
coupling patterns.  Since it seemed likely that the position of 
the phosphate on the ribose ring gives rise to these differences, 
1H-31P HMQC experiments were carried out to assign the position of 
each phosphate, explicitly.  The 1H-31P HMQC spectra for iso-CoA, 
shown in Figure 31, unequivocally establishes that the 
monophosphate is attached at the 2’-carbon; thus designating this 
compound as iso-CoA.  
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Figure 28.  1H-NMR of HPLC-purified Samples of CoA and Iso-CoA.  HPLC-purified samples of CoA and 
iso-CoA analyzed by 1H-NMR exhibit significant differences in the region between 4-5 ppm, which 
corresponds to the ribose ring region.  Labels corresponding to the numbering scheme shown in 
Scheme 1, 
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Figure 29.  1H-1H COSY of Iso-CoA.  The 1H-1H COSY of HPLC-
purified iso-CoA unequivocally assigns the proton chemical shifts 
of the ribose ring.  The inserted marker lines illustrate how the 
indicative chemical shift of the anomeric proton, labeled at 6.18 
ppm, was used to determine the position of each proton on the 
ribose ring.
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Figure 30.  The Chemical Structures and Interconversion of NAD(P)H and NAD(P)+.  Modified from 
Voet and Voet (323).   
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Figure 31.  1H-31P HMQC of Iso-CoA.  The 1H-31P HMQC for the HPLC-
purified isomer unequivocally demonstrates that the 
monophosphate, located at 0.9 ppm, clearly corresponds to the 2’-
proton of the ribose ring; thus, this isomer is designated as 
iso-CoA.  Additionally, since the two phosphates of the 
pyrophosphate linkage couple with the protons on the 5’ and 1’’ 
carbons, no other phosphate rearrangements are evident. 
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Table 15.  Iso-CoA 1H- and 31P-NMR Chemical Shift Assignments and 
Coupling Constants. 
1H Chemical
Shift 
Proton 
Position
Integration Multiplicity J 
(MHz) 
8.41  8  1 s    
8.18  2 1 s    
6.18  1’ 1 d  J1’-2’ 5.15
4.98  2’ 1 m  J2’-3’ 
J2’-P2’ 
5.09
8.69
4.56  3’ 1 t  J3’-4’ 4.56
4.32  4’ 1 m  J4’-5’a 
J4’-5’b 
J4’-P5’ 
3.92
2.83
2.00
4.18  5’b 1 m  J5’b-P5’ 4.58
4.13  5’a 1 m  J5’a-P5’ 
J5’a-5’b 
5.08
11.63
3.92  3” 1 s   
3.73  1” 1 dd  J1”-1” 
J1”-P1” 
9.90
5.09
3.48  1” 1 dd  J1”-P1” 4.83
3.38  5” 2 t  J5”-6” 6.53
3.24  8” 2 t  J8”-J9” 6.59
2.54  9” 2 t    
2.37  6” 2 t    
0.89  10” 3 s    
0.67   11” 3 s    
31P Chemical 
Shift 
Phosphate
Position
    
 -0.90  2’ 1 s    
 -9.63  1” 1 d    
 -10.21  5’ 1 d    
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Table 16:  1H NMR Chemical Shift Parameters for Iso-coenzyme A.  
A Comparison of iso-CoA with the literature derived coupling 
constants for NADP+ and NADPH.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H  
Chemical 
Shift 
Proton  
Position 
J MHz Iso-
CoA 
 
NADP+ 
(324) 
NADPH 
(324) 
8.41 8     
8.18 2     
6.18 1’ J1’-2’  5.15 5.0 4.7 
4.977 2’ J2’-3’ 
J2’-P2’ 
 5.09 
 8.69 
5.3 
7.1 
4.9 
6.8 
4.557 3’ J3’-4’  4.56 4.6 5.1 
4.317 4’ J4’-5’a 
J4’-5’b 
J4’-P5’ 
 3.92 
 2.83 
 2.00 
4.6 
2.6 
2.0 
4.4 
2.7 
2.0 
4.180 5’b  J5’b-P5’  4.58 4.9 4.8 
4.129 5’a  J5’a-P5’
J5’a-5’b 
 5.08 
11.63 
5.0 
11.8 
5.2 
11.8 
3.92 3”     
3.73 1” J1”-1” 
J1”-P1” 
 9.90 
 5.09 
  
3.48 1” J1”-P1”  4.83   
3.38 5” + 8” 
ox. 
J5”-6”  6.53   
3.24 8” J8”-J9”  6.59   
2.54 9”     
2.37 6”     
0.89 10”     
0.67 11”     
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HPLC of Commercial Samples of CoA, Acetyl-CoA, Acetoacetyl-
CoA, and β-hydroxybutyryl-CoA.  The overlaid HPLC chromatograms, 
presented in Figure 29, established that commercial samples of 
CoA, acetyl-CoA, acetoacetyl-CoA and β-hydroxybutyryl-CoA, which 
were designated as 93%, 93%, 90% and 99% pure, also contained 
approximately 10%, 15%, 18% and 3% of the 2’-monophosphate 
isomers, respectively. 
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Figure 32.  The HPLC Elution Profile of Commercial CoA, Acetyl-
CoA, Acetoacetyl-CoA, and β-hydroxybutyryl-CoA.  Two peaks are 
observed for each compound and have the following retention 
times: 4.25 min, CoA; 5.5 min, iso-CoA; 12.75 min, AcCoA, acetyl-
CoA; 14.5 min, AcAcCoA, acetoacetyl-CoA; 17.1 min, Iso-AcCoA, 
acetyl-iso-CoA; 18.25 min, HBCoA, β-hydroxybutyryl-CoA; 19.5 min, 
Iso-AcAcCoA, acetoacetyl-iso-CoA; 24.6 min, Iso-HBCoA, β-
hydroxybutyryl-iso-CoA
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Iso-CoA-containing Compounds are Substrates for the β-
ketothiolase, the Acetoacetyl-CoA Reductase, and the PHB Synthase 
enzymes.  The reaction time courses shown in Figure 33 for CoA, 
acetyl-CoA, and β-hydroxybutyryl-CoA and their respective iso-
CoA-isomers demonstrate that the three enzymes, β-ketothiolase, 
acetoacetyl-CoA reductase, and PHB synthase, can catalyze 
reactions with either isomer.  These data represent the first 
examples of iso-CoA-containing compounds acting as substrates in 
enzymatic acyl-transfer reactions.  In the coupled two-enzyme 
system in Panel A, β-ketothiolase converts two molecules of 
acetyl-CoA to acetoacetyl-CoA, which is immediately reduced to β-
hydroxybutyryl-CoA by the second enzyme acetoacetyl-CoA 
reductase.  In Panel B a third enzyme, PHB synthase, has been 
added which converts the β-hydroxybutyryl-CoA to poly-(β)-
hydroxybutyric acid.  It is evident from the time courses in both 
panels that in all cases both the CoA- and iso-CoA-isomers are 
processed with equal facility.  In other experiments, we find 
that acetoacetyl-CoA and its iso-CoA isomer react with equal 
facility in the back reaction to produce the acetyl-CoA product 
(data not shown).
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Figure 33.  The First Example of Enzymatic Acyl-transfer 
Reactions occurring with the 2’-isomers of CoA-containing 
Compounds.  Enzymatic reaction time courses for the enzymes β-
ketothiolase, acetoacetyl-CoA-reductase, and PHB synthase 
indicate that these enzymes catalyze identical reactions 
exhibiting equivalent kinetic rates with both the 2’- and the 3’-
isomers of acetyl-CoA, CoA, and β-hydroxybutyryl-CoA.  Panel A:  
β-ketothiolase and acetoacetyl-CoA reductase are added to a 150 
mM EPPS solution containing acetyl-CoA and its isomer, NADPH and 
TCEP at a final pH of 7.8.  This coupled-enzyme reaction 
initiates the consumption of two molecules of acetyl-CoA or 
acetyl-iso-CoA; thus, generating one molecule of CoA or iso-CoA 
and one molecule of β-hydroxybutyryl-CoA or the isomer.  Panel B:  
Addition of PHB synthase to the previous coupled-enzyme system 
(Panel A) results in the conversion of β-hydroxybutyryl-CoA and 
its isomer to poly-(β)-hydroxybutyric acid; this irreversible 
polymerization stimulates the consumption of further acetyl-CoA 
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isomers, with CoA or iso-CoA liberation during both processes.  
Acetoacetyl-CoA, the product of the β-ketothiolase mediated 
condensation of 2 acetyl-CoA molecules, is below the limit of 
detection by HPLC.  ▲ AcCoA, acetyl-CoA; ∆ Iso-AcCoA, acetyl-iso-
CoA; ■ CoA; □ Iso-CoA; ♦ HBCoA, β-hydroxybutyryl-CoA; ◊ Iso-
HBCoA, β-hydroxybutyryl-iso-CoA.
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Regioselective Synthesis of Iso-CoA.  Since iso-CoA and 
acyl-iso-CoA compounds may be useful as potential inhibitors or 
pseudosubstrates, a synthesis capable of producing high yields of 
the 2’-phosphate isomer is desirable; to this end, we report a 
simple synthesis of iso-CoA from CoA.  As shown in Scheme 2, CoA 
was initially converted to the dimeric disulfide, and the water 
soluble coupling agent 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) was then used to form the 2’,3’-cyclic-CoA 
intermediate in a reaction analogous to the synthesis of 2’,3’-
cyclic-NADP (325).  We note that the first steps of the synthesis 
are carried out using the CoA dimer to avoid possible quenching 
of the EDC.  The dimer is reduced back to the free CoA form in 
Step 3, in which base-catalyzed hydrolysis is carried out in the 
presence of β-cyclodextrin and high salt at pH 9.5 to produce 
iso-CoA with a 92% yield.  
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Figure 34.  Regioselective Synthesis of Iso-CoA from CoA.  This is the first regioselective 
chemical synthesis of iso-CoA, and utilizes β-cyclodextrin in high salt to confer iso-CoA 
regioselectively in high yields.  
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Acid-Catalyzed Phosphate Migration.  We investigated the 
acid-catalyzed migration of the CoA monophosphate group, in an 
attempt to furnish a plausible mechanism for the existence of the 
2’-phosphate isomers in commercial preparations of CoA-containing 
compounds.  In these experiments, HPLC-purified CoA was incubated 
in the presence of 0.5 M HCl and the relative amounts of CoA and 
iso-CoA were determined by HPLC as a function of time.  As shown 
in Figure 35, a final equilibrium mixture of 60% CoA and 40% iso-
CoA was attained within 60 hours.  We note that approximately 10% 
of iso-CoA is present after only 4 hours, so the iso-CoA content 
of commercial preparations may indeed be produced in this fashion 
during the processing of the product.
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Figure 35.  Acid-catalyzed Synthesis of Iso-CoA.  HPLC-purified CoA was incubated in the presence 
of 0.5 M HCl, and the relative quantities of ♦ CoA and ■ iso-CoA were monitored by HPLC as 
described in the text.  Note that this iso-CoA formation occurs in the presence of strong acid and 
that formation of the CoA : iso-CoA equilibrium does not spontaneously occur in neutral solution 
to any appreciable rate.  
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CHAPTER 9 
 
ISO-COENZYME A:  DISCUSSION 
 
 
The vital role of coenzyme A in metabolism is underscored 
by the sheer quantity of classified enzymes (326) that react with 
CoA-containing molecules; we count greater than 9% of the total 
known enzymes to be of this type.  The 2’-phosphate isomer of 
CoA, first named iso-CoA in Khorana’s 1959 report (265,266), has 
traditionally been considered an undesirable synthetic byproduct 
or has been simply ignored.  Indeed, a review of the literature, 
presented in Table 17, reveals that only eight of the more than 
350 CoA-utilizing enzymes (326) have been examined for the 
ability to discriminate between the 2’- and 3’-phosphate isomers 
(265,266,288,293,294,297,298,301,305).  Additionally, two of 
these enzymes, N-myristoyl transferase [E.C. 2.3.1.97] and 
choline acetyltransferase [E.C. 2.3.1.6], have been shown to 
accept purified 2’-phosphate isomers as inhibitors or substrates, 
respectively (294,298,305).  Moreover, the majority of the 
compounds examined in these eight cases are synthetic analogs of 
CoA, such as the dethia- or seleno-derivatives, and not iso-CoA 
itself.  Clearly, these results suggest that other enzymes should 
be examined for their reactivities towards the 2’-phosphate 
isomers of their CoA-containing substrates.  
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Table 17.  Eight Literature Accounts that Examine 2'- vs. 3'-phosphate Specificity. 
[E.C. Number]     Enzyme Name      Enzyme Reaction 
Pure Isomer  Accepts 2’-isomers 
Mixture 
2’-isomer substrates 2’-isomer inhibitor 
Rejects 2’-isomers 
[E.C. 2.3.1.97] N-myristoyltransferase (294,311) 
Pure --- Myristoyl-CH2-iso-CoA Accepts 2’-isomers 
[E.C. 2.3.1.6] Choline Acetyltransferase (305,307,308) 
Pure --- Se-iso-CoA Accepts 2’-isomers 
[E.C. 1.3.99.3] AcCoA Dehydrogenase (298,306) 
Mixtures† Heptadecan-2-only-CH2-iso-CoA --- Accepts 2’-isomers†
[E.C. 4.1.3.7] Citrate Synthase (296,297,312,313) 
Mixture‡ --- Acetonyl-CH2-iso-CoA; 
Heptadecan-2-only-CH2-iso-CoA
Accepts 2’-isomers 
(Unclear‡) 
[E.C. 2.3.1.21] Carnitine Palmitoyltransferase (297) 
Mixture‡ --- Heptadecan-2-only-CH2-iso-CoA Accepts 2’-isomers 
(Unclear‡) 
[E.C. 2.3.1.8] Phosphotransacetylase (265,300,301,303,304,327) 
Pure No, Rejects Iso-CoA; Oxy-iso-CoA No, Rejects Iso-CoA Rejects 2’-isomers 
[E.C. 1.3.99.12] FAD-dependent isobutanoyl-CoA Dehydrogenase (293) 
Pure No, Rejects Isobutanoyl-CH2-iso-CoA --- Rejects 2’-isomers 
[E.C. 2.1.3.1] Methylmalonyl-CoA pyruvate carboxylase (transcarboxylase) (288,289) 
Pure No, Rejects Propionyl-CH2-iso-CoA -- Rejects 2’-isomers 
†Results derived from experiments showing identical reaction rates with 1:1 and 65:45 isomeric 
mixtures.  
‡Specificity is unclear.  The authors suggest that since purified S-heptadecyl-CoA inhibits and an 
isomeric mixture of Heptadecanoyl-dethia-CoA inhibits there must be no difference between the 
isomers and the enzyme accepts 2’-phosphate; this is a very poor argument proposed by the authors.
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The results presented here represent the first complete 
structural characterization of iso-CoA.  CoA and iso-CoA were 
purified by HPLC, and high resolution exact mass and MS/MS 
analyses unequivocally established that the compounds are 
constitutional isomers with extremely similar fragmentation 
patterns.  Direct structural identification of the two HPLC-
purified isomers was then performed using 1H-NMR, 1H-1H COSY, and 
1H-31P HMQC, and the results unequivocally established that the 
monophosphate of the iso-CoA isomer is attached to the 2’-carbon 
of the ribose ring.  All previous characterizations of the 
structure of iso-CoA have been based on chromatographic analyses 
(265,266), which ultimately rest on comparisons with the 
degradation products of CoA and NADPH (267,277,315), or have been 
based on assumptions regarding enzyme specificity (284,285,287).  
The HPLC-MS and HPLC-MS/MS experiments on acetyl-CoA 
samples reported here also reveal the presence of two compounds, 
both of which exhibited ions (m/z 810) corresponding to acetyl-
CoA’s molecular mass, and showed identical product ion spectra.  
Similarly, HPLC-MS and HPLC-MS/MS analyses of commercial 
preparations of acetoacetyl-CoA, and β-hydroxybutyryl-CoA also 
confirmed the presence of isomeric forms of both of these 
compounds. 
We report here the first example of iso-CoA-containing 
compounds acting as substrates in acyl-transfer reactions.  Three 
enzymes, β-ketothiolase, acetoacetyl-CoA reductase, and PHB 
synthase, successfully react with the 2’-isomers of their natural 
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substrates, and the reaction time courses indicate that all three 
enzymes react with either isomer with equal facility.  Our 
investigation has provided three additional clear-cut cases of 
enzymes that accept the 2’-phosphate isomers.  A larger 
population of enzymes needs to be examined to determine how the 
phosphate position affects ligand binding, catalysis or 
inhibition. 
 
The Role of the 3’-phosphate of CoA.  The role of the 3’-
phosphate of CoA in enzyme binding and catalysis has been 
investigated somewhat more thoroughly by investigations 
evaluating the ability of an enzyme to interact with dephospho-
CoA analogues.  Approximately 40 enzymes, detailed in Table 18, 
have been evaluated, and the vast majority of enzymes reported in 
the literature do accept the 3’-dephospho-CoA compounds as 
substrates or inhibitors; though, the enzymes typically exhibit 
less affinity for the dephospho-derivatives.  We have found only 
three literature examples, highlighted in red in Table 18, of 
enzymes that reject the dephospho-CoA compounds.  
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Table 18.  Enzymatic Interactions with Dephospho-CoA-containing Compounds. 
Enzyme/Compound R 2’3’Substrate (KM*) Inhibitor (KI*) 
Accepts DPCoA as a Substrate:  Green 
Accepts Iso-CoA as a Substrate:  Bright Green 
Accepts DPCoA as an Inhibitor:  Dark Blue 
Accepts Iso-CoA as an Inhibitor:  Light Blue 
Rejects DPCoA as a Substrate:  Dark Red 
Rejects Iso-CoA as a Substrate:  Red 
Rejects DPCoA as a Inhibitor:  Violet 
Rejects Iso-CoA as a Inhibitor:  Lavender 
Unknown Specificity:  Tan 
Accepts DPCoA as an Inhibitor but DPCoA has greater activity than CoA:  Turquoise 
CoA-Pyrophosphate analyzed:  Yellow 
 
 
Enzyme/Compound R 2’3’Substrate (KM*) Inhibitor (KI*) 
[E.C. 1.1.1.36] NADPH-dependent Acetoacetyl-CoA Reductase C. necator (160,222), Rhizobium (Cicer) 
Sp. Strain CC 1192 (328) Methylobacterium extorquens (329) Zoogloea ramigeria (220) 
Acetoacetyl-CoA + NADPH ⇌ β-hydroxybutyryl-CoA + NADP+ 
Accepts 2’-isomers as substrates with equal affinity.  Isomers were run together in the same assay 
but were quantitated separately by HPLC. 
Acetoacetyl-CoA  AcAcS H P Yes (222) ---  
Acetoacetyl-CoA  AcAcS H P 5 µM (160) >32 µM substrate inhibition 
Acetoacetyl-CoA  AcAcS H P 22 ± 10 µM (328) >100 µM substrate inhibition 
Acetoacetyl-CoA  AcAcS H P 11.6 µM (329) --- 
    KM  
(M) 
Kcat 
(S-1)
Kcat/KM  
(M-1S-1) 
 
Acetoacetyl-CoA (220) AcAcS H P 2 x 10-6 300 1.8 x 108 >10 µM substrate inhibition 
Table 18 Continued 
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Propionylacetyl-CoA (220) PrAcS H P 2 x 10-6 124 6.2 x 107  
Butyrylacetyl-CoA (220) BrAcS H P   1 x 10-5 9 9.0 x 105  
2-Methylacetoacetyl-CoA (220) MeAsS H P 7.4 x 10-4 27 3.6 x 104  
Acetoacetyl-S-(D-pantetheine)11-
pivalate (220) 
AcAcS ----9.9 x 10-4 267 2.7 x 105  
        
        
        
Acetoacetyl-iso-CoA  AcAcS H H Yes (222) --- 
Acetoacetate AcAcO ---- No (328) --- 
NADPH  --- P H  19 µM (160) --- 
NADPH  --- P H  44 ± 24 µM (328) --- 
NADPH  --- P H  41 µM (329) --- 
NADH  --- H H 400 µM (160) --- 
NADP+  --- P H  31 µM (222) --- 
NADP+  --- P H 135 µM (220)  
NADP+  --- P H  38 ± 16 µM (328)  % inhibition at given [NADP+] 
     0.2 mM NADP+ 0.4 mM NADP+ 
     35% 50% 
NAD+  --- H H --- No inhibition (328) 
NAD+  --- H H 250 µM (222) --- 
β-hydroxybutyryl-CoA  HBS H P Yes (222)  --- 
DL-(β)-hydroxybutyryl-CoA HBS H P  33 µM  (222) --- 
R-β-hydroxybutyryl-CoA [0.2 mM] HBS H P 120 ± 29 µM (328) No inhibition (328) 
D-β-hydroxybutyryl-CoA HBS H P  26 µM (220) kcat 90 s-1  
β-hydroxybutyryl-iso-CoA HBS H H Yes (222) --- 
[1.1.1.157] 3-hydroxybutyryl-CoA Dehydrogenase (330)   
AcAcCoA + NADPH ⇌ L-(+)-HBCoA + CoA 
Table 18 Continued 
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Accepts DPCoA as a Substrate 2x better % Activity with CoA 
    % Activity w.r.t. AcAcCoA  
Acetoacetyl-CoA AcAcS H P 100 --- 
Acetoacetyl-dephospho-CoA AcAcS H H  47 --- 
Acetoacetylpantetheine  AcAcS ---- 10 --- 
N-acetyl-S-acetoacetyl-
cysteamine 
AcAcS ---- 15 --- 
[1.2.99.2] Acetyl-CoA decarbonylase/synthase complex (331-333) 
Accepts DPCoA as a Inhibitor   5 x better KI with CoA 
Accepts DPCoA as a Substrate 1.4 x better KM with CoA  
Carbonyl Exchange Assay:  [1-14C]-acetyl-CoA + CO ⇌ 14CO + acetyl-CoA (333) 
CoA SH H P ---    7 µM 
Dephospho-CoA SH H H ---   35 µM 
Desulfo-CoA CH3 H P --- 6000 µM  
Pivaloylpantetheine-SH SH   --- 1200 µM  
[1-14C]-acetyl-CoA AcS H P 600 µM / VMax 440 min-1  --- 
Propionyl-CoA PrS H P --- 1300 µM  
[1-14C]-propionyl-CoA PrS H P --- None after 2h  
Crotonyl-CoA CrS H P --- 1400 µM  
Butyryl-CoA BuS H P --- 1450 µM 
CODH-Catalyzed CoA exchange:  [3’-32P]-CoA + AcCoA ⇌ CoA +[3’-32P]-AcCoA (332) 
AcCoA AcS H P 1500 µM 
VMax 2.5 µmol/min 
--- 
CoA SH H P   50 µM ND 
Propionyl-CoA PrS H P 5000 µM 
VMax 0.15 µmol/min 
--- 
Acetyltransferase:  Acetyl-CoA + 3’-dephospho-CoA ⇌ CoA + S-acetyl-3’-dephospho-CoA (331) 
 
Table 18 Continued 
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Acetyl-CoA AcS H P 30.8 µM / kcat 3100 min-145.4 µM 
3’-dephospho-CoA SH H H 42.2 µM  
CoA SH H P --- 6.8µM 
[1.3.99.3] Acyl-CoA Dehydrogenase/Acyl-CoA Oxidase (298,306,334,335)  
Acyl-CoA + acceptor ⇌ 2,3-dehydroacyl-CoA + reduced acceptor 
Accepts DPCoA as a Substrate 2x better KM than CoA ; Same VMax as CoA (306) 
9x better KM; 3.7 x better kcat with CoA (335) 
Study discrepancies purportedly because of sub-saturating 
concentrations of the electron acceptor or possibly because of 
different biological origins. 
Accepts DPCoA as an Inhibitor Qualitative:  Diminished inhibitor 
CoA SH H P --- 63µM 
Dephospho-CoA SH H H --- Diminished inhibitor  
Heptadecan-2-onyldethia-CoA 1:1 CH2 Mix Yes(58% P-CoA)  --- 
Heptadecan-2-onyldethia-CoA 
65:45  
CH2 Mix Yes --- 
S-heptadecyl-CoA -S- H P No Competitive Kd = 17nM KI < 40 nM
    
KM (µM) 
VMax 
(min-1) 
 
Octanoyl-CoA (306) SH H P 2.21±0.28 674.68±40.94 --- 
Octanoyl-dephospho-CoA (306) SH H H 1.09±0.17 656.63±66.71 --- 
Octanoyl-pantetheine (306) --- ----106.6±15.5  14.1±1.6 --- 
Octanoyl-1,N6-etheno-CoA (306)    9.28±1.72 415.95±27.07 --- 
    
KMapp (µM) 
Kcatapp 
(S-1) 
 
Octanoyl-CoA [FPF6 350 µM] OcSH H P  2.6±0.4 15.6±0.5 ---(335) 
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Octanoyl-dephospho-CoA [FPF6 1mM] OcSH H H 25.1±2.8 58.3±1.9 ---(335) 
Butyryl-CoA [FPF6 300µM] BuSH H P 356±56  8.0±0.6 ---(335) 
Butyryl-dephospho-CoA[FPF6 300µM] BuSH H H 1608±134  1.55±0.1 ---(335) 
[1.3.99.12] FAD-dependent isobutanoyl-CoA dehydrogenase (293)  
isobutanoyl-CoA + FAD ⇌ Methacrylyl-CoA + FADH2  
Rejects 2’-phosphate isomer as a substrate 
Isobutanoyl-dethia-CoA CH2 H P Yes --- 
Isobutanoyl-dethia-Iso-CoA CH2 P H No --- 
[1.4.3.3] D-amino-acid oxidase sus scrofa (336)   
D-amino-acid + H20 + O2 ⇌ 2-oxo-acid + NH3 + H2O2 
Accepts DPCoA as a Inhibitor Qualitative: no comparison possible 
Dephospho-CoA SH H H --- Inhibitor 
[1.6.1.2] NAD(P)+ Transhydrogenase (337-339)  
NADPH + NAD+ ⇌ NADP+ + NADH 
Accepts DPCoA as a Inhibitor DPCoA KI is 22 x better than CoA  
Ac-DPCoA is 18 x better than CoA 
Rejects 3’-NADP(H) isomer as a substrate 
2,4-dinitrophenyl-CoA DNPS H P --- No inhibition up to 200 µM 
2,4-dinitrophenyl-dephospho-CoA DNPS H H --- 3 µM competitive w.r.t. NAD+ 
Non-Competitive w.r.t. NADP+ 
S-7-nitrobenzofurazan-4-yl-CoA NBFS H P --- 2.6 µM Competitive w.r.t. NADPH 
Non-Competitive vs. NAD+ 
S-7-nitrobenzofurazan-4-yl-
dephospho-CoA 
NBFS H H --- 0.3µM Competitive w.r.t. both 
NADPH & NAD+ 
     Site-specific inhibitors 
Table 18 Continued 
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     Specificity KI 
     NAD(H)NADP(H) Nonenergy-
linked 
(µM) 
Energy-
linked (µM)
CoA SH H P --- - + 200 700 
Dephospho-CoA SH H H --- + - 9 40 
Acetyl-CoA AcS H P --- - + 200 700 
Acetyl-dephospho-CoA AcS H H --- + - 11 40 
Palmitoyl-CoA PalmS H P --- - + 0.15 0.15 
ADP PP OHOH--- + - 300 400 
5’-AMP P OHOH--- + - 300 700 
2’-AMP  P OH--- - + 700 1200 
3’-AMP  OHP --- - + 700 1200 
3’,5’-AMP P OHP --- + + 400 400 
Adenosine  OHOH--- + - 500 500 
Ribose  OHOH--- --- --- --- --- 
Adenine    --- --- --- --- --- 
Nicotinamide    --- --- --- --- --- 
4’-phosphopantheteine    --- --- --- --- --- 
Palmitoyl-carnitine    --- --- --- --- --- 
Nicotinamide mononucleotide    --- --- --- --- --- 
palmitate    --- --- --- --- --- 
2’-NADP(H)  P OHYes --- --- --- --- 
3’-NADP(H)  OHP  No --- --- --- --- 
[1.8.1.14]  Coenzyme A disulfide reductase (340-342)  
CoA-S-S-CoA + NAD(P)H+H+ ⇌ 2CoA-SH+ NAD(P)+ 
S. aureus accepts DPCoA as a Substrate 12x better KM; 1.4 x better VMax than CoA  
Table 18 Continued 
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P. horikoshii rejects DPCoA as a substrate 
    KM 
(µM) 
Kcat 
(S-1) 
Kcat/KM 
(M-1S-1x10-6)
Enzyme Species Origin 
CoA disulfide CoASS H P   11±2 1000±200     80±10 S. aureus (341) 
Dephospho-CoA disulfide CoASS H H  140±40 1400±200     10±2 S. aureus (341) 
4,4’-diphospho-pantethine --- ----  80±10  540±40    3.3±0.4 S. aureus (341) 
CoASSG CoASS H P 1100±200 800±70   0.72±0.8 S. aureus (341) 
NADPH --- P H  1.6±0.51020±60    600±100 S. aureus (341) 
    KM 
(µM) 
Kcat 
(S-1) 
Kcat/KM 
(M-1S-1x10-6)
 
CoA disulfide CoASS H P   30   7.1    4.2 P. horikoshii (342) 
Dephospho-CoA disulfide  CoASS H H   No   ---    --- P. horikoshii (342) 
NADPH --- P H   <9.0   7.2    0.8 P. horikoshii (342) 
NADH --- P H   73   8.1    0.11 P. horikoshii (342) 
[1.11.1.9] (Miss)Glutathione peroxidase (343) 
2 GSH + H2O2 ⇌ GSSG + 2 H2O 
Accepts DPCoA as a Inhibitor 11-13 x better inhibitor than CoA 
CoA SH H P --- Inhibits 
Dephospho-CoA SH H H --- 11-13 x less than CoA 
ATP --- OHOH--- Inhibition equals CoA 
[E.C. 2.1.3.1] Methylmalonyl-CoA pyruvate carboxylase (transcarboxylase) (288,289)   
Propionyl-CoA + oxaloacetate ⇌ Methylmalonyl-CoA + pyruvate 
Rejects 2’-phosphate isomer as a substrate.  Good qualitative example with pure isomers 
Propionyl-CH2-CoA PrCH2 H P Yes --- 
Propionyl-CH2-iso-CoA PRCH2 H   No --- 
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[2.3.1.5] Arylamine  N-acetyltransferase (300)  
AcCoA + an arylamine ⇌ CoA + an N-acetylarylamine  
specifically:  4-aminoazobenzene+ ATP ⇌ 4-acetamidoazobenzene 
Accepts DPCoA as a Substrate Qualitative Results; Bad example, doesn’t name the enzyme; not 
purified 
Accepts 2’-phosphate isomer as substrate (but not Se-iso-CoA) 
CoA SH H P Yes --- 
Iso-CoA SH P H Yes [slight] --- 
Se-CoA SeH H P Yes --- 
Se-Iso-CoA SeH P H  No --- 
Dephospho-CoA SH H H Yes --- 
dephospho-Se-CoA SeH H H Yes --- 
[2.3.1.6] Choline  Acetyltransferase (305,307,308,344)   
Choline + Acetyl-CoA ⇌ CoA + Acetyl-Choline 
[values in brackets were gathered at low anion concentration] 
Accepts DPCoA as a Substrate 10 x better KM [108 x better KM with low salt] 
Accepts DPCoA as a Inhibitor 100 x better KI than CoA 
Accepts 2’-phosphate isomer as an inhibitor:  Se-CoA has a 3.5 x better KI than Se-iso-CoA 
CoA SH H P   3.8±0.1 µM   
[0.25±0.03 µM] (307) 
1.8 µM competitive w.r.t. to 
AcCoA 
Se-CoA SeH H P --- 7 µM competitive 
Se-iso-CoA SeH P H --- 25 µM competitive 
dephospho-CoA SH H H  39±3 µM 
[27±2 µM] (307)  
500 µM competitive 
dephospho-Se-CoA SH H H --- 700 µM competitive 
Ado-3’-P-5’-P --- H P --- 415 µM competitive 
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Ado-2’-P-5’-P --- P H --- 2200 µM competitive 
Ado-5’-P --- H H --- 2500 µM competitive 
Acetyl-CoA AcS H P Y 25.7 µM Yes 
Acetyl-dephospho-CoA AcS H H Y 54.8 µM Yes Info not in abstract 
Acetylcholine --- - -  900±100 µM 
[400±60 µM] (307)  
  
[2.3.1.8] Phosphotransacetylase (265,300,301,303,304,327,345,346)  
Acetylphosphate + CoA ⇌ Acetyl-CoA + Pi  
Accepts DPCoA as a Substrate 20 x better KM; 17 x better kcat; 350 x better kcat/KM (347) 
Rejects 2’-phosphate isomers as substrates 
Rejects 2’-phosphate isomers as inhibitors 
CoA SH H P Yes  No 
Dephospho-CoA SH H H 0.5% CoA --- 
Dephospho-CoA SH H H  10% of CoA --- 
    KM 
(mM) 
Kcat 
(S-1) 
Kcat/KM (mM-
1s-1) 
 
CoA (347) SH H P 0.07±0.01 4,880±448 70,000  
Dephospho-CoA (347) SH H H  1.4±0.1 272±14 198  
Iso-CoA SH P H No No 
Se-CoA SeH H P No No 
Oxy-CoA OH H P No KI 0.35 µM Competitive 
Isomeric Mix of Oxy-CoA OH Mix No 0.6 µM 
Oxy-Iso-CoA OH P H No No 0.5 % of oxy-CoA 
3’-pyrophospho-CoA SH H PPYes 2x CoA --- (also from C. kluyveri,  
CoA-SS-CoA SCoA H P No --- L. mesenteroides, E. coli) 
      
     Inhibition Rate 
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     E. coli Cl. kluyveri 
Ado-3’-P-5’-PP --- OHP No       62        33 
Ado-2’-P-5’-PP --- P OHNo        5         5 
Ado-3’-P-5’-PP-CH3 --- OHP No       33        22 
Ado-2’-P-5’-PP-CH3 --- P OHNo        0         2 
Ado-5’-P --- OHOHNo        2         0 
Ado-3’-P --- OHP No        0         0 
ADP --- OHOHNo       48         0 
ATP --- OHOHNo       37         0 
Ado-3’-P-5’-P --- OHP No       36         2 
Ado-3’-P-5’-PP-CH2CH(CH3)2 --- OHP No       81        43 
[E.C. 2.3.1.9] Biosynthetic β-ketothiolase (222) 
2 Acetyl-CoA ⇌ Acetoacetyl-CoA + CoA 
Accepts 2’-phosphate isomers as substrates with equal facility.  Isomers assayed simultaneously 
but were quantified HPLC which adequately resolved the isomers. 
    KM (µM) Kcat (s-1) Kcat/KM (M-1s-1)  KI (µM) 
CoA SH H P  Yes (222) --- --- --- 
CoA SH H P   16 (348) --- --- 16 µM 
CoA SH H P    9 (242) --- --- --- 
Iso-CoA SH P H  Yes (222) --- --- --- 
Acetyl-CoA AcS H P  Yes (222) --- --- --- 
Acetyl-CoA AcS H P 1100 (348) --- --- --- 
Acetyl-CoA AcS H P 1200 (242) For. 71 For. 60 x 103 --- 
Acetyl-iso-CoA AcS P H  Yes (222) --- --- --- 
Acetoacetyl-CoA AcAcS H P   44 (348) --- --- --- 
Acetoacetyl-CoA AcAcS H P  Yes (222) --- --- --- 
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Acetoacetyl-CoA AcAcS H P   15 (242) Rev. 810  Rev. 53 x 106 --- 
Acetoacetyl-CoA AcAcS H P   24 (215) Kcat  465 s-1 
Vmax 10.7 mM·s-1/mg 
2.0 x 107 --- 
Acetoacetyl-S-(D)-pantetheine AcAcS ---- 120 (215) Kcat  353 s-1 
Vmax  8.1 mM·s-1/mg
3.8 x 105 --- 
Acetoacetyl-S-(D-pantetheine)-
11-pivalate 
AcAcS ----  73 (215) Kcat  469 s-1 
Vmax 10.8 mM·s-1/mg
6.9 x 106 --- 
Acetoacetyl-S-(L-pantetheine)-
11-pivalate 
AcAcS ---- 670 (215) Kcat  256 s-1 
Vmax  5.9 mM·s-1/mg
3.8 x 105 --- 
Acetoacetyl-iso-CoA AcAcS P H  Yes (222) --- --- --- 
[2.3.1.21] Carnitine  Palmitoyltransferase (297)  
Palmitoyl-CoA + carnitine ⇌ palmitoylcarnitine + CoA 
Accepts 2’-phosphate isomer compound as an inhibitor (Isomeric Mixture)  
Heptadecan-2-onyldethia-CoA 1:1 CH2 Mix --- 1.35 µM (@ <30 µM P-CoA) 
S-heptadecyl-CoA -S- H P --- 3.34 µM (@ <30 µM P-CoA) 
[2.3.1.44] AcCoA : Sialate 4-O-acetyltransferase (349) 
acetyl-CoA + N-acetylneuraminate ⇌ CoA + N-acetyl-4-O-acetylneuraminate 
Accepts DPCoA as a Inhibitor 1.3 x better KI than CoA 
Acetyl-CoA AcS H P 32.1 µM     
VMax 1.21 pmol/mg 
 
CoA SH H P  KI 240 µM 
     % Inhibition at 1 mM final 
concentration 
CoA SH H P --- 100% 
0.1 mM CoA SH H P ---  40% 
Dephospho-CoA SH H H ---  79% 
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5’-IMP --- OHOH---  --- 
5’-IDP --- OHOH---  17% 
5’-AMP --- OHOH---  --- 
5’-ADP --- OHOH---  36% 
β-NAD --- H H ---  25% 
β-NADP --- H P ---  --- 
4,4’-diisothiocyanatostilbene --- H H ---  95% 
[2.3.1.48] Histone Acetyltransferase P300 (350)  
Acetyl-CoA + histone ⇌ CoA + acetylhistone 
Accepts DPCoA as a Inhibitor 31.25 x better KI than CoA 
Lys-CoA SH H P No Y IC50 50 nM 
Dephospho-Lys-CoA SH H H No Y IC50 1.6 µM 
[2.3.1.54] Formate C-acetyltransferase (Pyruvate formate lyase) (351)  
Acetyl-CoA + formate ⇌ CoA + pyruvate 
Accepts DPCoA as a Substrate 2.5 x better KM 
CoA SH H P   12 µM Inhibited > 75 µM 
Pyruvate --- ----1600 µM --- 
Dephospho-CoA SH H H Yes, replaces CoA up to 
40% 
--- 
[2.3.1.57] Spermidine/spermine N-acetyltransferase (352)  
Acetyl-CoA + an alkane-alpha, omega-diamine ⇌ CoA + an N-acetyldiamine 
Accepts DPCoA as a Inhibitor Qualitative; 3’-phosphate considered essential for activity.  
Importance of 3’-phosphate explains why alkaline phosphatase 
inactivates the reaction. 
CoA S H P --- Prevents Inactivation 
Dephospho-CoA S H H --- < Inactivation than CoA 
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Acetyl-CoA AcS H P --- Prevents Inactivation 
NAD --- P H --- Did nothing 
[2.3.1.71] Glycine N-benzoyltransferase (353)   
Benzoyl-CoA + glycine ⇌ CoA + N-benzoylglycine  
Accepts DPCoA as a Inhibitor Qualitative Results 
CoA SH H P --- Yes 0.1 mM CoA inhibits at 40% 
w/o KCl & 10% w/KCL  
Dephospho-CoA SH H H --- Yes (ions diminishes inhib. 
ability) 
[2.3.1.74] Chloramphenicol Acetyltransferase or Chalcone Synthase (354-356)   
3 Malonyl-CoA + 4-coumaryl-CoA ⇌ 4 CoA + naringenin chalcone + 3 CO2 
Accepts DPCoA as a Substrate 9 x better KM (Depends on acyl group) 
Accepts DPCoA as a Inhibitor CoA is better than DPCoA (Qualitative-Depends on acyl group) 
Acetyl-CoA AcS H P  90 µM --- 
Acetyl-dephospho-CoA AcS H H 840 µM --- 
Malonyl-CoA (355) MalS H P   3 µM  Substrate inhibition above 50µM 
Malonyl-dephospho-CoA (355) MalS H H  No Y 50% inhibition at 3µM  
4-coumaryl-CoA (355) CouS H P 0.6 µM (primer)  substrate inhibition > 10µM  
4-coumaryl-dephospho-CoA CouS H H Yes (primer)  --- 
CoA SH H P --- Yes 
Dephospho-CoA SH H H --- No 
[2.3.1.85] Fatty acid Synthase (299,309,310) 
AcCoA + n malonyl-CoA + 2n NADPH + 2n H+ ⇌ long-chain fatty acid + (n+1) CoA + n CO2 + 2n NADP+ 
Accepts DPCoA as a Inhibitor Qualitative Results 
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2’-phosphate vs. 3’-phosphate specificity unclear.  Isomeric mixture inhibits; authors propose 
that enzyme doesn’t discriminate.  Further experiments warranted.   
Acetonyldethia-CoA + isomer CH2 Mix --- N 
Ado-2’-P --- P H --- Protects against inactivation 
Ado-3’-P --- H P --- No protection 
CoA SH H P --- Increase inactivation Rate 
(stops inhib.)  [17] 
Dephospho-CoA SH H H --- Increase inactivation Rate 
(stops inhib.)  [17] 
[2.3.1.87] Serotonin N-acetyltransferase (357)  
acetyl-CoA + an arylalkylamine ⇌ CoA + an N-acetylarylalkylamine 
CoA is 2x better  
Accepts DPCoA as a Inhibitor 1.25 x better KI for Acetyltransferase Activity 
2 x better KI for Alkyltransferase Activity 
Inhibition of Stated Activity 
Acetyltransferase Alkyltransferase 
Tryptamine-acetyl-CoA SH H P --- 
0.048 µM 33 µM 
Tryptamine-acetyl-dephospho-CoA SH H H --- 0.060 µM 60 µM 
[2.3.1.97] N-myristoyltransferase (294,311,358)  
Octapeptide + myristoyl-CoA ⇌ myristoyl-peptide + CoA 
Accepts DPCoA as a Substrate Myristoyl-compounds:  8.3 x better KD; 1.4 x better % Activity 
Palmitoyl-compounds:  8.9 x better KD; 2.5 x better % Activity 
Lauryl-compounds:  135 x better KD; 2 x better % Activity 
Accepts 2’-phosphate isomers as inhibitors:  Myristoyl-inhibitors:  6.7 x better KI 
Myristoyl-carba(dethia)-CoA CH2 H P --- Competitive KI 0.3 µM 
Myristoyl-carba(dethia)-iso-CoA CH2 P H --- Competitive KI 2 µM 
        Kd nM % Act   
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Lauryl-CoA S P H      62      44   
Lauryl-dephospho-CoA S H H    8380      21   
Myristoyl-CoA S P H      15     100   
Myristoyl-dephospho-CoA S H H     124      73   
Palmitoyl-CoA S P H      26     1.6   
Palmitoyl-dephopho-CoA S H H     232       4   
[2.3.3.1] Citrate Synthase (296,297,312,359)  
Oxaloacetate + AcCoA ⇌ CoA + Citrate   
Accepts DPCoA as a Inhibitor Qualitative:  Approximately the same inhibition 
2’-phosphate vs. 3’-phosphate specificity is unclear.  Isomeric mixture inhibits so authors 
suggest no discrimination based on the comparison with S-heptadecyl-CoA but further experiments 
are warranted.   
Acetonyldethia-CoA + Iso CH2 Mix --- Competitive 13.2 µM 
Heptadecan-2-onyldethia-CoA 1:1 CH2 Mix --- Non-Competitive 6-7.5 µM; 3.7 µM 
is ≈ to P-CoA @ 4.1 µM  
S-heptadecyl-CoA -S- H P --- Non-Competitive 1-1.5 µM; 1.2 µM 
is ≈ to P-CoA @ 4.1 µM  
110 µM CoA SH H P --- 109% activity after 10 min  
130 µM dephospho-CoA SH H H --- 110% activity after 10 min 
Acetyl CoA       4 x 10-4  --- 
[2.3.3.8] ATP : Citrate Lyase (360)  
Citrate + CoA + ATP ⇌ AcCoA + oxaloacetate + ADP + Pi 
Enzyme is protected from thermal and proteolytic inactivation by 2 classes of compounds that bind 
at Site 1:  the NADPH binding site and Site 2:  the CoA binding site 
Rejects DPCoA as an Inhibitor CoA protects against inhibition at 1µM but DPCoA does not at 1mM 
Compounds that provide 50% Protection 
Site 1 (NADPH) Site 2 (CoA) 
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 R 2’ 3’ mM  R’ 2’ 3’ µM 
β-NADPH --- P H  0.25 CoA SH H P      1 
β-NADP+ --- P H  3 Acetyl-CoA AcS H P      5 
2’,5’-ADP --- P OH  2.5 3’-NADP+ --- H P     25 
2’-AMP --- P OH  20 3’-AMP --- OH P   8000 
2’-GMP --- P OH  40 3’,5’-ADP --- OH P    100 
α-NADPH --- H P <0.25 Etheno-CoA CH2 H P    100 
α-NADP+ --- H P  2.5 2’-deoxy 3’,5’-ADP --- H P   <100 
2’,5’-ADP+NMNH --- P H  2.5      
Compounds that do not Protect (Concentration given is the highest tested) 
Site 1 (NADPH) Site 2 (CoA) 
 R’ 2’ 3’ mM  R’ 2’ 3’ mM 
Nicotinamide --- -- -- 10 Dephospho-CoA SH H H     1 
NMNH --- -- -- 10 Pantothenate --- -- --    10 
NMN --- -- -- 10 Ribose 5-phosphate --- OH OH    10 
Ribose 5-phosphate --- OH OH 10 AMP --- OH OH    10 
Nicotinamide hypoxanthine-DPH --- -- -- 10 ADP-Ribose --- OH OH    10 
AMP --- OH OH 10 3’-GMP --- OH P    40 
ADP-ribose --- OH OH 10 Guanosine 3’-phosphate 5’-diphosphate --- OH P     2 
NAD+ --- P OH 10 2’,3’-cyclic AMP ---      10 
NADH --- P OH 10 2’,3’-cyclic NADP+ ---      10 
2’,3’-Cyclic AMP ---   10 3’,5’-cyclic AMP ---      10 
2’,3’-Cyclic NADP+ ---   10      
3’,5’-Cyclic AMP ---   10      
Pyrophosphate --- -- -- 10      
[2.3.3.9] Malate Synthase (361,362)   
Acetyl-CoA + H2O + glyoxylate ⇌ L-malate + CoA 
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Rejects DPCoA as a Substrate  
Accepts DPCoA as a Inhibitor Qualitative:  No comparison available 
Acetyl-CoA AcS H P Yes --- 
Acetyl-dephospho-CoA AcS H H No Inhibitor of Gossypium hirsutum 
[2.3.3.10] HMG-CoA Synthase (363,364)  
Acetyl-CoA + acetoacetyl-CoA + H2O ⇌ HMG-CoA + CoA 
Accepts DPCoA as a Substrate Qualitative:  No comparison Available 
CoA SH H P --- 30 µM w.r.t. Acetyl-CoA 
CoA SH H P --- 60 µM w.r.t. Acetoacetyl-CoA 
    Acetyl transfer from acetyl-CoA to acceptor 
(µmol/min/unit enzyme) 
Dephospho-CoA SH H H 0.48 
Cysteamine SH ----0.24 
Dithiothreitol SH ----0.020 
Glutathione SH ----0.008 
[2.3.3.13] α-isopropylmalate synthase  (312)  
Acetyl-CoA + α-ketoisovalerate ⇌ α-isopropylmalate 
Accepts DPCoA as a Inhibitor Qualitative:  Direct comparison not possible but  
CoA is at least 8x better as an inhibitor than DPCoA 
     % Inhibition after 10 min 
CoA [11 µM] S H P Salt changes profiles             83±3 
CoA [110 µM] S H P ---            >95 
Dephospho-CoA [130 µM] S H H ---             12±14 
Oxidized-CoA [110 µM] S-S H P ---              7±6 
Reduced Glutathione [100µM] SH -------              6±9 
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[2.3.3.14] Homocitrate Synthase (312)   
Acetyl-CoA + H2O + 2-oxoglutarate ⇌ 2-hydroxybutane-1,2,4-tricarboxylate + CoA 
Accepts DPCoA as a Inhibitor Qualitative:  Direct comparison not possible but  
CoA is at least 5x better as an inhibitor than DPCoA 
     % Inhibition after 10 min 
CoA [11 µM] S H P ---              81±4 
CoA [110 µM] S H P ---             >95 
Dephospho-CoA [130 µM] S H H ---              18±14 
Oxidized-CoA [110 µM] S-S H P ---              13±4 
Reduced Glutathione [100µM] SH -------               9±7 
[2.7.1.33] Pantothenate Kinase (365-367)   
ATP + D-pantothenate ⇌ ADP + D-4’-phosphopantothenate 
Accepts DPCoA as a Inhibitor At 0.25 µM ATP CoA is 44 x better  
At 1.00 µM ATP CoA is 2.7 x better 
At 4.00 µM ATP CoA is 2.8 x better 
DPCoA 1.3 x better relative activity than CoA (difference is 
slight and may be due to species differences 
     % Inhibition at given ATP 
Concentration (µM) 
E. coli Pantothenate Kinase 
     0.25µM 1.0µM 4.0µM 
CoA SH H P ---    44 76 94 
Dephospho-CoA SH H H ---     1 28 51 
Acetyl-CoA AcS H P ---    49 80 96 
Palmitoyl-CoA PS H P ---     2 24 80 
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     Relative Activity at 50 µM of 
the Stated Inhibitor (367) 
Rat Heart Pantothenate Kinase 
CoA SH H P --- 0.77 
Dephospho-CoA SH H H --- 0.99 
3’,5’-ADP --- H P --- 0.98 
Acetyl-CoA AcS H P --- 0.94 
Succinyl-CoA SuS H P --- 0.84 
Malonyl-CoA MaS H P --- 0.91 
Acetoacetyl-CoA AcAcS H P --- 0.95 
[2.7.8.7] holo-[acyl-carrier-protein] synthase / Surfactin synthetase-activating enzyme (Sfp) 
(368,369) 
CoA + apo-[acyl-carrier protein] ⇌ adenosine 3',5'-bisphosphate + holo-[acyl-carrier protein] 
Rejects DPCoA as a Substrate DPCoA does not react at all 
    Modification of E. coli 
holo-ACP as demonstrated by 
MS (368) 
% Relative Activity from 
Streptococcus pneumoniae 
(369) 
CoA SH H P Yes 100 
dephospho-CoA SH H H No               0 
desulfo-CoA CH2 H P Yes              76 
homocysteamine-CoA HCSH H P Yes --- 
acetonyldethio-CoA AcylS H P Yes --- 
benzoyl-CoA BnS H P Yes --- 
phenylacetyl-CoA PhAcS H P Yes --- 
malonyl-CoA MaS H P --- 12 
acetoacetyl-CoA AcAcS H P --- 65 
acetyl-CoA AcS H P Yes 91 
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[2.8.3.5] Succinyl-CoA:3-oxoacid CoA Transferase (370)  
Succinyl-CoA + Acetoacetate ⇌ acetoacetyl-CoA + succinate  
3’-P little effect  on kcat/KM for thiol ester intermediate 
Accepts DPCoA as a Substrate KS is approximately the same  
CoA SH H P --- 1.7 ± 0.5 mM 
Desulfo-CoA CH3 H P 2.7 ± 0.7 mM --- 
Acetoacetyl-CoA AcAcS H P KS 0.2-1 mM --- 
Acetoacetyl-dephospho-CoA AcAcS H H KS 0.2-1mM --- 
Acetyl-CoA AcS H P KS 1.7 mM --- 
Succinyl-CoA SuccS H P KS 2-7mM --- 
5’-ADP -- OHOH 45mM 
Reactivity of Thiol Esters of CoA Transferase with Carboxylate Substrates 
    Succinate Acetoacetate 
    Kcat/KM 
(M-1s-1) 
KM 
(M) 
Kcat/KM 
(M-1s-1) 
KM 
(M) 
E-CoA E-S H P 8.3 x 104 0.02 5 x 105  9 x 10-5 
E-dephospho-CoA E-S H H   5 x 104 0.007 ND ND 
E-deamino-CoA E-S H P   2 x 103 ≥0.05 ND ND 
[2.8.3.10] Citrate-CoA Transferase (371)  
Acetyl-CoA + citrate ⇌ Acetate + (3S)-citryl-CoA 
Accepts DPCoA as a Substrate Same KM; 28 x better VMax :isolated transferase 
1.8 x better KM; 2.6 better VMax :transferase + deAc-citrate lyase
    Isolated Transferase Transferase Integrated 
into deacetyl citrate 
lyase 
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    KM  
(µM) 
VMax  
µmol/min/mg 
KM 
(µM) 
VMax µmol/min/mg
Acetyl-CoA AcS H P 1300 25 (kcat 1300 min-1)  6700  9.1 
Acetyl-dephospho-CoA AcS H H 1300 0.9 12500  3.4 
Propionyl-CoA PrS H P 1300   25  3300 5500 
Butyryl-CoA BuS H P 1300 0.17  n.d.  n.d. 
(3S)-citryl-CoA CitS H P  200 (kcat 1600 min-1)   
[2.8.3.12] Glutaconate CoA-Transferase (372)   
Glutaryl-CoA + Acetate ⇌ AcCoA + Glutaconate 
Accepts DPCoA as a Substrate 6.5 x better KM; 3 x better VMax 
 
KM (µM) 
VMax 
(relative)
 
Glutaryl-CoA GS H P   15 100  
AcCoA + (E)-Glutaconate ⇌ Acetate + glutaconyl-CoA 
Acetyl-CoA AcS H P  170  12  
Acetyl-dephospho-CoA AcS H H 1100   4  
[3.1.3.16] Phosphoprotein Phosphatase (373)   
A phosphoprotein + nH2O ⇌ A protein + n phosphate   
Assume does not discriminate, paper doesn’t specify the actual values 
Accepts DPCoA as a Inhibitor ND 
Dephospho-CoA SH H H --- 0.1-0.18mM 
Acetyl-CoA AcS H P --- 0.1-0.18mM 
Isovaleryl-CoA IVS H P --- 0.1-0.18mM 
Isobutyryl-CoA IBS H P --- 0.1-0.18mM 
[3.4.21.26] Proline endopeptidase [Prolyl oligopeptidase] (374)  
hydrolysis of Pro-/-, Ala-/- in oligopeptides 
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Accepts DPCoA as a Inhibitor CoA is better than DPCoA but values are unclear 
Acyl-CoA AcS H P --- Y:  Most Inhibition 
CoA SH H P --- Y:  Middle Inhibition 
Dephospho-CoA SH H H --- Y:  Least Inhibition 
[4.1.1.31] Phosphoenolpyruvate Carboxylase (375) 
phosphate + oxaloacetate ⇌ H2O + phosphoenolpyruvate + CO2 
CoA-pyrophosphate analyzed in this example:  Pyrophospho-derivative 6 x more active  
Acetyl-CoA AcS H P --- Allosteric effector 
Acetyl-pyrophospho-CoA AcS H PP--- 6 x more active 
[5.4.99.2] Methylmalonyl-CoA mutase (288)  
(R)-methylmalonyl-CoA ⇌ succinyl-CoA; Propionyl-CoA + oxaloacetate  Methylmalonyl-CoA + pyruvate 
Rejects 2’-phosphate isomers as substrates 
Propionylcarba(dethia)-CoA CH2 H P Y --- 
Propionylcarba(dethia)-iso-CoA CH2 P H N --- 
[6.2.1.1] Acetyl-CoA Synthetase (376-378)  
ATP + acetate + CoA ⇌ AMP + diphosphate + acetyl-CoA 
Accepts DPCoA as a Substrate 1.24 x better KM  
CoA SH H P 247 µM  
(better at lower ATP) 
--- 
Dephospho-CoA SH H H 307 µM --- 
ATP  --- OHH 235 µM >36 mM 
Acetyl-CoA AcS H P Yes --- 
Acetyl-dephospho-CoA AcS H H Yes --- 
[6.2.1.3] Long Chain Fatty Acid CoA Ligase (379-381)  
ATP + long chain carboxylic acid + CoA ⇌ AMP + PPi + Acyl-CoA  
   
 
266 
Table 18 Continued 
 
Accepts DPCoA as a Substrate 9 x better KM; 2.2 x better VMax with R. norvegicus 
2.75 x better KM with C. lipolytica 
    KM (µM) Relative VMax (%) Species 
CoA SH H P       26-28       100 R. norvegicus 
CoA SH H P          40  C. lipolytica 
Dephospho-CoA SH H H     230-290     45-46 R. norvegicus 
Dephospho-CoA SH H H         110  C. lipolytica 
Pantetheine --- ----  1100-1200     26-27 R. norvegicus 
Pantetheine --- ----       2500  C. lipolytica 
ATP --- OHOH  2300-2400  R. norvegicus 
ATP --- OHOH        500  C. lipolytica 
dATP  H OH12500-13000   
4’-phosphopantetheine        410-430     25-26 R. norvegicus 
4’-phosphopantetheine           3300  C. lipolytica 
[6.2.1.4] Succinic thiokinase (382,383)  
GTP + succinate + CoA ⇌ GDP + phosphate + succinyl-CoA 
Accepts DPCoA as a Substrate Equal to CoA, values not available 
CoA SH H P Yes  --- 
Dephospho-CoA SH H H Yes equal to CoA --- 
3’-pyrophospho-CoA   PPYes equal to CoA --- 
[6.2.1.5] Pig Heart Mitochondrial succinic thiokinase / Succinyl-CoA Synthetase (304,382,383)  
GTP + succinate + CoA ⇌ GDP + phosphate + succinyl-CoA 
Accepts DPCoA as a Substrate Equal to CoA, values not available 
CoA SH H P Yes  --- 
Dephospho-CoA SH H H Yes equal to CoA --- 
3’-pyrophospho-CoA   PPYes equal to CoA --- 
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[6.2.1.26] O-Succinylbenzoate-CoA  Ligase (384)   
ATP + o-succinylbenzoate + CoA ⇌ AMP + PPi + o-succinylbenzoyl-CoA 
Accepts DPCoA as a Substrate Equal to CoA, values not available 
CoA SH H P 10 µM --- 
Dephospho-CoA SH H H Yes --- 
ATP --- OHOH400 µM --- 
[6.4.1.1] Pyruvate carboxylase (385)  
ATP + pyruvate + HCO3- ⇌ ADP + phosphate + oxaloacetate 
Discriminates 3’-phosphate considered important since acetyldeamino-CoA is a 7x better inhibitor 
Accepts DPCoA as a Inhibitor DPCoA is an inhibitor no direct comparison possible 
    KM µM % VMax  
CoA SH H P 1070   6 Weak activator 
Acetyl-CoA AcS H P 22.7 100 Most Potent activator 
Acetyl-3’-dephospho-CoA AcS H H --- --- [I]0.5 1.1 mM 
Acetyldeamino-CoA AcS H P --- --- [I]0.5 0.15 mM 
Adenosine 3’,5’-diphosphate --- H P 8000   4 Weak Activator 
Adenosine-2’,5’-diphosphate --- P H  No --- inhibitor 
3’-AMP --- OHP  No --- --- 
Propionyl-CoA  PrS H P 155 100 Activators 
[6.4.1.2] Acetyl-CoA Carboxylase (299,314,386,387)   
ATP + acetyl-CoA + HCO-3 ⇌ ADP + phosphate + malonyl-CoA 
Accepts DPCoA as a Substrate Nearly equal  
Accepts DPCoA derivative as an Inhibitor:  CoA is 40 x better 3’-phosphate is considered essential
Specificity for 2’-phosphate compounds is unclear.  Isomeric mixture inhibits but experiments with 
purified isomers were not performed.  Further experiments are warranted. 
Acetonyldethia-CoA + iso CH2 Mix KM 96 µM, Vmax 1U --- 
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Acetyl-CoA     Yes   --- 
Acetyl-dephospho-CoA     Yes Nearly Same as 
Acetyl-CoA 
--- 
CoA  SH H P Ka 25 µM; Kd 27 µM Binding of CoA to AcCoA 
carboxylase stimulates 
inactivation of the carboxylase 
by AcCoA carboxylase kinase 
Dephospho-CoA SH H H Yes Also Stimulates inactivation by 
the kinase 
Palmitoyl-CoA PalmS H P --- 6.5 nM (387) 
Palmitoyl-CoA(L) PalmS H P --- 22 nM 
Palmitoyl-keto-CoA PalmS H P --- 21 nM 
Palmitoyl-1,N6-etheno-CoA PCH2 H P  15 nM 
Palmitoyl-inosino-CoA PalmS H P  14 nM 
Palmitoyl-dephospho-CoA PalmS H H  260 nM 
Palmitoyl-4’-phosphopantetheine PalmS ---- 650 nM 
S-Cetyl-Coa -OS- H P  10 nM 
      
[E.C.  Not Currently Classified] PHB Synthase C. necator (222) (A-(172)(B-(135))(D-(118)),(E 
(166))(F (165)) (G (161)) (H (167))  
 
Ectothiorhodospira shaposhnikovii (I (169)) 
Bacillus megaterium (Granule bound)  (388) , Chromatium vinosum (389)(C-Jossek), Allochromatium 
vinosum (A-(172)) 
β-hydroxybutyryl-CoA ⇌ PHB + CoA 
Accepts 2’-phosphate isomers as substrates with equal facility.  Isomers were assayed 
simultaneously but HPLC analysis permitted individual quantification. 
iso-CoA SH P H Yes (Product) (222) --- 
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CoA SH P H --- KI 370 µM (118) 
CoA SH P H --- KI 108 µM (165) 
CoA SH P H Yes (Product) (222) --- 
β-hydroxybutyryl-iso-CoA HBS P H Yes (222) --- 
β-hydroxybutyryl-CoA HBS H P Yes (222) --- 
β-hydroxybutyryl-CoA HBS H P 92.5 µM (388)  
β-hydroxybutyryl-CoA HBS H P 63 µM (389) --- 
β-hydroxybutyryl-CoA HBS H P 232 µM (118) --- 
β-hydroxybutyryl-CoA (soluble) HBS H P 680 µM (161)  
β-hydroxybutyryl-CoA (granule) HBS H P 720 µM (161)  
β-hydroxybutyryl-CoA HBS H P 243 µM (166)  
β-hydroxybutyryl-CoA HBS H P KM 65 µM Kcat 320 s-1 
(169) 
 
β-hydroxyvaleryl-CoA HVS H P 1630 µM (161)  
    KM 
(M) 
Kcat 
(s-1)
kcat/KM 
(M-1s-1) 
 
β-hydroxybutyryl-CoA (165) HBS H P 103 µM 339 3.3 x 106  
β-hydroxyvaleryl-CoA (165) HVS H P 141 µM 253 3.3 x 106  
4-hydroxyvaleryl-CoA (165) 4HBS H P 301 µM 287 9.5 x 106  
3-hydroxypropionyl-CoA (167) HPS H P 119 µM 10   
β-hydroxyvaleryl-CoA HVS H P 202 µM (118)  
    C. necator 
(172) 
A. vinosum  
(172) 
    % Rel. 
Activity 
% Rel. 
Activity 
kcat  
(min-1) 
KM  
(mM) 
β-hydroxybutyryl-CoA HBS H P 100 100 3920a 
1120b 
0.13a 
0.45b 
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(R)-3-hydroxypentanoyl-CoA HPS H P 10 43 1680a 
86b 
0.18a 
0.32b 
3-hydroxypropionyl-CoA HPrS H P 0.5 1.9 76 0.22 
(R)-3-hydroxyhexanoyl-CoA HHexS H P 0.2 1 43 0.25 
(2R,3R)—2-Methyl-3-
hydroxybutyryl-CoA 
MeHBS H P ND 0.2 8.8 0.43 
(R)-lactyl-CoA LacS H P ND 0.04 1.4 0.34 
(S)-3-hydroxybutyryl-CoA S-HBS H P ND --- --- --- 
4-hydroxybutyryl-CoA 4HBS H P 0.03 --- --- --- 
(R)-3-hydroxybutyryl-N-
acetylcysteamine thioester (172)
HNAcS ----Yes 0.02 0.09 39 86 
(R)-3-hydroxybutyryl-N-
acetylcysteamine thioester (135)
HNAcS ----No   --- --- --- 
(R)-3-hydroxybutyryl (D)-
pantetheine thioester (172) 
HPanS ----Yes 0.002 0.5 19 12 
(R)-3-hydroxybutyryl (D)- 
pantetheine thioester (135) 
HPanS ----No --- --- --- 
(R)-3-hydroxybutyryl-N-
pantetheinepivalate thioester  
HPiS ----No (135)  
(R)-3-hydroxybutyryl-N-
phosphopantetheine thioester 
HPPnS ----No (135)  
    % Reactivity  
    C. necator E. Shaposhnikovii  
3-hydroxybutyryl-CoA HBS H P 100 100 (169)  
[R]-3-hydroxypropionyl-CoA HPS H P 3.5 0.65 (169)  
[R]-3-hydroxyvaleryl-CoA HVS H P 59 40 (169)  
[R,S]-3-hydroxy-4,4,4-
trichlorobutyryl-CoA 
HBS H P 14 14 (169)  
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[R,S]-3-cyclopropane-3-
hydroxypropionyl-CoA 
HPS H P ND 3.9 (169)  
[R]-3-hydroxyhexanoyl-CoA HHS H P 0.94 0.86 (169)  
[R,S]-3-hydroxy-4-methyl 
valeryl-CoA 
HVS H P 0.45 0.15 (169)  
[R,S]-3-hydroxy-4.4-
dichlorobutyryl-CoA 
HBS H P ND 0.2 (169)  
[R]-3-hydroxy-4-chlorobutyryl-
CoA 
HBS H P ND ND (169)  
[R,S]-3-hydroxy-4-methyl 
hexanoyl-CoA 
HHS H P ND 0.1 (169)  
[R]-3-hydroxyoctanoyl-CoA HOS H P ND ND (169)  
[R,S]-3-hydroxy-4-phenyl 
butyryl-CoA 
HPhS H P ND ND (169)  
*unless noted otherwise 
a First Phase of the PHB synthase reaction 
b Second Phase of the PHB synthase reaction 
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Enzymes that Reject Dephospho-CoA Compounds.  ATP-citrate 
lyase, was found by Vogel and Bridger (360) to be protected from 
thermal or proteolytic inactivation by 1 µM CoA but not by very 
high (1 mM) concentrations of dephospho-CoA.  These authors (360) 
reported several small molecules which protect ATP-citrate lyase 
against inactivation by binding to one of two sites.  These two 
sites exhibit remarkable specificity in that a 3’-phosphoryl 
group on a nucleotide is the most important structural feature 
for interaction at the CoA-binding site (site 2), and that the 
NADPH binding site (site 1) is exclusive for 2’-phosphate 
compounds.  Vogel and Bridger (360) further suggest that the 
existence of this NADPH binding site, which is independent of the 
catalytic center,  may be a regulatory mechanism for lipogenesis.   
Holo-[acyl-carrier-protein]-synthase [E.C. 2.7.8.7] from 
Streptococcus pneumoniae and E. coli , which catalyze the 
transfer of the 4’-phosphopantetheinyl moiety of CoA to a serine 
residue of apo-acyl carrier protein and thereby activates the 
protein for reactions, including fatty acid biosynthesis, also 
interacts exclusively with CoA.  The impetus for the stringent 
selectivity of the holo-[acyl-carrier-protein]-synthase is 
currently unknown; however, this might possibly result from the 
need for this enzyme to exclude NADP(H), which is present during 
fatty acid biosynthesis.  Considering this unusually stringent 
enzyme specificity, it seems reasonable that this selectivity may 
result from evolutionary demands on the enzyme to maintain 
distinct binding sites for CoA and NADPH.   
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Reactivity of Enzymes with NADP(H) and CoA Binding Sites 
with Dephospho-CoA.  Remarkably, another enzyme that rejects 
dephospho-CoA analogues, Coenzyme A disulfide reductase from P. 
horikoshii (340-342), also employs both a NADPH and a CoA-
containing compound.  Considering that several enzymes that have 
both NADPH and CoA binding sites exhibit strong specificity for 
the presence of a 3’-phosphate of CoA, it seems reasonable to 
conclude that this phenomena may result from the particular 
evolutionary pressures on this class of enzymes.  On the other 
hand, the Coenzyme A disulfide reductase enzyme from S. aureus 
(341), does react with dephospho-CoA disulfide.  Furthermore, 3-
hydroxybutyryl-CoA dehydrogenase [E.C. 1.1.1.157] and fatty acid 
synthase [E.C. 2.3.1.85], enzymes that both employ NADP(H) and a 
CoA-containing-compound, accept dephospho-CoA substrates.  
Collectively, these studies appear to suggest that suggest the 
rejection of dephospho-CoA compounds may be influenced by the 
enzyme binding to both 2’- and 3’-phosphate; however, other 
unknown factors are clearly involved.  We note that many more 
enzymes, which reject dephospho-CoA compounds, may exist, but 
unfortunately, literature accounts are skewed toward reports of 
compounds that do interact with enzymes rather than those that do 
not. 
Enzymes that Accept or Prefer the Dephospho-CoA Compounds.  
Most of the enzymes reported in the literature accept the 
dephospho-CoA derivatives albeit with less affinity than the CoA-
containing compound.  NAD(P)+ transhydrogenase, highlighted in 
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purple in Table 18, is the only enzyme we found in the literature 
that actually showed a preference for the dephospho-CoA-
derivatives (337,339).  The enzyme, NAD(P)+ transhydrogenase, 
catalyzes the reversible transfer of a hydride ion between NADPH 
and NAD+.  Rydstrom (339) reported that the presence of a 2’- or 
3’-phosphate on the adenosine moiety determines the site 
specificity of the inhibitor.  Specifically, that 2’- or 3’- 
phosphate-containing compounds inhibit with respect to NADP(H) 
whereas only dephospho-adenosine compounds inhibit with respect 
to NAD(H).  Moreover, although Rydstrom (339) found that both 2’-
ATP and 3’-ATP inhibit NAD(P)+ transhydrogenase with equal 
facility, the synthesized 3’-NADP(H) is not a substrate.  This 
indicates that during enzymatic catalysis, in which optimal 
binding conditions must be met, that this enzyme differentiates 
between phosphate locations.  The author (339) further discusses 
how inhibition of NAD(P)+ transhydrogenase by CoA-containing 
compounds might be a regulatory mechanism since palmitoyl-CoA 
(and other saturated long-chain acyl-CoA compounds) is a highly 
potent enzyme inhibitor within physiological ranges.  Thus, 
Rydstrom (339) suggests that palmitoyl-CoA inhibition may help 
regulate between NAD+ use in fatty acid β Oxidation and NADP+ 
consumption in biosynthesis.     
 
Mechanisms of 3’-phosphate Enzyme Binding.  Our survey of 
the literature indicates that the 3’-phosphate moiety of CoA is a 
rigid requirement for only a select few enzymes, and while most 
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enzymes prefer the presence of the CoA-phosphate moiety, the 
extent of this preference is dependent on the individual enzyme.  
To further elucidate the mechanisms behind this enzyme 
selectivity we undertook a comprehensive PDB databank search and 
a review of the literature to determine the specific residues 
involved in enzyme recognition of the 3’-phosphate moiety, and in 
some cases the ribose and/or the adenosine moieties of CoA, 
presented in Table 19.  The data gathered in Table 19 was cross 
listed with Table 18 and annotations are inserted (in color) for 
those enzymes in which information was available in the 
literature regarding enzyme specificity for the dephospho-CoA or 
2’-phosphate isomers, and the residues involved in CoA binding.   
The information presented in Table 19, indicates that 
charged amino acid side chains (highlighted in yellow for 
arginine; green for lysine; and pink for histidine, and 
aspartate) comprise the majority of interactions with the 
negatively charged 3’-phosphate moiety of CoA.  Most enzymes 
utilize arginine and/or lysine to interact with the 3’-phosphate 
of CoA but histidine and/or aspartate are also often involved.  
Additionally, several interactions were reported with the 
residues serine, threonine, asparagine, and tyrosine, which 
possess uncharged polar side chains and are able to form 
hydrogen-bonds with the phosphate moiety.  
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Table 19.  Protein Residue Interactions with the 3'-phosphate of CoA. 
[E.C.] Enzyme Name  Reaction  
Accepts DPCoA-Derivatives as Substrates:  Green 
Accepts DPCoA Derivatives as Inhibitors:  Dark Blue 
Accepts 2’-phosphate-derivatives as Inhibitors:  Light Blue 
Rejects DPCoA-derivatives as Substrates:  Dark Red 
Rejects 2’-phosphate-derivatives as Substrates:  Red 
Rejects 2’-phosphate-derivatives as inhibitors:  Lavender 
• Presence and/or Location of specific residues that interact with the 3’-phosphate, ribose, or 
ADP moiety of CoA and CoA-derivatives 
• Coloring Schemes of amino acid residues:   
• Charged Amino Acids:  Arginine (R); Lysine (L); Histidine (H); Aspartate (D) 
• Uncharged polar side chains:  Serine (S); Threonine (T); Asparagine (N); Tyrosine (Y) 
• Nonpolar side chains:  Phenylalanine (F); Tryptophan (W); Isoleucine (I) 
[E.C. 1.1.1.34] HMG-CoA reductase (390,391) 
(R)-mevalonate + CoA + 2 NADP+ ⇌ (S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+ 
• Y479 (OH) near (4.0-5.0 Å) 3’-phosphate 
• R571 1H-bonds to 3’-Phosphate.   
• N567 (3.0-3.2 Å) 1H-bonds to ribose-2’-hydroxyl. 
• CoA is tightly bound in a positively charged pocket near the enzyme surface. 
• Pantothenic acid moiety extends deep into protein’s interior. 
 
• NADPH binding:  S626; R627 1H-bond to 2’-hydroxyl of NADPH  
[E.C. 1.1.1.35] L-3-hydroxyacyl-CoA dehydrogenase (392) 
(S)-3-hydroxyacyl-CoA + NAD+ ⇌ 3-oxoacyl-CoA + NADH + H+ 
• K68 (a conserved basic residue) 1H-bonds with 3’-phosphate group  
• 3’-phospho-ADP of CoA is poorly defined suggests fairly mobile. 
 
• NAD+ Binding:  S137 OH interacts with 2’-hydroxyl group of the nicotinamide ribose of NAD+  
[E.C. 1.3.99.2] Butyryl-CoA Dehydrogenase (393) 
butanoyl-CoA + acceptor ⇌ 2-butenoyl-CoA + reduced acceptor 
• N182 weak 1H-bond with 3’-phosphate (393) 
• other interactions similar to MCAD (394) 
Table 19 Continued 
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[E.C. 1.3.99.3] medium-chain acyl-CoA dehydrogenase from Pig Liver mitochondria (395) 
acyl-CoA + acceptor ⇌ 2,3-dehydroacyl-CoA + reduced acceptor 
Accepts DPCoA-Derivatives as Substrates:  2x better KM than CoA ; Same VMax as CoA (306) 
                                          9x better KM; 3.7 x better kcat with CoA (335) 
                                           
Study discrepancies purportedly because of sub-saturating concentrations of the electron acceptor 
or possibly because of different biological origins. 
Accepts DPCoA-Derivatives as an Inhibitor:  Qualitative:  Diminished inhibitor 
• S19 potentially 1H-bonds with 3’-AMP moiety of octanoyl-CoA 
• solvent exposed 3’-AMP moiety of octanoyl-CoA 
[E.C. 1.3.99.10] Isovaleryl-CoA dehydrogenase (396) 
3-methylbutanoyl-CoA + acceptor ⇌ 3-methylbut-2-enoyl-CoA + reduced acceptor 
• R191; S190; Y245 1H-bonds with 3’-phosphate  
[E.C. 2.1.3.1] Methylmalonyl-CoA carboxytransferase (397) 
(S)-methylmalonyl-CoA + pyruvate ⇌ propanoyl-CoA + oxaloacetate 
Rejects 2’-phosphate-derivatives as Substrates:  Good qualitative example with pure isomers 
• R35 1H-bonds with the 3’-phosphate  
[E.C. 2.3.1.6] Choline Acetyltransferase (307,344,398) 
Choline + Acetyl-CoA ⇌ CoA + Acetyl-Choline 
[values in brackets were gathered at low anion concentration] 
Accepts DPCoA-Derivatives as Substrates:      10 x better KM [108 x better KM with low salt] Accepts DPCoA Derivatives as Inhibitors:      100 x better KI than CoA 
Accepts 2’-phosphate-derivatives as Inhibitors:  Se-CoA has a 3.5 x better KI than Se-iso-CoA • K413; K417 interact with the 3’-phosphate (398),  
• Previous reports (307,344) that the 3’-phosphate interacts with R452 appear to be incorrect 
since this residue is too far away (11A) to interact with the 3’-phosphate group of CoA.   
[E.C. 2.3.1.7] Carnitine Acetyltransferase (399) 
acetyl-CoA + carnitine ⇌ CoA + O-acetylcarnitine 
• K419; K423 (conserved residues) recognize the 3’-phosphate group. 
[E.C. 2.3.1.8] Phosphotransacetylase (346,347,400) 
Acetylphosphate + CoA ⇌ Acetyl-CoA + Pi 
Table 19 Continued 
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Accepts DPCoA-Derivatives as Substrates:  20 x better KM; 17 x better kcat; 350 x better kcat/KM 
(347) 
Rejects 2’-phosphate-derivatives as Substrates 
Rejects 2’-phosphate-derivatives as inhibitors 
• R87 salt bridge with the 3’-phosphate.   
[E.C. 2.3.1.9] β-ketothiolase bacterial synthetic thiolase from Z. ramigeria (215,401-403)  
AcCoA + AcCoA ⇌ AcAcCoA + CoA 
Accepts DPCoA-Derivatives as Substrates:  Biosynthetic thiolase is almost as active towards 
dephospho-Acetoacetyl-CoA as towards acetoacetyl-CoA (215,402,403) 
• no direct contacts and no 1H-bonding of 3’-phosphate and ribose moiety with protein observed for 
CoA (403) and Acetyl-CoA (402) bound crystal structures (402,403). 
[E.C. 2.3.1.9] Human Cytosolic Thiolase (404) 
2 acetyl-CoA ⇌ CoA + acetoacetyl-CoA 
• K210; K211 point toward the 3’-phosphate.   
• R223 side-chain 1H-bonds to the ribose O2 atom 
• 2’-endo ribose conformation.. 
[E.C. 2.3.1.18] Galactoside acetyltransferase of E. coli (405) 
 acetyl-CoA + a beta-D-galactoside ⇌ CoA + a 6-acetyl-beta-D-galactoside 
• K166; R180 interacts with 3’-phosphate.   
• solvent exposed 3’-phosphate group  
• anti glycosidic linkage of the adenine base directs it toward the protein.   
• T165 1H-bonds to the ribose 2’-hydroxyl.   
[E.C. 2.3.1.48]  Histone acetyltransferase (406,407) 
acetyl-CoA + histone ⇌ CoA + acetylhistone 
Accepts DPCoA Derivatives as Inhibitors:  CoA is 31.25 x better KI  • No residues specifically interact with the 3’-phosphate or the ADP group  
• Solvent exposed 3’-phosphate and ADP group.   
[E.C. 2.3.1.54] formate c-acetyltransferase/pyruvate formate-lyase (408)  
acetyl-CoA + formate ⇌ CoA + pyruvate 
Accepts DPCoA-Derivatives as Substrates:  CoA’s KM is 2.5 x better than DPCoA 
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• K161 salt bridge with the 3’- and 5’-phosphates  
• R160 (strictly conserved) weak 1H-bonds with ribose ring oxygen.   
• 2’-endo ribose conformation. 
[E.C. 2.3.1.74] Chalcone synthase (354-356,409) 
3 Malonyl-CoA + 4-coumaryl-CoA ⇌ 4 CoA + naringenin chalcone + 3 CO2 Accepts DPCoA-Derivatives as Substrates:  CoA is 9 x better KM Accepts DPCoA Derivatives as Inhibitors:  CoA is CoA is better than DPCoA (Qualitatively) 
• R58; K77 1H-bonds with 3’-phosphate (409) 
• R58; K55 interacts with 3’-phosphate (410) 
• anti-glycosidic bond torsion angle of ribose 
• 2’-endo ribose conformation  
[E.C. 2.3.1.81] aminoglycoside N-acetyltransferase (411) 
acetyl-CoA + a 2-deoxystreptamine antibiotic ⇌ CoA + N3'-acetyl-2-deoxystreptamine antibiotic 
• CoA adopts different positions in the two halves of the asymmetric unit 
• In complex 1: R119 (NH1-H2O = 2.3 Å and H2O-O32 = 3.0 Å) water-mediated interaction with 3’-
phosphate. 
• In complex 2, R119 interacts directly (NH1-O32 = 2.8 Å) with the 3’-phosphate oxygen 
• solvent-exposed 3’-phosphate  
• 2’-endo ribose conformation 
[E.C. 2.3.1.97] N-myristoyltransferase (294,311,358,412) 
Octapeptide + myristoyl-CoA ⇌ myristoyl-peptide + CoA 
Accepts DPCoA-Derivatives as Substrates:  (294,311,358) 
                                    Myristoyl-compounds:  8.3 x better KD; 1.4 x better % Activity
                                    Palmitoyl-compounds:  8.9 x better KD; 2.5 x better % Activity
                                    Lauryl-compounds:  135 x better KD; 2 x better % Activity  Accepts 2’-phosphate-derivatives as Inhibitors:  6.6 x better KI for CoA-derivatives (294,311) 
R181 (guanido) salt bridge with 3’-phosphate (412). 
H38 interacts with the 3’-phosphate (412). 
K39; F40; W41 backbone amides interact with 3’-phosphate (412). 
[E.C. 2.3.1.117] Tetrahydrodipicolinate (THDP) N-Succinyltransferase (413) 
tetrahydrodipicolinate + succinyl-CoA ⇌ L-2-(succinylamino)-6-oxopimelate + CoA 
 
Table 19 Continued 
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• R217; R213 interact with 3’-phosphate 
• solvent exposed 3’-phosphate  
[E.C. 2.3.3.1] Citrate Synthase (414,415) 
acetyl-CoA + H2O + oxaloacetate ⇌ citrate + CoA 
Accepts DPCoA as a Inhibitor:  Qualitative:  Approximately the same inhibition 
2’-phosphate vs. 3’-phosphate specificity is unclear.  Isomeric mixture inhibits so authors
suggest no discrimination based on the comparison with S-heptadecyl-CoA but further experiments 
are warranted. 
• R164 interacts with 3’-phosphate from Pig  
• K254; K305 interacts with 3’-phosphate from Pyrococcus furiosus 
• K313 interacts with 3’-phosphate from Antarctic bacterial strain DS2-3R overexpressed in E. 
coli; unlike the previous two, all CoA binding residues are on a single monomer (415).  
[E.C. 2.3.3.9] Malate Synthase (416) 
acetyl-CoA + H2O + glyoxylate ⇌ (S)-malate + CoA 
Rejects DPCoA-derivatives as Substrates 
Accepts DPCoA Derivatives as Inhibitors:  Qualitative:  No comparison available 
• R125; R312 salt bridge 3’-phosphate 
• Specifically, 3’-phosphate salt bridge between R125 (NH2 being 2.6 and 2.7 A away from A07 and 
A09 phosphate oxygens, respectively) and R312 (NH1 and NH2 are 3.0 and 2.8 A away from the 
phosphate oxygen A08)   
• 2’-endo nucleoside conformation. 
[E.C. 2.7.1.33] Pantothenate Kinase (417) 
ATP + (R)-pantothenate ⇌ ADP + (R)-4'-phosphopantothenate  CoA inhibits competitively w.r.t. ATP 
Accepts DPCoA Derivatives as Inhibitors:  DPCoA is a less potent inhibitor than CoA (417) 
 
                                At 0.25 µM ATP CoA is 44 x better  
                                At 1.00 µM ATP CoA is 2.7 x better 
                                At 4.00 µM ATP CoA is 2.8 x better 
                                DPCoA 1.3 x better relative activity than CoA (difference is       
                                slight and may be due to species differences 
• R106 (guanidinium) salt bridge with the 3’-phosphate  
• S102 (OH); I42 (amide) 1H-bonds to 3’-phosphate  
Table 19 Continued 
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[E.C. 2.7.7.3] Phosphopantetheine Adenylyltransferase 
ATP + pantetheine 4'-phosphate ⇌ diphosphate + 3'-dephospho-CoA 
D95 (Amide); a H2O molecule 1H-bond to the 3’-phosphate  
[E.C. 2.7.7.23]  UDP-N-acetylglucosamine diphosphorylase (418) 
UTP + N-acetyl-alpha-D-glucosamine 1-phosphate ⇌ diphosphate + UDP-N-acetyl-D-glucosamine 
• K446 interacts with 3’-phosphate through a conformationally mobile C-terminal tail that forms a 
portion of the acyltransferase active site.   
• R429 1H-bond with 3’-phosphate 
• 3’-phosphate may be critical to proper active site formation   
[E.C. 2.7.8.7] Surfactin synthetase-activating enzyme (Sfp)/ holo-[acyl-carrier-protein] synthase 
(419,420) 
CoA + apo-[acyl-carrier protein] ⇌ adenosine 3',5'-bisphosphate + holo-[acyl-carrier protein] 
Rejects DPCoA-derivatives as Substrates:  DPCoA does not react at all (368,369) 
 
“The strong binding of the 3’-phosphate group agrees with other results that this moiety is 
indispensable for CoA binding (420).”   
• K28; K31 (ζ-amino); H90 (imidazole ε-nitrogen) salt bridge with the 3’-phosphate (420) 
• T44 1H-bonds to 3’-phosphate (420) (SFP) 
• 3’-endo ribose conformation with axial 2’-hydroxyl and equatorial 3’-phosphate group.  This 
contrasts all other known protein-bound CoA structures (420) (SFP). 
• R53; H105 1H-bond to 3’-phosphate (419) (holo-[acyl-carrier-protein] synthase) 
• 3’-endo ribose conformation with axially 2’-hydroxyl and an equatorial 3’-phosphate (419) 
(holo-[acyl-carrier-protein] synthase) 
[E.C. 2.8.3.16] Formyl-CoA transferase (421) 
formyl-CoA + oxalate ⇌ formate + oxalyl-CoA 
• R104 1H-bonded to 3’-phosphate,  
• Solvent exposed 3’-phosphate, ribose, and pyrophosphate. 
• Adenine moiety wedged into a thin cleft and solvent buried 
[E.C. 3.1.2.23] 4-Hydroxybenzoyl-CoA Thioesterase (422) 
4-Hydroxybenzoyl-CoA + H2O ⇌ 4-hydroxybenzoate + CoA 
• R102; R150 interact with 3’-phosphate. 
 
Table 19 Continued 
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[E.C. 3.8.1.7] 4-Chlorobenzoyl Coenzyme A Dehalogenase (423) 
4-chlorobenzoyl-CoA + H2O ⇌ 4-hydroxybenzoyl-CoA + chloride 
H23; R67 form positively charged pocket possibly interacting with the 3’-phosphate group 
No electron density for the 3’-phosphate was observed; suggests study was contaminated by 
dephospho-CoA or dephosphorylation occurred (423). 
[E.C. 4.1.1.41] Methylmalonyl-CoA Decarboxylase (424) 
(S)-methylmalonyl-CoA ⇌ propanoyl-CoA + CO2 
Solvent exposed 3’-phosphate  
• K253 (Nζ) within 1H-bonding distance of ribose 2’-hydroxyl  
[E.C. 5.4.99.2] Methylmalonyl-CoA mutase (288,425)   
(R)-methylmalonyl-CoA ⇌ succinyl-CoA 
Rejects 2’-phosphate-derivatives as Substrates:  Specifically rejects Propionylcarba(dethia)-iso-
CoA 
5 arginines; 1 lysine  
[R45, R321, R283, K321] (425) 
[E.C. 6.2.1.1] Acetyl-CoA synthetase (426) 
ATP + acetate + CoA ⇌ AMP + diphosphate + acetyl-CoA 
Accepts DPCoA-Derivatives as Substrates:  1.24 x better KM • R584 (From CT-domain) interact with 3’-phosphate 
• R194 (adopts two conformations) may interact with the 3’-phosphate from the CoA bound to a 
symmetry related Acetyl-CoA Synthetase molecule—purportedly a crystal artifact and not true 
dimerization.   
• Nucleotide portion of CoA is bound on the surface of the protein 
• Phosphopantetheine moiety directed into the active site (426).     
[E.C. 6.2.1.5] Succinyl-CoA Synthetase (427,428) 
Succinyl-CoA + NDP + Pi ⇌ Succinate + CoA + NTP 
Accepts DPCoA as a Substrate:  DPCoA is equal to CoA and 3’-pyrophospho-CoA 
• K42; S36; K66; T39 interact with 3’-phosphate. 
• Anti glycosidic bond of adenine ring and the ribose moiety.   
• 1’-exo ribose conformation (unusual); equatorial ribose OH and 5’-group and axial 3’-phosphate  
[6.4.1.2] Acetyl-CoA Carboxylase (299,314,386,387)   
ATP + acetyl-CoA + HCO-3 ⇌ ADP + phosphate + malonyl-CoA 
Table 19 Continued 
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Accepts DPCoA as a Substrate:  Nearly equal 
Accepts DPCoA derivative as an Inhibitor:  CoA is 40 x better 3’-phosphate is considered essential
Specificity for 2’-phosphate compounds is unclear.  Isomeric mixture inhibits but experiments with 
purified isomers were not performed.  Further experiments are warranted. 
• K2034’ interacts with the 3’-phosphate 
[E.C. Currently Not Classified] ZhuH, the priming β-ketoacyl synthase of the R1128 biosynthetic 
pathway.  (429) Decarboxylative condensation between an acyl group derived from the corresponding 
acyl-CoA and a malonyl extender unit attached to an acyl carrier protein (ACP), resulting in the 
formation of a β-ketoacyl-ACP product. 
• No interactions with the 3’-phosphate or ribose moieties 
• Solvent exposed 3’-phosphate and ribose,.   
[E.C. Currently Not Classified]  Vat(D) a Streptogramin Acetyltransferase (430) 
Inactivates Streptogramin Group A Antibiotics 
• Solvent exposed 3’-Phosphate  
• Anti glycosidic linkage of adenine and ribose 
• Adenine ring points toward the protein.   
[E.C. Currently Not Classified]  CaiB:  a CoA transferase (431) 
γ-butyrobetaine-CoA + carnitine ⇌ γ-butyrobetaine + carnityl-CoA  
• K97 and R104 coordinated by 3’-phosphate. 
• CoA induces a substantial (3 Å) movement of the small domain toward the large domain which 
somewhat closes the active site.   
[E.C. Currently Not Classified ] Hexapeptide Xenobiotic Acetyltransferase (432) 
Utilizes Acetyl-CoA to acylate a variety of hydroxyl-bearing acceptors 
• R159 contacts the 3’-phosphate  
• K144 1H-bonds to ribose 2’-hydroxyl  
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Salt Bridge Interactions with the 3’-phosphate of CoA.  
Salt bridges are reported to occur with the 3’-phosphate moiety 
of CoA in seven different enzymes.  In the case of pyruvate 
formate-lyase [E.C. 2.3.1.54], Becker and Kabsch (408) observed 
formation of a salt bridge between Lys-161 and the 3’- and 5’-
phosphate of CoA.  This is the only literature report in which a 
single residue generates salt bridges with two separate phosphate 
groups.  Since Lys-161 is already donating a portion of its 
electron density to the ion pair with the 5’-phosphate, the 
presence of a 3’-phosphate may not substantially perturb the 
system.  This might explain the why the KM of CoA is only 2.5 
fold better than that of the dephospho-derivative, since the 3’-
phosphate may not contribute a great deal to the energy to bind 
this enzyme.   
N-myristoyltransferase [E.C. 2.3.1.97] binds the 3’-
phosphate of CoA via a salt bridge to the guanidinium of Arg-181 
in addition to interactions with His-38, Lys-39, Phe-40, and Trp-
41.  Given the large number of interactions between the enzyme 
residues and the 3’-phosphate of CoA it is somewhat surprising 
that this enzyme does accept both the dephospho-derivatives and 
the 2’-phosphate isomers of CoA; however, the KD for myristoyl-
CoA is 8.3 fold better than the dephospho compound, and the KI 
for myristoyl-CH2-dethia-CoA is 6.6 fold better than for the 2’-
phosphate isomer.   
With pantothenate kinase [E.C. 2.7.1.33] the 3’-phosphate 
of CoA forms a salt bridge with the guanidinium group of Arg-106 
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and hydrogen bonds to the Ser-102 hydroxyl moiety and to the Ile-
42 amide.  Yun et al. (417) asserts that the interactions of the 
3’-phosphate of CoA are critical for CoA inhibition of 
pantothenate kinase since dephospho-CoA is significantly less 
potent.   
Malate synthase [E.C. 2.3.3.9] presents an interesting 
example because acetyl-dephospho-CoA is an inhibitor for but not 
a substrate of this enzyme.  The 3’-phosphate of CoA reacts with 
malate synthase via two salt bridges to separate arginine 
residues, Arg-125 and Arg-312.  It seems reasonable to speculate 
that the 3’-phosphate moiety is essential for optimal substrate 
binding with ensuing catalysis whereas less the favorable binding 
of the acetyl-dephospho-CoA is adequate to the task of inhibiting 
malate synthase.   
Iyer and Ferry (347) utilized mutagenesis studies of 
phosphotransacetylase [E.C. 2.3.1.8] to identify a specific 
arginine residue, Arg-87, that they report forms a salt bridge 
with the 3’-phosphate of CoA.  The authors suggest that it is 
this salt bridge, which imparts the 350-fold preference for CoA 
over dephospho-CoA.  Recently, Iyer and colleagues (400) 
published the first crystal structure of a phosphotransacetylase, 
and although this crystal was in its apo state (without CoA 
bound) the preliminary structure is consistent with formation of 
a salt bridge to the 3’-phosphate of CoA at Arg-87.   
A salt bridge between Arg-452 and the 3’-phosphate moiety 
of CoA has also been reported for choline acetyltransferase 
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[2.3.1.6] by Wu and Hersh (307) and Mautner et al (344).  
However, McKenna and coworkers (398) recently refuted the 
conclusions of these two previous studies in their investigation 
of the apo crystal structure of choline acetyltransferase with 
modeled CoA and acetylphosphate substrate binding.  McKenna and 
coworkers (398) state that the distance between Arg-452 and the 
3’-phosphate moiety is too great (11 Å) for salt bridge formation 
and suggest instead that Lys-413 and Lys-417 interact with the 
3’-phosphate moiety of CoA.  Clearly, this discrepancy 
underscores the importance of unambiguous data from crystals with 
the ligand bound in order to determine the minute structural 
variations, which affect the binding of important substrates.   
Perhaps the most intriguing example of salt bridge 
formation occurs with surfactin synthetase-activating enzyme 
(SFP) [E.C. 2.7.8.7] (420) which flatly rejects the dephospho-CoA 
as a substrate and maintains fully three salt bridges between the 
3’-phosphate of CoA and Lys-28, Lys-31, and His-90 in addition to 
a hydrogen bond to Thr-44.  Remarkably, the ribose unit of CoA is 
bound to SFP in a 3’-endo conformation, in which the 3’-phosphate 
is oriented equatorially, and the 2’-OH is oriented axially.  
This differs from all other known orientations of CoA bound to 
proteins, since the 2’-endo conformation is most common and the 
1’-endo conformation observed only in the succinyl-CoA synthetase 
enzyme [E.C. 6.2.1.5] (427,428).  Clearly, it is the tight 
binding of the 3’-phosphate CoA to this molecule in addition to 
other bonds, such as an additional ion pair between His-90 and 
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the 5’-phosphate of CoA, which maintain the unusual sugar 
conformation and results in this enzyme’s strict specificity for 
the 3’-phosphate containing compounds (420).   
As previously mentioned, the succinyl-CoA synthetase 
[6.2.1.5] enzyme (427,428) also binds the ADP-moiety of CoA in an 
unusual conformation.  In this enzyme, the ribose is positioned 
in the 1’-exo conformation in which the hydroxyl-group of ribose 
is equatorial and the 3’-phosphate is axial via interactions with 
two lysines, a serine and a threonine.  In contrast to SFP, 
succinyl-CoA synthetase accepts dephospho-CoA and 3’-pyrophospho-
CoA with apparently equal facility as the physiological substrate 
CoA (304,382,383).  In this case, despite the large number of 
interactions and the unusual conformation of the ribose ring, the 
3’-phosphate of CoA is not critical to the functioning of 
succinyl-CoA synthetase.   
Hydrogen Bonding Interactions with the 3’-phosphate of CoA. 
Hydrogen bonding interactions are also an important mode of 
binding the 3’-phosphate of CoA.  Hall et al. (397) reported the 
occurrence of a hydrogen bond between the 3’-phosphate of CoA and 
Arg-35 of methylmalonyl-CoA carboxytransferase [E.C. 2.1.3.1] 
(397).  This enzyme accepts purified propionyl-CH2-CoA as a 
substrate but rejects the purified 2’-phosphate isomer, 
propionyl-CH2-iso-CoA (288,289).  In contrast, medium-chain acyl-
CoA dehydrogenase [E.C. 1.3.99.3] (298,306,334,335) and chalcone 
synthase [E.C. 2.3.1.74] (354-356) accept dephospho-CoA 
derivatives as substrates and inhibitors (the specificity for the 
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2’-phosphate isomers is currently unknown) with the former enzyme 
generating a hydrogen bond between the 3’-phosphate and Ser-19, 
and the latter enzyme hydrogen bonding to an arginine and a 
lysine.   
Enzymes with No Contacts to the 3’-phosphate of CoA.  The 
crystal structures of several enzymes revealed no contacts 
between residues and the 3’-phosphate moiety of CoA.  In the case 
of histone acetyltransferase [E.C. 2.3.1.48] (406,407) there are 
no interactions with the 3’-phosphate; this probably accounts for 
the promiscuity of this enzyme which is reported to accept 
dephospho-CoA derivates as inhibitors.  However, Cebrat et al. 
(350) report that this enzyme exhibits a 31 fold preference for 
lys-CoA over dephospho-lys-CoA.  The mechanism for the 
specificity with the lys-CoA isomers is not explained by the 
crystal results and remains to be determined.   
 
Crystal Structure and Substrate Specificity for the Enzymes 
Involved in PHB Synthesis.   
β-ketothiolase.  Regarding the enzymes studied in this 
laboratory, the crystal structure has been reported for the β-
ketothiolase enzyme [E.C. 2.3.1.9] from the prokaryote Z. 
ramigeria.  Modis and Wierenga (402,403) have reported in two 
separate investigations that no direct contacts are observed in 
the crystal structure between the β-ketothiolase protein and 
either the 3’-phosphate or the ribose moieties of CoA and acetyl-
CoA.  These structural studies indicate that β-ketothiolase 
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should not discriminate on the basis of the position or presence 
of the 3’-phosphate; this is consistent with our own (222) as 
well as other  investigations into the specificity of this 
enzyme.  Davis et al. (215) reported that acetoacetyl-S-(L-
pantetheine) is a substrate for the β-ketothiolase enzyme from Z. 
ramigeria, although the catalytic efficiency (Kcat/KM) for this 
substrate (which lacks the adenosine 3’-phosphate, 5’-diphosphate 
moiety) is 53 fold lower than the native substrate, acetoacetyl-
CoA (215).  These results corroborate the studies performed in 
this laboratory that demonstrate clearly that the β-ketothiolase 
enzyme from C. necator accepts both the 3’-phosphate and the 2’-
phosphate isomers of CoA with equal facility (222).   
Acetoacetyl-CoA Reductase.  While no crystal structure has 
been obtained for the NADPH-dependent acetoacetyl-CoA reductase 
[E.C. 1.1.1.36] enzyme that was studied in this laboratory, a 
crystal structure does exist for the closely related L-3-
hydroxyacyl-CoA dehydrogenase enzyme [E.C. 1.1.1.35], which 
catalyses the same reaction, except NADH instead of NADPH is 
used.  Baryckii et al. (392) reported that the electron density 
of the 3’-phospho-ADP moiety of β-hydroxybutyryl-CoA and 
acetoacetyl-CoA was poorly defined in the crystal structure of L-
3-hydroxyacyl-CoA dehydrogenase.  The authors (392) suggest that 
this indicates that the moiety is relatively mobile in the 
binding pocket.  However, the authors further discuss how the 
current x-ray model supports a hydrogen bonding interaction 
between a conserved lysine residue, Lys-68, and the 3’-phosphate 
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group of CoA.  The NADH-dependent L-3-hydroxyacyl-CoA 
dehydrogenase crystal data is in relatively good accord with our 
own laboratory results, which demonstrate that the closely 
related NADPH-dependent acetoacetyl-CoA reductase enzyme reacts 
with both the 2’- and 3’-phosphate isomers with apparently equal 
affinity (222).  Our results are compatible with the kinetic 
studies performed by Ploux, Masamune and Walsh (220) on the 
acetoacetyl-CoA reductase from Z. ramigeria in which they 
demonstrated that acetoacetyl-S-(D-pantetheine)11-pivalate 
(absent the adenosine 3’-phosphate, 5’-diphosphate moiety) is an 
enzyme substrate, albeit with a catalytic efficiency 667 fold 
less than the physiological substrate, acetoacetyl-CoA.  Further 
crystal studies of the NADPH-dependent acetoacetyl-CoA reductase 
enzyme would certainly be of interest.   
PHB Synthase.  PHB synthase was observed to react with both 
isomers of CoA-containing compounds in our laboratory (433), and 
this is the first report of an alteration to the structure of the 
CoA portion of the moiety which does not destroy or substantially 
diminish the capacity for enzymatic catalysis.  Gerngross and 
Martin (135) reported that the PHB synthase enzyme from C. 
necator does not catalyze polymerization reactions with the (R)-
3-hydroxybutyryl thioesters of pantetheine, pantetheinepivalate, 
phosphopantetheine, and N-acetylcysteamine, which are all absent 
the 3’,5’-ADP moiety of CoA.  In contrast, further studies by 
Sinskey, Stubbe and coworkers (172) demonstrate that the N-
acetylcysteamine and the pantetheine thioesters are substrates 
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but with rates, respectively, 1/5,000 and 1/50,000 that of the 
native substrate.  Despite this minor disparity, both groups 
agree that the 3’,5’-ADP moiety of CoA is critical to the 
polymerization reaction of PHB synthase (135,172).  To date, no 
studies have been performed regarding enzyme specificity for 
substrates altered in the 3’,5’-ADP moiety of CoA, thus our 
results are the first to demonstrate that PHB synthase can accept 
alterations to this portion of the CoA molecule.  Unfortunately, 
this membrane-associated enzyme is difficult to obtain in high 
yields with good purity; thus, no crystal structure is currently 
available.  However, crystallization studies are currently 
underway at the USDA.     
This careful review of the literature data has revealed 
that the specificity for the 3’-phosphate of CoA is somewhat of a 
mixed bag, and while some inferences can be drawn from the 
crystal data, few sweeping generalities can be made.  For many 
enzymes, it remains to be determined whether salt bridges, 
hydrogen bonds and other binding interactions would be distorted 
by the presence of a phosphate in the 2’-position, rather than 
the 3’-position, of the ribose ring.  From the literature, it is 
clear that each enzyme must be evaluated on a case-by-case basis 
using purified isomers to determine how the phosphate position 
would affect the binding of CoA. 
 
High Performance Liquid Chromatography.  The traditional 
method for resolving isomers of CoA-containing compounds, ion 
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exchange chromatography (265,266,301), is often lengthy and, 
historically, neither ion exchange nor reversed phase separations 
have achieved baseline resolution.  This limitation may have 
hampered investigations into isomers of CoA (305).  Indeed, 
Rossier (305) reported using iso-seleno-CoA instead of iso-CoA in 
investigations of the importance of the CoA 3’-phosphate moiety 
on the activity of choline acetyltransferase.  Wagner and Retey 
(294) resorted to multiple rounds of a complex 500 min gradient 
elution profile in order to adequately purify the isomers of 
myristoyl-carba(dethia)-CoA.  
We report here efficient HPLC methodology, which achieves 
baseline resolution of CoA and acyl-CoA isomers.  This technique, 
improves upon and simplifies the earlier work by Norwood et al. 
(225), and is the first HPLC method to separate a series of iso-
CoA compounds, and we are able to separate four iso-CoA isomers 
within 30 minutes with baseline resolution using convenient 
isocratic elution.  The methodology employed by Norwood et al. 
(225), which resolved short and medium chain (C2-C8) acyl-CoA 
compounds (including acetyl-CoA and β-hydroxybutyryl-CoA), 
required a two-step linear gradient and a complex mobile phase 
consisting of Buffer A:  0.2M ammonium acetate: 1.75% 
acetonitrile:2% glycerol; Buffer B:  acetonitrile.  We note that 
inspection of published HPLC elution profiles of CoA-containing 
compounds reveal several chromatograms which appear to contain 
iso-CoA-compounds that were not identified as such by the authors 
(434-438).  Furthermore, iso-CoA isoforms may have been 
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overlooked by previous authors because the isomers will co-elute 
under stronger HPLC elution conditions. 
 
The First Regioselective Chemical Synthesis of Iso-CoA.  We 
also report here the first regioselective chemical synthesis of 
iso-CoA from CoA.  Previously reported methods which produce iso-
CoA as a byproduct of cyclic-CoA (I) hydrolysis yield mixtures 
containing both the 2’- and 3’-phosphate isomers in ratios of 
approximately 40%; 60%, respectively (265,266,284,285,287).  In 
our simple synthesis, the cyclic-CoA moiety is efficiently 
produced from CoA, and then base-catalyzed hydrolysis in the 
presence of β-cyclodextrin in high salt produces iso-CoA 
regioselectively in high yields.  Our results are in agreement 
with those of Komiyama and coworkers (439,440), who previously 
reported that β-cyclodextrin-based hydrolysis of adenosine and 
guanosine 2’,3’-cyclic phosphates gives reversed regioselectivity 
(i.e. 3’-clevage) as compared to the enzyme, ribonuclease. 
As illustrated in Figure 36, Komiyama and coworkers 
(439,440) theorize that an adenine moiety will form an inclusion 
complex with β-cyclodextrin, resulting in steric constraints that 
direct base-catalyzed hydrolysis toward the 3’-bond; thus, 
producing the 2’-phosphate species, regioselectively.  Selection 
of the alkali-metal halide is critical to the reaction 
selectivity.  The chloride anion purportedly facilitates 
penetration of the adenine moiety deep into the β-cyclodextrin 
cavity, this enhances the steric clash at the 2’-position thus 
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favoring hydrolysis of the 3’-phosphate bond.  Komiyama et al. 
demonstrate that the 2’/3’ selectivity is proportional to the 
electronegativity and inversely proportional to the size of the 
metal-halide anion such that the 2’/3’ selectivity follows the 
F>Cl>Br>I trend.  We note that high concentrations of KF salted 
out some of the β-cyclodextrin and prevented easy rotary 
evaporation; the slight increase in regioselectivity afforded by 
KF over KCl did not merit these difficulties.   
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Figure 36.  Proposed Structure of the [β-cyclodextrin-CL—
adenosine cyclic phosphate] Ternary Complex.  Base-catalyzed 
hydrolysis at the 2’-position is less favorable due to steric 
hindrance; thus, the 3’-position is hydrolyzed leading to 
regioselective formation of the 2’-phosphate compound.  
(reproduced from (440))
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Mechanism of Acid Catalysis for Iso-CoA Formation.  We 
propose acid-catalysis as a plausible mechanism to account for 
the existence of the 2’-phosphate isomers in commercial 
preparations of CoA-containing compounds.  In 1954, Kaplan and 
coworkers published preliminary reports about the acid-catalyzed 
synthesis of iso-CoA from CoA (278,315).  These authors did not 
prove iso-CoA formation and only demonstrated that exposing CoA 
to strong acid decreased specific 3’-nucleotidase activity.  
Nevertheless, the acid-catalyzed migration of the 2’- and 3’-
phosphate groups of NADPH (441) and nucleotides (156,442-444) is 
well established in the literature.  The theoretical mechanism 
for the acid-catalyzed migration of phosphate compounds is 
depicted in Figure 37.  In our hands, treatment of CoA with 0.5 M 
HCl produces an equilibrium mixture of 40% iso-CoA and 60% CoA 
within 60 hours, and 10% of the isomer can be generated within 4 
hours.  These results indicate that acid catalysis is a viable 
mechanism for rapidly producing iso-CoA from CoA, especially 
considering that strong acids are often used in several published 
CoA isolation procedures (273,445-448).   
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Figure 37.  The Theoretical Mechanism for the Acid-catalyzed 
Hydrolysis of CoA to Iso-CoA.  In the presence of strong acid the 
phosphate group of CoA forms a 2’, 3’-cyclic intermediate, which 
then is hydrolyzed forming an equilibrium mixture of CoA and iso-
CoA. 
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The Biological Significance of Iso-CoA.  The biological 
significance of iso-CoA-compounds is currently unknown.  
Khorana’s original report (265,266) stating that  
phosphotransacetylase excludes iso-CoA probably has led to the 
generally held contention that the 2’-isomers are unnatural 
compounds.  In contrast, Kurooka et al. (449) suggested that iso-
CoA might be formed from crude cell extracts of Proteus mirabilis 
in the presence of 3’-dephospho-CoA.  Kurooka et al. (449) 
reported that in buffered cell extracts containing a 
phosphotransferase from P. mirabilis, radioactive pNP32P (p-
nitrophenyl phosphate) and 3’-dephospho-CoA generated 
radiolabeled [32P]-CoA.  Detection of the radiolabeled [32P]-CoA 
was accomplished using three separate methodologies:  1.) 0.0134 
µmol of [32P]-CoA was found with the phosphotransacetylase-
hydroxamic acid assay that used CoA from Sigma as a standard; 2.)  
0.016 µmol of [32P]-CoA was detected by UV absorbance (260 nm; 
ε=14,600); 3.)  0.0175 µmol of [32P]-CoA was detected via a 
radioactivity assay utilizing pNP32P as the radioactive standard.  
Of these three detection methodologies, only the 
phosphotransacetylase-hydroxamic acid assay is specific for CoA, 
since the enzyme phosphotransacetylase does not accept iso-CoA as 
a substrate or inhibitor.  The UV and radioactivity assay results 
indicate that more CoA is present than was detected using the 
stereospecific enzymatic assay.  Furthermore, the results of the 
radioactivity assay suggest that the additional material is 
generated de novo by the phosphotransferase reaction or 
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radioactivity would not have been detected.  These results lead 
the authors to suggest that the 3’-dephospho-CoA is also 
enzymatically phosphorylated at 2’-phosphate position giving rise 
to [32P]-iso-CoA.  Further, Kurooka et al. (449) cite two studies 
by Mitsugi et al. (450,451) which support Kurooka’s contention 
for de novo generation of [32P]-iso-CoA.  The Mitsugi et al. 
studies (450,451) demonstrate production of adenosine 2’,5’-
diphosphate and adenosine 3’,5’-diphosphate from the treatment of 
crude cell extracts with 5’-DMP and p-nitrophenyl phosphate 
(pNPP).  
Similarly, Michaelson (282) reported that an unnamed 
partially-purified enzyme from calf brain selectively generated 
iso-CoA from cyclic-CoA in vitro.  Michaelson stated that this 
enzyme (although unnamed) was known to cleave adenosine 2’,3’-
cyclic phosphates to the 2’-phosphate.  This enzyme was probably 
2’,3’-cyclic 3’-phosphodiesterase [3.1.4.37], which belongs to 
the 2H phosphodiesterase superfamily of enzymes.  This enzyme 
selectively produces 2’-phosphate nucleosides from their 2’,3’-
cyclic species, such as NADP+ generation from cyclic-NADP+ (325).  
Although this enzyme constitutes approximately 4% of all myelin 
protein, to date the in vivo substrate for the 2’,3’-cyclic 3’-
phosphodiesterase’s [3.1.4.37] esterase activity has not been 
established (452-455).  Kurooka et al. (449) and Michaelson’s 
(282) reports suggest that iso-CoA could possibly be generated 
enzymatically in vivo from dephospho-CoA or 2’, 3’-cyclic-CoA; 
however, no definitive evidence for this notion exists.   
   
 300
 
Could Iso-CoA or a derivative be a substrate for the 2’,3’-
cyclic-nucleotide 3’-phosphodiesterase (CNP) class of enzymes?  
Despite the importance of the 2’,3’-cyclic-nucleotide 3’-
phosphodiesterase (CNP), which has been implicated in several 
myelin-related diseases including Alzheimer’s and multiple 
sclerosis (455), the in vivo substrate remains an enigma.  It is 
attractive to speculate that this enzyme may be involved in 
processing CoA, iso-CoA or some derivative of CoA.  Indeed, in a 
2003 report Kozlov et al. (454) postulated a similar hypothesis:  
that CNP might potentially act on signaling molecules such as 
nicotinic acid-adenine dinucleotide phosphate and cADP-ribose.   
Structure and Specificity of CNP Proteins.  The solution 
NMR structure of the catalytic fragment of the human brain 2’,3’-
cyclic-nucleotide 3’-phosphodiesterase (hCNP-CF) was determined 
by Kozlov et al (454).  The authors measured the dissociation 
constants (KD) obtained by NMR titrations, and demonstrated a 
preference for 3’-AMP (KD 0.57 ± 0.04) over 2’-AMP (KD 1.49 ± 
0.14) and 5’-AMP (KD 1.68 ± 0.04); this was consistent with the 
measured competitive inhibition constants of 0.239 ± 0.013, 0.417 
± 0.012, and 1.10 ± 0.14, respectively.  In addition, ATP was a 
very poor inhibitor with a KI ~13 mM.  The authors also compared 
the binding of NADP+ (KD 5.38 ± 0.55) and NAD+ (KD 21.19 ± 0.72), 
and determined that the phosphate group of NADP+ significantly 
improved binding affinity.  The binding affinity of the 
oligonucleotide, A6, for hCNP-CF was also examined because the 
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enzyme binding site resembles RNA-binding proteins in that it 
contains several aromatic (Tyr-168, Phe-172, Phe-235, and Tyr-
352) and positively charged (Lys-214, Lys-234, R307) residues 
which are located on β-sheets.  Furthermore, similar enzymes from 
this 2H phosphodiesterase family bind RNA and/or are active in 
RNA-processing pathways.  Kozlov et al. (454) was surprised to 
find that the A6 RNA was a relatively weak inhibitor of hCNP-CF, 
with a KI of ~0.8, and that the chemical shift changes were 
smaller than with 3’-AMP or 5’-AMP, indicating weaker binding 
than the nucleoside phosphates.  The authors do note that a 3’- 
or 5’- terminal phosphate might be important for binding since 
positively charged arginine and lysine residues are frequently 
present in CoA-binding sites.  Certainly, determining the kinetic 
activity of the CoA isomers and derivatives with the hCNP-CF 
would be very interesting.   
Crystal structure of the human CNP-catalytic fragment.  The 
crystal structure for the catalytic fragment of human brain 
2’,3’-cyclic-nucleotide 3’-phosphodiesterase (hCNP-CF) complexed 
with a phosphate ion at 1.8 Å resolution was recently published.  
In this report, Sakamoto et al. (455) suggests that the enzyme’s 
narrow V-shaped active site cleft could accommodate only an 
extended single-stranded oligonucleotide or a mononucleotide.  
The small size of this enzyme’s active site cleft effectively 
excludes double-stranded RNAs and RNAs containing secondary 
structures, such as tRNA, as potential substrates.  A structural-
homology search performed on this enzyme indicated that bacterial 
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RNA ligase and plant CPDase, which both belong to the 2H 
phosphoesterase superfamily, have similar topologies as hCNP-CF.  
A comparison of the electrostatic surface potentials of these 
three similar enzymes indicated that hCNP-CF is most similar to 
plant CPDase in terms of the size of the active site cleft and 
the array of positive charges surrounding it.  Surprisingly, the 
physiological substrate for plant CPDase is the recently 
discovered small molecule, ADP-ribose 1”,2”-cyclic phosphate 
(Appr>p), shown in Figure 38, Panel B.  This discovery certainly 
raises the possibility that hCNP-CF might act on other small 
nucleotide phosphates, such as CoA and or CoA-derivatives.  
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Figure 38.  Nucleotide Phosphate Derivatives Known or Suggested 
to have Activity as Second Messengers in Cellular Signal 
Transduction.   
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Figure 39.  The tRNA Splicing Pathway of Yeast.  Gene names are 
given in parenthesis for the proteins of the pathway.  CPDase, 
cyclic phosphodiesterase; ASTase, adenylyl synthetase.  
Reproduced from Abelson et al (456).   
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Novel Substrates for the CPDase Enzyme Family.  A specific 
class of enzymes in the CPDase family (known as Cpd1p in yeast) 
have been discovered, which catalyze the hydrolysis of ADP-ribose 
1”,2”-cyclic phosphate (Appr>p) generating ADP-ribose 1” 
phosphate (Appr-1”p) (455,457,458).  Appr>p, shown in Figure 38, 
Panel B, was first identified in vivo in Zenopus oocytes by 
Culver et al. (459) in 1993, and is presumed to be a by-product 
of tRNA splicing (459,460).  As illustrated in Figure 39, the 
Appr>p generated during the final step of tRNA splicing, in both 
plants (458,460,461) and yeast (457,462), is produced in 
equimolar quantities to the tRNA spliced.  Deletion mutants of 
yeast CPDase (Cpd1p), prepared by Nasr and Filipowicz (457), 
established that all in vivo Appr>p hydrolyzing activity 
originated with the Cpd1p enzyme.  When Appr>p was first 
discovered in 1993 Culver et al. (459) speculated that there may 
be some other cellular capacity for Appr>p.  This speculation has 
been promoted in the literature (457,460-464) by two key points.  
First, this unique tRNA splicing pathway is conserved in 
vertebrates (457,459,465), although vertebrates preferentially 
splice tRNA using another RNA ligase; thus this pathway could 
function as a redundant tRNA splicing pathway or as a mechanism 
to generate Appr>p or its metabolites (457).  Second, Appr>p is 
produced in yeast during each tRNA splicing event which is 
estimated to occur with up to 500,000 molecules of tRNA per 
generation (462).  Furthermore, recent evidence suggests that 
baseline levels of Appr-1”p may be maintained by the cellular 
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environment because generation of Appr-1”p exceeds the rate of 
removal by the Poa1p-specific catabolic enzyme (462).   
In contrast, studies of deletion mutants of Cpd1p performed 
by Nasr and Filipowicz (457), and Poa1p (the specific phosphatase 
that acts on Appr-1”p generating ADP-ribose in vitro) performed 
by Shull et al. (462), indicated that these deletion mutants grew 
normally and did not exhibit any unusual phenotype.  These 
reports suggest that Appr>p and Appr-1”p do not play a critical 
role in vivo.  Additionally, overexpression of Cpd1p to levels 
which should deplete Appr>p generate no change in the growth 
profile of yeast cells in standard media (457).  Furthermore, 
Genschik et al. (461) found that neither Appr>p nor Appr-1”p had 
any affect on cADPR induced calcium release in sea urchin egg 
homogenates.  Although these results tend to suggest that Appr>p 
and Appr-1”p are non-essential and do not mediate calcium 
release, unknown functions of these unique metabolites may still 
exist and are still under investigation (462).   
 
Second Messengers.  In spite of initial strong criticism 
from the scientific community, the concept of second messengers 
like cyclic-adenosine monophosphate (cAMP), which Sutherland 
(466) explored in the late fifties and received the 1971 Nobel 
Prize in Physiology or Medicine, is now an established concept in 
biochemistry.  Indeed, an entire host of small molecules, such as 
cGMP and inositol-1,4,5-triphosphate (IP3), were discovered in 
subsequent years and established to be involved as second 
   
 307
messengers in multiple molecular pathways.  In the late eighties, 
while researching the effect of Ca++ mobilization on sea urchin 
egg microsomes, Lee and Coworkers (467) discovered that pyridine 
nucleotide metabolites could release nearly as much Ca++ as the 
well established calcium mediator IP3.  Extensive further studies 
have indicated that the NAD+ metabolite, cyclic-ADP-ribose 
(cADPR) (468), as well as the NADP+ metabolites, nicotinic acid 
adenine dinucleotide phosphate (NAADP+) (469-471) and 2’-phospho-
cyclic ADP-ribose (cADPRP) (472,473), shown in Figure 38, appear 
to act as second messengers which ultimately mediate Ca++ 
mobilization.  Several experimentally established and proposed 
pathways for the generation of pyridine nucleotide phosphate 
derivatives are illustrated in Figure 40.
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Figure 40.  NAD+-dependent Signaling Pathways generating Pyridine 
Nucleoside Diphosphate Derivatives (474). 
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Recently Discovered Second Messengers: cADPR and cADPRP.  
The first discovered and most extensively studied of these new 
second messengers is cADPR (467,468) which has been shown to 
mediate calcium mobilization by acting on the ryanodine receptors 
(RYRs) (475); moreover, release of Ca++ from intracellular stores 
has been demonstrated in 50 different cell types from various 
phyla and species (475) suggesting widespread importance of this 
second messenger.  The structurally similar NADPH metabolite 
cADPRP (2’-phospho-cyclic ADP-ribose) which was first identified 
in 1996 by Vu and coworkers (472,473) occurs naturally in 
mammalian tissues (473) and utilizes the same binding site and 
exhibits the same affinity as cADPR.  Both cADPR and cADPRP 
elicit identical Ca++ mobilizing activity in rat brain microsomes 
(472,474,476), and Jurkat and HPB.ALL T-lymphocyte cell lines 
(477).  In contrast, cADPRP exhibited no Ca++ releasing activity 
in sea urchin egg homogenates (478); this indicates a difference 
between higher and lower eukaryotes (479).   
Considering the wealth of information presently available 
and currently in progress for the activity of cADPR there is 
comparatively little research into cADPRP.  The similarities 
between cADPR and cADPRP in higher eukaryotes seems to have 
discouraged researchers from further investigating cADPRP.  This 
dearth of information regarding cADPRP is discouraging in view of 
the importance of NADP(H) in reductive biosynthesis and the added 
energetic expense for NADP(H) biosynthesis (480).  Frivolous 
biosynthesis of cADPRP seems odd since lower eukaryotes 
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putatively cannot utilize this substrate and higher eukaryotes 
would receive equal benefit from using NAD to produce cADPR.  
Certainly, further studies regarding the 2’-phosphate derivative 
of cADPR, cADPRP, are warranted.   
Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP).  
Within a two week time-span in 1995, two groups published the 
discovery of NAADP (nicotinic acid adenine dinucleotide 
phosphate), shown in Figures 18 and 19 (469,481).  NAADP is  
derivative of NADP+ and is reported to mobilize Ca++ from 
intracellular stores in approximately 50 different cell (475) 
types ranging from plants to humans (482).  NAADP, which differs 
from NADP only in the exchange of NADP+’s amide for a carboxylic 
acid group, apparently functions via a mechanism independent of 
either the IP3 receptors or the ryanodine receptors, which bind 
cADPR (469,481).  Current research indicates the presence of a 
novel, as yet uncharacterized Ca++ channel receptor for NAADP.  
Research shows that NAADP binds a site on sea urchin eggs with a 
KD of 300 pM (483) and reports indicate that the Ca++ channels are 
located on novel lysosomal-like Ca++ stores (484,485) instead of 
the endoplasmic reticulum.  Further investigations also revealed 
a requirement for phospholipids for NAADP receptor binding (485).  
Interestingly, studies of NAADP analogues have revealed that NAAD 
is functionally inactive; this indicates that the ribose-
phosphate of NAADP is important to activity.  However, both 3’-
NAADP and 2’,3’-cyclic-NAADP exhibit activity suggesting that the 
position of the ribose phosphate is not critical but that a 
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phosphate must be present on the ribose moiety for activity.  
Moreover, the reduced form of NAADP+, NAADPH, has been shown to 
be functionally inactive at the NAADP receptor.  Billington et 
al. (486) suggests that this may be a mechanism for inactivating 
the second messenger NAADP+ in vivo.  While NAADP research is in 
its infancy, it is ongoing and future studies into this novel 
second messenger may reveal entirely new pathways of signal 
transduction.   
While the role of NADP+ as a redox facilitator has been 
established for most of the century, the role of NADP+ 
metabolites had been overlooked until the last few decades.  It 
is clear that the potential significance for these metabolites is 
substantial.  Possibly, this research will be crucial to 
elucidating the machinery of signaling pathways in a similar 
manner to Sutherland’s pioneering work with cAMP and the once 
controversial second messengers.   
 
Could CoA Derivatives Exist In vivo In a Regulatory 
Capacity.  Given the relatively recent discovery of the NADP+ 
metabolites, it is certainly sensible to consider the possibility 
that derivatives of CoA might exist in vivo, potentially acting 
in a regulatory capacity.  The chemical structures of CoA and 
NADP+ both contain an adenosine diphosphate moiety, as shown in 
Figures 2 and 10, but the structures differ in that CoA contains 
the pantothenic acid and mercaptoethylamine groups while NADP+ 
possesses the nicotinamide ribose moiety.  Despite obvious 
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structural dissimilarities, the CoA and NAD(P)+ biosynthetic 
schemes, detailed in Figures 21 and 22, demonstrate that the 
biosynthesis of CoA does not necessarily consume more energy (in 
terms of ATP equivalents) than does the biosynthesis of NADP+.  
This suggests that the likelihood of in vivo CoA derivatives is 
similar to the probability of NAD(P)+ metabolites.  In the case 
of CoA, shown in Figure 41, biosynthesis from pantothenate 
requires the conversion of 3 ATP to 3 ADP and the consumption of 
one ATP with liberation of pyrophosphate yielding a net 
consumption of 5 ATP equivalents.  The situation with NAD(P)+, 
illustrated in Figure 42, is somewhat more complex because two 
pathways are possible.  When nicotinate or quinolinate are the 
starting materials, NADP+ biosynthesis entails consumption of one 
ATP, and conversion of 3 ATP to 1 ADP and 2 AMP yielding a net 
consumption of 7 ATP equivalents (like the activation reaction in 
β-oxidation of fatty acids, conversion of each ATP to AMP 
consumes 2 ATP equivalents).  If on the other hand NADP+ 
biosynthesis begins with nicotinamide, a net of 5 ATP will be 
consumed—1 ATP consumed, and 2 ATP converted to 1 AMP (2ATP 
equivalents) and 1 ADP.  Therefore, it is clear from the studies 
presented here that there is no inherent energetic advantage to 
utilizing metabolites of NADP+ rather than CoA and that a 
derivative of CoA, such as iso-CoA, cyclic-CoA or a metabolite, 
might possibly be present in vivo.  Nevertheless, it still 
remains to be determined if metabolites of CoA such as iso-CoA or 
cyclic CoA actually do exist in vivo. 
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Figure 41.  Biosynthesis of Coenzyme A.  Reproduced from Voet and 
Voet (487). 
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Figure 42.  Biosynthesis of NAD(P)H.  Modified from Voet and Voet 
(488). 
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While the biological significance of iso-CoA is presently 
unknown, the potential for this class of isomeric compounds is 
clearly significant.  Iso-CoA isoforms have potential as 
pseudosubstrates, inhibitors, and as probes for investigating CoA 
binding to the extensive class of CoA-utilizing enzymes.  We 
anticipate that our investigation, in addition to generating the 
first reports of enzymes that perform acyl-transfer reactions 
with iso-CoA isomers, will provide the necessary methodology for 
future studies into iso-CoA and acyl-iso-CoA compounds.
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CHAPTER 10 
 
ISO-COENZYME A:  CONCLUSION  
 
 
Herein we have reported the first structural analysis of 
iso-CoA, which was accomplished by 1D NMR, 2D NMR, MS, and MS/MS 
analyses of HPLC-purified samples.  The isomers of acetyl-CoA, 
acetoacetyl-CoA, and β-hydroxybutyryl-CoA were also identified by 
HPLC-MS.  These isomers were found to be good substrates for the 
enzymes β-ketothiolase, acetoacetyl-CoA reductase, and PHB 
synthase, which are the first enzymes shown to catalyze acyl 
transfer reactions with the 2’-phospho isomers of their natural 
compounds.  We report the first HPLC method that separates a 
series of iso-CoA-containing isomers with baseline resolution, 
and this methodology was used to detect the presence of the 2’-
phospho isomers in commercial preparations of CoA, acetyl-CoA, 
acetoacetyl-CoA and b-hydroxybutyryl-CoA.  A novel regioselective 
synthesis of iso-CoA from CoA or cyclic-CoA is reported which 
uses β-cyclodextrin in high salt to produce iso-CoA in high 
yield.  The generation of iso-CoA from CoA in the presence of 
strong acid is established, and this route is proposed as 
plausible mechanism, which may account for the presence of the 
iso-CoA isoforms in commercial preparations.  Finally, we discuss 
the biological significance of the iso-CoA-containing molecules 
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in vivo, in vitro as probes for exploring enzyme binding, and as 
potential model compounds for the rational design of 
pseudosubstrates or inhibitors.
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CHAPTER 11 
 
SELENIUM REDOX CYCLING:  INTRODUCTION 
 
 
The biological role of selenium and selenium-containing 
compounds has been a subject of intense current interest.  
Selenium has been recognized for its antioxidant properties for 
at least 40 years (489).  Selenium-containing compounds and 
proteins have been implicated in the amelioration of oxidative 
stress, which results from either a relative excess of pro-
oxidants and/or a dearth of antioxidants (489).  As many as 
thirty seleno-proteins have been identified (489) and many small 
molecular weight organoselenium compounds, including 
selenomethionine and ebselen (2-phenyl-1,2-benzisoselenazole-
3(2H)-one), have been shown to exhibit antioxidative properties 
(489).   
 
 Peroxynitrite.  Peroxynitrite is one of the major 
endogenous prooxidant and nitrating species (490,491).  This 
cytotoxic compound is generated in vivo via the diffusion-limited 
reaction between superoxide anion and nitric oxide as shown in 
Figure 43 (489).   
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−•• ⎯→⎯+ ONOOONO -2  
Figure 43.  The Formation of Peroxynitrite 
 
Peroxynitrite is highly reactive and overproduction of this 
species is believed to be involved in the pathways mediating 
tissue damage and inflammation (492).  Several oxidation and 
nitration events within the body are known to be initiated by 
peroxynitrite, including lipid peroxidation, oxidation of sulfur 
groups such as sulfhydryls and methionine, tyrosine nitration, 
and the generation of single- and double-strand breaks in DNA 
supercoils (492).  
 
 Glutathione.  Glutathione is an important endogenous 
antioxidant, which also acts as a general cellular reductant and 
is involved in metabolism of toxins (492).  The so-called 
antioxidant status of the cell is in part maintained by 
glutathione.  Glutathione can react in vivo with peroxynitrite.  
The reaction of glutathione with peroxynitrite can follow either 
a two-electron oxidation or a one-electron pathway, the latter 
reaction generating a sulfur-centered radical which then 
undergoes further metabolism (492,493).  Glutathione can also 
protect against peroxynitrite-mediated oxidative damage via the 
action of the selenoprotein, glutathione peroxidase (GPx), as 
shown in Figure 44 where GSH is reduced glutathione and GSSG is 
the disulfide dimer of glutathione (492).   
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GSSGOHNO2GSHONOO 22
GPx ++⎯→⎯+−  
Figure 44:  The Reaction of Peroxynitrite with Reduced 
Glutathione. 
 
Organoselenium Compounds.  Small organoselenium compounds, 
including selenomethionine, selenocystine, and ebselen have been 
found to be effective antioxidants against peroxynitrite-mediated 
damage (494,495).  A study by Sies and coworkers (496) reported 
that the selenoorganic compounds, selenomethionine, 
selenocystine, and ebselen, are capable of protecting DNA from 
peroxynitrite-mediated single-strand breaks.   The putative 
mechanism of DNA protection by organoselenium compounds is via 
the reaction of the selenium-compound with peroxynitrite to yield 
the corresponding organoselenoxide and nitrite as shown in Figure 
45 (494).  Selenoxides formed from a reaction with peroxynitrite 
can be reduced back to the corresponding selenides by the action 
of reduced glutathione (GSH).  This ability of glutathione to 
reduce selenoxides can generate a catalytic cycle, which 
effectively increases the available quantity of selenium.  
Recycling with GSH does not occur with sulfur-containing 
compounds, as GSH does not reduce sulfoxides to sulfides.   
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Figure 45.  The Peroxynitrite-dependent Oxidation of Organoselenium Compounds.  Modified from 
Masumoto and Sies (494) 
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Phenylaminoethyl Selenides.  Recently, this laboratory 
demonstrated that phenylaminoethyl selenides (PAESe), which were 
developed as inhibitors of dopamine-β-monooxygenase, react 
efficiently with peroxynitrite to yield the selenoxide as the 
sole selenium-containing product (See Figure 45) (497).  In 
addition, the second order rate constants for the reaction of 
PAESe and (S)-HOMePAESe with peroxynitrite are comparable to 
those of selenomethionine and the major metabolite of ebselen, 2-
(methylseleno)benzanilide, measured at pH 7.0 and 25 C (497).  
Consequently, it seems reasonable to anticipate that these 
compounds could protect against oxidative damage and may have 
future pharmacological potential.   
 
Herein we report that phenylaminoethyl selenide compounds 
protect DNA from peroxynitrite-mediated single-strand breaks (1).  
Moreover, these organoselenium compounds protect DNA more 
effectively than their sulfur analogues.  Additionally, the 
ability of glutathione to enhance the protective effects of the 
selenium-containing compounds against peroxynitrite-induced DNA 
damage suggests that a selenium redox cycle, in which the 
peroxynitrite-generated selenoxide is recycled back to a selenide 
via glutathione, has been established.  The mechanism of 
protection against peroxynitrite mediated DNA damage was 
investigated by HPLC for the selenium- and corresponding sulfur-
containing compounds.  HPLC analysis shows that phenylaminoethyl 
selenides are quickly oxidized by peroxynitrite forming 
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selenoxides as the sole selenium-containing product.  Moreover, 
in the presence of reduced glutathione, the selenide to 
selenoxide ratio was higher suggesting the establishment of a 
glutathione-mediated catalytic redox cycle.  Phenylaminoethyl 
sulfide (PAES) was, likewise, shown to react slowly with 
peroxynitrite to form a small quantity of the sulfoxide as the 
main product but no redox cycle could be established with the 
sulfur analogues (1).  Finally, the unique chemistry of the 
reaction between peroxynitrite and HOMePAES was investigated 
using HPLC and HPLC/MS.   
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CHAPTER 12 
 
SELENIUM REDOX CYCLING:  EXPERIMENTAL 
 
 
 Reagents.  Hydrogen peroxide and diethylenetriamine 
pentaacetic acid were obtained from Aldrich Chemical Co. 
(Milwaukee, WI).  Reduced glutathione was obtained from Sigma 
Chemical Co.(St. Louis, MO).  Selenomethionine was purchased from 
Acros Organics(Morris Plains, NJ).  All other chemicals and 
solvents were purchased from standard commercial sources and were 
of the highest grade available.  HPLC columns(C-8) were obtained 
from Alltech.   
 
Synthesis of selenides and sulfides.  (S)-HOMePAESe [(S)-1-
(4’-hydroxyphenylseleno)-2-aminoethane] (498), PAESe[1-
(phenylseleno)-2-aminopropane] (499) and the sulfur analogs 
HOMePAES (500,501) and  PAES (501) were synthesized as described 
previously. 
 
 Synthesis of the selenoxides.  Hydrogen peroxide oxidation 
of the selenides and was performed as previously described 
(497,498).  Briefly, the hydrochloride salt of each selenide was 
dissolved in H2O and reacted with a 30% solution of H2O2 in a 1:1 
mole ratio.  The reactions were monitored by HPLC and, once 
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complete, lyophilized overnight.  Each phenyl-2-aminoethyl 
selenoxide product was recrystallized (methanol/ether) and 
characterized as follows:   
 HOMePAESeO:  mp 76 C (dec.); 1H NMR(D2O) δ7.55(m, 2H), 
7.0(m, 2H), 3.7-3.6(m, 2H), 3.0-3.4(m, 2H), 1.35-1.25(dd, 2H); 
IR(KBr) strong Se=O stretch at 795 cm-1.  
 PAESeO:  mp 95-96 C; 1H NMR(D2O) δ7.65(d, 2H), 7.55(m, 3H), 
3.1-3.45(m, 4H); IR(KBr) strong Se=O stretch at 815 cm-1.   
 
Synthesis of HOMePAES Oxide.  [(±)1-(4’-Hydroxyphenylthio)-
2-aminopropane] hydrochloride(HOMePAES) (221.5 g, 1.0 mmol) was 
dissolved in 12.5 ml of H2O on ice and mixed with 10 ml of TiCl4(2 
mmol, 88 mM) followed by the dropwise addition of 971 µL of 30% 
H2O2 (10 mmol).  The reaction was quenched after 20 s with MnO2.  
The mixture was basified (pH 12), filtered and the pH adjusted to 
8.9.  After extraction with brine/THF (12 x 100 ml) the combined 
extracts were dried (MgSO4) and filtered.  The resulting oil was 
dissolved in acidified H2O and the precipitate removed by 
filtration the remaining supernatant was evaporated by vacuum 
centrifugation.  A brown oil was recovered, dissolved in ethanol, 
filtered, and recrystallized(ethanol/ether) resulting in a white 
crystalline solid.  (77 mg, 32%):  mp 209 C (dec.); 1H NMR (D2O) δ 
6.94-7.56(d,d 4H), 3.22-2.83(m, 3H), 1.20(d, 3H).  Anal. 
(C9H13NO2S HCl)  C:  calcd., 45.86; found, 44.13; H:  calcd., 
5.98; found, 5.83.  IR:  S=O str. 1033cm-1. 
 
   
 326
Synthesis of PAES Oxide.  [2-(Phenylthio)ethylamine 
Hydrochloride] (PAES) (189.6 mg, 0.97 mmol) was dissolved in 3 ml 
of H2O on ice, mixed with 0.225 g of NaIO4 (1.05 mmol) and allowed 
to react at 4 C overnight.  The resulting solution was filtered, 
the pH adjusted to 12, and extracted with chloroform/water (4 x 
25 ml).  The combined extracts were dried(MgSO4) and filtered.  
The resulting yellow oil was dissolved in acidified methanol and 
recrystallized(methanol/ether) as a white crystalline solid.  
(191 mg, 93%):  mp 160-162 C(lit. mp156-158 C); 1H NMR (D2O) δ 
7.369(m, 5H), 3.20-3.31(m, 4H).  Anal. (C9H13NO2S HCl)  C:  calcd, 
46.71; found, 46.66; H:  calcd, 5.89; found, 5.90.IR:  S=O str. 
1039cm-1.     
 
Synthesis of Peroxynitrite.  Peroxynitrite was synthesized 
by the autooxidation of 10 mM hydroxylamine in 0.5 M aqueous NaOH 
solution containing 100 µM DTPA, as previously described 
(497,502,503).  Oxygen was bubbled through the solution (200 mL) 
for 3 h at room temperature.  The resulting yellow solution was 
treated with granular MnO2 to remove excess H2O2, filtered, and 
concentrated by freeze fractionation at –20 C.  Peroxynitrite 
concentration was determined spectrophotometrically at 302 nm 
(ε302=1670 M-1cm-1) (497,504) in 0.5 M sodium hydroxide with a 
Hewlett Packard Model 8453 diode array spectrophotometer.   
 
Plasmid DNA Reaction System.  pUC 19 plasmid (25 µg/ µl) was 
incubated with peroxynitrite (0.5 mM) in the presence and absence 
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of various sulfur- and selenium-containing compounds (0.5 mM) in 
200 mM phosphate buffer, pH 6.8, for 3 min at room temperature.  
The DNA bands were resolved by agarose gel electrophoresis and 
scanned with a Molecular Dynamics Laser densitometer.  The band 
intensities were determined using the ImageQuaNT analysis 
program.  % Damaged DNA = (Open Circular DNA + Linear DNA)/ (Open 
Circular DNA + Linear DNA + Supercoiled DNA) x100 %.  Each 
percentage was corrected for the level of damage in pUC 19 
plasmid DNA in the absence of peroxynitrite.  The level of damage 
caused by peroxynitrite in the absence of sulfur- and selenium- 
containing compounds was set to 100 %.  The DNA gel 
electrophoresis experiments were performed by Ms. Veronica De 
Silva.   
 
Reaction system.  Typically, 250 µM of peroxynitrite was 
added to a solution of sulfide or selenide (250 µM) in 200 mM 
sodium phosphate buffer pH 8.0 and vortexed at room temperature.  
In appropriate experiments, 250 µM of reduced glutathione was 
added prior to peroxynitrite addition.  Following a standard 
incubation time of at least 3 minutes the samples were injected 
on to a C-8 reverse phase HPLC column and analyzed.  
Peroxynitrite and its reduction product eluted in the void peak.   
 
HPLC Analysis.  Samples (10 µM) were injected into a C-8 
reverse phase column (RP Allsphere Octyl C8, 5µ).  Separation was 
performed in isocratic mode with a mobile phase containing 20% of 
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acetonitrile, 80% water, and 0.1% trifluoroacetic acid on a 
LDC/Milton Roy ConstaMetric III metering pump at a flow rate of 
1.5 mL/min.  Compounds were monitored with an Analytical 
SpectroMonitor 3100 variable wavelength UV Detector at 236 nm for 
HOMePAESe, 254 nm for HOMePAES and 238 nm for PAES.  
Quantification of the concentrations of the reaction products was 
carried out based on calibration curves calculated using peak 
height verses concentration of authentic selenide and selenoxide 
samples.  The identities of the selenide and sulfide peaks as 
well as their corresponding oxides were confirmed by retention 
time and by spiking with authentic samples.          
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CHAPTER 13 
 
SELENIUM REDOX CYCLING:  RESULTS AND DISCUSSION 
 
 
 Phenylaminoethyl Selenides Protect Against Peroxynitrite-
induced DNA damage.  The electrophoresis results shown in Figure 
46 clearly indicate that the phenylaminoethyl selenide and 
phenylaminoethyl sulfide compounds protect plasmid DNA against 
peroxynitrite-mediated nicking.  The phenylaminoethyl selenium 
compounds protect plasmid DNA at a level comparable to 
selenomethionine and are significantly more effective than the 
corresponding phenylaminoethyl sulfide analogues.  Quantitative 
results indicate that under these experimental conditions as much 
as 46% of the DNA damage generated by peroxynitrite could be 
prevented by selenomethionine.  The reduction in the quantity of 
DNA damage for PAESe, HOMePAESe was 31 and 38%, respectively, 
while PAES, HOMePAES, and methionine could only decrease DNA 
damage by 15, 11, and 27% respectively.  For further discussion 
please refer to De Silva et al (1).     
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Figure 46.  Selenium and Sulfur-Containing Compounds protect pUC19 plasmid DNA from Peroxynitrite-
mediated Single Strand Nicks.  Unnicked pUC19 plasmid DNA, which is in the Supercoiled form, 
undergoes single strand nicking via peroxynitrite to generate the open circular form that is 
detected by electrophoresis.  Data obtained by Ms. Veronica De Silva (1).   
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HPLC Analysis of the Phenylaminoethyl Selenide Compounds.  
The plasmid DNA reaction system was investigated by HPLC analysis 
as shown in Figure 47.  In the case of the reactions with 
phenylaminoethyl selenide compounds, quantitative HPLC confirmed 
stoichiometric formation of the phenylaminoethyl selenoxide by 
peroxynitrite and that the selenoxide was the sole selenium-
containing moiety, as illustrated in Panel B.  The locations of 
the selenide and selenoxide peaks were identified by HPLC spiking 
experiments with authentic selenoxide and by retention times.   
 
 
 
Figure 47.  HPLC Chromatograms Illustrating the Protective 
Effects of HOMePAESe against Peroxynitrite-mediated DNA Damage.  
Panel A:  Reaction Mixture containing 250 •M HOMePAESe, 25 ng/uL 
pUC19 plasmid DNA.  Panel B:  Reaction mixture containing 250 •M 
HOMePAESe, 25 ng/•L pUC19 plasmid DNA, 250 •M peroxynitrite.  
Panel C:  Reaction mixture containing 250 •M HOMePAESe, 25 ng/•L 
pUC19 plasmid DNA, 250 •L peroxynitrite, 250 •M GSH (1).  HPLC 
performed as detailed in the text.    
A B C 
   
 332
The HPLC results further suggest that reduced glutathione, 
GSH, can reduce and/or prevent formation of the selenoxide; thus, 
maintaining quantitatively higher levels of the selenide moiety, 
as shown in Panel C.  As previously discussed, quantitative HPLC 
gel electrophoresis experiments showed that HOMePAESe was capable 
of decreasing the peroxynitrite-mediated damage to DNA by 31%.  
Moreover, the addition of GSH to this reaction mixture results in 
a further statistically significant enhancement of protection of 
up to 14.5% (1).  This HPLC evidence coupled with the enhancement 
of protection of plasmid DNA from peroxynitrite mediated damage 
as measured by gel electrophoresis suggests that GSH is capable 
of propagating a catalytic redox cycle, similar to that 
illustrated in Figure 48, which may enhance the protective 
effects of phenylaminoethyl selenides against peroxynitrite-
induced DNA damage.   
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Figure 48.  Catalytic Redox Cycle Established with reduced Glutathione and Phenylaminoethyl 
Selenides can Protect DNA from Peroxynitrite-induced Damage.(1) 
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 HPLC Analysis of the Phenylaminoethyl Sulfide Compounds.  
In the course of our experiments, HPLC analysis was performed on 
the phenylaminoethyl sulfide compounds as well as the selenium-
containing compounds.  While the sole sulfur-containing compound 
generated by reaction of PAES with peroxynitrite was the 
corresponding sulfoxide, PAESO, unusual results were obtained 
with HOMePAES.  As shown in Figure 49, Panel 2, HPLC analysis of 
a reaction mixture containing 250 µM HOMePAES and 250 µM of 
peroxynitrite generated not only the expected HOMePAES oxide peak 
but also an additional two peaks of unknown composition.  Peak 1 
in Figure 49, Panel B has been identified as HOMePAES Oxide by 
spiking experiments and by comparing the retention time at 2 min 
40 s to authentic HOMePAES Oxide and Peak 2 at 4 min 20 s is 
clearly the reagent HOMePAES, in which a control is shown in 
Panel A for comparison.  Peaks 3 and 4 in Panel B were 
investigated further using electrospray HPLC-MS experiments. 
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Figure 49.  HPLC Chromatograms of the Reactions between HOMePAES, 
Peroxynitrite, and GSH.  Panel A:  Authentic HOMePAES.  Panel B:  
Reaction mixture containing 250 •M of peroxynitrite and 250 •M 
HOMePAES.  Panel C:  Reaction mixture containing 250 •M 
peroxynitrite, 250 •M HOMePAES, and 250 •M GSH.  HPLCs performed 
as detailed in text. 
Peak 
1 Peak 
1 
Peak 
2 
Peak 
2 
Peak 
3 Peak 3 
Peak 
4 
Peak 
4 
Peak 
2 A B C 
   
 336
 Electrospray HPLC/MS Analysis of the Products of the 
Reaction between HOMePAES and Peroxynitrite.  The identity of the 
unidentified peaks, 3 and 4 in Figure 49, was tentatively 
determined using electrospray LC/MS analysis.  Electrospray 
analysis of Figure 49, Peak 2 revealed the expected molecular ion 
m/z 184, which corresponds to the molecular weight of HOMePAES, 
and a decomposition product was observed with m/z 167, which 
would suggest the loss of ammonia from the HOMePAES compound 
during electrospray analysis.  Analysis of Peak 3 showed a 
compound with a molecular ion 368 m/z, which likely results from 
the formation of a HOMePAES dimer as shown in Figure 50.  
Electrospray analysis of Peak 4 revealed a molecular ion m/z 230.  
We suggest that this is the nitration product of HOMePAES which 
we tentatively designate as 3-nitro-HOMePAES as shown in Figure 
50.  The formation of 3-nitro-HOMePAES is further supported by 
the observed decomposition product in the electrospray analysis, 
which exhibited a molecular ion m/z 213; this corresponds to the 
loss of ammonia and parallels the observed loss of ammonia for 
HOMePAES.  
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Figure 50.  Proposed reaction between HOMePAES and ONOO- 
Producing Nitro-HOMePAES and a HOMePAES dimer.  
 
 
Tyrosine Nitration as a Model for the Reaction of HOMePAES 
with Peroxynitrite.  The reaction of tyrosine with peroxynitrite 
has been shown to produce 3-nitro-tyrosine as well as a dimer of 
tyrosine as shown in Figure 51.  This reaction is well 
characterized and is known to occur with free tyrosine as well as 
with tyrosine that is incorporated into a protein (505,506).  We 
suggest that the electronic configuration of the phenyl ring in 
HOMePAES is similar to that of tyrosine and that this results in 
the nitration and dimerization of HOMePAES in a reaction 
analogous to tyrosine nitration and dimerization.  Moreover, HPLC 
analysis of PAES (data not shown) does not show evidence of 
nitration; this supports the contention that the p-hydroxy moiety 
of the phenyl ring is important to activate the ring to nitration 
and dimerization by peroxynitrite.   
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Figure 51.  Nitration and Dimerization of Tyrosine in the 
Presence of Peroxynitrite.   
 
 
HPLC analysis of the reaction between HOMePAES and 
peroxynitrite in the presence of GSH, shown in Figure 49, Panel 
C, revealed a reduction in the nitrated and dimer peaks (Peaks 3 
and 4).  Further experiments indicated that GSH is unable to 
react with either of the reaction products, the nitro-HOMePAES or 
the HOMePAES dimer.  Consequently, we propose that in the 
presence of GSH, peroxynitrite reacts more quickly with GSH (to 
form GSSG) than with HOMePAES; thus, less of the nitro-HOMePAES 
or HOMePAES dimer are formed as seen in Figure 49, Panel C.  
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CHAPTER 14 
 
CYCLOOXYGENASE INHIBITORS 
 
 
Prostaglandin H Synthase.  Prostaglandin H Synthase (PGH 
Synthase; PGHS) catalyzes the first step in the so-called cyclic 
pathway of eicosanoid metabolism.  The eicosanoids are a class of 
C20 compounds (Greek: eikosi, twenty) which include 
prostaglandins, prostacyclins, thromboxanes, leukotrienes, and 
lipoxins, and which act like localized paracrine hormones in that 
they act by binding G-protein-coupled receptors, which are 
mediated by the cAMP cascade.  Eicosanoid metabolism follows two 
main pathways; the linear pathway, shown in Figure 52, which 
generates the leukotrienes and HPETEs, and the cyclic pathway, 
shown in Figure 53, which generates the prostacyclins, 
prostaglandins and thromboxanes, and is named for the formation 
of the cyclopentane ring which is characteristic of the 
prostaglandins (247).
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Figure 52.  The Cyclic and Linear Pathways of Arachidonic Acid Metabolism.  Reproduced from Voet 
and Voet (247).    
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Figure 53.  The Cyclic Pathway of Arachidonic Acid Metabolism.  Modified from Voet and Voet (247). 
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Catalytic Function of Prostaglandin H Synthase.  
Prostaglandin H Synthase is a heme-containing bifunctional enzyme 
which contains both cyclooxygenase and peroxidase activities.  As 
Figure 54 illustrates, the cyclooxygenase activity of 
Prostaglandin H Synthase catalyzes the tyrosyl-radical-mediated 
addition of two O2 to arachidonic acid, a major prostanoid 
precursor, which generates PGG2 and it is this functionality, 
which lends the name COX to the enzyme.  The peroxidase activity 
of Prostaglandin H Synthase is responsible for converting the 
hydroperoxy moiety of PGG2 to a hydroxyl group, which yields the 
final product PGH2 (247).  
   
 343
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54.  The Reactions Catalyzed by PGH Synthase (PGHS).  The 
enzyme contains two activities:  a cyclooxygenase, which 
catalyzes steps 1 to 3 and is inhibited by aspirin, and a 
peroxidase, which catalyzes Step 4.  1.)  A radical at Tyr-385 
that is generated by the enzyme’s heme cofactor 
stereospecifically abstracts a hydrogen atom from C13 of 
arachidonic acid, which then rearranges so that the radical is on 
C11.  2.)  The radical reacts with O2 to yield a hydroperoxide 
radical.  3.)  The radical cyclizes and reacts with a second O2 
molecule at C15 to yield a peroxide in a process that regenerates 
the tyrosyl radical.  4.)  The enzyme’s peroxidase activity 
converts the peroxide at C15 to a hydroxyl group.  Reproduced 
from Voet and Voet (247).
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Discovery and Function of COX Isozymes.  In 1991 a second 
isozyme of PGHS, designated as COX-II, was discovered.  COX-II is 
a stimulus inducible enzyme, which is involved in pathogenic 
processes such as pain, inflammation, and cancer.  COX-I is 
constitutively expressed in many cell types and acts in a house 
keeping manner in vivo (507,508).  The similarities and 
differences between COX-I and COX-II are summarized in Table 20.  
A third isozyme of COX, COX-III, has also been tentatively 
proposed in the literature but currently no consensus regarding 
the validity of this isozyme has been reached.  The proposed COX-
III isozyme is a splice variant of COX-I and appears to be 
expressed mainly in the central cortex of mammals (509).   
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Table 20.  Overview of the Activities and Active Sites of COX-I and COX-II (510). 
 
 COX-I COX-II 
Activity Constituitive (constant inhibition can cause gastric ulceration) Inducible (Desirable target for inhibition) 
Cyclooxygenase  Vmax ~3500 mol/min of arachidonate/mol of dimer 
Activity KM arachidonate ~ 5µM 
 KM O2 5µM 
  Cyclooxygenase activity activated at 10x lower 
hydroperoxide concentrations thus permits 
COX-II to out compete COX-I. 
1o Structure 576 aa 587aa (18aa inserted 6 residues in from C 
terminus) 
2o Structure Homodimers which independently catalyze reactions 
 N-glycosylated at 3 sites which is required for enzyme binding so 
problems w enzyme production 
Variably glycosylated at 2-4 sites.  Expressed in 
baculovirus systems. 
Peroxidase  
Activity 
Catalyzes heterolytic 2e- reduction of hydroperoxidase substrates Catalyzes 60% 2e- and 40% 1e- reductions 
  
Slower 
 
Faster rates of formation of oxyferryl group + 
protoporphyrin IX 
 Preference for secondary alkyl hydroperoxides 
Cyclooxygenase Smaller Larger More Accommodating 
Active Site   
 Exhibits negative allosterism at low arachiodonate concentrations No allosterism 
 Global catalytic domain contains a 25 Å, 25 residue, hydrophobic channel that originates at the membrane binding 
domain, where the substrate/NSAID and O2 enters, and protrudes into the globular domain core where the 
substrate/NSAID binds.  The NSAID binding site involves the upper half of the channel from Arg-120 to Tyr-385.  
[Only 3 polar residues line the channel Arg-120, Ser-353, Ser-530 (Aspirin Acetylation site)] 
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Table 20 Continued 
 
 -- *Binding site is 20% larger than COX-I which 
leads to greater substrate flexibility 
 
 Ile 523 Val-523 produces a small side pocket adjacent to 
the active site channel 
   
 Ile 434 Val-434 further increases side pocket size; 
induces a movement of Phe518 which further 
increases the size  
   
 His513 Arg-513 alters the chemical environment of the 
side pocket forming a stable positive charge in 
the center of the pocket; interacts with the 4-
methylsulfonyl substituents of COX-II 
inhibitors; gives rise to the time-dependent 
inhibition displayed by this class of inhibitors. 
  Helix D is cantilevered upward to provide a 
larger opening and displace Arg-120. 
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Similarities between COX-I and COX-II.  COX-I and COX-II 
share 60% sequence identity and are integral membrane proteins, 
which reside in the ER and perinuclear envelopes.  The COX 
isozymes have homologous and superimposable crystal structures 
with both enzymes existing as homodimers.  Three structural 
domains make up the COX monomer; a membrane-binding domain, a 
catalytic binding domain that is located on the luminal side and 
contains a heme-binding site, and an N-terminal epidermal growth 
factor (EGF)-like domain.  The COX active site lies between the 
helices of the membrane-binding site, and it is proposed that 
this site undergoes significant conformational changes to allow 
for substrate binding and release (507).  The isozymes also have 
similar cyclooxygenase turnover numbers, KM values for 
arachidonate and O2, and the key residues for catalysis are 
conserved (511).  
 
Structure of the COX Active Site.  The COX-I and COX-II 
monomer binding site is located at the upper end of a 25 Ǻ 
hydrophobic channel, which begins at the membrane binding site 
and reaches toward the heme in the globular domain.  The 
hydrophobic active site is lined by 24 amino acid residues 
beginning with Arg-120 and ending at Tyr-385.  Substrates bind 
the hydrophobic COX active site in an L-shaped formation with 
Tyr-385 positioned to perform tyrosal-radical mediated catalysis 
(510).   
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Differences between the COX-I and COX-II Active Site.  The 
COX-II active site is approximately 20% larger than in COX-I.  
This is due to three notable variations in the structures between 
the COX-I and COX-II active sites.  The residues Ile-523, Ile-
434, and His-513 in COX-I are replaced by Val-523, Val-434, and 
Arg-513 in COX-II, respectively.  The replacement of the COX-I 
residues Ile-523 and Ile-434 with Val in COX-II create a small 
side pocket in COX-II; this generates the larger COX-II binding 
site.  In addition, the substitution of His-513 in COX-I with the 
Arg-513 in COX-II substantially alters the chemical environment 
inside the COX-II side pocket; this effectively forms a stable 
positive charge in the center of the COX-II side pocket.  Arg-120 
is an important residue for binding to the carboxylate groups of 
fatty acids and many NSAIDS in both COX-I and COX-II.  In COX-II 
Arg-120 is displaced somewhat since helix D is cantilevered 
upward; this provides a larger opening in the membrane binding 
domain (510).   
 
Rationale for Selective COX-II Inhibitors.  The differences 
between the COX-I and COX-II binding site have been exploited in 
the design of selective COX-II NSAID inhibitors.  Approximately 
1% of all patients receiving chronic treatment with traditional 
NSAIDS develop serious gastrointestinal complications such as 
ulcers.  COX-I is the major cyclooxygenase isozyme present in the 
lining of the stomach and inhibition of this isozyme has been 
historically implicated in the promotion of gastrointestinal 
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complications and ulcerogenesis (508).  Consequently, the COX-II 
hypothesis (512) suggests that selective NSAID inhibition of COX-
II, the inducible isozyme involved in inflammation and disease 
sates, without inhibition of the constitutive Cox I isozyme, 
would provide the same anti-inflammatory, analgesic, and 
antipyretic qualities as traditional, nonselective NSAIDS without 
the possibility of serious GI complications (510). 
 
Questions Regarding the Safety and Efficacy of Selective 
COX-II inhibitors.  The clinical picture regarding the success of 
the selective NSAIDS has certainly been mixed.  The first COX-II 
selective NSAIDS reached market in 1999 (513) and are shown in 
Figure 55.  These new drugs were marketed heavily and through 
direct to the public advertising, which quickly elevated them to 
so-called blockbuster status (513).  However, in September 2004, 
Merck, Sharp and Dohme Limited (MSD) withdrew rofecoxib following 
evidence of an increased risk of cardiovascular disease in the 
preliminary results of the APPROVe trial (513).  Then in 2005, 
the FDA asked Pfizer to voluntarily withdraw valdecoxib from the 
market (514).  The FDA has also called into question the 
cardiovascular risk of all NSAIDS which includes over the counter 
and prescription drugs (514).
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Figure 55.  Selective COX-II Inhibitors that have been or are 
currently commercially available.  
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The Fitzgerald Hypothesis for the Increased Risk of 
Cardiovascular Disease with Selective COX-II Inhibitors.  The 
increased risk for cardiovascular disease, which prompted removal 
of several selective COX-II NSAIDS from the market, seems to be a 
direct result of the mechanism of this class of drugs instead of 
a spurious side effect of the individual drugs themselves.  The 
Fitzgerald hypothesis suggests that inhibition of COX-II sans 
COX-I inhibition is doubly detrimental to the cardiovascular 
system (513).  As summarized in Table 21 (513), COX-I negatively 
effects the endothelium by inducing production of thromboxane A2 
which facilitates platelet aggregation, vasoconstriction, and 
smooth muscle proliferation.  COX-II acts beneficially on the 
endothelium by facilitating the production of prostacyclin which 
counterbalances COX-I by opposing the effects of thromboxane A2 
(512).  Consequently, NSAIDS, which inhibit the beneficial 
effects of COX-II on the endothelium without inhibiting the 
detrimental effects on the endothelium produced by COX-I, can 
result in an increased risk of cardiovascular disease in 
susceptible individuals (513).  Nevertheless, the absolute risk 
of a detrimental cardiovascular outcome while taking a selective 
COX-II NSAID is quite low.  Specifically, a 1.1% chance of any 
cardiovascular event was observed with rofecoxib in contrast to 
0.47% for naproxen (Alleve).  We note that it does seem 
reasonable to consider treatment with COX-II selective NSAIDS for 
select populations with low cardiovascular risk factors.  
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Table 21.  The Fitzgerald Hypothesis.  A single mechanism, 
blockage of COX-II, could explain increased cardiovascular risk.  
Reproduced from Hazleman et al.  (513) 
 
Mechanism Outcome 
COX-I induction via 
thromboxane A2 
Platelet aggregation, vasoconstriction 
and vascular smooth muscle proliferation 
 
COX-II induction via 
prostacyclin 
Vasodilatation, inhibition of vascular 
smooth muscle proliferation, inhibition 
of platelet aggregation 
 
Inhibition of COX-II Elevation of blood pressure, acceleration 
of atherogenesis, predisposes to an 
exaggerated thrombotic response 
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Modalities of COX-Mediated Inhibition.  Three modes of 
NSAID-mediated COX inhibition have been reported and the 
particular mode of inhibition appears to be dependent on the 
chemical structure of the specific NSAID (510,515).  The first 
mode of inhibition is a rapid, reversible binding followed by 
covalent modification of Ser-530.  This classic mode of suicide 
inhibition of COX occurs with compounds containing an acetyl-
moiety like aspirin, which is the only commercial inhibitor of 
this type.  Aspirin’s irreversible, suicide inhibition of COX-I 
is believed to be responsible for it’s ability to prevent COX-I-
mediated thromboxane-induced platelet aggregation, because mature 
platelets are essentially non-nucleated thus are incapable of 
generating fresh COX-I enzymes after inhibition with aspirin 
(515).   
A second method of COX inhibition is the rapid and 
reversible binding, which is characteristic of ibuprofen; this is 
likely the most common mode of binding COX to traditional NSAIDs.  
A third mode of inhibitor binding is the rapid, lower affinity, 
reversible binding followed by time-dependent, higher affinity, 
slowly reversible binding; this is the binding mode for the 
traditional NSAID, flurbiprofen.  The mechanism of binding for 
this mode of inhibition with traditional COX inhibitors is not 
clearly understood and likely dependent on the individual drug 
structure.   
The COX-II selective inhibitors bind COX-I via the 
previously discussed, rapid, competitive, reversible mechanism, 
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but inhibition of COX II occurs via the third mode, a time-
dependent pseudoirreversible mechanism.  With selective COX-II 
inhibitors that contain a sulfonamide or a methylsulfone moiety, 
the time-dependent pseudoirreversible inhibition of COX-II is 
believed to be due to the interaction with the Arg-513 side 
group, and rarely with Arg-120 (510).   
 
The Development of a Selective Terphenyl COX Inhibitor.  In 
1998 May, Pollock, and Coworkers (508) published a study which 
evaluated a novel arylacetic acid, 1-(carboxymethyl)-3,5-
diphenyl-2-methylbenzene (CDB), which is shown in Figure 56.  CDB 
was shown to inhibit carrageenan edema in rat hind paws in a dose 
dependent manner (ED50 of 41 mg/kg at 3 h) (508).  The compound 
also inhibited hind paw inflammation (70%) and arthogram scores 
in rats with adjuvant-induced arthritis.  Moreover, CDB possessed 
significant analgesic activity in mice (70% inhibition with 50 
mg/kg).  Studies suggest that the pharmacological activity 
observed in the study is a direct result of CDB’s inhibition of 
COX-I activity (IC50 ≈ 17 µM); the compound inhibited PAM and COX-
II only weakly.  The terphenyl scaffold of CDB is attractive 
since the increased stability and the lipophilicity may enhance 
absorption and distribution.  While CDB is certainly of interest 
for the treatment of anti-inflammatory diseases, a more desirable 
compound would have more potent and selective COX-II activity.  
We are now working to turn this meta-terphenyl scaffold into a 
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selective COX-II inhibitor.  Herein we report the development of 
novel CDB derivatives, which are selective COX-II inhibitors.  
   
 
356 
H
N MST       
IC50 ~ 10uM
CH3C
O
S
O
O
CH3
H
NCn-Bu
O
S
O
O
CH3
Cl
MST-ClCDB  
1-(carboxymethyl)-3,5- 
diphenyl-2-methylbenzene
H
NCH3C
O
S
O
O
CH3
CH3
MST-CH3
HN
CH3
S
O
O
H3C
O
HO
MDB 
1-methanesulfonamide-
3,5-diphenyl benzene
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56.  Meta-terphenyl Compounds Developed as COX Inhibitors.   
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The Design of Selective COX-II Inhibitors.  The CDB 
derivatives developed in this study are shown in Figure 56.  An 
optimized synthesis illustrated in Figure 57 was used to generate 
these meta-terphenyl derivatives.  This synthesis is efficient 
and convenient and from this basic MDB scaffold, a variety of 
derivatives can be generated as shown in Figure 56.  Functional 
groups can be added onto the terminal phenyl groups by placing 
electron withdrawing groups on the benzaldehyde precursor and 
electron donating groups on the acetophenone precursor prior to 
the cyclization reaction.  Nothing can be done with the nitrile 
groups except for hydrolysis.  However, the free amine on the 
aniline compound can be converted to several moieties via 
reactions like the Sandmeyer reaction.   
Our meta-terphenyl compounds have a more open orientation 
than the commercial COX-II inhibitors, which would be more 
analogous to an ortho-orientation.  Furthermore, the sulfonamide 
moiety is on the center phenyl of MDB instead of on the terminal 
phenyl moieties as is nearly always seen with COX-II selective 
inhibitors.  The sulfonamide position is considered critical for 
enzyme binding selectivity because it forms an electrostatic 
interaction with the Arg-513 residue.  Consequently, a series of 
compounds, designated as MST (methylsulfone terphenyl) in Figure 
56, were designed with a methylsulfone moiety at the para 
position on the outer phenyl ring.  
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Figure 57.  Synthesis of MDB as a Scaffold for other Meta-
terphenyl Derivative Compounds.  
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Experimental Setup for Assaying COX Inhibitors.  The 
compounds investigated in this study were screened for the 
ability to inhibit COX-I and COX-II in vitro using the 
Colorimetric COX (ovine) Inhibitor Screening assay from Cayman 
Chemical as directed.  This assay utilizes the peroxidase 
activities of COX-I and COX-II, which are colorimetrically 
assayed by monitoring the appearance of oxidized N,N,N’,N’-
tetramethyl-p-phenylenediamine at 590 nm.   
Whole Blood ELISA Assay  Promising compounds were also 
screened for and COX-2 activity in whole blood using the 
following procedure.  Whole blood, 25 mL, from a volunteer 
predosed with aspirin was collected in heperinzed tubes, pooled, 
and 0.5 mL of whole blood was transferred to microcentrifuge 
tubes containing 2 µL of inhibitor in DMSO or DMSO only; the 
inhibitors were set up in triplicate.  The blood was incubated 
for 15 min at 37 C in the presence of the inhibitor or vehicle 
and then 10 µL of lipopolysaccharide (LPS) was added to induce 
Cox-II activity.  The blood was then incubated for 24 hours.   
The blood samples were then assayed using an Enzyme-Linked 
Immunosorbent Assay (ELISA) for the quantitative analysis of 
Prostaglandin E2 (See Figure 53) levels using a kit from Oxford 
Biomedical Research.  This assay operated on the basis of 
competition between the enzyme-PGE2 horseradish peroxidase 
conjugate and the PGE2 in the sample for a limited number of 
binding sites on the antibody-coated plate.  In this situation 
the extent of color development, measured at 650 nm.  is 
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inversely proportional to the amount of PGE2 in the sample or 
standard; thus a stronger the inhibitor would generate less PGE2 
which would generate more color development.   
 
Results of the In Vitro Colorimetric Inhibitor Screening.  
Of the compounds assayed with the in vitro colorimetric inhibitor 
screen, the MST derivatives show the most promise.  As shown in 
Figure 58, MST appears to be a selective inhibitor of COX-II and 
does not inhibit COX-I at the measured concentrations.  The 
results of the control compounds indomethacin, which is a non-
selective COX- inhibitor, and celecoxib, which is a selective 
COX-II inhibitor, were somewhat less clear.  Celecoxib 
(illustrated in Figure 59) completely inhibited COX-1 at both 
measured concentrations and inhibited COX-II in a dose dependent 
manner.  The results with indomethacin are unclear, inhibition of 
COX-I is clearly observed at 0.1 µM but a dose response curve is 
not observed since the inhibition at 0.1 µM is less that at 0.1 
µM.  Finally, the results with MST-Cl and MST-CH3 cannot be 
interpreted, as there is simply too much error involved with the 
results of this assay.   
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Figure 58.  Percent Inhibition of COX-I and COX-II In Vitro.  
Results were determined using the Colorimetric COX (ovine) 
Inhibitor Screening assay from Cayman Chemical, which was used as 
per the instructions.   
   
 362
Celebrex                               
Celecoxib  
 (G.D. Searle LCC, Pfizer)
N
N
H3C
CF3
S
O
O
H2N
Cl
N
O
OCH3
HO
O
H
N MST       
IC50 ~ 10uM
CH3C
O
S
O
O
CH3
H
NCH3C
O
S
O
O
CH3
Cl
MST-Cl
H
NCH3C
O
S
O
O
CH3
CH3
MST-CH3
Indomethacin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59.  Meta-terphenyl Derivatives Assayed for the Ability to 
Inhibit COX-I and Cox-II in an In Vitro Colorimetric Assay.   
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Results of the Whole Blood ELISA Screening.  The results of 
the in vitro colorimetric inhibitor screen (Figure 58) indicate 
that MST is a selective inhibitor of COX-II.  Consequently, we 
investigated the ability of this compound to inhibit COX-II in 
whole blood using the procedure described above.  The results 
shown in Figure 60 clearly indicate that MST is indeed an 
inhibitor of COX-II in whole blood cells.  The magnitude of the 
inhibition observed with the control inhibitors, celecoxib and 
indomethacin, is a function of concentration; both compounds have 
low IC50’s so all COX-II activity is inhibited at the measured 
concentrations.   
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Figure 60.  Percent Inhibition of COX-II in Whole Blood.    
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Herein we report the development of a novel selective COX-
II inhibitor.  MST inhibits COX-II but not COX-I in the in vitro 
colorimetric inhibitor screen and MST inhibits COX-II in the 
whole blood ELISA assay.  The ability of MST to inhibit COX I in 
whole blood is being investigated.  The presence and location of 
the methylsulfone moiety on MST likely facilitates the inhibition 
of COX-II by allowing an electrostatic interaction to form 
between the MST inhibitor and the Arg-513 residue of COX-II.  
Further experiments are currently underway to examine 
modifications in the MST scaffold such at generating a meta-
sulfone moiety on the terminal phenyl group and modifying the 
amide moiety on the central ring.   
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APPENDIX 1:  PHB MODEL 
 
This is the first structured kinetic metabolic model 
developed using in vitro data of metabolite concentrations, which 
simulates the in vitro biosynthesis of PHB.  The equations for 
the β-ketothiolase and PHB synthase reaction were based on the 
work of Leaf and Srienc (190), while the equation for the 
Acetoacetyl-CoA Reductase enzyme was from Daae et al (191).  
Kinetic and thermodynamic parameters used in this model were 
gathered from the literature, from laboratory analysis, by 
fitting the simulation to the time course data, and by 
calculations based on the kinetic rate and Haldane equations. 
 
β-ketothiolase.  β-ketothiolase has been shown to proceed 
via a bi bi ping-pong mechanism as described by the following 
integrated rate equation: 
 
[ ][ ] [ ][ ]( )
[ ] [ ] [ ][ ] [ ] [ ]
[ ][ ] [ ][ ] [ ][ ] iqraeqiafqeqf
eqfpeqfqrrarb
eqrf
o
KVKKKVKKV
KVKKVKVVKVK
KVV
v
/QB/PA/QP
/Q/PBABA
/QPBA
+++
++++
−=
 
Equation 1:  The integrated rate equation for the reversible bi 
bi ping-pong mechanism, where the reaction substrates [A] and [B] 
are acetyl-CoA, and [P] and [Q] are the products, CoA and 
acetoacetyl-CoA, respectively.  The rate constants for the four 
compounds are Ka, Kb, Kp and Kq and the inhibition constants are 
Kia, Kib, Kip, and Kiq.  Vf and Vr are respectively the maximal 
velocities in the forward and reverse directions, and Keq is the 
equilibrium constant.     
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Equation 1 can be solved at the initial rate, vo, by assuming 
there are no products (i.e. [P]=[Q]=0); this simplification 
yields the equation:   
 
 
[ ][ ]
[ ] [ ] [ ][ ]BABA
BA
rrarb
rf
o VVKVK
VV
v ++=  
Equation 2:  Initial rate equation for the bi bi ping-pong 
mechanism with zero initial product quantities.
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Table 22.  Kinetic and Thermodynamic Parameters for the β-
ketothiolase, Acetoacetyl-CoA Reductase and PHB Synthase 
Reactions.  The values listed in blue were gathered from the 
literature; those determined by simulated fit are in red.  Values 
calculated from the Haldane or laboratory equilibrium data are in 
green.  The ratios were calculated based on the data from Haywood 
et al. and laboratory data and are listed in pink and underlined 
in blue.    
 
 
 
 
 
Literature 
Simulated fit 
Calculated from the Haldane equations or with equilibrium data 
Generated from the model and literature data. 
Laboratory data 
Kinetic 
parameters 
β-ketothiolase 
 
Acetoacetyl-CoA 
Reductase 
PHB Synthase 
Keq 4 x 10-5 2.16 x 109 --- 
Vr (µM/s) 2924  135.09 --- 
Vf (µM/s) 9.75 1486  0.309    
Ratio Vr/Vf = 300  Vf/Vr = 11 --- 
KM (AcCoA) µM 0.158 --- --- 
KM (AcCoA) µM 1237.84 --- --- 
KM (CoA) µM 16 --- --- 
KM (AcAcCoA) µM 44 5 --- 
KM (NADPH) µM --- 19 --- 
KM (HBCoA) µM --- 16.5 103 
KM (NADP+) µM --- 31 --- 
KI (AcCoA) µM 46.74 --- --- 
KI (AcCoA) µM 1237.84 --- --- 
KI (CoA) µM 15.78 --- 108 
KI (AcAcCoA) µM 0.1467 28.83 --- 
KI (NADPH) µM --- 50 --- 
KI (HBCoA) µM --- 5 --- 
KI (NADP+) µM --- 47.15 --- 
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The kinetic constants for β-ketothiolase reaction are presented 
in Table 22.  In the case of β-ketothiolase, further 
simplifications are made because the reaction substrates are the 
same, i.e. [A]=[B]=[acetyl-CoA]. 
 
 
[ ]
( ) [ ] [ ]
[ ]
[ ]A
A
AA
A
2
2
++=++= ab
f
rrab
rf
o KK
V
VVKK
VV
v  
Equation 3:  Initial rate equation for the bi bi ping-pong 
mechanism with zero initial product and identical reaction 
substrates.   
 
 
We note that even though the reactants, [A] and [B], are the 
same, the rate constants and inhibition constants for the 
reactants are not the same, so Ka ≠ Kb and Kia ≠ Kib.  However, we 
can state that Ka + Kb = Ksum, and the measured rate Ksum for 
acetyl-CoA is 1.238 mM (160).  Under these considerations, the 
initial rate equation collapses to into the form of a simple 
Michaelis-Menten equation:   
 
 
[ ]
[ ]A
A
+= sum
f
o K
V
v  
Equation 4.  Simplified initial rate equation for the bi bi ping-
pong mechanism with zero initial product and assuming that Ka + Kb 
= Ksum.  
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Accordingly, this relationship and the five known Haldane 
relationships (Equation 5) were utilized to calculate the kinetic 
constants that were not reported in the literature.   
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eq KK
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KKV
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KK
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2
2
−
−=====  
Equation 5:  Haldane equations for the reversible bi bi ping-pong 
mechanism.   
 
 
Four of the kinetic constants, Kq, Kp, Kip, and Keq are known from 
the literature, and the ratio Vr/Vf was determined by comparing 
the modeled data against the data gathered from the initial rate 
plot from Haywood et al. (348), which is shown in Figure 61.   
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Figure 61.  Initial Rate Plots for Inhibition of the Condensation 
Reaction by CoA.  Plots were generated by inserting the values 
from Table 22 into Equation 1 and taking the concentration of 
acetoacetyl-CoA, [Q], to be zero.  The data points gathered from 
Haywood et al. (348) are shown next to the solid lines which were 
generated by the model in accord with Leaf et al.   
 
 
Equation 5, combined with the known quantities for Kq, Kp, Kip, Keq 
and Vr/Vf yield direct solutions to the remaining unknown 
parameters.  These equations are listed below for convenience.  
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Equation 6:  The quadratic equation is used here to determine Ka.   
 
 
asumb KKK −=  
Equation 7:  Relationship used in the Determination of Kb.   
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Equation 8:  Haldane Relationship used in the determination of 
Kia.   
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Equation 9:  Haldane Relationship used in the Determination of 
Kib.   
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Equation 10:  Haldane Relationship used in the determination of 
Kiq.   
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Acetoacetyl-CoA Reductase.  The kinetic mechanism for 
acetoacetyl-CoA reductase from C. necator has not been 
determined.  However, the corresponding enzyme in Z. ramigeria 
purportedly proceeds via an ordered bisubstrate mechanism: 
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Equation 11.  Integrated rate equation for the reversible ordered 
bi substrate reaction.  [A] = NADPH, [B] = acetoacetyl-CoA, [P] = 
β-hydroxybutyryl-CoA, [Q] = NADP+ and the rate constants for the 
four compounds are Ka, Kb, Kp, and Kq and the inhibition constants 
are Kia, Kib, Kip, and Kiq.   
 
 
Kinetic parameters utilized in the simulation for the reaction 
catalyzed by acetoacetyl-CoA reductase are provided in Table 22 
and the known Haldane relationships are:   
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Equation 12:  Haldane equations for the reversible ordered 
bisubstrate mechanism. 
 
 
Acetoacetyl-CoA reductase displays significant substrate 
inhibition; however, this behavior was not included in the 
simulation because it introduces unnecessary complexity 
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considering the very low in vitro and in vivo concentrations 
observed for this metabolite.   
The combined equilibrium for the β-ketothiolase and 
acetoacetyl-CoA reductase reactions was obtained from the HPLC 
data at t = 10 min for the two-enzyme system at equilibrium:   
 
 
[ ][ ][ ]( )
[ ] [ ]( ) ( ) ( )ductaseCoAlAcetoacetyeqseketothiolaeqcombinedeq KKK Re2 NADPHAcCoA NADPHBCoACoA −−
+
•== β  
Equation 13:  Combined equation for the equilibrium constant, 
which is reached in the presence of β-ketothiolase and 
acetoacetyl-CoA reductase.   
 
 
From this combined equilibrium constant and the known equilibrium 
constant for β-ketothiolase, which was reported in the literature 
(190), the acetoacetyl-CoA equilibrium constant was calculated.  
This calculated value is approximately one-half of the literature 
value for the acetoacetyl-CoA reductase equilibrium constant, 
which correlates relatively well, and this is most likely due to 
differing experimental conditions.   
 
PHB Synthase.  PHB synthase, in this simulation, is 
represented by the simple irreversible one-substrate Michaelis-
Menten equation exhibiting product inhibition as shown in 
Equation 14.  The pertinent kinetic parameters are listed in 
Table 22.   
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Vv  
Equation 14:  Integrated rate equation for the irreversible one 
substrate Michaelis-Menten mechanism.  KM is the Michaelis-Menten 
constant; [S] and [I] are the concentrations of the substrate, β-
hydroxybutyric acid, and the inhibitor, CoA, respectively.  VMax 
is the maximal velocity of the reaction upon saturation of the 
enzyme by the substrate. 
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APPENDIX 2:  PHB LABORATORY 
Production of poly-3-hydroxybutyrate using 
Cupriavidus necator 
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Figure 62.  The Chemical Structure of Poly-β-hydroxybutyrate. 
 
Poly-3-hydroxybutyrate (PHB), shown in Figure 62, is an 
intracellular polymer that accumulates in the cytoplasm of 
bacterial cells if a carbon source is provided, and if at least 
one nutrient, such as nitrogen, is limited.  Because it is a 
biodegradable polyester, there is much interest in its 
production.  In addition to being biodegradable, PHB possesses 
piezoelectric properties and has characteristics similar to 
polypropylene, making it suitable for a wide range of 
applications in surgery, medicine, agriculture, the food 
industry, and environmental protection.   
Cupriavidus necator is one of many bacterial species that 
will produce PHB under nitrogen-limiting conditions.  It has been 
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reported in the literature that C. necator is able to produce up 
to 60% of its biomass in the form of PHB when using fructose as 
the carbon source.   
The purpose of this experiment is to familiarize the 
student with the production of PHB using C. necator, and to 
provide a biopolymer sample that can be characterized and 
compared with other types of polymers. 
 
Initial Growth of C. necator 
 
1. Remove vial labeled C. necator H16 from the freezer and 
rapidly thaw cells at 30 ºC.   
 
2. Place 35mL of C. necator growth medium (Table 23) in a 
125mL Erlenmeyer flask.  Inoculate the media by adding 250µL 
of the C. necator cells to the nutrient broth.  
 
 
 
Table 23.  Components of C. necator Growth Medium 
Media component Mass (g/L) 
Nutrient Broth 16.0 
Yeast Extract 10.0 
Ammonium Sulfate 5.0 
The nutrient broth should have a pH of 6.4 upon completion and 
should need no further pH adjustment.   
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3. Incubate the flask in a small shaking incubator at 30 ºC 
and 325 RPM.   
 
4. (This step should take about 12 hours.)  When the turbidity 
of the medium becomes significant, aseptically remove a 1mL 
aliquot from the shake flask and measure the optical 
density at 600 nanometers (OD600) by UV-Vis.  If the measured 
absorbance is greater than 1, appropriately dilute the 
solution and calculate the OD600 by multiplying the 
absorbance of the diluted sample by the dilution factor.  
Repeat this step until the calculated OD600 is 15-16.  (After 
this step, cells may be refrigerated for up to two days.)      
 
5. At this point, the cells are ready to transfer to the 
Nitrogen-Limited medium.  Harvest the cells by 
centrifugation at 13,800 x g for 5 min.  The cells will 
form a pellet at the bottom of the sterile 50mL centrifuge 
tube.  Decant the nutrient broth and save the pellet.  This 
is the harvested C. necator cell paste. 
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Preparation of Nitrogen-Limited Media  
Table 24.  Components of Nitrogen-Limited Media 
Compound 
(Parentheses denote volume needed for 
1L) 
Mass  
(g/L) 
Final Media 
Concentration 
Solution #1:  Phosphates (1 L)   
                           KH2PO4 2.8687 19.50mM 
                           Na2HPO4 4.1385 26.97mM 
Solution #2:  Magnesium (25mL)   
                           MgSO4⋅7H2O 213.1521 20.00mM 
Solution #3:  Iron (5mL)   
              Ferric Ammonium Citrate5.1420 91  µM 
                           CaCl2 1.4300 60  µM 
Solution #4:  Trace Elements (1mL)   
                           NaMoO4⋅2H2O 0.0057 0.024µM 
                           MnCl2⋅4H2O 0.0050 0.023µM 
                           ZnSO4⋅6H2O 0.0874 0.300µM 
                           H3BO3 0.0648 0.970µM 
                           CuSO4⋅5H2O 0.1295 0.480µM 
                           CoCl2⋅6H2O 0.1543 0.600µM 
                           
Cr2(SO4)3⋅6H2O 
0.1352 0.250µM 
                           NiCl2⋅6H2O 0.1927 0.750µM 
Solution #5:  Fructose (50mL)   
                           Fructose 300 15 
 
1. The pH of solution #1 (Table 24) should be pH 6.9, adjust 
as necessary with NaOH or H3PO4.   
 
2. Autoclave, separately, 35mL of solution #1 in a 125mL 
Erlenmeyer, and also a stock solution of #2. 
 
3. Individually, sterile filter stock solutions #3, #4, and 
#5. 
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4. When autoclaved solutions #1 and #2 are cool, add the 
following quantities to solution #1(Phosphate):   
  875µL of solution #2 (Magnesium);  
175µL of solution #3 (Iron);  
35µL of solution #4 (Trace);  
1.75mL of solution #5 (Fructose).   
***Note:  To avoid precipitation,  
solutions #1 and #2 must be cool.  *** 
 
PHB Production Stage of Bacterial Growth  
 
1. Resuspend the harvested C. necator cell paste by 
aseptically adding approximately 15mL of the pre-prepared 
nitrogen-limited medium to the cell pellet in the 
centrifuge tube.  Gently swirl or shake the capped 
centrifuge tube until the cell pellet is fully resuspended. 
2. Transfer the resuspended C. necator cells to the 125mL 
Erlenmeyer flask containing nitrogen-limited media.   
3. Incubate the flask for 24 hours in a small shaking 
incubator at 30 ºC and 325 RPM.  Incubation may continue 
for up to 48 hours. 
4. When cell growth is complete, record the OD600 as described 
above.  The OD600 should reach 30-40 within 24 hours.  These 
cells can be stored in the refrigerator for as long as a 
week or two.  
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This is the beginning of the Laboratory Experiment. 
 
 
SDS Extraction of PHB 
 
Procedure Overview:   
SDS, a common detergent, is used in this procedure to extract the 
PHB from the bacterial cells.  Essentially, SDS dissolves away 
everything except the PHB.  Initially, a small aliquot of cell 
suspension is removed, centrifuged, the supernatant is discarded 
and the cell pellet allowed to dry in an oven to obtain the dry 
cell weight of the C. necator cells.  Then the remaining cell 
suspension is centrifuged, resuspended in water, SDS and EDTA are 
added, and the mixture is autoclaved.  After autoclaving, the PHB 
is pelleted by centrifuging, resuspended in water, and then 
centrifuged again to remove all the SDS and any residual cellular 
debris.  Finally, the crude PHB pellet is acetone dried by vacuum 
filtration yielding the crude PHB.  
 
 
1. Each Erlenmeyer flask contains PHB-laden C. necator cells 
in 35mL of nitrogen-limited media.   
2. To a pre-weighed 15mL polypropylene centrifuge tube, add a 
10mL aliquot of the C. necator  cells.  Set this aliquot 
aside; it will be used later to determine the dry cellular 
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weight.  To ensure that the aliquot is a good 
representation of the entire cell sample, be sure to swirl 
the Erlenmeyer flask so that the cell mixture becomes 
homogeneous before removing this aliquot.   
3. Harvest the remaining 25mL of C. necator cells by 
transferring the cells to a 50mL centrifuge tube and 
centrifuging at 3440 x g for 5 min.  Decant the media and 
save the pellet.   
4. Add 25mL of deionized water to the cell pellet and 
resuspend by shaking vigorously. 
5. To the resuspended C. necator cells, add 0.2g SDS and 0.18g 
EDTA.  Cap the centrifuge tube and shake to mix the 
ingredients. 
6. Remove the cap from the centrifuge tube, and autoclave for 
30 min.   
7. While the cells are autoclaving, centrifuge the 10mL 
aliquot (set aside in Step 2) of C. necator cells at 3200 x 
g for 10 min.  Decant the supernatant, save the pellet, and 
allow the cell pellet to dry overnight in a 60oC oven.  The 
weight of the pellet will be determined during the next lab 
period.  
8. After autoclaving the 25mL of C. necator cells, centrifuge 
the cell suspension at 13800 x g for 10 min.  Decant the 
supernatant and save the pellet.   
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9. To remove residual SDS, add 25mL of deionized water to the 
centrifuge tube and resuspend PHB pellet by stirring with a 
wooden applicator stick and then shaking vigorously. 
10. Centrifuge the PHB/SDS mixture at 13800 x g for 10 
min, decant the supernatant, and save the crude PHB pellet. 
11. Resuspend the PHB pellet in a minimal amount of 
deionized water (not more than 2mL) to create a white PHB 
slurry.  Add approximately 10mL of acetone to the PHB 
slurry.  This will induce aggregation of the PHB to 
facilitate filtering.   
12. Filter the PHB/Acetone/Water mixture, under vacuum, 
with a Buchner funnel containing a Whatman #1 filter.  
Rinse the centrifuge tube with additional acetone to remove 
all PHB.  
13. Rinse the PHB, by adding approximately 5mL of 
deionized water to the PHB on the filter to ensure removal 
of all SDS.  
14. Rinse the PHB with acetone and allow PHB to dry under 
vacuum.  This is the crude purification of PHB. 
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Chloroform Purification of PHB 
 
Procedure Overview:   
In this procedure, the PHB is extracted and filtered three times 
with chloroform.  The filtrate, containing the PHB, is collected 
after each extraction.  The PHB solution is concentrated by 
boiling off some of the chloroform and the PHB is precipitated by 
addition of methanol.  The purified PHB is collected on a Whatman 
#1 filter paper.  
 
 
 
1. Place the crude PHB in a clean Erlenmeyer flask.  Add 
approximately 30mL of chloroform and a wooden boiling stick 
to the Erlenmeyer flask, and carefully allow the chloroform 
to come to a boil on a hot plate.  Gentle swirling and 
addition of the boiling stick will help prevent bumping.   
WARNING!  Handle hot glass with a paper towel to prevent 
burns.   
2. After boiling the mixture for about 1 min, remove the flask 
from the heat and add two scoopulas of celite filtering 
agent.  Filter this mixture under vacuum with a Buchner 
funnel containing a Whatman #1 filter.  Remember that the 
filtrate, collected in the filter flask, contains the 
desired PHB. 
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3. Scrape the residual PHB and celite from the filter paper 
back into the 125mL Erlenmeyer flask.  Add another 30mL of 
chloroform, boil, and then filter (as performed in step 2) 
to extract the residual PHB.   
4. Repeat step 3, so that a total volume of 90mL is used for 
the PHB extraction. 
5. Rinse the Erlenmeyer flask twice with a total of 10mL of 
chloroform to remove any residual PHB. 
6. Remove the filtration flask from the vacuum system, and 
concentrate the PHB/chloroform mixture by boiling on a hot 
plate until approximately 30mL of chloroform remains.  The 
solution will become slightly more viscous.  Be careful to 
stop boiling the sample when 30mL of the chloroform/PHB 
mixture remains or the polymer will stick and burn on the 
bottom of the flask. 
7. Briefly cool the concentrated PHB/chloroform mixture, and 
then precipitate the PHB with 150mL of methanol.  Up to 
300mL of methanol may be necessary depending on the PHB 
concentration.  The PHB should precipitate as a white floc.   
8. Collect the precipitated PHB by filtering, under vacuum, 
with a Buchner funnel containing a Whatman #1 filter.  
Gently scrape the filter to impede the formation of a PHB 
mat, which clogs the filter.  Do not allow the filter to 
dry out and clog, or another filter will be necessary.   
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9. When the filtration is nearly complete, rinse the walls of 
the filtration unit with a small volume of acetone.  Allow 
the PHB to form a mat on the filter paper.   
10. When adequately dry, remove the filter paper 
containing the PHB mat from the filtration unit.  Then 
carefully remove the PHB by peeling the paper away from the 
PHB mat. 
11. Air-dry the PHB overnight.  The PHB will appear as a 
clear to white sheet of stiff plastic.   
 
 
PHB Production Workup:  To be performed during the next lab 
period 
 
 
1. Obtain the weight of the PHB.  This is the final yield of 
PHB. 
2. Obtain the weight of the dry cell pellet.  This is the DCW 
of 10mL of C. necator cells.   
3. Determine the percent of PHB obtained per gram dry cellular 
weight of C. necator cells using the following formula:   
Equation 15.  Determination of the Percent of PHB per Gram 
DCW.   
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